EP1383893A2 - Proteins and nucleic acids encoding same - Google Patents
Proteins and nucleic acids encoding sameInfo
- Publication number
- EP1383893A2 EP1383893A2 EP02707409A EP02707409A EP1383893A2 EP 1383893 A2 EP1383893 A2 EP 1383893A2 EP 02707409 A EP02707409 A EP 02707409A EP 02707409 A EP02707409 A EP 02707409A EP 1383893 A2 EP1383893 A2 EP 1383893A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino acid
- nucleic acid
- polypeptide
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 412
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 340
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 340
- 102000004169 proteins and genes Human genes 0.000 title abstract description 391
- 108090000623 proteins and genes Proteins 0.000 title description 403
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 179
- 229920001184 polypeptide Polymers 0.000 claims abstract description 172
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 172
- 241000282414 Homo sapiens Species 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 85
- 239000012634 fragment Substances 0.000 claims abstract description 65
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 4
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 4
- 239000002157 polynucleotide Substances 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 134
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 133
- 239000002773 nucleotide Substances 0.000 claims description 132
- 125000000539 amino acid group Chemical group 0.000 claims description 111
- 208000035475 disorder Diseases 0.000 claims description 97
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 230000000694 effects Effects 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 53
- 239000000523 sample Substances 0.000 claims description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 230000000295 complement effect Effects 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 7
- 239000013068 control sample Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 230000004075 alteration Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 230000037353 metabolic pathway Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 108
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 30
- 238000011160 research Methods 0.000 abstract description 11
- 238000003745 diagnosis Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 383
- 238000004458 analytical method Methods 0.000 description 81
- 210000004556 brain Anatomy 0.000 description 61
- 230000007170 pathology Effects 0.000 description 58
- 108020004999 messenger RNA Proteins 0.000 description 56
- 210000001519 tissue Anatomy 0.000 description 51
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 50
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 49
- 230000006870 function Effects 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 41
- 108091081024 Start codon Proteins 0.000 description 39
- 235000001014 amino acid Nutrition 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 37
- 108010085895 Laminin Proteins 0.000 description 34
- 230000027455 binding Effects 0.000 description 34
- 102000007547 Laminin Human genes 0.000 description 33
- 230000000875 corresponding effect Effects 0.000 description 33
- 108020004705 Codon Proteins 0.000 description 32
- 239000002243 precursor Substances 0.000 description 32
- 108020005038 Terminator Codon Proteins 0.000 description 31
- 230000035790 physiological processes and functions Effects 0.000 description 31
- 230000001605 fetal effect Effects 0.000 description 29
- 239000000126 substance Substances 0.000 description 29
- 208000008589 Obesity Diseases 0.000 description 28
- 108700026244 Open Reading Frames Proteins 0.000 description 28
- 230000004048 modification Effects 0.000 description 28
- 238000012986 modification Methods 0.000 description 28
- 235000020824 obesity Nutrition 0.000 description 28
- 101000868880 Homo sapiens Serpin B13 Proteins 0.000 description 27
- 108010076504 Protein Sorting Signals Proteins 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 27
- 206010018338 Glioma Diseases 0.000 description 24
- 108010074223 Netrin-1 Proteins 0.000 description 24
- 102000009065 Netrin-1 Human genes 0.000 description 24
- 238000011161 development Methods 0.000 description 24
- 230000018109 developmental process Effects 0.000 description 24
- 208000032612 Glial tumor Diseases 0.000 description 23
- 102100032322 Serpin B13 Human genes 0.000 description 23
- 238000002169 hydrotherapy Methods 0.000 description 22
- 210000003734 kidney Anatomy 0.000 description 22
- 239000013615 primer Substances 0.000 description 22
- 102100034569 Pregnancy zone protein Human genes 0.000 description 20
- 101710195143 Pregnancy zone protein Proteins 0.000 description 20
- 241000699660 Mus musculus Species 0.000 description 19
- 210000000349 chromosome Anatomy 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 19
- 239000012528 membrane Substances 0.000 description 19
- 210000003486 adipose tissue brown Anatomy 0.000 description 18
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 18
- 108010088360 laminin alpha5 Proteins 0.000 description 18
- 208000011580 syndromic disease Diseases 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 101150032479 UNC-5 gene Proteins 0.000 description 17
- 230000002438 mitochondrial effect Effects 0.000 description 17
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 16
- 210000002500 microbody Anatomy 0.000 description 16
- 210000002824 peroxisome Anatomy 0.000 description 16
- 210000002307 prostate Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 210000001550 testis Anatomy 0.000 description 16
- 208000009999 tuberous sclerosis Diseases 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 206010020772 Hypertension Diseases 0.000 description 15
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 210000004901 leucine-rich repeat Anatomy 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 15
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- 208000035478 Interatrial communication Diseases 0.000 description 14
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 14
- 208000013914 atrial heart septal defect Diseases 0.000 description 14
- 206010003664 atrial septal defect Diseases 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 238000007385 chemical modification Methods 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 238000002405 diagnostic procedure Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000010230 functional analysis Methods 0.000 description 14
- 238000001415 gene therapy Methods 0.000 description 14
- 239000002547 new drug Substances 0.000 description 14
- 210000000496 pancreas Anatomy 0.000 description 14
- 230000007017 scission Effects 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 14
- 201000003130 ventricular septal defect Diseases 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 description 13
- 108010063605 Netrins Proteins 0.000 description 13
- 102100029500 Prostasin Human genes 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 206010039710 Scleroderma Diseases 0.000 description 13
- 238000002679 ablation Methods 0.000 description 13
- 210000003050 axon Anatomy 0.000 description 13
- 230000001472 cytotoxic effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 238000013508 migration Methods 0.000 description 13
- 102000027257 transmembrane receptors Human genes 0.000 description 13
- 108091008578 transmembrane receptors Proteins 0.000 description 13
- 210000004291 uterus Anatomy 0.000 description 13
- 206010025323 Lymphomas Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 231100000433 cytotoxic Toxicity 0.000 description 12
- 239000003596 drug target Substances 0.000 description 12
- 238000001476 gene delivery Methods 0.000 description 12
- 230000002163 immunogen Effects 0.000 description 12
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 12
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 12
- 230000005012 migration Effects 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 108010031970 prostasin Proteins 0.000 description 12
- 229940126586 small molecule drug Drugs 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 230000017423 tissue regeneration Effects 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 108010030865 Netrin Receptors Proteins 0.000 description 11
- 102000005951 Netrin Receptors Human genes 0.000 description 11
- 102100030169 Tetraspanin-1 Human genes 0.000 description 11
- 108091023045 Untranslated Region Proteins 0.000 description 11
- 208000032839 leukemia Diseases 0.000 description 11
- 210000003712 lysosome Anatomy 0.000 description 11
- 230000001868 lysosomic effect Effects 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 210000001103 thalamus Anatomy 0.000 description 11
- 108010079996 thymosin beta(4) Proteins 0.000 description 11
- 208000023275 Autoimmune disease Diseases 0.000 description 10
- 102000000584 Calmodulin Human genes 0.000 description 10
- 108010041952 Calmodulin Proteins 0.000 description 10
- 108700024394 Exon Proteins 0.000 description 10
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- 208000006011 Stroke Diseases 0.000 description 10
- 102100035000 Thymosin beta-4 Human genes 0.000 description 10
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 208000036546 leukodystrophy Diseases 0.000 description 10
- 201000006417 multiple sclerosis Diseases 0.000 description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 238000011144 upstream manufacturing Methods 0.000 description 10
- JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical class Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 9
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 9
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 9
- 206010012335 Dependence Diseases 0.000 description 9
- 208000023105 Huntington disease Diseases 0.000 description 9
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 9
- 102000010803 Netrins Human genes 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 101710151653 Tetraspanin-1 Proteins 0.000 description 9
- 108091036066 Three prime untranslated region Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 238000001994 activation Methods 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000036506 anxiety Effects 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 9
- MWUYLQGOGOLRQS-UHFFFAOYSA-N bis(acetyloxymethyl) 4-[6-[13-[2-[2,4-bis(acetyloxymethoxycarbonyl)phenyl]-5-methoxy-1-benzofuran-6-yl]-1,4,10-trioxa-7,13-diazacyclopentadec-7-yl]-5-methoxy-1-benzofuran-2-yl]benzene-1,3-dicarboxylate Chemical compound COC1=CC=2C=C(C=3C(=CC(=CC=3)C(=O)OCOC(C)=O)C(=O)OCOC(C)=O)OC=2C=C1N(CCOCC1)CCOCCOCCN1C(C(=CC=1C=2)OC)=CC=1OC=2C1=CC=C(C(=O)OCOC(C)=O)C=C1C(=O)OCOC(C)=O MWUYLQGOGOLRQS-UHFFFAOYSA-N 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 210000001638 cerebellum Anatomy 0.000 description 9
- 206010008129 cerebral palsy Diseases 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 208000037765 diseases and disorders Diseases 0.000 description 9
- 206010015037 epilepsy Diseases 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- 210000001685 thyroid gland Anatomy 0.000 description 9
- 102000002266 Dual-Specificity Phosphatases Human genes 0.000 description 8
- 108010000518 Dual-Specificity Phosphatases Proteins 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 8
- 206010062767 Hypophysitis Diseases 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 8
- 102100034393 Netrin-3 Human genes 0.000 description 8
- 210000004100 adrenal gland Anatomy 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 208000024908 graft versus host disease Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 108010081713 netrin-3 Proteins 0.000 description 8
- 230000004112 neuroprotection Effects 0.000 description 8
- 210000003635 pituitary gland Anatomy 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 235000019833 protease Nutrition 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000002027 skeletal muscle Anatomy 0.000 description 8
- 210000003523 substantia nigra Anatomy 0.000 description 8
- 208000002330 Congenital Heart Defects Diseases 0.000 description 7
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 7
- 101001125574 Homo sapiens Prostasin Proteins 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 102100023206 Neuromodulin Human genes 0.000 description 7
- 101710144282 Neuromodulin Proteins 0.000 description 7
- 208000031481 Pathologic Constriction Diseases 0.000 description 7
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 210000004727 amygdala Anatomy 0.000 description 7
- 206010002906 aortic stenosis Diseases 0.000 description 7
- 208000028831 congenital heart disease Diseases 0.000 description 7
- 108091036078 conserved sequence Proteins 0.000 description 7
- 210000003017 ductus arteriosus Anatomy 0.000 description 7
- 108091022862 fatty acid binding Proteins 0.000 description 7
- 210000005075 mammary gland Anatomy 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 7
- 208000030390 pulmonic stenosis Diseases 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 210000003079 salivary gland Anatomy 0.000 description 7
- 239000003001 serine protease inhibitor Substances 0.000 description 7
- 210000000278 spinal cord Anatomy 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 208000037804 stenosis Diseases 0.000 description 7
- 210000003437 trachea Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 208000005595 Chronic Idiopathic Jaundice Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 201000004943 Dubin-Johnson syndrome Diseases 0.000 description 6
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 6
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 6
- 206010021263 IgA nephropathy Diseases 0.000 description 6
- 102100024022 Inactive heparanase-2 Human genes 0.000 description 6
- 108010015301 Neurogranin Proteins 0.000 description 6
- 208000020870 Ochoa syndrome Diseases 0.000 description 6
- 206010033645 Pancreatitis Diseases 0.000 description 6
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 6
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 6
- 206010038378 Renal artery stenosis Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 6
- 208000026589 Wolman disease Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 208000024042 cholesterol ester storage disease Diseases 0.000 description 6
- 208000013760 cholesteryl ester storage disease Diseases 0.000 description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 6
- 206010011005 corneal dystrophy Diseases 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000009795 derivation Methods 0.000 description 6
- 230000000913 erythropoietic effect Effects 0.000 description 6
- 201000008220 erythropoietic protoporphyria Diseases 0.000 description 6
- 230000035558 fertility Effects 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 201000006334 interstitial nephritis Diseases 0.000 description 6
- 230000000527 lymphocytic effect Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 201000008968 osteosarcoma Diseases 0.000 description 6
- 208000030761 polycystic kidney disease Diseases 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 201000010384 renal tubular acidosis Diseases 0.000 description 6
- 102000029752 retinol binding Human genes 0.000 description 6
- 108091000053 retinol binding Proteins 0.000 description 6
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 6
- 201000003251 split hand-foot malformation Diseases 0.000 description 6
- 229960005371 tolbutamide Drugs 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 201000002970 urofacial syndrome Diseases 0.000 description 6
- 208000009825 warfarin sensitivity Diseases 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 5
- 102100029184 Calmodulin regulator protein PCP4 Human genes 0.000 description 5
- 241000255601 Drosophila melanogaster Species 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 101000988362 Homo sapiens Calmodulin regulator protein PCP4 Proteins 0.000 description 5
- 206010020710 Hyperphagia Diseases 0.000 description 5
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 5
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 102000001775 Neurogranin Human genes 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 208000009292 Hemophilia A Diseases 0.000 description 4
- 101000672316 Homo sapiens Netrin receptor UNC5B Proteins 0.000 description 4
- 101000794194 Homo sapiens Tetraspanin-1 Proteins 0.000 description 4
- 206010020608 Hypercoagulation Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102100040604 Myotubularin-related protein 5 Human genes 0.000 description 4
- 108050003253 Myotubularin-related protein 5 Proteins 0.000 description 4
- 102100040289 Netrin receptor UNC5B Human genes 0.000 description 4
- 102100029514 Netrin receptor UNC5C Human genes 0.000 description 4
- 102000051614 SET domains Human genes 0.000 description 4
- 108700039010 SET domains Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 102000008847 Serpin Human genes 0.000 description 4
- 108050000761 Serpin Proteins 0.000 description 4
- 102000002938 Thrombospondin Human genes 0.000 description 4
- 108060008245 Thrombospondin Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003027 hypercoagulation Effects 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 108010042502 laminin A Proteins 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 4
- 230000000542 thalamic effect Effects 0.000 description 4
- 230000035924 thermogenesis Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 102000039356 unc-5 family Human genes 0.000 description 4
- 108091030276 unc-5 family Proteins 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- 206010004053 Bacterial toxaemia Diseases 0.000 description 3
- 101001062858 Bos taurus Fatty acid-binding protein 5 Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010049055 Cholestasis of pregnancy Diseases 0.000 description 3
- 208000012258 Diverticular disease Diseases 0.000 description 3
- 206010013554 Diverticulum Diseases 0.000 description 3
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 3
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 3
- 101710083187 Fatty acid-binding protein 5 Proteins 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 description 3
- 101000841744 Homo sapiens Netrin receptor UNC5C Proteins 0.000 description 3
- 101000888425 Homo sapiens Putative uncharacterized protein C11orf40 Proteins 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102100031900 Neogenin Human genes 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 206010066100 Polymorphic eruption of pregnancy Diseases 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 208000021974 Pruritic urticarial papules and plaques of pregnancy Diseases 0.000 description 3
- 102100039548 Putative uncharacterized protein C11orf40 Human genes 0.000 description 3
- 101100048278 Rattus norvegicus Ucp1 gene Proteins 0.000 description 3
- 102100039832 Ribonuclease pancreatic Human genes 0.000 description 3
- 101710123428 Ribonuclease pancreatic Proteins 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 102100036383 Serpin B3 Human genes 0.000 description 3
- 229930186949 TCA Natural products 0.000 description 3
- 108700031126 Tetraspanins Proteins 0.000 description 3
- 102000043977 Tetraspanins Human genes 0.000 description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 3
- 108010046075 Thymosin Proteins 0.000 description 3
- 102000007501 Thymosin Human genes 0.000 description 3
- 208000013222 Toxemia Diseases 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 3
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 3
- 230000003376 axonal effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 231100000359 cholestasis Toxicity 0.000 description 3
- 230000007870 cholestasis Effects 0.000 description 3
- 208000003908 cone-rod dystrophy 1 Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000018933 factor V and factor VIII, combined deficiency of, type 1 Diseases 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000126 in silico method Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003739 neck Anatomy 0.000 description 3
- 108010076969 neogenin Proteins 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000003594 spinal ganglia Anatomy 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 210000001587 telencephalon Anatomy 0.000 description 3
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 2
- RRZVGDGTWNQAPW-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-3-[2-(1-methylpyrazol-4-yl)ethyl]imidazol-4-yl]benzonitrile Chemical compound C1=NN(C)C=C1CCN1C(C=2C=CC(=CC=2)C#N)=C(C2=CN(C)N=C2)N=C1 RRZVGDGTWNQAPW-UHFFFAOYSA-N 0.000 description 2
- 108020005029 5' Flanking Region Proteins 0.000 description 2
- FBZFLXJHAMMUQM-UHFFFAOYSA-N 5-[(2-acetamidoethyl)amino]naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCNC(=O)C)=CC=CC2=C1S(O)(=O)=O FBZFLXJHAMMUQM-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102100026041 Acrosin Human genes 0.000 description 2
- 108090000107 Acrosin Proteins 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000283254 Balaenoptera acutorostrata Species 0.000 description 2
- 101000775871 Beet curly top virus (strain California/Logan) Protein V2 Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 206010010539 Congenital megacolon Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 2
- 102000010170 Death domains Human genes 0.000 description 2
- 108050001718 Death domains Proteins 0.000 description 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 102000004989 Hepsin Human genes 0.000 description 2
- 208000004592 Hirschsprung disease Diseases 0.000 description 2
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100398641 Homo sapiens LAMA5 gene Proteins 0.000 description 2
- 101001008527 Homo sapiens Laminin subunit alpha-5 Proteins 0.000 description 2
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 2
- 101000620458 Homo sapiens Leucine-rich repeat LGI family member 2 Proteins 0.000 description 2
- 101000939438 Homo sapiens Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 2
- 101001126471 Homo sapiens Plectin Proteins 0.000 description 2
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 description 2
- 101710083711 Leucine-rich alpha-2-glycoprotein Proteins 0.000 description 2
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 2
- 102100022270 Leucine-rich repeat LGI family member 2 Human genes 0.000 description 2
- 206010025282 Lymphoedema Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102000016647 Mitochondrial carrier proteins Human genes 0.000 description 2
- 108050006262 Mitochondrial carrier proteins Proteins 0.000 description 2
- 101100371846 Mus musculus Unc5c gene Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 241000282515 Papio hamadryas Species 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 208000019181 Pelizaeus-Merzbacher-like disease Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 102100034869 Plasma kallikrein Human genes 0.000 description 2
- 102100038411 Platelet glycoprotein V Human genes 0.000 description 2
- 108010054050 Plectin Proteins 0.000 description 2
- 102000056300 Plectins Human genes 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- -1 SEQ ID NOS:l Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101710187074 Serine proteinase inhibitor Proteins 0.000 description 2
- 102100030326 Serpin B4 Human genes 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 101150022052 UCP1 gene Proteins 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000005667 attractant Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 210000003239 corneal fibroblast Anatomy 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 102000044418 human PLEC Human genes 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 108010008094 laminin alpha 3 Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000002502 lymphedema Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 108010081726 netrin-2 Proteins 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 108010000416 ovomacroglobulin Proteins 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000000413 sensory ganglia Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZMERMCRYYFRELX-UHFFFAOYSA-N 5-{[2-(iodoacetamido)ethyl]amino}naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1NCCNC(=O)CI ZMERMCRYYFRELX-UHFFFAOYSA-N 0.000 description 1
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 101710187168 Alpha-2-macroglobulin Proteins 0.000 description 1
- 101710136034 Alpha-2-macroglobulin homolog Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 238000007809 Boyden Chamber assay Methods 0.000 description 1
- 101100182883 Caenorhabditis elegans aex-3 gene Proteins 0.000 description 1
- 101100334001 Caenorhabditis elegans rib-1 gene Proteins 0.000 description 1
- 101100048444 Caenorhabditis elegans unc-40 gene Proteins 0.000 description 1
- 101100371856 Caenorhabditis elegans unc-6 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 101710131551 Chymotrypsin-like serine proteinase Proteins 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000039963 DCC family Human genes 0.000 description 1
- 108091069213 DCC family Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 108700023507 Drosophila trx Proteins 0.000 description 1
- 101150058423 EGFLAM gene Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100037735 Fatty acid-binding protein 9 Human genes 0.000 description 1
- 101710083193 Fatty acid-binding protein 9 Proteins 0.000 description 1
- 108091067402 Fatty-acid binding protein (FABP) family Proteins 0.000 description 1
- 102000039826 Fatty-acid binding protein (FABP) family Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108700042658 GAP-43 Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 101800001783 Hematopoietic system regulatory peptide Proteins 0.000 description 1
- 102400000564 Hematopoietic system regulatory peptide Human genes 0.000 description 1
- 108090001101 Hepsin Proteins 0.000 description 1
- 101000781650 Heteractis magnifica PI-stichotoxin-Hmg3d Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000720330 Homo sapiens Acrosin Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001116514 Homo sapiens Myotubularin-related protein 13 Proteins 0.000 description 1
- 101100133201 Homo sapiens NTN3 gene Proteins 0.000 description 1
- 101000672311 Homo sapiens Netrin receptor UNC5A Proteins 0.000 description 1
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 1
- 101001033026 Homo sapiens Platelet glycoprotein V Proteins 0.000 description 1
- 101000872580 Homo sapiens Serine protease hepsin Proteins 0.000 description 1
- 101000700735 Homo sapiens Serine/arginine-rich splicing factor 7 Proteins 0.000 description 1
- 101000713575 Homo sapiens Tubulin beta-3 chain Proteins 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108091030087 Initiator element Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 101710146560 Leukocyte antigen CD37 Proteins 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 101710120476 Murinoglobulin-1 Proteins 0.000 description 1
- 101000980832 Mus musculus CD180 antigen Proteins 0.000 description 1
- 101100539369 Mus musculus Ucp1 gene Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 102000004128 Myotubularin Human genes 0.000 description 1
- 108090000697 Myotubularin Proteins 0.000 description 1
- 102100024960 Myotubularin-related protein 13 Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102100040288 Netrin receptor UNC5A Human genes 0.000 description 1
- 102100022159 Neurogranin Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001495084 Phylo Species 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 101710195077 Platelet glycoprotein V Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 1
- 101150098638 RNASE1 gene Proteins 0.000 description 1
- 101001016386 Rattus norvegicus Endothelial differentiation-related factor 1 Proteins 0.000 description 1
- 101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100029287 Serine/arginine-rich splicing factor 7 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241001446311 Streptomyces coelicolor A3(2) Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 101710145873 Thymosin beta Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100036790 Tubulin beta-3 chain Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 101150065336 Unc5c gene Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000034525 diet induced thermogenesis Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000008622 extracellular signaling Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 208000008487 fibromuscular dysplasia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 208000027833 hibernoma Diseases 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047031 human FABP5 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000002425 internal capsule Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000029774 keratinocyte migration Effects 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 108010008097 laminin alpha 2 Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007905 lung morphogenesis Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 102000040180 neuromodulin family Human genes 0.000 description 1
- 108091074180 neuromodulin family Proteins 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 108010009099 nucleoside phosphorylase Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000005853 oncogenic activation Effects 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 108010025221 plasma protein Z Proteins 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108700021680 recombinant acrylodated intestinal fatty acid binding Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000025488 response to cold Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000005850 skin morphogenesis Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000003461 thalamocortical effect Effects 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 102000043154 thymosin beta family Human genes 0.000 description 1
- 108091084367 thymosin beta family Proteins 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5759—Thymosin or related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
Definitions
- the invention generally relates to nucleic acids and polypeptides encoded thereby.
- the invention generally relates to nucleic acids and polypeptides encoded therefrom. More specifically, the invention relates to nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.
- the invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides.
- novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9, NOV10, NOV11, NOV12, NOV13, and NOV14 nucleic acids and polypeptides.
- NOVX nucleic acid or polypeptide sequences.
- the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
- the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence.
- the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.
- the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198.
- the nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
- an oligonucleotide e.g., an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (e.g., SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197) or a complement of said oligonucleotide.
- a NOVX nucleic acid e.g., SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197
- substantially purified NOVX polypeptides SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 19
- the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.
- the invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.
- the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically- acceptable carrier.
- the therapeutic can be, e.g., a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide.
- the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.
- the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.
- the invention includes a method of detecting the presence of a NOVX polypeptide in a sample.
- a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound.
- the complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.
- the invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.
- Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.
- the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide.
- the compound can be, e.g., a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.
- a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Von Hippel- Lindau (VHL) syndrome, tuberous sclerosis, hypercalceimia, Lesch-Nyhan syndrome, multiple sclerosis, Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Retinol binding protein, deficiency of; SEMD, Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; myasthenia gravis, endometriosis, pancreatitis, hyperparathyroidism, hypoparathyroidism, xerostomia, actinic keratosis, acne, hair growth/loss, allopecia, pigmentation disorders, endocrine disorders, tonsillitis, cystitis, in
- the therapeutic can be, e.g. , a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.
- compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
- the polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds.
- a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof.
- the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
- the invention further includes a method for screening for a modulator of disorders or syndromes including, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
- the method includes contacting a test compound with a NOVX polypeptide and dete ⁇ mning if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.
- Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes.
- the test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly- expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome.
- the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (e.g., a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample.
- an alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject.
- the predisposition includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
- the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.
- the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (e.g. , a human subject), in an amount sufficient to alleviate or prevent the pathological condition.
- the disorder includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
- the invention can be used in a method to identity the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are inco ⁇ orated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control, i addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description and claims.
- the present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table A provides a svrmmary of the NOVX nucleic acids and their encoded polypeptides.
- NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts.
- the various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.
- NOV1 is homologous to a Human laminin alpha 5-like family of proteins.
- VHL Von Hippel-Lindau
- the NOV1 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch- Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuro
- NOV2 is homologous to the Human Hu ⁇ in/PI 13-like family of proteins.
- NOV2 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in Colorectal cancer; Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; Leukemia/lymphoma, B-cell, 2; Lymphoma/leukemia, B-cell, variant; Protoporphyria, erythropoietic; Protoporphyria, erythropoietic, recessive, with liver failure; Obesity, autosomal dominant; Osteosarcoma; cancer, skin psoriasis, and/or other pathologies and disorders.
- NOV3 is homologous to a family of Set Binding Factor (SBFl)-like proteins.
- VHL Von Hippel-Lindau
- the NOV3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch- Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-
- NOV4 is homologous to the TSPAN-1-like family of proteins.
- NOV4 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: adrenoleukodystrophy, congenital adrenal hyperplasia, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, asthma, immunodeficiencies, transplantation, graft versus host disease, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, arthritis, tendonitis, fertility, atherosclerosis, aneurysm, hypertension, fibromuscular dysp
- NOV5 is homologous to the Fatty Acid-Binding Protein, Epidermal-like family of proteins.
- NOV5 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, fatty acid transport of skin, oral mucosa, and/or other disorders and conditions.
- NOV6 is homologous to the Uncoupling Protein 1 -like family of proteins.
- NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: obesity, hype ⁇ hagia, and/or other pathologies/disorders.
- NOV7 is homologous to members of the Leucine-Rich Glioma-Inactivated Protein-like family of proteins.
- the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; uveitis and corneal fibroblast proliferation, allergic encephalomyelitis, amyotrophic lateral sclerosis, acute pancreatitis, cerebral cryptococcosis, autoimmune disease including Type 1 diabetes mellitus (DM), experimental allergic encephalomyelitis (EAE), systemic lupus erythematosus (SLE), colitis, thyroiditis and various forms of arthritis, cancer such as AML, bacterial infections, and/or other pathologies/disorders.
- DM Type 1 diabetes mellitus
- EAE experimental allergic encephalomyelitis
- SLE systemic lupus erythematosus
- colitis thyroiditis and various forms of arthritis,
- NOV8 is homologous to the RNase-like family of proteins.
- NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; DiabetesNon Hippel- Lindau (VHL) syndrome , Pancreatitis,Obesity, Hyperthyroidism and Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other pathologies/disorders.
- VHL DiabetesNon Hippel- Lindau
- Pancreatitis,Obesity Hyperthyroidism
- Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other pathologies/disorders.
- ⁇ OV9 is homologous to the Insulin like growth factor binding protein-like family of proteins.
- NOV9 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in diabetes, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, cirrhosis, transplantation, hemophilia, hypercoagulation, idiopathic thrombocytopenic pu ⁇ ura, autoimmume disease, allergies, immunodeficiencies, graft versus host disease (GVHD), lymphaedema, and/or other pathologies or disorders.
- VHL Von Hippel-Lindau
- NOV10 is homologous to the Pregnancy Zone Protein Precursor -like family of proteins.
- NOV10 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in pregnancy, hypertensive toxemia, pre- eclampsia/eclampsia (gestational proteinuric hypertension), glomerular endotheliosis, cholestasis, and pruritic urticarial papules and plaques of pregnancy, and/or other pathologies or disorders.
- NOVl 1 is homologous to the Transmembrane Receptor UNC5H2-like family of proteins. Thus, NOVl 1 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in various pathologies or disorders.
- NOV12 is homologous to the Thymosin-like family of proteins.
- NOV12 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; osteoporosis, osteoarthritis, cardiac hypertrophy, atherosclerosis, hypertension, restenosis, and or other pathologies/disorders .
- NOV13 is homologous to the Neirromodulin-like family of proteins.
- NOV13 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in various pathologies/disorders.
- NOV14 is homologous to the Prostatin Precursor-like family of proteins.
- NOVl 4 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in
- Atherosclerosis Hypertension, Congenital heart defects, Aortic stenosis ,Atrial septal defect (ASD),Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases,Tuberous sclerosis, Scleroderma, Obesity,Transplantation, and/or other pathologies/disorders.
- the NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function.
- nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis. Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.
- NOVl includes three novel human laminin alpha 5-like proteins disclosed below. The disclosed sequences have been named NOVla, NOVlb, and NOVlc. NOVla
- a disclosed NOVla nucleic acid of 10809 nucleotides (also referred to as CG55974- 01) encoding a human laminin alpha 5-like protein is shown in Table 1 A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 10801-10803.
- a putative untranslated region downstream from the termination codon is underlined in Table 1A. The start and stop codons are in bold letters.
- Table 1A NOVla nucleotide sequence (SEQ ID NO:l).
- the NOVla nucleic acid sequence, located on chromsome 20 is 80% identical to a gb:GENBANK-ID:MMU37501
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- the "E- value” or “Expect” value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched.
- the probability that the subject (“Sbjct”) retrieved from the NOVl BLAST analysis, e.g., Mus musculus laminin alpha 5 chain (Lama5) mRNA, matched the Query NOVl sequence purely by chance is 0.0.
- the Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.
- the Expect value is used as a convenient way to create a significance threshold for reporting results.
- the default value used for blasting is typically set to 0.0001.
- the Expect value is also used instead of the P value (probability) to report the significance of matches.
- P value probability
- an E value of one assigned to a hit can be inte ⁇ reted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance.
- An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g., http://www.ncbi.nlm.mh.gov/Education/BLASTinfo/.
- NOVla polypeptide (SEQ ID NO:2) encoded by SEQ ID NO:l has 3600 amino acid residues and is presented in Table IB using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOVla has a signal peptide and is likely to be localized extracelhilarly with a certainty of 0.8200.
- NOVla may also be localized to the lysosome (lumen) with acertamty of 0.1900, the endoplasmic reticulum (membrane) with a certainty of 0.1000 or in the endoplasmic reticulum (lumen) with a certainty of 0.1000.
- the most likely cleavage site for a NOVla peptide is between amino acids 14 and 15, at: CVR-GP.
- Table IB Encoded NOVla protein sequence (SEQ ID NO:2).
- Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
- NOVla is expressed in at least the following tissues: brain, Prostate, ovary, kidney, melanocyte+heart+uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung+testis+b-cell, dorsal root ganglia. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
- NOVlb nucleic acid of 3126 nucleotides also referred to as CGI 02167- 01
- Table IC An open reading frame was identified beginning with an ATG initiation codon at nucleotides 121-123 and ending with a TGA termination codon at nucleotides 2845-2847. The start and stop codons are in bold letters in Table IC, and the 5' and 3' untranslated regions are underlined. Table IC. NOVlb nucleotide sequence (SEQ ID NO:3).
- the NOVlb nucleic acid sequence, located on chromsome 20 has 2495 of 2495 bases (100%) identical to a gb:GENBANK- ID:HSLAMA5
- acc:Z95636.1 mRNA from Homo sapiens (H.sapiens mRNA for laminin alpha 5 chain) (E 0.0).
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- NOVlb polypeptide encoded by SEQ ID NO:3 has 908 amino acid residues and is presented in Table IB using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOVlb has no signal peptide and is likely to be locahzed the microbody (peroxisome) with a certainty of 0.5371.
- NOVlb may also be localized to the lysosome (lumen) with acertainty of 0.3191, the mitochondrial matrix space with a certainty of 0.1000 or in the nucleus with a certainty of 0.1000.
- Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
- NOVlb is expressed in at least the following tissues: brain, Prostate, ovary, kidney, melanocyte, heart, uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung, testis, b-cell, dorsal root ganglia.
- Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CGI 02167-01.
- the sequence is predicted to be expressed in placenta because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSLAMA5
- NOVlc nucleic acid of 10800 nucleotides also referred to as CG55974- 02 encoding a novel human laminin alpha 5-like protein is shown in Table IE.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA termination codon at nucleotides 10792-10794.
- the start and stop codons are in bold letters in Table IE, and the 5' and 3' untranslated regions are underlined. Since the start codon of NOVlc is not a traditional initiation codon, and NOVlc has no termination codon, NOVlc could be a partial open reading frame that could be extended in the 5' and/or 3' direction(s).
- Table IE NOVlc nucleotide sequence (SEQ ID NO:5).
- the NOVlc nucleic acid sequence, located on chromsome 20 has 3800 of 4840 bases (78%) identical to a gb:GENBANE - ID:MMU37501
- acc:U37501.1 mRNA from Mus musculus (Mus musculus laminin alpha 5 chain (Lama5) mRNA, partial eds) (E 0.0).
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- NOVlc polypeptide (SEQ ID NO:6) encoded by SEQ ID NO:5 has 3597 amino acid residues and is presented in Table IF using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOVlc has a signal peptide and is likely to be localized the mitochondrial matrix space with a certainty of 0.4318.
- NOVlc may also be localized to the microbody (peroxisome) with acertamty of 0.3000, the lysosome (lumen) with a certainty of 0.2055 or in the mitochondrial inner membrane with a certainty of 0.1122.
- the most likely cleavage site for NOVlc is between positions 14 and 15: CVR-GP
- NOVlc is expressed in at least the following tissues: Mammalian Tissue, Small Intestine, Bone Marrow, brain, Prostate, ovary, kidney, melanocyte, heart, uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung, testis, b-cell, dorsal root ganglia. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55974-02.
- NOVld nucleic acid of 5204 nucleotides also referred to as 164875783 encoding a novel Human laminin alpha 5-like protein is shown in Table 1 G.
- An open reading frame was identified beginning with an TGT codon at nucleotides 3-5 and ending with a TAG codon at nucleotides 4923-4925.
- the start and stop codons are in bold letters and the 5' and 3' untranslated regions are underlined in Table IG. Because the start codon is not a traditional initiation codon, NOVld could be a partial reading frame. NOVld could extend further in the 5' direction.
- Table IG NOVld nucleotide sequence (SEQ ID NO:7).
- the NOVld nucleic acid sequence, located on chromsome 20 has 4573 of 4573 bases (100%) identical to a gb:GENBANK- ID: ABOl 1105
- acc: AB011105.1 mRNA from Homo sapiens (Homo sapiens mRNA for KIAA0533 protein, partial eds) (E 0.0).
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- NOVld polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 has 1640 amino acid residues and is presented in Table 1H using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOVld has no signal peptide and is likely to be localized the cytoplasm with a certainty of 0.5050.
- NOVlb may also be localized to the microbody (peroxisome) with acertainty of 0.3000, the lysosome (lumen) with a certainty of 0.2741 or in the mitochondrial matrix space with a certainty of 0.1000.
- Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
- NOVl Homologies to any of the above NOVl proteins will be shared by the other NOVl proteins insofar as they are homologous to each other as shown below. Any reference to NOVl is assumed to refer to all four of the NOVl proteins in general, unless otherwise noted.
- the disclosed NOVla polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table II.
- DOMAIN results for NOVl as disclosed in Tables 1K-1L were collected from the conserveed Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Table IK and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (
- the "strong" group of conserved amino acid residues maybe any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MTLF, HY, FYW.
- Tables 1K-S list the domain descriptions from DOMAIN analysis results against NOVla. This indicates that the NOVla sequence has properties similar to those of other proteins known to contain this domain. Below are representative domain results. There are additional areas on NOVla that also have homology to these Domains.
- Table IK Domain Analysis of NOVla gnl I Smart I smart00136, LamNT, Laminin N-terminal domain (domain VI); N- terminal domain of laminins and laminin-related protein such as Unc-6/ netrins. (SEQ ID NO: 52)
- CD-Length 239 residues, 96.7% aligned
- CD-Length 135 residues, 100.0% aligned
- This family is like pfam00008 but has 8 conserved cysteines instead of
- CD-Length 49 residues, 100.0% aligned
- Table 1R Domain Analysis of NOVla gnl I Pfam
- the myosm molecule is a multi- subunit complex made up of two heavy chains and four light chains it is a fundamental contractile protein found m all eukaryote cell types.
- This family consists of the coiled-coil myosm heavy chain tail region.
- the coiled-coil is composed of the tail from two molecules of myosm These can then assemble into the macromolecular thick filament
- the coiled-coil region provides the structural backbone the thick filament.
- Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth, migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consist of a coiled coil structure contributed by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module.
- Miner et al (1) identified a fifth member of the alpha subfamily of vertebrate laminin chains. Consistent with the trimeric structure of laminin, all basal laminae characterized to that time contained at least 1 beta and at least 1 gamma chain. For the alpha chains, on the other hand, the situation was less clear. Using PCR, Miner et al. identified a novel murine alpha chain called alpha-5.
- novel sequence described here is a human homolog of mouse laminin alpha 5.
- laminin laminin al ⁇ ha5 plays role in the development of the human lung and skin morphogenesis.
- temporal and spatial expression of these chains during proliferative and differentiation stages, possibly reflecting different functions (4).
- the disclosed NOVl nucleic acid of the invention encoding a Human laminin alpha 5 - like protein includes the nucleic acid whose sequence is provided in Table 1A ,1C, IE, IG, or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases maybe changed from the corresponding base shown in Table 1A, IC, IE, or IG while still encoding a protein that maintains its Human laminin alpha 5-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.
- the mutant or variant nucleic acids, and their complements up to about 31% percent of the bases maybe so changed.
- the disclosed NOVl protein of the invention includes the Human laminin alpha 5-like protein whose sequence is provided in Table IB, ID, IF, or 1H.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table IB, ID, IF, or 1H while still encoding a protein that maintains its Human laminin alpha 5-like activities and physiological functions, or a functional fragment thereof.
- a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table IB, ID, IF, or 1H while still encoding a protein that maintains its Human laminin alpha 5-like activities and physiological functions, or a functional fragment thereof.
- up to about 54% percent of the residues may be so changed.
- the invention further encompasses antibodies and antibody fragments, such as F a b or (F ab )2, that bind immunospecifically to any of the proteins of the invention.
- NOVl Human laminin alpha 5-like protein
- the above defined information for this invention suggests that this Human laminin alpha 5-like protein (NOVl) may function as a member of a "Human laminin alpha 5 family". Therefore, the NOVl nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below.
- the potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
- NOVl nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in cancer including but not limited to various pathologies and disorders as indicated below.
- a cDNA encoding the Human laminin alpha 5- like protein (NOVl) may be useful in gene therapy, and the Human laminin alpha 5 -like protein (NOVl) may be useful when administered to a subject in need thereof.
- compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, TMel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of;
- VHL Von Hippel-Lindau
- SEMD Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, neuroprotection, fertility, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonepliritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, ulcers, systemic
- NOVl nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVl substances for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOVl proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- NOV2 includes three novel Human Hurpin/PI 13-like proteins disclosed below. The disclosed sequences have been named NOV2a, NOV2b, and NOV2c. NOV2a
- a disclosed NOV2a nucleic acid of 3105 nucleotides (also referred to as CG55999-01) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 38-40 and ending with a TAA codon at nucleotides 1238-1240.
- a The start and stop codons are in bold letters in Table 2A.
- Table 2A NOV2a nucleotide sequence (SEQ ID NO:9).
- the disclosed NOV2a nucleic acid sequence, localized to the q21.3-22 region of chromsome 18, has 2854 of 2866 bases (99%) identical to a gb:GENBANK- BD:HSPI1371 l
- acc:AJ001696.2 mRNA from Homo sapiens (Homo sapiens mRNA for hurpin, clone R7-1.1) (E 0.0).
- a NOV2a polypeptide (SEQ ID NO: 10) encoded by SEQ ID NO:9 has 400 amino acid residues and is presented using the one-letter code in Table 2B.
- Signal P, Psort and/or Hydropathy results predict that NOV2a contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900.
- NOV2a may also be localized to the microbody (peroxisome) with a certainty of 0.7106, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000.
- the most likely cleavage site for NOV2a is between positions 50 and 51 : ATA-SQ.
- Table 2B Encoded NOV2a protein sequence (SEQ ID NO:10).
- NOV2a is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, and/or RACE sources.
- sequence is predicted to be expressed in keratinocytes because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSPI13711
- the target sequence identified previously, NOV2a was subjected to the exon linking process to confirm the sequence.
- PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached.
- Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species.
- primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- resulting amplicons were gel purified, cloned and sequenced to high redundancy.
- the resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp.
- sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported below, which is designated NOV2b. This differs from the previously identified sequence (NOV2a) in having 2 different aminoacids.
- a disclosed NOV2b nucleic acid of 1238 nucleotides (also referred to as CG55999-02) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2C.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 24-26 and ending with a TAA codon at nucleotides 1224-1226.
- a The start and stop codons are in bold letters in Table 2C and the 5' and 3' untranslated regions are underlined.
- acc:AFl 69949.1 mRNA from Homo sapiens (Homo sapiens headpin mRNA, complete eds) (E 1.4e "215 ).
- a NOV2b polypeptide (SEQ ID NO: 12) encoded by SEQ LD NO:l 1 has 400 amino acid residues and is presented using the one-letter code in Table 2D.
- NOV2b contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900.
- NOV2b may also be localized to the microbody (peroxisome) with a certainty of 0.7147, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000.
- the most likely cleavage site for NOV2b is between positions 50 and 51 : ATA-SQ.
- Table 2D Encoded NOV2b protein sequence (SEQ ID NO:12).
- NOV2b is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus, Buccal mucosa, Cervix, Coronary Artery, Skin, Vulva. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55999-02.
- the sequence is predicted to be expressed in keratinocytes because of the expression pattern of (GENBANK-ID: gb:GENBANK-LO:AF169949
- NOV2c nucleic acid of 1559 nucleotides also referred to as CG55999-05
- Table 2E An open reading frame was identified beginning with an ATG initiation codon at nucleotides 353-355 and ending with a TAA codon at nucleotides 1553-1555. A The start and stop codons are in bold letters in Table 2E and the 5' and 3' untranslated regions are underlined.
- Table 2E NOV2c nucleotide sequence (SEQ ID NO:13).
- the disclosed NOV2c nucleic acid sequence localized to the q21.3-22 region of chromsome 18, has 519 of 519 bases (100%) identical to a gb:GENBANK- ID:AF216854
- acc:AF216854.1 mRNA from. Homo sapiens (Homo sapiens headpin gene, complete eds) (E 2.3e "303 ).
- a NOV2c polypeptide (SEQ ID NO: 14) encoded by SEQ ID NO:13 has 400 amino acid residues and is presented using the one-letter code in Table 2F.
- Signal P, Psort and/or Hydropathy results predict that NOV2c contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900.
- NOV2c may also be localized to the microbody (peroxisome) with a certainty of 0.7024, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000.
- the most likely cleavage site for NOV2c is between positions 50 and 51 : ATA-SQ.
- Table 2F Encoded NOV2c protein sequence (SEQ ID NO:14).
- a disclosed NOV2d nucleic acid of 818 nucleotides (also referred to as CG55999-06) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2G.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 40-42 and ending with a TAA codon at nucleotides 565-567.
- a The start and stop codons are in bold letters in Table 2G and the 5' and 3' untranslated regions are underlined.
- the disclosed NOV2d nucleic acid sequence localized to the q21.3-22 region of chromsome 18, has 214 of 214 bases (100%) identical to a gb:GENBANK- ID:AF216854
- acc:AF216854.1 mRNA from Homo sapiens (Homo sapiens headpin gene, complete eds) (E 1.3e "134 ).
- ANOV2d polypeptide (SEQ ID NO: 16) encoded by SEQ ID NO: 15 has 175 amino acid residues and is presented using the one-letter code in Table 2H.
- Signal P, Psort and/or Hydropathy results predict that NOV2d contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900.
- NOV2d may also be localized to the microbody (peroxisome) with a certainty of 0.3878, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000.
- the most likely cleavage site for NOV2d is between positions 50 and 51 : ATA-SQ.
- NOV2d is expressed in at least the following tissues: Mammalian Tissue, Coronary Artery, Buccal mucosa, Pituitary Gland, Cervix, Uterus, Vulva, Skin. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55999-06.
- NOV2e nucleic acid of 1062 nucleotides also referred to as 166485357 encoding a novel Human Hurpin PI 13-like protein is shown in Table 21.
- An open reading frame was identified beginning with an GGA initiation codon at nucleotides 1-3 and ending with a GAG codon at nucleotides 1060-1062.
- the start and stop codons are in bold letters in Table 21. Since the start and stop codons are not traditional initiation and termination codons, NOV2e may be a partial reading frame that extends further in the 5' and 3' directions.
- Table 21 NOV2e nucleotide sequence (SEQ ID NO: 197).
- a NOV2e polypeptide (SEQ ID NO:14) encoded by SEQ ID NO:13 has 354 amino acid residues and is presented using the one-letter code in Table 2J.
- NOV2a 300 NOV2b ILGIPYK NDLSMFVLLPNDIDGLEKIIDKISPE LVEWTSPGHMEERKVWLHLPRFEVi 3 00 NOV2c I GIPYKNNDLSMFVL PNDIDGLEKIIDKISPEK VE TSPGHMEERKVNLHLPRFEVI 300 NOV2d 175 NOV2e GIPYKNNDLSMFVLLPNDIDGLEKIIDKISPEK VEWTSPGHMEERKVNLHLPRFEV 252 gi 8393956 ref ILGIPYKNNDLSMFV PNDIDG E IIDKISPEKLVEWTSPGHMEERKVN HLPRFEV; 291 gi 6018510 emb 290 g 7522623 pir 291 gi 9801227 emb A'M ⁇ -MI ⁇ I ⁇ iAM ⁇ i' ⁇ wmitmansnLVB 239 gi 266995 ' sp
- CD-Length 377 residues, 98.4% aligned
- CD-Length 360 residues, 100.0% aligned
- Proteolysis is the key feature of programmed cell death. Extracellular proteinases can activate cell surface receptors which trigger apoptosis, and the effector machinery requires the activation and activity of numerous intracellular proteinases (primarily caspases). Effective control of proteolysis is essential for homeostasis and can occur at two levels: regulation of proteinase activation, and regulation of the activated proteinase.
- the serpins a family of proteins that inhibit chymotrypsin-like serine proteinases, control activated proteinases and several have been imphcated in the regulation of cell death.
- Hurpin is a novel serine proteinase inhibitor recently cloned by Abts HF et al. (1999, J. Mol. Biol, Vol.
- SCCA1 squamous cell carinoma antigenl
- SCCA2 squamous cell carcinoma antigen 2
- the disclosed NOV2 nucleic acid of the invention encoding a Human Hurpin/Pi 13- like protein includes the nucleic acid whose sequence is provided in Tables 2 A, 2C, 2E, 2G or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Tables 2A, 2C, 2E, or, 2G while still encoding a protein that maintains its Human Hurpin/Pi 13 -like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject, hi the mutant or variant nucleic acids, and their complements, up to about 3 percent of the bases may be so changed.
- the disclosed NOV2 protein of the invention includes the Human Hurpin/PI 13 -like protein whose sequence is provided in Tables 2B, 2D, 2F, or 2H.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2B, 2D, 2F, or 2H while still encoding a protein that maintains its Human Hurpin/PI 13-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 48 percent of the residues may be so changed.
- NOV2 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in Colorectal cancer; Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; Leukemia/lymphoma, B-cell, 2; Lymphomaleukemia, B-cell, variant; Protoporphyria, erythropoietic; Protoporphyria, erythropoietic, recessive, with liver failure; Obesity, autosomal dominant; Osteosarcoma; cancer, skin psoriasis, and/or other pathologies and disorders.
- NOV2 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV2 protein has multiple hydrophilic regions, each of which can be used as an immunogen.
- These novel proteins can be used in assay systems for functional analysis of various human disorders, which are useful in understanding of pathology of the disease and development of new drug targets for various disorders.
- NOV3 includes three novel Set Binding Factor (SBFl)-like proteins disclosed below. The disclosed sequences have been named NOV3a and NOV3b.
- SBFl Set Binding Factor
- NOV3a nucleic acid of 5316 nucleotides also referred to as CG56019-01
- SBFl Set Binding Factor
- the disclosed NOV3a nucleic acid sequence maps to the ql3.3 region of chromosome 22 and has 3553 of 3902 bases (91%) identical to a gb:GENBANK- 1D:HSU9318 l]acc:U93181.1 mRNA from.
- a disclosed NOV3a protein (SEQ ID NO:18) encoded by SEQ LO NO:17 has 1723 amino acid residues, and is presented using the one-letter code in Table 3B.
- Signal P, Psort and or Hydropathy results predict that NOV3a does have a signal peptide, and is likely to be localized to the mitochondrial membrane space with a certainty of 0.5000.
- NOV3a is also likely to be localized to the microbody (peroxisome) with a certainty of 0.3000, to mitochondrial imier membrane with a certainty of 0.2187, or to the mitochondrial intermembrane space with a certainty of 0.2187.
- the most likely cleavage site for NOV3a is between positions 33 and 34, (SFT-YV).
- Table 3B Encoded NOV3a protein sequence (SEQ ID NO: 18).
- IRHEVFLSRSYQRLADACRGLLALLFPLRYSFTYVPILPAQLLEVLSTPTPFIIGVNAAFQAETQELLDVI VA ⁇ LDGGTVTIPECVHIPPLPEPLQSQTHSVLSMVLDPELELADLAFPPPTTSTS ⁇ LKMQDKELRAVFLRL FAQLLQGYR CLHWRIHPEPVIRFHKAAFLGQRGLVEDDFLMKVLEGMAFAGFVSERGVPYRPTDLFDEL VAHEVARMRADENHPQRVLRHVQELAEQLYKNENPYPAVAMHKVQRPGESSHLRRVPRPFPRLDEGTVQWI VDQAAAKMQGAPPAVKAERRTTVPSGPPMTAILERCSGLHVKSARRLEWRNCISYVFEGKMLEAKKLLPA VLRALKGRVARRCLAQELHLHVQQNRAVLDHQQFDFWRMMNCCLQDCTSLDEHGIAAALLPLVTAFCRKL SPGVTQFAYSCVQEHW
- NOV3 is expressed in at least the following tissues: Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, and or RACE sources.
- NOV3b hi the present invention the target sequence identified previously, NOV3a, was subjected to the exon linking process to confirm the sequence.
- PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached.
- Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species.
- primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- a disclosed NOV3b nucleic acid of 5740 nucleotides (also referred to as Curagen Accession No. CG56019-02) encoding a novel Set Binding Factor 1 -like protein is shown in Table 3C.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 396-398 and ending with a TGA codon at nucleotides 2439-2441.
- a putative untranslated region downstream from the termination codon are underlined in Table 3C. The start and stop codons are in bold letters.
- the NOV3b nucleic acid sequence, located on chromosome 11, has 4947 of 4963 bases (99%) identical to a gb:GENBANK- ID:HSU93181
- acc:U93181.1 mRNA from Homo sapiens (Homo sapiens nuclear dual-specificity phosphatase (SBFl) mRNA, partial eds) (E 0.0).
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- NOV3b polypeptide encoded by SEQ ID NO: 19 has 1681 amino acid residues and is presented in Table 3B using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOV3b has a signal peptide and is likely to be localized to the Golgi body with a certainty of 0.9000.
- NOV3b may also be localized to the plasma membrane with a certainty of 0.7900, in the microbody (peroxisome) with a certainty of 0.3525, or in the endoplasmic reticulum (membrane) with a certainty of 0.2000.
- the most likely cleavage site for NOV3b is between positions 46 and 47, ALT-EH. Table 3D.
- Encoded NOV3b protein sequence SEQ ID NO:20).
- Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
- NOV3b is expressed in at least the following tissues: Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, maimnary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- tissues Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart,
- Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG56019-02. The sequence is predicted to be expressed with a similar pattern to (GENBANK-ID: gb:GENBANK- ID :HSU93181
- SBFl Homo sapiens nuclear dual-specificity phosphatase
- NOV3a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 3E.
- XLA X-linked agammaglobulmaemia
- Sbfl shares extensive sequence similarity with myotubularm, a dual specificity phosphatase (dsPTPase) that is mutated in a subset of patients with inherited myopathies.
- dsPTPase dual specificity phosphatase
- Both Sbfl and myotubularin interact with the SET domains of Hrx and other epigenetic regulatory proteins, but Sbfl lacks phosphatase activity due to several evolutionarily conserved amino acid changes in its structurally preserved catalytic pocket.
- Sbfl has shown to prevent myoblast differentiation in vitro and induce oncogenic changes in NTH 3T3 fibroblasts.
- the disclosed NOV3 nucleic acid of the invention encoding a Set Binding Factor (SBFl)-like protein includes the nucleic acid whose sequence is provided in Table 3A, 3C, or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 3A, or 3C while still encoding a protein that maintains its Set Binding Factor (SBFl)-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject, hi the mutant or variant nucleic acids, and their complements, up to about 9 percent of the bases may be so changed.
- the disclosed NOV3 protein of the invention includes the Set Binding Factor (SBF1)- like protein whose sequence is provided in Table 3B, or 3D.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 3B, or 3D while still encoding a protein that maintains its Set Binding Factor (SBFl)-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 63 percent of the residues maybe so changed.
- SBFl Set Binding Factor
- NOV3 Set Binding Factor (SBFl)-like protein and nucleic acid (NOV3) disclosed herein suggest that NOV3 may have important structural and/or physiological functions characteristic of the citron kinase-like family. Therefore, the NOV3 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications.
- SBFl Set Binding Factor
- NOV3 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications.
- nucleic acid or protein diagnostic and/or prognostic marker serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.
- compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer;
- VHL Von Hippel-Lindau
- NOV3 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV3 protein have multiple hydrophilic regions, each of which can be used as an immunogen.
- This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- a disclosed NOV4 nucleic acid of 762 nucleotides (designated CuraGen Ace. No. CG55692-01) encoding a novel TSPAN-1-like protein is shown in Table 4A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 9-11 and ending with a TAA codon at nucleotides 732-734.
- a putative untranslated region downstream from the termination codon is underlined in Table 4A, and the start and stop codons are in bold letters.
- the nucleic acid sequence, localized to chromosome 12, has 616 of 765 bases (80%) identical to a gb:GENBANK-ID:AF065388
- acc:AF065388.1 mRNA from Homo sapiens (Homo sapiens tetraspan NET-1 mRNA, complete eds) (E 1.8e " ).
- a NOV4 polypeptide (SEQ ID NO:22) encoded by SEQ ID NO:21 is 241 amino acid residues and is presented using the one letter code in Table 4B.
- Signal P, Psort and/or Hydropathy results predict that NOV4 has no signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6400.
- NOV4 may also be localized to the Golgi body with a certainty of 0.4600, the endoplasmic reticulum (membrane) with a certainty of 0.3700, or the endoplasmic reticulum (lumen) with a certainty of 0.1000.
- the most likely cleavage site for NOV4 is between positions 36 and 37: VDG-TS.
- NOV4 is expressed in at least Colon, Testis, prostate, melanocyte, heart, uterus, kidney, stomach because of the expression pattern of (GENBANK- ID:AF065388
- NOV4 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 4C.
- Table 4E lists the domain description from DOMAIN analysis results against N0V4. This indicates that the N0V4 sequence has properties similar to those of other proteins known to contain this domain.
- CD-Length 222 residues, 100.0% aligned
- TM4SF transmembrane 4 superfamily'
- TM4SF proteins form complexes with integrins and other cell-surface proteins.
- a number of eukaryotic cell surface antigens have been shown to be related, including mammalian leukocyte antigen CD37, mammalian lysosomal membrane protein CD63, human tumour-associated antigen CD-029, and several others.
- These proteins are all type II membrane proteins: they contain an N-terminal transmembrane (TM) domain, which acts both as a signal sequence and a membrane anchor, and 3 additional TM regions (hence the name 'TM4'). The sequences contain a number of conserved cysteine residues.
- the disclosed NOV4 nucleic acid of the invention encodmg a TSPAN-1 -like protein includes the nucleic acid whose sequence is provided in Table 4A or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 4A while still encodmg a protein that maintains its TSPAN-1 -like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 20 percent of the bases may be so changed.
- the disclosed NOV4 protein of the invention includes the TSPAN-1 -like protein whose sequence is provided in Table 4B.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 4B while still encoding a protein that maintains its TSPAN-1 -like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 69 percent of the residues may be so changed.
- NOV4 protein similarity information, expression pattern, and map location for the TSPAN-1 -like protein and nucleic acid (NOV4) disclosed herein suggest that this NOV4 protein may have important structural and/or physiological functions characteristic of the TSPAN-1 family. Therefore, the NOV4 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications.
- nucleic acid or protein diagnostic and or prognostic marker serving as a specific or selective nucleic acid or protein diagnostic and or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.
- compositions of the present invention will have efficacy for treatment of patients suffering from Hypercalceimia, Ulcers, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease , Crohn's Disease, Appendicitis, Fertility, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomeralonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy,
- Hypercalceimia Lesch-Nyhan syndrome, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD),Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, and/or other pathologies.
- the NOV4 nucleic acids, or fragments thereof may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
- NOV4 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies” section below.
- These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- a disclosed NOV5 nucleic acid of 469 nucleotides (also referred to as CG56073-01) encoding a novel Fatty Acid-Binding Protein, Epidermal-like protein is shown in Table 5A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 148-150 and ending with a TGA codon at nucleotides 395-397. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5 A, and the start and stop codons are in bold letters.
- the NOV5 nucleic acid was identified on chromosome 2 and has 313 of 411 bases (76%) identical to a gb:GENBANK-ID:AF059507
- acc:AF059507.1 mRNA from Bos taurus (Bos taurus epidermal fatty acid-binding protein (E-FABP) mRNA, complete eds) (E 4.5e "
- a disclosed NOV5 polypeptide (SEQ ID NO:24) encoded by SEQ ID NO:23 is 145 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and or Hydropathy results predict that NOV5 has no signal peptide and is likely to be localized in the nucleus with a certainty of 0.9775. In other embodiments, NOV5 may also be localized to the microbody (peroxisome) with acertainty of 0.3925, the mitochondrial matrix space with a certainty of 0.3600, or the lysosome (lumen) with a certainty of 0.1000.
- the disclosed NOV5 amino acid sequence has 80 of 132 amino acid residues (60%) identical to, and 96 of 132 amino acid residues (72%) similar to, the 135 amino acid residue ptnr:SWISSPROT-ACC:P55052 protein from Bos taurus (Bovine) (Fatty Acid-Binding
- E 0.0
- NOV5 is expressed in at least retina. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and or RACE sources. NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.
- the fatty acid-binding protein (FABP) family consists of small, cytosolic proteins believed to be involved in the uptake, transport, and solubilization of their hydrophobic ligands. Members of this family have highly conserved sequences and tertiary structures.
- FABP fatty acid-binding protein
- E-FABP human epidermal fatty acid-binding protein
- bovine E-FABP comprised 0.9%, 0.1%, and 2.4%> of retina, testis, and lens cytosolic proteins, respectively. Binding studies using the fluorescent probe ADIFAB indicated that this protein bound fatty acids of differing levels of saturation with relatively high affinities. Kd values ranged from 27 to 97 nM. fn addition, the protein was immunolocalized to the MuUer cells in the retina as well as to Sertoli cells in the testis.
- bovine E-FABP in cells known to be supportive to other cell types in their tissues and the ability of E-FABP to bind a variety of fatty acids with similar affinities indicate that it may be involved in the uptake and transport of fatty acids essential for the nourishment of the surrounding cell types.
- the disclosed NOV5 nucleic acid of the invention encoding a Fatty Acid-Binding Protein, Epidermal -like protein includes the nucleic acid whose sequence is provided in Table 5A or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 5A while still encoding a protein that maintains its Fatty Acid-Binding Protein, Epidermal -like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 24 percent of the bases may be so changed.
- the disclosed NOV5 protein of the invention includes the Fatty Acid-Binding Protein,
- Epidermal -like protein whose sequence is provided in Table 5B.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 5B while still encoding a protein that maintains its Fatty Acid-Binding Protein, Epidermal-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 52 percent of the residues may be so changed.
- the NOV5 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in psoriasis, basal and squamous cell carcinomas, obesity, diabetis, and/or other pathologies and disorders involving fatty acid transport of skin, oral mucosa, and or other diseases, disorders and conditions of the like.
- the NOV5 nucleic acid, or fragments thereof may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
- NOV5 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV5 protein have multiple hydrophilic regions, each of which can be used as an immunogen.
- This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- NOV6 nucleic acid of 816 nucleotides also referred to as CG50261-02 encoding a novel Uncoupling Protein 1-like protein is shown in Table 6 A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAA codon at nucleotides 814-816. The start and stop codons are in bold letters in Table 6A.
- Table 6A NOV6 Nucleotide Sequence (SEQ ID NO:25)
- the disclosed NOV6 nucleic acid sequence located on chromosome 4, has 628 of 628 bases (100%) identical to a gb:GENBANK-LO:HSU28480
- acc:U28480.1 mRNA from Homo sapiens (Human uncoupling protein (UCP) mRNA, complete eds) (E Lie "176 ).
- a disclosed NOV6 polypeptide (SEQ ID NO:26) encoded by SEQ LO NO:25 is 271 amino acid residues and is presented using the one-letter amino acid code in Table 6B.
- Signal P, Psort and/or Hydropathy results predict that NOV6 contains no signal peptide and is likely to be localized extracellularly with a certainty of 0.4753.
- NOV6 is also likely to be localized to the plasma membrane with a certainty of 0.1900, to the microbody (peroxisome) with a certainty of 0.1544, or to the endoplasmic reticulum (membrane) with a certainty of 0.1000
- Table 6B Encoded NOV6 protein sequence (SEQ ID NO:26).
- NOV6 is expressed in at least the following tissues: Adrenal Gland/Suprarenal gland and Brown adipose. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
- NOV6 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 6C. Table 6C. BLAST results for NOV6
- thermogenin,- mitochondrial brown fat uncoupling protein [Homo sapiens] gi
- Tables 6E-F list the domain description from DOMAIN analysis results against NOV6. This indicates that the NOV6 sequence has properties similar to those of other proteins known to contain this domain.
- CD-Length 96 residues, 95.8% aligned
- CD-Length 95 residues , 99 .0% aligned
- the uncoupling protein (UCP) of mitochondria in brown adipose tissue is a specific component unique to mammalian cells.
- Complementary DNAs for rat and mouse UCP were isolated in several laboratories (Jacobson et al., 1985; Bouillaud et al., 1986; Ridley et al., 1986).
- the cDNAs have been used to determine the sequence of rat UCP and to monitor changes in UCP mRNA levels under various physiologic, pathologic, and pharmacologic circumstances.
- Bouillaud et al. (1988) screened a human genomic library with a cDNA corresponding to the UCP of rat brown adipose tissue mitochondria. They succeeded in cloning a 0.5-kb fragment containing 2 intronic regions and 2 exonic regions. The exonic regions encode a sequence of 84 amino acids with a strong homology to the central domain of rat UCP. Southern analysis experiments suggested that there is 1 copy of the gene in the human, as there is in rodents, hi Northern analysis experiments, the probe detected a specific 1.8-kb mRNA in human brown adipose tissue obtained from 6 patients with pheochromocytoma and from 1 patient with a hibernoma.
- Brown adipose tissue because of its capacity for uncoupled mitochondrial respiration, is an important site of facultative energy expenditure. It has been speculated that this tissue normally functions to prevent obesity. Surgical efforts to ablate or denervate the brown adipose tissue have been unsuccessful because of the diffuse deposits and substantial capacity for regeneration and hypertrophy.
- Lowell et al. (1993) used a transgenic toxigene approach to create 2 lines of transgenic mice with primary deficiency of brown adipose tissue. In constructing these transgenic mice, Lowell et al. (1993) used the regulatory elements of the gene for uncoupling protein to drive expression of the diphtheria toxin A chain (UCP-DTA) or an attenuated mutant.
- UCP-DTA diphtheria toxin A chain
- Uncoupling protein is a mitochondrial proton channel that is not coupled to oxidative phosphorylation. Therefore, when a proton gradient is established across the inner mitochondrial membrane, activation of the uncoupling protein leads to the uncoupled passage of protons through the channel and the generation of heat. Expression and activation of uncoupling proteins is usually mediated by the sympathetic nervous system and is directly controlled by norepinephrine. This mechanism is part of the adaptive response to cold temperatures. It also regulates energy balance. Manipulation of thermogenesis could be an effective strategy against obesity (Lowell et al., 1993). Enerback et al. (1997) determined the role of UCP in the regulation of body mass by targeted inactivation of the UCP gene in mice.
- Adrenaline and noradrenaline are thought to control adiposity and energy balance through several mechanisms. They promote catabolism of triglycerides and glycogen, stimulate food intake when injected into the central nervous system, activate thermogenesis in brown adipose tissue, and regulate heat loss through modulation of peripheral vasoconstriction and piloerection. Thermogenesis in brown adipose occurs in response to cold and overeating, and there is an inverse relationship between diet-induced thermogenesis and obesity both in humans and animalmodels.
- mice that could not synthesize noradrenaline or adrenaline by inactivating the gene that encodes dopamine beta-hydroxylase (DBH; 223360). These mice were cold intolerant because they had impaired peripheral vasoconstriction and were unable to induce thermogenesis in brown adipose tissue through uncoupling protein (UCPl). The mutants had increased food intake but did not become obese because their basal metabolic rate (BMR) was also elevated. The unexpected increase in BMR was not due to hyperthyroidism, compensation by the widely expressed UCP2, or shivering.
- UCPl uncoupling protein
- the disclosed NON6 nucleic acid of the invention encoding a Leucine-Rich Glioma- Inactivated Protein-like protein includes the nucleic acid whose sequence is provided in Table 6A or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 6A while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.
- up to about 10% percent of the bases may be so changed.
- the disclosed ⁇ OV6 protein of the invention includes the Leucine-Rich Glioma- Inactivated Protein-like protein whose sequence is provided in Table 6B.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 6B while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 29 percent of the residues may be so changed.
- NOV6 Leucine-Rich Glioma-Inactivated Protein-like proteins
- the potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
- the nucleic acids and proteins of NOV6 are useful in any inflammatory diseases such as obesity, hyperphagia, and or other pathologies and disorders.
- NOV6 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV6 protein have multiple hydrop ilic regions, each of which can be used as an immunogen.
- This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- NOV7 includes three novel Leucine-Rich Glioma-Inactivated Protein -like proteins disclosed below. The disclosed sequences have been named NOV7a, and NOV7b. NOV7a
- a disclosed NOV7a nucleic acid of 1859 nucleotides (also referred to CG56077-01) encodmg a novel Leucine-Rich Glioma-Inactivated Protein-like protein is shown in Table 7A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 101-103 and ending with a TGA codon at nucleotides 1760-1762.
- Table 7A the 5' and 3' untranslated regions are underlined and the start and stop codons are in bold letters.
- acc:U53204.1 mRNA from Homo sapiens (Human plectin (PLEC1) mRNA, complete eds) (E 7.0e "301 ).
- a disclosed NOV7a polypeptide (SEQ ID NO:28) encoded by SEQ ID NO:27 is 553 amino acid residues and is presented using the one-letter amino acid code in Table 7B.
- Signal P, Psort and/or Hydropathy results predict that NOV7a has a signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.6562.
- NOV7A is also likely to be localized to the lysosome (lumen) with a certainty of 0.2474, or to the mitochondrial matrix space with a certainty of 0.1000.
- Table 7B Encoded NOV7a protein sequence (SEQ ID NO:28).
- tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
- sequence is predicted to be expressed in skin and muscle because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSU53204
- NOV7b the target sequence identified previously, NOV7a, was subjected to the exon linking process to confirm the sequence.
- PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer.
- the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached.
- primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species.
- primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus.
- NOV7b nucleic acid of 1482 nucleotides also referred to CG56077-02 encoding a novel Leucine-Rich Glioma-Inactivated Protein-like protein is shown in Table 7C.
- Table 7C An open reading frame was identified beginning with an TTC initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1480-1482.
- Table 7C the 5' and 3' untranslated regions are underlined and the start and stop codons are in bold letters. Because the start codon for NOV7b is not a traditional initiation codon, NOV7b may be a partial reading frame that extends further in the 5' direction.
- NOV7b nucleic acid sequence localized to the q24 region of chromosome 10, has 559 of 919 bases (60%) identical to a gb:GENBANK- ID:SC6D10
- acc:AL138538.1 mRNA from Streptomyces coelicolor A3(2) (Streptomyces coelicolor cosmid 6D10) (E 9.8e "10 ).
- a disclosed NOV7b polypeptide (SEQ ID NO:30) encoded by SEQ ID NO:29 is 493 amino acid residues and is presented using the one-letter amino acid code in Table 7D.
- Signal P, Psort and or Hydropathy results predict that NOV7b has a signal peptide and is likely to be localized in the endoplasmic reticulum (membrane) with a certainty of 0.8200.
- NOV7b is also likely to be localized to the microbody (peroxisome) with a certainty of 0.3264, to th plasma membrane with a certainty of 0.1900, or to the endoplasmic reticulum (lumen) with a certainty of 0.1000.
- the most likely cleavage site for NOV7b is between positions 25 and 26: LFL-LE.
- Table 7D Encoded NOV7b protein sequence (SEQ ID NO:30).
- NOV7b is expressed in at least brain. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG56077-02.
- NOV7 also has homology to the amino acid sequence shown in the BLASTP data listed in Table 7E.
- Table 7F Domain Analysis of NOV7 gnl I Pfam
- LGIl Leucine-rich gene-Glioma Inactivated
- LGIl The LGIl gene encodes a protein with a calculated molecular mass of 60 kD and contains 3.5 leucine-rich repeats (LRR) with conserved flanking sequences, hi the LRR domain, LGIl has the highest homology with a number of transmembrane and extracellular proteins which function as receptors and adhesion proteins. LGIl is predominantly expressed in neural tissues, especially in brain; its expression is reduced in low grade brain tumors and it is significantly reduced or absent in malignant gliomas. Its localization to the 10q24 region, and rearrangements or inactivation in malignant brain tumors, suggest that LGIl is a candidate tumor suppressor gene involved in progression of glial tumors.
- LRR leucine-rich repeats
- the disclosed NOV7 nucleic acid of the invention encodmg a Leucine-Rich Glioma- Inactivated Protein-like protein includes the nucleic acid whose sequence is provided in Table 7A, 7C or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 7A or 7C while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.
- the mutant or variant nucleic acids, and their complements up to about 40 percent of the bases may be so changed.
- the disclosed NOV7 protein of the invention includes the Leucine-Rich Glioma-
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 7B or 7D while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 69 percent of the residues may be so changed.
- NOV7 Leucine-Rich Glioma-Inactivated Protein-like protein and nucleic acid
- nucleic acid or protein diagnostic and/or prognostic marker serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.
- the NOV7 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies.
- compositions of the present invention will have efficacy for treatment of patients suffering from cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, anemia , bleeding disorders, scleroderma,diabetes, Von Hippel-Lindau (VHL) syndrome, pancreatitis, obesity, fertility, cirrhosis, inflammatory bowel disease, diverticular disease,hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease
- NOV7 nucleic acid, or fragments thereof may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
- NOV7 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV7 protein have multiple hydrophihc regions, each of which can be used as an immunogen.
- This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- a disclosed NOV8 nucleic acid of 430 nucleotides (also referred to as AL163195_dal) encoding a novel RNase-like protein is shown in Table 8A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 16-18 and ending with a TAA codon at nucleotides 408-410.
- a putative untranslated region upstream from the initiation codon is underlined in Table 8 A. The start and stop codons are in bold letters.
- Table 8A NOV8 nucleotide sequence (SEQ ID NO:31).
- the NOV8 nucleic acid sequence is located on chromsome 14.
- the disclosed NOV8 polypeptide (SEQ ID NO:32) encoded by SEQ LD NO:31 has
- NOV8 has a signal peptide and is likely to be localized to the microbody (peroxisome) with a certainty of 0.8000. In other embodiments, NOV8 may also be localized to the mitochondrial matrix space with a certainty of 0.1000, orthe lysosome (lumen) with a certainty of 0.1000.
- Table 8B Encoded NOV8 protein sequence (SEQ ID NO:32).
- NOV8 also has homology to the amino acid sequence shown in the BLASTP data listed in Table 8C.
- RNASE 1 RNASE A (SEQ ID NO: 103)
- Human pancreatic RNase is monomeric and is devoid of any biologic activity other than its RNA degrading ability.
- Piccoli et al. (Proc. Nat. Acad. Sci. 96: 7768-7773, 1999) engineered the monomeric form into a dimeric protein with cytotoxic action on mouse and human tumor cells, but lacking any appreciable toxicity on human and mouse normal cells.
- the dimeric variant of human pancreatic RNase selectively sensitized cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein was thought to represent an attractive tool for anticancer therapy.
- the disclosed NOV8 nucleic acid of the invention encoding a RNase-like protein includes the nucleic acid whose sequence is provided in Table 8A, or a fragment thereof.
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 8A while still encoding a protein that maintains its RNase-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.
- modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.
- the disclosed NOV8 protein of the invention includes the RNase-like protein whose sequence is provided in Table 8B.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2 while still encoding a protein that maintains its RNase-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 72 percent of the residues may be so changed.
- the invention further encompasses antibodies and antibody fragments, such as F a or (F ab ) 2 ,that bind immunospecifically to any of the proteins of the invention.
- NOV8 RNase-like protein
- the above defined information for this invention suggests that this RNase-like protein (NOV8) may function as a member of a "RNase family". Therefore, the NOV8 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below.
- the potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
- the NOV8 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in DiabetesNon Hippel-Lindau (VHL) syndrome , PancreatitiSjObesity, Hyperthyroidism and Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other diseases or pathologies.
- VHL DiabetesNon Hippel-Lindau
- PancreatitiSjObesity Hyperthyroidism
- Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other diseases or pathologies.
- NOV8 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV8 substances for use in therapeutic or diagnostic methods.
- These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below.
- the disclosed NOV8 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- a disclosed NOV9 nucleic acid of 1860 nucleotides (also referred to as CG56069-01) encoding a novel Insulin like growth factor binding protein-like protein is shown in Table 9A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1858-1860.
- the start and stop codons are in bold letters in Table 9A.
- Table 9A NOV9 nucleotide sequence (SEQ ID NO:33).
- the disclosed NOV9 nucleic acid sequence localized to the ql2 region of chromosome 1, has 410 of 699 bases (58%) identical to a gb:GENBANK- ID:MMU91967
- acc:U91967.1 mRNA fromMus musculus (Mus musculus platelet glycoprotem lb-alpha gene, complete eds) (E 0.031).
- the disclosed NOV9 polypeptide (SEQ ID NO:34) encoded by SEQ ID NO:33 has
- NOV9 619 amino acid residues is presented in Table 9B using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOV9 has a signal peptide and is likely to be localized in the lysosome (lumen) with a certainty of 0.6400.
- NOV9 is predicted to be localized extracellularly with a certainty of 0.5087, to the endoplasmic reticulum (membrane) with a certainty of 0.1000, or to the endoplasmic reticulum (lumen) with a certainty of 0.1000.
- the most likely ceavage site for NOV9 is between positions 19 and 20, TAG-WT.
- NOV9 is expressed in at least brain and liver. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources. hi addition, the sequence is predicted to be expressed in B-cells and blood cells because of the expression pattern of (GENBANK-LO: gb:GENBANK- ID:MMU91967
- the disclosed NOV9 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 9C.
- Table 9E lists the domain description from DOMAIN analysis results against NOV9. This indicates that the NOV9 sequence has properties similar to those of other proteins known to contain this domain.
- LRRs Leucine-rich repeats
- IGFBP insulin like growth factor binding protein
- RP105 a novel B cell surface molecule. It contains five leucine-rich repeat domains.
- Leucine-rich repeats (LRRs) are relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins (1) . Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair (1) . LRRs form elongated non-globular structures and are often flanked by cysteine rich domains.
- the circulating insulin-like growth factors occur largely as components of a 140kDa protein complex with IGF binding protein-3 and the acid-labile subunit (ALS).
- This ternary complex regulates the metabolic effects of the serum IGFs by limiting their access to tissue fluids.
- a cDNA for baboon ALS was isolated by Delhanty and Baxter (2) and used to screen Northern blots of total RNA from the lung, liver, kidney, adrenal, muscle, intestine, and spleen of adult baboons. The expression of the single approximately 2.2 kb baboon ALS mRNA transcript was restricted to the liver, suggesting that serum ALS levels are controlled by regulation of hepatic expression of this peptide in primates (2).
- the RP105 Ag is a murine B cell surface molecule that transmits an activation signal into B cells or dexamethasone-induced apoptosis, and to B cell proliferation.
- a cDNA encoding the RP 105 Ag was isolated by Miyake, et al (3).
- An encoded protein is a type I transmembrane protein consisting of 641 amino acids in a mature form.
- Northern hybridization with a probe specific for the cDNA clone detected a transcript with a size of approximately 3 kb. The transcript was observed in spleen, but not in thymus, kidney, muscle, heart, brain, or liver.
- RP105 Ag on a pro-B cell line, which was confirmed by immunofluorescence staining and immunoprecipitation with anti-RP 105 mAb.
- the RP 105 molecule possesses 22 tandem repeats of a leucine-rich motif. These repeated motifs are observed in members of the leucine-rich repeat protein family, and have been implicated in protein-protein interactions, such as cell adhesion or receptor-ligand binding. Amino- and carboxyl-flanking regions that are characteristically conserved among members of the family are located on both sides of tandemly repeated leucine-rich motifs in RP 105 molecule.
- RP105 is a novel member of the leucine-rich repeat protein family, and the first member that is specifically expressed on B cells (3).
- the disclosed NOV9 nucleic acid of the invention encoding a Insulin like growth factor binding protein-like protein includes the nucleic acid whose sequence is provided in
- the invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 9A while still encoding a protein that maintains its Insulin like growth factor binding protein-like activities and physiological functions, or a fragment of such a nucleic acid.
- the invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described.
- the invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized.
- the disclosed NOV9 protein of the invention includes the Insulin like growth factor binding protein-like protein whose sequence is provided in Table 9B.
- the invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2 while still encoding a protein that maintains its Insulin like growth factor binding protein-like activities and physiological functions, or a functional fragment thereof, h the mutant or variant protein, up to about 74 percent of the residues may be so changed.
- the invention further encompasses antibodies and antibody fragments, such as F a or (F ab ) 2 , that bind immunospecifically to any of the proteins of the invention.
- NOV9 Insulin like growth factor binding protein-like protein
- the above defined information for this invention suggests that this Insulin like growth factor binding protein-like protein (NOV9) may function as a member of a "Insulin like growth factor binding protein family". Therefore, the NOV9 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below.
- the potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
- NOV9 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in diabetes, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease,
- VHL Von Hippel-Lindau
- NOV9 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV9 substances for use in therapeutic or diagnostic methods.
- NOV9 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
- a disclosed NOV10 nucleic acid of 4660 nucleotides (also referred to as SC133419534_A) encoding a novel pregnancy zone protein precursor -like protein is shown in Table 10A.
- An open reading frame was identified beginning with an ATG initiation codon at nucleotides 141-143 and ending with a TAA codon at nucleotides 4578-4580.
- a putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 10A. The start and stop codons are in bold letters.
- Table 10A NOV10 nucleotide sequence (SEQ ID NO:35).
- the NOVIO nucleic acid sequence, localized to chromosome 12 has 4170 of 4478 bases (93%) identical to a gb:GENBANK- ID:HSPZHEP
- acc:X54380 mRNA from Homo sapiens (Human mRNA for pregnancy zone protein (E 0.0).
- Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
- NOV10 polypeptide (SEQ ID NO:36) encoded by SEQ ID NO:35 has 1479 amino acid residues and is presented in Table 10B using the one-letter amino acid code.
- Signal P, Psort and/or Hydropathy results predict that NOV10 has no signal peptide and is likely to be localized extracellularly with a certainty of 0.8200.
- NOV10 may also be localized to the lysosome (lumen) with a certainty of 0.1900, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or in the endoplasmic reticulum (lumen) with a certainty of 0.1000.
- the most likely cleavage site for NOV10 is between positions 23 and 24: SDS-NS.
- Public amino acid databases include the GenBank databases, SwissProt, PDB and PLR.
- NOV10 is predicted to be expressed in late-pregnancy sera because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSPZHEP
- the disclosed NOV10 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table IOC.
- Tables 10E-10F lists the domain description from DOMAIN analysis results against
- NOVIO NOVIO. This indicates that the NOVIO sequence has properties similar to those of other proteins known to contain this domain.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Vascular Medicine (AREA)
Abstract
Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these human nucleic acids and proteins.
Description
PROTEINS AND NUCLEIC ACIDS ENCODING SAME
FIELD OF THE INVENTION
The invention generally relates to nucleic acids and polypeptides encoded thereby.
BACKGROUND OF THE INVENTION
The invention generally relates to nucleic acids and polypeptides encoded therefrom. More specifically, the invention relates to nucleic acids encoding cytoplasmic, nuclear, membrane bound, and secreted polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.
SUMMARY OF THE INVENTION
The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, NOV9, NOV10, NOV11, NOV12, NOV13, and NOV14 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homo logs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.
Ixi one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197. i some embodiments, the NOVX nucleic acid molecule will hybridize under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198. The nucleic acid can be, for example, a genomic DNA fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
Also included in the invention is an oligonucleotide, e.g., an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (e.g., SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197) or a complement of said oligonucleotide. Also included in the invention are substantially purified NOVX polypeptides (SEQ ID
NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.
The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.
In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically- acceptable carrier. The therapeutic can be, e.g., a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.
In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.
In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the NOVX polypeptide within the sample.
The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.
Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.
In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the
activity of said polypeptide. The compound can be, e.g., a small molecule, such as a nucleic acid, peptide, polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.
Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, e.g., Von Hippel- Lindau (VHL) syndrome, tuberous sclerosis, hypercalceimia, Lesch-Nyhan syndrome, multiple sclerosis, Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Retinol binding protein, deficiency of; SEMD, Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; myasthenia gravis, endometriosis, pancreatitis, hyperparathyroidism, hypoparathyroidism, xerostomia, actinic keratosis, acne, hair growth/loss, allopecia, pigmentation disorders, endocrine disorders, tonsillitis, cystitis, incontinence, fatty acid transport of skin, oral mucosa, uveitis and corneal fibroblast proliferation, amyotrophic lateral sclerosis, acute pancreatitis, cerebral cryptococcosis, colitis, thyroiditis, cirrhosis, Alzheimer's disease, stroke, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, ataxia-telangiectasia, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Pakistani type; Spinocerebellar ataxia, infantile-onset, with sensory neuropathy, neuroprotection, muscular dystrophy, leukodystrophies, Leukemia, T-cell acute lymphocytic; Colorectal cancer; Leukemia lymphoma, B-cell, 2; Lymphoma/leukemia, Osteosarcoma; cancer, lymphedema, Cholesteryl ester storage disease; diabetes, obesity, fertility, growth and reproductive disorders, pregnancy, hypertensive toxemia, pre- eclampsia/eclampsia (gestational proteinuric hypertension), glomerular endotheliosis, cholestasis, and pruritic urticarial papules and plaques of pregnancy autoimmune disease, lupus erythematosus, tuberous sclerosis, scleroderma, B-cell, variant; Protoporphyria, erythropoietic; Protoporphyria, erythropoietic, recessive, with liver failure; skin psoriasis, allergic encephalomyelitis, various forms of arthritis, cancer such as AML, bacterial infections, graft versus host disease (GVHD), lymphaedema renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic renal tubular acidosis, IgA nephropathy, asthma, emphysema, scleroderma, allergy, ARDS, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect
(ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, transplantation, ulcers, and/or other pathologies and disorders of the like.
The therapeutic can be, e.g. , a NOVX nucleic acid, a NOVX polypeptide, or a NOVX- specific antibody, or biologically-active derivatives or fragments thereof.
For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
The invention further includes a method for screening for a modulator of disorders or syndromes including, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and deteπmning if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.
Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly- expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity of NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome. In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (e.g., a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a
control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.
In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (e.g. , a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.
In yet another aspect, the invention can be used in a method to identity the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incoφorated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control, i addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description and claims.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to
any of the novel sequences disclosed herein. Table A provides a svrmmary of the NOVX nucleic acids and their encoded polypeptides.
TABLE A. Sequences and Corresponding SEQ ID Numbers
NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.
NOV1 is homologous to a Human laminin alpha 5-like family of proteins. Thus, the NOV1 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis,
hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch- Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, neuroprotection, fertility, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, ulcers, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, or other pathologies or conditions.
NOV2 is homologous to the Human Huφin/PI 13-like family of proteins. Thus NOV2 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in Colorectal cancer; Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; Leukemia/lymphoma, B-cell, 2; Lymphoma/leukemia, B-cell, variant; Protoporphyria, erythropoietic; Protoporphyria, erythropoietic, recessive, with liver failure; Obesity, autosomal dominant; Osteosarcoma; cancer, skin psoriasis, and/or other pathologies and disorders.
NOV3 is homologous to a family of Set Binding Factor (SBFl)-like proteins. Thus, the NOV3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch- Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, and or other pathologies.
i
NOV4 is homologous to the TSPAN-1-like family of proteins. Thus, NOV4 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: adrenoleukodystrophy, congenital adrenal hyperplasia, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, asthma, immunodeficiencies, transplantation, graft versus host disease, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, arthritis, tendonitis, fertility, atherosclerosis, aneurysm, hypertension, fibromuscular dysplasia, stroke, scleroderma, obesity, myocardial infarction, embolism, cardiovascular disorders, bypass surgery, cirrhosis, inflammatory bowel disease, diverticular disease, Hirschsprung's disease , Crohn's Disease, appendicitis, ulcers, diabetes, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, laryngitis, emphysema, ARDS, lymphedema , muscular dystrophy, myasthenia gravis, endometriosis, pancreatitis, hypeφarathyroidism, hypoparathyroidism, growth and reproductive disorders, xerostomia, psoriasis, actinic keratosis, acne, hair growth/loss, allopecia, pigmentation disorders, endocrine disorders, tonsillitis, cystitis, incontinence, and/or other pathologies. NOV5 is homologous to the Fatty Acid-Binding Protein, Epidermal-like family of proteins. Thus NOV5 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, fatty acid transport of skin, oral mucosa, and/or other disorders and conditions.
NOV6 is homologous to the Uncoupling Protein 1 -like family of proteins. Thus NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example: obesity, hypeφhagia, and/or other pathologies/disorders.
NOV7 is homologous to members of the Leucine-Rich Glioma-Inactivated Protein-like family of proteins. Thus, the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; uveitis and corneal fibroblast proliferation, allergic encephalomyelitis, amyotrophic lateral sclerosis, acute pancreatitis, cerebral cryptococcosis, autoimmune disease including Type 1 diabetes mellitus (DM), experimental allergic encephalomyelitis (EAE), systemic lupus erythematosus (SLE), colitis, thyroiditis and various
forms of arthritis, cancer such as AML, bacterial infections, and/or other pathologies/disorders.
NOV8 is homologous to the RNase-like family of proteins. Thus, NOV8 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; DiabetesNon Hippel- Lindau (VHL) syndrome , Pancreatitis,Obesity, Hyperthyroidism and Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other pathologies/disorders.
ΝOV9 is homologous to the Insulin like growth factor binding protein-like family of proteins. Thus, NOV9 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in diabetes, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, cirrhosis, transplantation, hemophilia, hypercoagulation, idiopathic thrombocytopenic puφura, autoimmume disease, allergies, immunodeficiencies, graft versus host disease (GVHD), lymphaedema, and/or other pathologies or disorders.
NOV10 is homologous to the Pregnancy Zone Protein Precursor -like family of proteins. Thus, NOV10 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in pregnancy, hypertensive toxemia, pre- eclampsia/eclampsia (gestational proteinuric hypertension), glomerular endotheliosis, cholestasis, and pruritic urticarial papules and plaques of pregnancy, and/or other pathologies or disorders.
NOVl 1 is homologous to the Transmembrane Receptor UNC5H2-like family of proteins. Thus, NOVl 1 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in various pathologies or disorders.
NOV12 is homologous to the Thymosin-like family of proteins. Thus, NOV12 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example; osteoporosis, osteoarthritis, cardiac hypertrophy, atherosclerosis, hypertension, restenosis, and or other pathologies/disorders .
NOV13 is homologous to the Neirromodulin-like family of proteins. Thus, NOV13 nucleic acids and polypeptides, antibodies and related compounds according to the invention
will be useful in therapeutic and diagnostic applications implicated in various pathologies/disorders.
NOV14 is homologous to the Prostatin Precursor-like family of proteins. Thus, NOVl 4 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in
Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis ,Atrial septal defect (ASD),Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases,Tuberous sclerosis, Scleroderma, Obesity,Transplantation, and/or other pathologies/disorders. The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, hematopoiesis, wound healing and angiogenesis. Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.
NOVl
NOVl includes three novel human laminin alpha 5-like proteins disclosed below. The disclosed sequences have been named NOVla, NOVlb, and NOVlc. NOVla
A disclosed NOVla nucleic acid of 10809 nucleotides (also referred to as CG55974- 01) encoding a human laminin alpha 5-like protein is shown in Table 1 A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAG codon at nucleotides 10801-10803. A putative untranslated region downstream from the termination codon is underlined in Table 1A. The start and stop codons are in bold letters.
Table 1A. NOVla nucleotide sequence (SEQ ID NO:l).
ATGGCGAAGCGGCTCTGCGCGGGGAGCGCACTGTGTGTTCGCGGCCCCCGGGGCCCCGCGCCGCTGCTGCTG CACCCGCCCTACTTCAACCTGGCCGAGGGCGCCCGCATCGCCGCCTCCGCGACCTGCGGAGAGGAGGCCCCG GCGCGCGGCTCCCCGCGCCCCACCGAGGACCTTTACTGCAAGCTGGTAGGGGGCCCCGTGGCCGGCGGCGAC CCCAACCAGACCATCCAGGGCCAGTACTGTGACATCTGCACGGCTGCCAACAGCAACAAGGCACACCCCGCG AGCAATGCCATCGATGGCACGGAGCGCTGGTGGCAGAGTCCACCGCTGTCCCGCGGCCTGGAGTACAACGAG GTCAACGTCACCCTGGACCTGGGCCAGGTCTTCCACGTGGCCTACGTCCTCATCAAGTTTGCCAACTCACCC CGGCCGGACCTCTGGGTGCTGGAGCGGTCCATGGACTTCGGCCGCACCTACCAGCCCTGGCAGTTCTTTGCC GCCTCCAAGAGGGACTGTCTGGAGCGGTTCGGGCCACAGACGCTGGAGCGCATCACACGGGACGACGCGGCC ATCTGCACCACCGAGTACTCACGCATCGTGCCCCTGGAGAACGGAGAGATCGTGGTGTCCCTGGTGAACGGA CGTCCGGGCGCCATGAATTTCTCCTACTCGCCGCTGCTACGTGAGTTCACCAAGGCCACCAACGTCCGCCTG CGCTTCCTGCGTACCAACACGCTGCTGGGCCATCTCATGGGGAAGGCGCTGCGGGACCCCACGGTCACCCGC CGGTATTATTACAGCATCAAGGATATCAGCATCGGAGGCCGCTGTGTCTGCCACGGCCACGCGGATGCCTGC GATGCCAAAGACCCCACGGACCCGTTCAGGCTGCAGTGCACCTGCCAGCACAACACCTGCGGGGGCACCTGC GACCGCTGCTGCCCCGGCTTCAATCAGCAGCCGTGGAAGCCTGCGACTGCCAACAGTGCCAACGAGTGCCAG TGTGAGTGCTACGGCCATGCCACCGACTGTTACTACGACCCTGAGGTGGACCGGCGCCGCGCCAGCCAGAGC CTGGATGGCACCTATCAGGGTGGGGGTGTCTGTATCGACTGCCAGCACCACACCACCGGCGTCAACTGTGAG CGCTGGCTGCCCGGCTTCTACCGCTCTCCCAACCACCCTCTCGACTCGCCCCACGTCTGCCGCGGCTGCAAC TGCGAGTCCGACTTCACGGATGGCACCTGCGAGGACCTGACGGGTCGATGCTACTGCCGGCCCAACTTCTCT GGGGAGCGGTGTGACGTGTGTGCCGAGGGCTTCACGGGCTTCCCAAGCTGCTACCGTGAGCACCTGCCAGGG AATGACACCAGGGAGCAGGTGCTGCCAGCCGGCCAGATTGTGAGTTGTGACTGCAGCGCGGCAGGGACCCAG GGCAACGCCTGCCGGAAGGACCCAAGGGTGGGACGCTGTCTGTGCAAACCCAACTTCCAAGGCACCCATTGT GAGCTCTGCGCGCCAGGGTTCTACGGCCCCGGCTGCCCTGCCAGTGTTCCAGCCCTGGAGTGGCCGATGACC GCTGTGACCCTGACACAGGCCAGTGCAGGTGCCGAGTGGGCTTCGAGGGGGCCACATGTGATCGCTGTGCCC CCGGCTACTTTCACTTCCCTCTCTGCCAGTCACCCGCTCCGCTCTGCAGTGTGTGGCTGCAGCCCTGCAGGA ACCTTGCCCGAGGGCTGCGATGAGGCCGGCCGCTGCCTATGCCAGCCTGAGTTTGCTGGACCTCATTGTGAC CGGTGCCGCCCTGGCTACCATGGTTTCCCCAACTGCGCAGCATGCACCTGCGACCCTCGGGGAGCCCTGGAC CAGCTCTGTGGGGCGGGAGGTTTGTGCCGCTGCCGCCCCGGCTACACAGGCACTGCCTGCCAGGAATGCAGC CCCGGCTTTCACGGCTTCCCCAGCTGTCCTGCCACTGCTCTGCTGAAGGCTCCCTGCACGCAGCCTGTGACC CCCGGAGTGGGCAGTGCAGCTGCCGGCCCCGTGCGGGGCTGCGGTGTGACACATGTGTGCCCGGTGCCTACA ACTTCCCCTACTGCGAAGCCTCTCTTCACAGCTGGCTCTTGCCACCCTGCCGGTCTGGCCCCAGTGGATCCT GCCCTTCCTGAGGTGAGCCCACCCTGTATGTGCCGGGCTCACGTGGAGGGGCCGAGCTGTGACCGCTGCAAA CCTGGGTTCTGGGGACTGAGCCCCAGCAAGGCCGAGGGCTGTACCCGTTGCAGCTGCGACCTCAGGGGCACA CTGGGTGGAGTTGCTGAGTGCCAGGGCACCGGCCAGTGCTTCTGCAAGCCCCACGTGTGCGGCCAGGCCTGC GCGTCCTGCAAGGATGGCTTCTTTGGACTGGATCAGGCTGACTATTTTGGCTGCCGCAGTTGCCGGTGTGAC ATTGGCGGTGCACTGGGCCAGAGCTGTGAACCGAGGACGGGCGTCTGCCGGTGCCGCCCCAACACCCAGGGC CCCACCTGCAGCGAGCCTGCGAGGGACCACTACCTCCCGGACCTGCACCACCTGCGCCTGGAGCTGGAGGAG GCTGCCACACCTGAGGGTCACGCCGTGCGCTTTGGCTTCAACCCCCTCGAGTTCGAGAACTTCAGCTGGAGG GGCTACGCGCAGATGGCACCTGTCCAGCCCAGGATCGTGGCCAGGCTGAACCTGACCTCCCCTGACCTTTTC TGGCTCGTCTTCCGATACGTCAACCGGGGGGCCATGAGTGTGAGCGGGCGGGTCTCTGTGCGAGAGGAGGGC AGGTCGGCCACCTGCGCCAACTGTACAGCACAGAGTCAGCCCGTGGCCTTCCCACCCAGCACGGAGCCTGCC TTCATCACCGTGCCCCAGAGGGGCTTCGGAGAGCCCTTTGTGCTGAACCCTGGCACCTGGGCCCTGCGTGTG GAGGCCGAAGGGGTGCTCCTGGACTACGTGGTTCTGCTGCCTAGCGCATACTACGAGGCGGCGCTCCTGCAG CTGCGGGTGACTGAGGCCTGCACATACCGTCCCTCTGCCCAGCAGTCTCCCCCCAGCTGCCTCCTCTACACA CACCTCCCCCTGGATGGCTTCCCCTCGGCCGCCGGGCTGGAGGCCCTGTGTCGCCAGGACAACAGCCTGCCC CGGCCCTGCCCCACGGAGCAGCTCAGCCCGTCGCACCCGCCACTGATCACCTGCACGGGCAGTGATGTGGAC GTCCAGCTTCAAGTGGCAGTGCCACAGCCAGGCCGCTATGCCCTAGTGGTGGAGTACGCCAATGAGGATGCC CGCCAGGAGGTGGGCGTGGCCGTGCACACCCCACAGCGGGCCCCCCAGCAGGGGCTGCTCTCCCTGCACCCC TGCCTGTACAGCACCCTGTGCCGGGGCACTGCCCGGGATACCCAGGACCACCTGGCTGTCTTCCACCTGGAC TCGGAGGCCAGCGTGAGGCTCACAGCCGAACAGGCACGCTTCTTCCTGCACGGGGTCACTCTGGTGCCCATT GAGGAGTTCAGCCCGGAGTTCGTGGAGCCCCGGGTCAGCTGCATCAGCAGCCACGGCGCCTTTGGCCCCAAC AGTGCCGCCTGTCTGCCCTCGCGCTTCCCAAAGCCGCCCCAGCCCATCATCCTCAGGGACTGCCAGGTGATC CCGCTGCCGCCCGGCCTCCCGCTGACCCACGCGCAGGATCTCACTCCAGCCATGTCCCCAGCTGGACCCCGA CCTCGGCCCCCCACCGCTGTGGACCCTGATGCAGAGCCCACCCTGCTGCGTGAGCCCCAGGGCACCGTGGTC TTCACCACCCATGTGCCCACGCTGGGCGGCTATGCCTTCCTGCTGCACGGCTACCAGCCAGCCCACCCCACC TTCCCCGTGGAAGTCCTCATCAACGCCGGCCGCGTGTGGCAGGGTCACGCCAACGCCAGCTTCTGTCCACAT GGCTACGGCTGCCGCACCCTGGTGGTGTGTGAGGGCCAGGCCCTGCTGGACGTGACCCACAGCGAGCTCACT GTGACCGTGCGTGTGCCCAAGGGCCGGTGGCTCTGGCTGGATTATGTACTCGTGGTCCCTGAGAACGTCTAC AGCTTTGGCTACCTCCGGGAGGAGCCCCTGGATAAATCCTATGACTTCATCAGCCACTGCGCAGCCCAGGGC TACCACATCAGCCCCAGCAGCTCATCCCTGTTCTGCCGAAACGCTGCTGCTTCCCTCTCCCTCTTCTATAAC AACGGAGCCCGTCCATGTGGCTGCCACGAAGTAGGTGCTACAGGCCCCACGTGTGAGCCCTTCGGGGGCCAG TGTCCCTGCCATGCCCATGTCATTGGCCGTGACTGCTCCCGCTGTGCCACCGGATACTGGGGCTTCCCCAAC TGCAGGGCCTGTGACTGCGGTGCCCGCCTCTGTGACGAGCTCACGGGCCAGTGCATCTGCCCGCCACGCACC ATCCCGCCCGACTGCCTGCTGTGCCAGCCCCAGACCTTTGGCTGCCACCCCCTGGTCGGCTGTGAGGAGTGT AACTGCTCAGGGCCCGGCATCCAGGAGCTCACAGACCCTACCTGTGACACAGACAGCGGCCAGTGCAGGTGC AGACCCAACGTGACTGGGCGCCGCTGTGATACCTGCTCTCCGGGCTTCCATGGCTACCCCCGCTGCCGCCCC TGTGACTGTCACGAGGCGGGCACTGCGCCTGGCGTGTGTGACCCCCTCACAGGGCAGTGCTACTGTAAGGAG AACGTGCAGGGCCCCAAATGTGACCAGTGCAGCCTTGGGACCTTCTCACTGGATGCTGCCAACCCCAAAGGT
TGCACCCGCTGCTTCTGCTTTGGGGCCACGGAGCGCTGCCGGAGCTCGTCCTACACCCGCCAGGAGTTCGTG GATATGGAGGGATGGGTGCTGCTGAGCACTGACCGGCAGGTGGTGCCCCACGAGCGGCAGCCAGGGACGGAG ATGCTCCGTGCAGACCTGCGGCACGTGCCTGAGGCTGTGCCCGAGGCTTTCCCCGAGCTGTACTGGCAGGCC CCACCCTCCTACCTGGGGGACCGGGTAAGCTCCTACGGTGGGACCCTCCGTTATGAACTGCACTCAGAGACC CAGCGGGGAGATGTCTTTGTCCCCATGGAGAGCAGGCCGGATGTGGTGCTGCAGGGCAACCAGATGAGCATC ACATTCCTGGAGCCGGCATACCCCACGCCTGGCCACGTTCACCGTGGGCAGCTGCAGCTGGTGGAGGGGAAC TTCCGGCATACGGAGACGCGCAACACTGTGTCCCGCGAGGAGCTCATGATGGTGCTGGCCAGCCTGGAGCAG CTGCAGATCCGTGCCCTCTTCTCACAGATCTCCTCGGCTGTCTTCCTGCGCAGGGTGGCACTGGAGGTGGCC AGCCCAGCAGGCCAGGGGGCCCTGGCCAGCAATGTGGAGCTGTGCCTGTGCCCCGCCAGCTACCGGGGGGAC TCATGCCAGGAATGTGCCCCCGGCTTCTATCGGGACGTCAAAGGTCTCTTCCTGGGCCGATGTGTCCCTTGT CAGTGCCATGGACACTCAGACCGCTGCCTCCCTGGCTCTGGCGTCTGTGTGTGCCAGCACAACACCGAAGGG GCCCACTGTGAGCGCTGCCAGGCTGGCTTCGTGAGCAGCAGGGACGACCCCAGCGCCCCCTGTGTCAGCTGC CCCTGCCCCCTCTCAGTGCCTTCCAACAGGTGTGCGCCCGGATTCTTTGGGAACCCACTGGTGCTGGGCAGC TCCTGCCAGCCATGCGACTGCAGCGGCAACGGTGACCCCAACTTGCTCTTCAGCGACTGCGACCCCCTGACG GGCGCCTGCCGTGGCTGCCTGCGCCACACCACTGGGCCCCGCTGCGAGATCTGTGCCCCCGGCTTCTACGGC AACGCCCTGCTGCCCGGCAACTGCACCCGTTGCGACTGTACCCCATGTGGGACAGAGGCCTGCGACCCCCAC AGCGGGCACTGCCTGTGCAAGGCGGGCGTGACTGGGCGGCGCTGTGACCGCTGCCAGGAGGGACATTTTGGT TTCGATGGCTGCGGGGGCTGCCGCCCGTGTGCTTGTGGACCGGCCGCCGAGGGCTCCGAGTGCCACCCCCAG AGCGGACAGTGCCACTGCCGACCAGGGACCATGGGACCCCAGTGCCGCGAGTGTGCCCCTGGCTACTGGGGG CTCCCTGAGCAGGGCTGCAGGCGTTGCCAGTGCCCTGGGGGCCGCTGTGACCCTCACACGGGCCGCTGCAAC TGCCCCCCGGGGCTCAGCGGGGAGCGCTGCGACACCTGCAGCCAGCAGCATCAGGTGCCTGTTCCAGGCGGG CCTGTGGGCCACAGCATCCACTGTGAAGTGTGTGACCACTGTGTGGTCCTGCTCCTGGATGACCTGGAACGG GCCGGCGCCCTCCTCCCCGCCATTCACGAGCAACTGCGTGGCATCAATGCCAGCTCCATGGCCTGGGCCCGT CTGCACAGGCTGAACGCCTCCATCGCTGACCTGCAGGTACTGAGCGTCCTGGCCTTCCCTCCCCAACCCGGG CCAGTGCAGGCCTTCACCTTTCGCCTCCCACAGAGCCAGCTCCGGAGCCCCCTGGGCCCCCGCCATGAGACG GCACAGCAGCTGGAGGTGCTGGAGCAGCAGAGCACAAGCCTTCCTCCACAGGCCGTGGGGACCCGAGACCAG GCGAGCCAATTGCTGGCCGGCACCGAGGCCACACTGGGCCATGCGAAGACGCTGTTGGCGGCCATCCGGGCT GTGGACCGCACCCTGAGCGAGCTCATGTCCCAGACGGGCCACCTGGGGCTGGCCAATGCCTCGGCTCCATCA GGTGAGCAGCTGCTCCGGACACTGGCCGAGGTGGAGCGGCTGCTCTGGGAGATGCGGGCCCGGGACCTGGGG GCCCCGCAGGCAGCAGCTGAGGCTGAGTTGGCTGCAGCACAGAGAGTGCTGGCCCGGGTGCAGGAGCAGCTG AGCAGCCTCTGGGAGGAGAACCAGGCACTGGCCACACAAACCCGCGACCGGCTGGCCCAGCACGAGGCCGGC CTCATGGACCTGCGAGAGGCTTTGAACCGGGCAGTGGACGCCACACGGGAGGCCCAGGAGCTCAACAGCCGC AACCAGGAGCGCCTGGAGGAAGCCCTGCAAAGGAAGCAGGAGCTGTCCCGGGACAATGCCACCCTGCAGGCC ACTCTGCATGCGGCTAGGGACACCCTGGCCAGCGTCTTCAGATTGCTGGAGGGGCTAAGTCCACTCAAATTC CAGGAGCTGGAGCGCCTCGCCGCCAGCCTGGATGGGGCTCGGACCCCACTGCTGCAGAGGATGCAGACCTTC TCCCCGGCGGGCAGCAAGCTGCGTCTAGTGGAGGCCGCCGAGGCCCACGCACAGCAGCTGGGCCAGCTGGCA CTCAATCTGTCCATCATCCTGGACGTCAACCAGGACCGCCTCACCCAGAGGGCCATCGAGGCCTCCAACGCC TACAGCCGCATCCTGCAGGCCGTGCAGGCTGCCGAGGATGCTGCTGGCCAGGCCCTGCAGCAGGCGGACCAC ACGTGGCAGACGGTGGTGCGGCAGGGCCTGGTGGACCGAGCCCAGCAGCTCCTGGCCAACAGCACTGCACTA GAAGAGGCCATGCTCCAGGAACAGCAGAGGCTGGGCCTTGGTGAGTGCTGGGCTCCGATGGGGGCCCTTAGG CCTGCTGGGACCCAGCTCCGAGATGTCCGGGCCAAGAAGGACCAGCTGGAGGCGCACATCCAGGCGGCGCAG GCCATGCTTGCCATGGACACAGGTGAGACAAGCAAGAAGATCGCACATGCCAAGGCTGTGGCTGCTGAAGCC CAGGACACCGCCACCCGTGTGCAGTCCCAGCTGCAGGCCATGCAGGAGAATGTGGAGCGGTGGCAGGGCCAG TACGAGGGCCTGCGGGGCCAGGACCTGGGCCAGGCAGTGCTTGACGCAGGCTCTGCAGTGTCCACCCTGGAG AAGACGCTGCCCCAGCTGCTGGCCAAGCTGAGCATCCTGGAGAACCGTGGGGTGCACAACGCCAGCCTGGCC CTGTCCGCCAGCATTGGCCGCGTGCGAGAGCTCATTGCCCAGGCCCGGGGGGCTGCCAGTAAGGTGGTCAAG GTGCCCATGAAGTTCAACGGGCGCTCAGGGGTGCAGCTGCGCACCCCACGGGATCTTGCCGACCTTGCTGCC TACACTGCCCTCAAGTTCTACCTGCAGGGCCCAGAGCCTGAGCCTGGGCAGGGTACCGAGGATCGCTTTGTG ATGTACATGGGCAGCCGCGAGGCCACTGGGGACTACATGGGTGTGTCTCTGCGTGACAAGAAGGTGCACTGG GTGTATCAGCTGGGTGAGGCGGGCCCTGCAGTCCTAAGCATCGATGAGGACATTGGGGAGCAGTTCGCAGCT GTCAGCCTGGACAGGACTCTCCAGTTTGGCCACATGTCCGTCACAGTGGAGAGACAGATGATCCAGGAAACC AAGGGTGACACGGTGGCCCCTGGGGCAGAGGGGCTGCTCAACCTGCGGCCAGACGACTTCGTCTTCTACGTC GGGGGGTACCCCAGTACCTTCACGCCCCCTCCCCTGCTTCGCTTCCCCGGCTACCGGGGCTGCATCGAGATG GACACGCTGAATGAGGAGGTGGTCAGCCTCTACAACTTCGAGAGGACCTTCCAGCTGGACACGGCTGTGGAC AGGCCTTGTGCCCGGTCCAAGTCGACCGGGGACCCGTGGCTCACGGACGGCTCCTACCTGGACGGCACCGGC TTCGCCCGCATCAGCTTCGACAGTCAGATCAGCACCACCAAGCGCTTCGAGCAGGAGCTGCGGCTCGTGTCC TACAGCGGGGTGCTCTTCTTCCTGAAGCAGCAGAGCCAGTTCCTGTGCTTGGCCGTGCAAGAAGGCAGCCTC GTGCTGTTGTATGACTTTGGGGCTGGCCTGAAAAAGGCCGTCCCACTGCAGCCCCCACCGCCCCTGACCTCG GCCAGCAAGGCGATCCAGGTGTTCCTGCTGGGGGGCAGCCGCAAGCGTGTGCTGGTGCGTGTGGAGCGGGCC ACGGTGTACAGCGTGGAGCAGGACAATGATCTGGAGCTGGCCGACGCCTACTACCTGGGGGGCGTGCCGCCC GACCAGCTGCCCAGCCTGCGACGGCTCTTCCCCACCGGAGGCTCAGTCCGTGGCTGCGTCAAAGGCATCAAG GCCCTGGGCAAGTATGTGGACCTCAAGCGGCTGAACACGACAGGCGTGAGCGCCGGCTGCACCGCCGACCTG CTGGTGGGGCGCGCCATGACTTTCCATGGCCACGGCTTCCTTCGCCTGGCGCTCTCGAACGTGGCACCGCTC ACTGGCAACGTCTACTCCGGCTTCGGCTTCCACAGCGCCCAGGACAGTGCCCTGCTCTACTACCGGGCGTCC CCGGTGAGACCTCACCAGGTGTCCCTGCAGCAGGGCCGTGTGAGCCTACAGCTCCTGAGGACTGAAGTGAAA ACTCAAGCGGGCTTCGCCGATGGTGCCCCCCATTACGTCGCCTTCTACAGCAATGCCACGGGGGTCTGGCTG TATGTCGATGACCAGCTCCAGCAGATGAAGCCCCACCGGGGACCACCCCCCGAGCTCCAGCCGCAGCCTGAG GGGCCCCCGAGGCTCCTCCTGGGAGGCCTGCCTGAGTCTGGCACCATTTACAACTTCAGTGGCTGCATCAGC AACGTCTTCGTGCAGCGGCTCCTGGGCCCACAGCGCGTATTTGATCTGCAGCAGAACCTGGGCAGCGTCAAT
GTGAGCACGGGCTGTGCACCCGCCCTGCAAGCCCAGACCCCGGGCCTGGGGCCTAGACAGGCCTCCCGCCGC AGCCGTCAGCCCGCCCGGCATCCTGCCTGCATGCTGCCCCCACACCTCAGGACCACCCGAGACTCCTACCAG TTTGGGGGTTCCCTGTCCAGTCACCTGGAGTTTGTGGGCATCCTGGCCCGACATAGGAACGTCTCCGTGCGC TGGGAGAAGAACCGGATCCTGCTGGTGACGGACGGGGCCCGGGCCTGGAGCCAGGAGGGGCCGCACCGGCAG CACCAGGGGGCAGAGCACCCCCAGCCCCACACCCTCTTTGTGGGCGGCCTCCCGGCCAGCAGCCACAGCTCC AAACTTCCGGTGACCGTCGGGTTCAGCGGCTGTGTGAAGAGACTGAGGCTGCACGGGAGGCCCCTGGGGGCC CCCACACGGATGGCAGGGGTCACACCCTGCATCTTGGGCCCCCTGGAGGCGGGCCTGTTCTTCCCAGGCAGC GGGGGAGTTATCACTTTAGGTCTGCCAGGAGCTACACTGCCTGATGTGGGCCTGGAACTGGAGGTGCGGCCC CTGGCAGTCACCGGACTGATCTTCCACTTGGGCCAGGCCCGGACGCCCCCCTACTTGCAGTTGCAGGTGCTA CCCCGCCAGGTCCTGCTGCGGGCGGATGACGGAGCAGGGGAGTTCTCCACGTCAGTGACCCGCCCCTCAGTG CTGTGTGATGGCCAGTGGCACCGGCTAGCGGTGATGAAAAGCGGGAATGTGCTCCGGCTGGAGGTGGACGCG CAGAGCAACCACACCGTGGGCCCCTTGCTGGCGGCTGCAGCTGGTGCCCCAGCCCCTCTGTACCTCGGGGGC CTGCCTGAGCCCATGGCCGTGCAGCCCTGGCCCCCCGCCTACTGCGGCTGCATGAGGAGGCTGGCGGTGAAC CGGTCCCCCGTCGCCATGACTCGCTCTGTGGAGGTCCACGGGGCAGTGGGGGCCAGTGGCTGCCCAGCCGCC TAGAATAAA
In a search of public sequence databases, the NOVla nucleic acid sequence, located on chromsome 20 is 80% identical to a gb:GENBANK-ID:MMU37501|acc:U37501.1 Mus musculus laminin alpha 5 chain (Lama5) mRNA, and 61% identical to a gb:GENBANK- ID:DROLAMZ|acc:L07288.1 Drosophila melanogaster laminin A (Lam- A) mRNA. Public nucleotide databases include all GenBank databases and the GeneSeq patent database. In all BLAST alignments herein, the "E- value" or "Expect" value is a numeric indication of the probability that the aligned sequences could have achieved their similarity to the BLAST query sequence by chance alone, within the database that was searched. For example, the probability that the subject ("Sbjct") retrieved from the NOVl BLAST analysis, e.g., Mus musculus laminin alpha 5 chain (Lama5) mRNA, matched the Query NOVl sequence purely by chance is 0.0. The Expect value (E) is a parameter that describes the number of hits one can "expect" to see just by chance when searching a database of a particular size. It decreases exponentially with the Score (S) that is assigned to a match between two sequences. Essentially, the E value describes the random background noise that exists for matches between sequences.
The Expect value is used as a convenient way to create a significance threshold for reporting results. The default value used for blasting is typically set to 0.0001. In BLAST 2.0, the Expect value is also used instead of the P value (probability) to report the significance of matches. For example, an E value of one assigned to a hit can be inteφreted as meaning that in a database of the current size one might expect to see one match with a similar score simply by chance. An E value of zero means that one would not expect to see any matches with a similar score simply by chance. See, e.g., http://www.ncbi.nlm.mh.gov/Education/BLASTinfo/. Occasionally, a string of X's or N's will result from a BLAST search. This is a result of automatic filtering of the query for low- complexity sequence that is performed to prevent artifactual hits. The filter substitutes any
low-complexity sequence that it finds with the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNN") or the letter "X" in protein sequences (e.g., "XXXXXXXXX"). Low-complexity regions can result in high scores that reflect compositional bias rather than significant position-by-position alignment. (Wootton and Federhen, Methods Enzymol 266:554-571, 1996).
The disclosed NOVla polypeptide (SEQ ID NO:2) encoded by SEQ ID NO:l has 3600 amino acid residues and is presented in Table IB using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVla has a signal peptide and is likely to be localized extracelhilarly with a certainty of 0.8200. hi other embodiments, NOVla may also be localized to the lysosome (lumen) with acertamty of 0.1900, the endoplasmic reticulum (membrane) with a certainty of 0.1000 or in the endoplasmic reticulum (lumen) with a certainty of 0.1000. The most likely cleavage site for a NOVla peptide is between amino acids 14 and 15, at: CVR-GP.
Table IB. Encoded NOVla protein sequence (SEQ ID NO:2).
MAKRLCAGSALCVRGPRGPAPLLLHPPYFNLAEGARIAASATCGEEAPA GSPRPTEDLYCKLV GGPVAGGDPNQTIQGQYCDICTAANSNKAHPASNAIDGTER QSPPLSRGLEYNEVNVTLDLG QVFHVAYVLIKFANSPRPDL VLΞRSMDFGRTYQP QFFAASKRDCLERFGPQTLERITRDDAA ICTTEYSRIVP EWGEI VΥSLV GRPGAMNFSYSPLLRΞFTKATNVRLRF RTMT LGH MGKA LRDPTVTRRYYYSIKDISIGGRCVCHGHADACDAKDPTDPFRLQCTCQHNTCGGTCDRCCPGFN QQPWKPATANSA ECQCECYGHATDCYYDPEVTJRRRASQS DGTYQGGGVCIDCQHHTTGVNCE RCLPGFYRSPNHPLDSPHVCRGCMCESDFTDGTCEDLTGRCYCRPNFSGERCDVCAEGFTGFPS CYREHLPGNDTREQVLPAGQIVSCDCSAAGTQGHΆCRKDPRVGRC CKPN-FQGTHCELCAPGFY GPGCPASVPAIEWPMTAVTLTQASAGAEWASRGPHVIAVPPATFTS SASHPLRSAVCGCSPAG TLPEGCDΞAGRCLCQPEFAGPHCDRCRPGYHGFPNCAACTCDPRGALDQLCGAGGLCRCRPGYT GTACQECSPGFHGFPSCPATAL KAPCTQPVTPGVGSAAAGPVRGCGVTHVCPVPTTSPTAKP FTAGSCHPAGLAPVDPALPEVSPPCMCRAHVEGPSCDRCKPGF GLSPSNPEGCTRCSCDLRGT GGVAECQGTGQCFCKPHVCGQACASCKDGFFG DQADYFGCRSCRCDIGGA GQSCEPRTGVC RCRPNTQGPTCSEPARDHYLPDLHHLRLELEEAATPEGHAVRFGFNPLEFENFSWRGYAQMAPV QPRIVARLNLTSPDLFWLVFRYWRGA SVSGRVSVREEGRSATCANCTAQSQPVAFPPSTEPA
FITVPQRGFGEPFVLNPGTWA RVEAΞGVL DYWILPSAYYEAA LQLRVTEACTYRPSAQQS PPSCLLYTHLPLDGFPSAAGLEA CRQDNSLPRPCPTEQLSPSHPPLITCTGSDVDVQLQVAVP QPGRYA WEYANEDARQEVGVAλ TPQRAPQQG ΞLHPC YΞT CRGTARDTQDHLAVFHLD SEASVRLTAEQARFFLHGVTLVPIEEFSPEFVEPRVSCISSHGAFGPNSAACLPSRFPKPPQPI ILRDCQVIPLPPGLPLTHAQDLTPAMSPAGPRPRPPTAVDPDAEPTLLREPQATWFTTHVPTL GRYAFLLHGYQPAHPTFPVEV INAGRVWQGHAASFCPHGYGCRTLWCEGQA DVTHSELT VTVRVPKGRWL LDYVLWPEKTVYSFGYLREEPLDKSYDFISHCAAQGYHISPSSSSLFCRNAA ASLSLFYHNGARPCGCHEVGATGPTCEPFGGQCPCHAHVIGRDCSRCATGY GFPNCRACDCGA RLCDELTGQCICPPRTIPPDC CQPQTFGCHPLVGCEECNCSGPGIQELTDPTCDTDSGQCRC RPMVTGRRCDTCSPGFHGYPRCRPCDCHEAGTAPGVCDPLTGQCYCKENVQGPKCDQCSLGTFS LDAANPKGCTRCFCFGATERCRSSSYTRQEFVDMEGWVL STDRQWPHERQPGTEMLRAD RH VPEAVPEAFPELYWQAPPSYLGDRVSSYGGT RYE HSETQRGDVFVPMESRPDWLQGNQMSI TFLΞPAYPTPGHVHRGQ QLVEGNFRHTETRNTVSREELMMVLAS EQLQIRALFSQISSAVFL RRVALEVASPAGQGAASNVELCLCPASYRGDSCQECAPGFYRDVKGLFLGRCVPCQCHGHSDR CLPGSGVCVCQH TEGAHCERCQAGFVSSRDDPSAPCVSCPCPLSVPSNRCAPGFFGNPLV GS SCQPCDCSGNGDPNL FSDCDPLTGACRGCLRHTTGPRCEICAPGFYGNA LPGKTCTRCDCTPC GTEACDPHSGHCLCKAGVTGRRCDRCQEGHFGFDGCGGCRPCACGPAAEGSECHPQSGQCHCRP GTMGPQCRECAPGY GLPEQGCRRCQCPGGRCDPHTGRCNCPPGLSGERCDTCSQQHQVPVPGG PVGHSIHCEVCDHCWI.LLDD ERAGALLPAIHEQ RGINASSMA ARLHRLNASIADLQV SV
LAFPPQPGPVQAFTFRLPQSQLRSP GPRHETAQQLEVLEQQSTSLPPQAVGTRDQASQ LAGT EAT GHAKTLLAAIRAA7DRTLSELMSQTGHLGLANASAPSGEQI.LRTLAEVERL EMRARD G APQAAAEAE AAAQRVLARVQEQ SSLWEENQA ATQTRDRLAHEAGLMD REALHRAVDATR EAQELNSRNQERLEEA QRKQE SRDMATLQAT HAARDTLASVFRL EGLSPLKFQE ERLAA S DGARTPLLQRMQTFSPAGSKLRLVEAAEAHAQQLGQLALW SIILDVNQDRLTQRAIEASNA YSRILQAVQAAEDAAGQALQQADHT QTWRQGLVDRAQQLLANSTA EEAMLQEQQR GLGEC WAPMGALRPAGTQ RDVRA KDQLEAHIQAAQAMLAMDTGETSKKIAHAKAVAAEAQDTATRVQ SQLQAMQENVER QGQYEGLRGQDLGQAVLDAGSAVSTLEKTLPQLLAKLSILENRGVHNASLA LSASIGRVRELIAQARGAASKWKVPMKFNGRSGVQLRTPRDLADLAAYTALKFYLQGPEPEPG QGTEDRFVMYMGSRQATGDY GVSLRDKKVHWVYQLGEAGPAVLSIDEDIGEQFAAVSLDRTLQ FGHMSVTVΞRQMIQETKGDTVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLLRFPGYRGCIΞM DTLNΞEWS YNFERTFQLDTAVDRPCARSKSTGDP LTDGSYIJDGTGFARISFDSQISTTKRF ΞQELRLVSYSGVLFFLKQQSQFLCLAVQEGS V IiYDFGAGLKKAVPLQPPPP TSASKAIQVF LGGSRKRVLVRVERATVYSVEQD D E ADAYYLGGVPPDQLPSLRRLFPTGGSVRGCV GI ALGKYVDLKR NTTGVSAGCTAD LVGRAMTFHGHGFLRLALSNVAPLTG VYSGFGFHSAQDS ALLYYRASPVRPH VSLQQGRVS QLLRTEVKTQAGFADGAPHYVAFYSNATGVW YVDDQLQQ MKPHRGPPPE QPQPEGPPR LLGGLPESGTIYNFSGCISNVFVQR LGPQRVFDLQQNLGSV VSTGCAPALQAQTPGLGPRQASRRSRQPARHPACMLPPHLRTTRDSYQFGGSLSSH EFVGILA RHRVSVR EK RILLVTDGARA SQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSKLPVTVGF SGCVKRLRLHGRP GAPTRMAGVTPCILGP EAGLFFPGSGGVITLGLPGATLPDVGLE EVRP AVTGLIFHLGQARTPPYLQ QV PRQλ7LLRADDGAGEFSTSVTRPSV CDGQ HRIiA\7MKSGN VLRIiEVDAQSNHTVGPL AAAAGAPAPLY GGLPEPMAVQPWPPAYCGCMRRLA7NRSPVAMTR SVEVHGAVGASGCPAA
A search of sequence databases reveals that the NOVla amino acid sequence has 2566 of 3652 amino acid residues (70%) identical to, and 2823 of 3652 amino acid residues (77%) similar to, the 3652 amino acid residue ptnr:>ptnr: SWISSNEW-ACC:T10053 laminin alpha 5 chain from mouse (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
NOVla is expressed in at least the following tissues: brain, Prostate, ovary, kidney, melanocyte+heart+uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung+testis+b-cell, dorsal root ganglia. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
NOVlb
A disclosed NOVlb nucleic acid of 3126 nucleotides (also referred to as CGI 02167- 01) encoding a novel human laminin alpha 5-like protein is shown in Table IC. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 121-123 and ending with a TGA termination codon at nucleotides 2845-2847. The start and stop codons are in bold letters in Table IC, and the 5' and 3' untranslated regions are underlined.
Table IC. NOVlb nucleotide sequence (SEQ ID NO:3).
TCAGGGGTGCAGCTGCGCACCCCACGGGATCTTGCCGACCTTGCTGCCTACACTGCCCTCAAGTTCTACCTG CAGGGCCCAGAGCCTGAGCCTGGGCAGGGTACCGAGGATCGCTTTGTGATGTACATGGGCAGCCGCCAGGCC ACTGGGGACTACATGGGTGTGTCTCTGCGTGACAAGAAGGTGCACTGGGTGTATCAGCTGGGTGAGGCGGGC CCTGCAGTCCTAAGCATCGATGAGGACATTGGGGAGCAGTTCGCAGCTGTCAGCCTGGACAGGACTCTCCAG TTTGGCCACATGTCCGTCACAGTGGAGAGACAGATGATCCAGGAAACCAAGGGTGACACGGTGGCCCCTGGG GCAGAGGGGCTGCTCAACCTGCGGCCAGACGACTTCGTCTTCTACGTCGGGGGGTACCCCAGTACCTTCACG CCCCCTCCCCTGCTTCGCTTCCCCGGCTACCGGGGCTGCATCGAGATGGACACGCTGAATGAGGAGGTGGTC AGCCTCTACAACTTCGAGAGGACCTTCCAGCTGGACACGGCTGTGGACAGGCCTTGTGCCCGCTCCAAGTCG ACCGGGGACGCGTGGCTCACGGACGGCTCCTACCTGGACGGCACCGGCTTCGCCCGCATCAGCTTCGACAGT CAGATCAGCACCACCAAGCGCTTCGAGCAGGAGCTGCGGCTCGTGTCCTACAGCGGGGTGCTCTTCTTCCTG AAGCAGCAGAGCCAGTTCCTGTGCTTGGCCGTGCAAGAAGGCAGCCTCGTGCTGTTGTATGACTTTGGGGCT GGCCTGAAAAAGGCCGTCCCACTGCAGCCCCCACCGCCCCTGACCTCGGCCAGCAAGGCGATCCAGGTGTTC CTGCTGGGGGGCAGCCGCAAGCGTGTGCTGGTGCGTGTGGAGCGGGCCACGGTGTACAGCGTGGAGCAGGAC AATGATCTGGAGCTGGCCGACGCCTACTACCTGGGGGGCGTGCCGCCCGACCAGCTGCCCCCGAGCCTGCGA TGGCTCTTCCCCACCGGAGGCTCAGTCCGTGGCTGCGTCAAAGGCATCAAGGCCCTGGGCAAGTATGTGGAC CTCAAGCGGCTGAACACGACAGGCGTGAGCGCCGGCTGCACCGCCGACCTGCTGGTGGGGCGCGCCATGACT TTCCATGGCCACGGCTTCCTTCGCCTGGCGCTCTCGAACGTGGCACCGCTCACTGGCAACGTCTACTCCGGC TTCGGCTTCCACAGCGCCCAGGACAGTGCCCTGCTCTACTACCGGGCGTCCCCGGATGGGCTATGCCAGGTG TCCCTGCAGCAGGGCCGTGTGAGCCTACAGCTCCTGAGGACTGAAGTGAAAACTCAAGCGGGCTTCGCCGAT GGTGCCCCCCATTACGTCGCCTTCTACAGCAATGCCACGGGAGTCTGGCTGTATGTCGATGACCAGCTCCAG CAGATGAAGCCCCACCGGGGACCACCCCCCGAGCTCCAGCCGCAGCCTGAGGGGCCCCCGAGGCTCCTCCTG GGAGGCCTGCCTGAGTCTGGCACCATTTACAACTTCAGTGGCTGCATCAGCAACGTCTTCGTGCAGCGGCTC CTGGGCCCACAGCGCGTATTTGATCTGCAGCAGAACCTGGGCAGCGTCAATGTGAGCACGGGCTGTGCACCC GCCCTGCAAGCCCAGACCCCGGGCCTGGGGCCTAGAGGACTGCAGGCCACCGCCCGGAAGGCCTCCCGCCGC AGCCGTCAGCCCGCCCGGCATCCTGCCTGCATGCTGCCCCCACACCTCAGGACCACGCGAGACTCCTACCAG TTTGGGGGTTCCCTGTCCAGTCACCTGGAGTTTGTGGGCATCCTGGCCCGACATAGGAACTGGCCCAGTCTC TCCATGCACGTCCTCCCGCGAAGCTCCCGAGGCCTCCTCCTCTTCACTGCCCGTCTGAGGCCCGGCAGCCCC TCCCTGGCGCTCTTCCTGAGCAATGGCCACTTCGTTGCACAGATGGAAGGCCTCGGGACTCGGCTCCGCGCC CAGAGCCGCCAGCGCTCCCGGCCTGGCCGCTGGCACAAGGTCTCCGTGCGCTGGGAGAAGAACCGGATCCTG CTGGTGACGGACGGGGCCCGGGCCTGGAGCCAGGAGGGGCCGCACCGGCAGCACCAGGGGGCAGAGCACCCC CAGCCCCACACCCTCTTTGTGGGCGGCCTCCCGGCCAGCAGCCACAGCTCCAAACTTCCGGTGACCGTCGGG TTCAGCGGCTGTGTGAAGAGACTGAGGCTGCACGGGAGGCCCCTGGGGGCCCCCACACGGATGGCAGGGGTC ACACCCTGCATCTTGGGCCCCCTGGAGGCGGGCCTGTTCTTCCCAGGCAGCGGGGGAGTTATCACTTTAGAC CTCCCAGGAGCTACACTGCCTGATGTGGGCCTGGAACTGGAGGTGCGGCCCCTGGCAGTCACCGGACTGATC TTCCACTTGGGCCAGGCCCGGACGCCCCCCTACTTGCAGTTGCAGGTCCTGCTGCGGGCGGATGACGGAGCA GGGGAGTTCTCCACGTCAGTGACCCGCCCCTCAGTGCTGTGTGATGGCCAGTGGCACCGGCTAGCGGTGATG AAAAGCGGGAATGTGCTCCGGCTGGAGGTGGACGCGCAGAGCAACCACACCGTGGGCCCCTTGCTGGCGGCT GCAGCTGGTGCCCCAGCCCCTCTGTACCTCGGGGGCCTGCCTGAGCCCATGGCCGTGCAGCCCTGGCCCCCC GCCTACTGCGGCTGCATGAGGAGGCTGGCGGTGAACCGGTCCCCCGTCGCCATGACTCGCTCTGTGGAGGTC CACGGGGCAGTGGGGGCCAGTGGCTGCCCAGCCGCCTAGGACACAGCCAACCCCGGCCCCTGGTCAGGCCCC TGCAGCTGCCTCACACCGCCCCTTGTGCTCGCCTCATAGGTGTCTATTTGGACTCTAAGCTCTACGGGTGAC AGATCTTGTTTCTGAAGATGGTTTAAGTTATAGCTTCTTAAACGAAAGAATAAAATACTGCAAAATGTTTTT ATATTTGGCCCTTCCACCCATTTTTAATTGTGAGAGATTTGTCACCAATCATCACTGGTTCCTCCTTAAAAA TTAAAAAGTAACTTCTGTGTAAAAAAAAAA
In a search of public sequence databases, the NOVlb nucleic acid sequence, located on chromsome 20 has 2495 of 2495 bases (100%) identical to a gb:GENBANK- ID:HSLAMA5|acc:Z95636.1 mRNA from Homo sapiens (H.sapiens mRNA for laminin alpha 5 chain) (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOVlb polypeptide (SEQ ID NO:4) encoded by SEQ ID NO:3 has 908 amino acid residues and is presented in Table IB using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVlb has no signal peptide and is likely to be locahzed the microbody (peroxisome) with a certainty of 0.5371. In other embodiments, NOVlb may also be localized to the lysosome (lumen) with acertainty of 0.3191, the
mitochondrial matrix space with a certainty of 0.1000 or in the nucleus with a certainty of 0.1000.
Table ID. Encoded NOVlb protein sequence (SEQ ID NO:4).
MYMGSRQATGDYMGVSLRDKKVHWVYQLGEAGPAVLSIDEDIGEQFAAVSLDRTLQFGHMSVTVERQ IQET KGDTVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLIRFPGYRGCIEMDTLMEEVVSLYNFERTFQLDTAVD RPCARSKSTGDP LTDGSYLDGTGFARISFDSQISTTKRFEQELRLVSYSGVLFFLKQQSQFLCLAVQEGSL VLLYDFGAGL KAVPLQPPPPLTSASKAIQVFLLGGSRKVLVRVERATVYSVEQDNDLELADAYYLGGVPP DQLPPSLRWLFPTGGSVRGCV GIKALGKYVDL RLNTTGVSAGCTADLLVGRAMTFHGHGFLRLALSNVAP LTGNVYSGFGFHSAQDSALLYYRASPDGLCQVSLQQGRVSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVW LYVDDQLQQMKPHRGPPPELQPQPEGPPRLIJLGGLPESGTIYNFSGCISNVFVQRLLGPQRVFDLQQNLGSV NVSTGCAPALQAQTPGLGPRGLQATARKASRRSRQPARHPACMLPPHLRTTRDSYQFGGSLSSHLEFVGILA RHRN PSLSMHVLPRSSRGLLLFTARLRPGSPSLALFLSNGHFVAQMEGLGTRLRAQSRQRSRPGR HKVSV EKNRILLVTDGARA SQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSKLPVTVGFSGCVKRLRLHGRPLG APTRMAGVTPCILGPLEAGLFFPGSGGVITLDLPGATLPDVGLELEVRPLAVTGLIFHLGQARTPPYLQLQV LLRADDGAGEFSTSVTRPSVLCDGQ HRLAVMKSGNVLRLEVDAQSNHTVGPLILAAAAGAPAPLYLGGLPEP AVQP PPAYCGCMRRLAVNRSPVAMTRSVEVHGAVGASGCPAA
A search of sequence databases reveals that the NOVlb amino acid sequence has 908 of 913 amino acid residues (99%) identical to, and 908 of 913 amino acid residues (99%) similar to, the 1645 amino acid residue ptnr:SWISSNEW-ACC:O15230 protein from Homo sapiens (Human) (Laminin Alpha-5 Chain) (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR. NOVlb is expressed in at least the following tissues: brain, Prostate, ovary, kidney, melanocyte, heart, uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung, testis, b-cell, dorsal root ganglia. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CGI 02167-01. The sequence is predicted to be expressed in placenta because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSLAMA5|acc:Z95636.1) a closely related H.sapiens mRNA for laminin alpha 5 chain.
NOVlc
A disclosed NOVlc nucleic acid of 10800 nucleotides (also referred to as CG55974- 02) encoding a novel human laminin alpha 5-like protein is shown in Table IE. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA termination codon at nucleotides 10792-10794. The start and stop codons are in bold letters in Table IE, and the 5' and 3' untranslated regions are underlined. Since the start codon of NOVlc is not a traditional initiation codon, and NOVlc has no termination codon, NOVlc could be a partial open reading frame that could be extended in the 5' and/or 3' direction(s).
Table IE. NOVlc nucleotide sequence (SEQ ID NO:5).
ATGGCGAAGCGGCTCTGCGCGGGGAGCGCACTGTGTGTTCGCGGCCCCCGGGGCCCCGCGCCGCTGCTGCTG CACCCGCCCTACTTCAACCTGGCCGAGGGCGCCCGCATCGCCGCCTCCGCGACCTGCGGAGAGGAGGCCCCG
GCGCGCGGCTCCCCGCGCCCCACCGAGGACCTTTACTGCAAGCTGGTAGGGGGCCCCGTGGCCGGCGGCGAC CCCAACCAGACCATCCAGGGCCAGTACTGTGACATCTGCACGGCTGCCAACAGCAACAAGGCACACCCCGCG AGCAATGCCATCGATGGCACGGAGCGCTGGTGGCAGAGTCCACCGCTGTCCCGCGGCCTGGAGTACAACGAG GTCAACGTCACCCTGGACCTGGGCCAGGTCTTCCACGTGGCCTACGTCCTCATCAAGTTTGCCAACTCACCC CGGCCGGACCTCTGGGTGCTGGAGCGGTCCATGGACTTCGGCCGCACCTACCAGCCCTGGCAGTTCTTTGCC GCCTCCAAGAGGGACTGTCTGGAGCGGTTCGGGCCACAGACGCTGGAGCGCATCACACGGGACGACGCGGCC TCTGCACCACCGAGTACTCACGCATCGTGCCCCTGGAGAACGGAGAGATCGTGGTGTCCCTGGTGAACGGA CGTCCGGGCGCCATGAATTTCTCCTACTCGCCGCTGCTACGTGAGTTCACCAAGGCCACCAACGTCCGCCTG CGCTTCCTGCGTACCAACACGCTGCTGGGCCATCTCATGGGGAAGGCGCTGCGGGACCCCACGGTCACCCGC CGGTATTATTACAGCATCAAGGATATCAGCATCGGAGGCCGCTGTGTCTGCCACGGCCACGCGGATGCCTGC GATGCCAAAGACCCCACGGACCCGTTCAGGCTGCAGTGCACCTGCCAGCACAACACCTGCGGGGGCACCTGC GACCGCTGCTGCCCCGGCTTCAATCAGCAGCCGTGGAAGCCTGCGACTGCCAACAGTGCCAACGAGTGCCAG TGTGAGTGCTACGGCCATGCCACCGACTGTTACTACGACCCTGAGGTGGACCGGCGCCGCGCCAGCCAGAGC CTGGATGGCACCTATCAGGGTGGGGGTGTCTGTATCGACTGCCAGCACCACACCACCGGCGTCAACTGTGAG CGCTGCCTGCCCGGCTTCTACCGCTCTCCCAACCACCCTCTCGACTCGCCCCACGTCTGCCGCGGCTGCAAC GCGAGTCCGACTTCACGGATGGCACCTGCGAGGACCTGACGGGTCGATGCTACTGCCGGCCCAACTTCTCT GGGGAGCGGTGTGACGTGTGTGCCGAGGGCTTCACGGGCTTCCCAAGCTGCTACCGTGAGCACCTGCCAGGG AATGACACCAGGGAGCAGGTGCTGCCAGCCGGCCAGATTGTGAGTTGTGACTGCAGCGCGGCAGGGACCCAG GGCAACGCCTGCCGGAAGGACCCAAGGGTGGGACGCTGTCTGTGCAAACCCAACTTCCAAGGCACCCATTGT GAGCTCTGCGCGCCAGGGTTCTACGGCCCCGGCTGCCCTGCCAGTGTTCCAGCCCTGGAGTGGCCGATGACC GCTGTGACCCTGACACAGGCCAGTGCAGGTGCCGAGTGGGCTTCGAGGGGGCCACATGTGATCGCTGTGCCC CCGGCTACTTTCACTTCCCTCTCTGCCAGTCACCCGCTCCGCTCTGCAGTGTGTGGCTGCAGCCCTGCAGGA ACCTTGCCCGAGGGCTGCGATGAGGCCGGCCGCTGCCTATGCCAGCCTGAGTTTGCTGGACCTCATTGTGAC CGGTGCCGCCCTGGCTACCATGGTTTCCCCAACTGCGCAGCATGCACCTGCGACCCTCGGGGAGCCCTGGAC CAGCTCTGTGGGGCGGGAGGTTTGTGCCGCTGCCGCCCCGGCTACACAGGCACTGCCTGCCAGGAATGCAGC CCCGGCTTTCACGGCTTCCCCAGCTGTCCTGCCACTGCTCTGCTGAAGGCTCCCTGCACGCAGCCTGTGACC CCCGGAGTGGGCAGTGCAGCTGCCGGCCCCGTGCGGGGCTGCGGTGTGACACGTGTGTGCCCGGTGCCTACA ACTTCCCCTACTGCGAAGCTGGCTCTTGCCACCCTGCCGGTCTGGCCCCCAGTGGATCCTGCCCTTCCTGAG GCACAGGTTCCCTGTATGTGCCGGGCTCACGTGGAGGGGCCGAGCTGTGACCGCTGCAAACCTGGGTTCTGG GGACTGAGCCCCAGCAACCCCGAAGGCTGTACCCGCTGCAGCTGCGACCTCAGGGGCACACTGGGTGGAGTT GCTGAGTGCCAGCCGGGCACCGGCCAGTGCTTCTGCAAGCCCCACGTGTGCGGCCAGGCCTGCGCGTCCTGC AAGGATGGCTTCTTTGGACTGGATCAGGCTGACTATTTTGGCTGCCGCAGCTGCCGGTGTGACATTGGCGGT GCACTGGGCCAGAGCTGTGAACCGAGGACGGGCGTCTGCCGGTGCCGCCCCAACACCCAGGGCCCCACCTGC AGCGAGCCTGCGAGGGACCACTACCTCCCGGACCTGCACCACCTGCGCCTGGAGCTGGAGGAGGCTGCCACA CCTGAGGGTCACGCCGTGCGCTTTGGCTTCAACCCCCTCGAGTTCGAGAACTTCAGCTGGAGGGGCTACGCG CAGATGGCACCTGTCCAGCCCAGGATCGTGGCCAGGCTGAACCTGACCTCCCCCGACCTTTTCTGGCTCGTC TTCCGATACGTCAACCGGGGGGCCATGAGTGTGAGCGGGCGGGTCTCTGTGCGAGAGGAGGGCAGGTCGGCC GCCTGTGCCAACTGCACAGCACAGAGTCAGCCCGTGGCCTTCCCACCCAGCACGGAGCCTGCCTTCATCACC GTGCCCCAGAGGGGCTTCGGAGAGCCCTTTGTGCTGAACCCTGGCACCTGGGCCCTGCGTGTGGAGGCCGAA GGGGTGCTCCTGGACTACGTGGTTCTGCTGCCTAGCGCATACTACGAGGCGGCGCTCCTGCAGCTGCGGGTG ACTGAGGCCTGCACATACCGTCCCTCTGCCCAGCAGTCTCCCCCCAGCTGCCTCCTCTACACACACCTCCCC CTGGATGGCTTCCCCTCGGCCGCCGGGCTGGAGGCCCTGTGTCGCCAGGACAACAGCCTGCCCCGGCCCTGC CCCACGGAGCAGCTCAGCCCGTCGCACCCGCCACTGATCACCTGCACGGGCAGTGATGTGGACGTCCAGCTT CAAGTGGCAGTGCCACAGCCAGGCCGCTATGCCCTAGTGGTGGAGTACGCCAATGAGGATGCCCGCCAGGAG GTGGGCGTGGCCGTGCACACCCCACAGCGGGCCCCCCAGCAGGGGCTGCTCTCCCTGCACCCCTGCCTGTAC AGCACCCTGTGCCGGGGCACTGCCCGGGATACCCAGGACCACCTGGCTGTCTTCCACCTGGACTCGGAGGCC AGCGTGAGGCTCACAGCCGAACAGGCACGCTTCTTCCTGCACGGGGTCACTCTGGTGCCCATTGAGGAGTTC AGCCCGGAGTTCGTGGAGCCCCGGGTCAGCTGCATCAGCAGCCACGGCGCCTTTGGCCCCAACAGTGCCGCC GTCTGCCCTCGCGCTTCCCAAAGCCGCCCCAGCCCATCATCCTCAGGGACTGCCAGGTGATCCCGCTGCCG CCCGGCCTCCCGCTGACCCACGCGCAGGATCTCACTCCAGCCATGTCCCCAGCTGGACCCCGACCTCGGCCC CCCACCGCTGTGGACCCTGATGCAGAGCCCACCCTGCTGCGTGAGCCCCAGGCCACCGTGGTCTTCACCACC CATGTGCCCACGCTGGGCCGCTATGCCTTCCTGCTGCACGGCTACCAGCCAGCCCACCCCACCTTCCCCGTG GAAGTCCTCATCAACGCCGGCCGCGTGTGGCAGGGTCACGCCAACGCCAGCTTCTGTCCACATGGCTACGGC TGCCGCACCCTGGTGGTGTGTGAGGGCCAGGCCCTGCTGGACGTGACCCACAGCGAGCTCACTGTGACCGTG CGTGTGCCCAAGGGCCGGTGGCTCTGGCTGGATTATGTACTCGTGGTCCCTGAGAACGTCTACAGCTTTGGC TACCTCCGGGAGGAGCCCCTGGATAAATCCTATGACTTCATCAGCCACTGCGCAGCCCAGGGCTACCACATC AGCCCCAGCAGCTCATCCCTGTTCTGCCGAAACGCTGCTGCTTCCCTCTCCCTCTTCTATAACAACGGAGCC CGTCCATGTGGCTGCCACGAAGTAGGTGCTACAGGCCCCACGTGTGAGCCCTTCGGGGGCCAGTGTCCCTGC CATGCCCATGTCATTGGCCGTGACTGCTCCCGCTGTGCCACCGGATACTGGGGCTTCCCCAACTGCAGGGCC TGTGACTGCGGTGCCCGCCTCTGTGACGAGCTCACGGGCCAGTGCATCTGCCCGCCACGCACCATCCCGCCC GACTGCCTGCTGTGCCAGCCCCAGACCTTTGGCTGCCACCCCCTGGTCGGCTGTGAGGAGTGTAACTGCTCA GGGCCCGGCATCCAGGAGCTCACAGACCCTACCTGTGACACAGACAGGGGCCAGTGCAGGTGCAGACCCAAC GTGACTGGGCGCCGCTGTGATACCTGCTCTCCGGGCTTCCATGGCTACCCCCGCTGCCGCCCCTGTGACTGT CACGAGGCGGGCACTGCGCCTGGCGTGTGTGACCCCCTCACAGGGCAGTGCTACTGTAAGGAGAACGTGCAG GGCCCCAAATGTGACCAGTGCAGCCTTGGGACCTTCTCACTGGATGCTGCCAACCCCAAAGGTTGCACCCGC
TGCTTCTGCTTTGGGGCCACGGAGCGCTGCCGGAGCTCGTCCTACACCCGCCAGGAGTTCGTGGATATGGAG GGATGGGTGCTGCTGAGCACTGACCGGCAGGTGGTGCCCCACGAGCGGCAGCCAGGGACGGAGATGCTCCGT GCAGACCTGCGGCACGTGCCTGAGGGTGTGCGCGAGGCTTTCCCCGAGCTGTACTGGCAGGCCCCAGCCTCC TACCTGGGGGACCGGGTAAGCTCCTACGGTGGGACCCTCCGTTATGAACTGCACTCAGAGACCCAGCGGGGA GATGTCTTTGTCCCCATGGAGAGCAGGCCGGATGTGGTGCTGCAGGGCAACCAGATGAGCATCACATTCCTG GAGCCGGCATACCCCACGCCTGGCCACGTTCACCGTGGGCAGCTGCAGCTGGTGGAGGGGAACTTCCGGCAT ACGGAGACGCGCAACACTGTGTCCCGCGAGGAGCTCATGATGGTGCTGGCCAGCCTGGAGCAGCTGCAGATC CGTGCCCTCTTCTCACAGATCTCCTCGGCTGTCTTCCTGCGCAGGGTGGCACTGGAGGTGGCCAGCCCAGCA GGCCAGGGGGCCCTGGCCAGCAATGTGGAGCTGTGCCTGTGCCCCGCCAGCTACCGGGGGGACTCATGCCAG GAATGTGCCCCCGGCTTCTATCGGGACGTCAAAGGTCTCTTCCTGGGCCGATGTGTCCCTTGTCAGTGCCAT GGACACTCAGACCGCTGCCTCCCTGGCTCTGGCGTCTGTGTGTGCCAGCACAACACCGAAGGGGCCCACTGT GAGCGCTGCCAGGCTGGCTTCGTGAGCAGCAGGGACGACCCCAGCGCCCCCTGTGTCAGCTGCCCCTGCCCC CTCTCAGTGCCTTCCAACAGGTGTGCGCCCGGATTCTTTGGGAACCCACTGGTGCTGGGCAGCTCCTGCCAG CCATGCGACTGCAGCGGCAACGGTGACCCCAACTTGCTCTTCAGCGACTGCGACCCCCTGACGGGCGCCTGC CGTGGCTGCCTGCGCCACACCACTGGGCCCCGCTGCGAGATCTGTGCCCCCGGCTTCTACGGCAACGCCCTG CTGCCCGGCAACTGCACCCGTTGCGACTGTACCCCATGTGGGACAGAGGCCTGCGACCCCCACAGCGGGCAC TGCCTGTGCAAGGCGGGCGTGACTGGGCGGCGCTGTGACCGCTGCCAGGAGGGACATTTTGGTTTCGATGGC TGCGGGGGCTGCCGCCCGTGTGCTTGTGGACCGGCCGCCGAGGGCTCCGAGTGCCACCCCCAGAGCGGACAG TGCCACTGCCGACCAGGGACCATGGGACCCCAGTGCCGCGAGTGTGCCCCTGGCTACTGGGGGCTCCCTGAG CAGGGCTGCAGGCGTTGCCAGTGCCCTGGGGGCCGCTGTGACCCTCACACGGGCCGCTGCAACTGCCCCCCG GGGCTCAGCGGGGAGCGCTGCGACACCTGCAGCCAGCAGCATCAGGTGCCTGTTCCAGGCGGGCCTGTGGGC CACAGCATCCACTGTGAAGTGTGTGACCACTGTGTGGTCCTGCTCCTGGATGACCTGGAACGGGCCGGCGCC CTCCTCCCCGCCATTCACGAGCAACTGCGTGGCATCAATGCCAGCTCCATGGCCTGGGCCCGTCTGCACAGG CTGAACGCCTCCATCGCTGACCTGCAGGTACTGAGCGTCCTGGCCTTCCCTCCCCAACCCGGGCCAGTGCAG GCCTTCACCTTTCGCCTCCCACAGAGCCAGCTCCGGAGCCCCCTGGGCCCCCGCCATGAGACGGCACAGCAG CTGGAGGTGCTGGAGCAGCAGAGCACAAGCCTTCCTCCACAGGCCGTGGGGACCCGAGACCAGGCGAGGCAA TTGCTGGCCGGCACCGAGGCCACACTGGGCCATGCGAAGACGCTGTTGGCGGCCATCCGGGCTGTGGACCGC ACCCTGAGCGAGCTCATGTCCCAGACGGGCCACCTGGGGCTGGCCAATGCCTCGGCTCCATCAGGTGAGCAG CTGCTCCGGACACTGGCCGAGGTGGAGCGGCTGCTCTGGGAGATGCGGGCCCGGGACCTGGGGGCCCCGCAG GCAGCAGCTGAGGCTGAGTTGGCTGCAGCACAGAGAGTGCTGGCCCGGGTGCAGGAGCAGCTGAGCAGCCTC TGGGAGGAGAACCAGGCACTGGCCACACAAACCCGCGACCGGCTGGCCCAGCACGAGGCCGGCCTCATGGAC CTGCGAGAGGCTTTGAACCGGGCAGTGGACGCCACACGGGAGGCCCAGGAGCTCAACAGCCGCAACCAGGAG CGCCTGGAGGAAGCCCTGCAAAGGAAGCAGGAGCTGTCCCGGGACAATGCCACCCTGCAGGCCACTCTGCAT GCGGCTAGGGACACCCTGGCCAGCGTCTTCAGATTGCTGGAGGGGCTAAGTCCACTCAAATTCCAGGAGCTG GAGCGCCTCGCCGCCAGCCTGGATGGGGCTCGGACCCCACTGCTGCAGAGGATGCAGACCTTCTCCCCGGCG GGCAGCAAGCTGCGTCTAGTGGAGGCCGCCGAGGCCCACGCACAGCAGCTGGGCCAGCTGGCACTCAATCTG TCCATCATCCTGGACGTCAACCAGGACCGCCTCACCCAGAGGGCCATCGAGGCCTCCAACGCCTACAGCCGC ATCCTGCAGGCCGTGCAGGCTGCCGAGGATGCTGCTGGCCAGGCCCTGCAGCAGGCGGACCACACGTGGCAG ACGGTGGTGCGGCAGGGCCTGGTGGACCGAGCCCAGCAGCTCCTGGCCAACAGCACTGCACTAGAAGAGGCC ATGCTCCAGGAACAGCAGAGGCTGGGCCTTGGTGAGTGCTGGGCTCCGATGGGGGCCCTTAGGCCTGCTGGG ACCCAGCTCCGAGATGTCCGGGCCAAGAAGGACCAGCTGGAGGCGCACATCCAGGCGGCGCAGGCCATGCTT GCCATGGACACAGGTGAGACAAGCAAGAAGATCGCACATGCCAAGGCTGTGGCTGCTGAAGCCCAGGACACC GCCACCCGTGTGCAGTCCCAGCTGCAGGCCATGCAGGAGAATGTGGAGCGGTGGCAGGGCCAGTACGAGGGC CTGCGGGGCCAGGACCTGGGCCAGGCAGTGCTTGACGCAGGCTCTGCAGTGTCCACCCTGGAGAAGACGCTG CCCCAGCTGCTGGCCAAGCTGAGCATCCTGGAGAACCGTGGGGTGCACAACGCCAGCCTGGCCCTGTCCGCC AGCATTGGCCGCGTGCGAGAGCTCATTGCCCAGGCCCGGGGGGCTGCCAGTAAGGTGGTCAAGGTGCCCATG AAGTTCAACGGGCGCTCAGGGGTGCAGCTGCGCACCCCACGGGATCTTGCCGACCTTGCTGCCTACACTGCC CTCAAGTTCTACCTGCAGGGCCCAGAGCCTGAGCCTGGGCAGGGTACCGAGGATCGCTTTGTGATGTACATG GGCAGCCGCCAGGCCACTGGGGACTACATGGGTGTGTCTCTGCGTGACAAGAAGGTGCACTGGGTGTATCAG CTGGGTGAGGCGGGCCCTGCAGTCCTAAGCATCGATGAGGACATTGGGGAGCAGTTCGCAGCTGTCAGCCTG GACAGGACTCTCCAGTTTGGCCACATGTCCGTCACAGTGGAGAGACAGATGATCCAGGAAACCAAGGGTGAC ACGGTGGCCCCTGGGGCAGAGGGGCTGCTCAACCTGCGGCCAGACGACTTCGTCTTCTACGTCGGGGGGTAC CCCAGTACCTTCACGCCCCCTCCCCTGCTTCGCTTCCCCGGCTACCGGGGCTGCATCGAGATGGACACGCTG AATGAGGAGGTGGTCAGCCTCTACAACTTCGAGAGGACCTTCCAGCTGGACACGGCTGTGGACAGGCCTTGT GCCCGGTCCAAGTCGACCGGGGACCCGTGGCTCACGGACGGCTCCTACCTGGACGGCACCGGCTTCGCCCGC ATCAGCTTCGACAGTCAGATCAGCACCACCAAGCGCTTCGAGCAGGAGCTGCGGCTCGTGTCCTACAGCGGG GTGCTCTTCTTCCTGAAGCAGCAGAGCCAGTTCCTGTGCTTGGCCGTGCAAGAAGGCAGCCTCGTGCTGTTG TATGACTTTGGGGCTGGCCTGAAAAAGGCCGTCCCACTGCAGCCCCCACCGCCCCTGACCTCGGCCAGCAAG GCGATCCAGGTGTTCCTGCTGGGGGGCAGCCGCAAGCGTGTGCTGGTGCGTGTGGAGCGGGCCACGGTGTAC AGCGTGGAGCAGGACAATGATGTGGAGCTGGCCGACGCCTACTACCTGGGGGGCGTGCCGCCCGACCAGCTG CCCAGCCTGCGACGGCTCTTCCCCACCGGAGGCTCAGTCCGTGGCTGCGTCAAAGGCATCAAGGCCCTGGGC AAGTATGTGGACCTCAAGCGGCTGAACACGACAGGCGTGAGCGCCGGCTGCACCGCCGACCTGCTGGTGGGG CGCGCCATGACTTTCCATGGCCACGGCTTCCTTCGCCTGGCGCTCTCGAACGTGGCACCGCTCACTGGCAAC GTCTACTCCGGCTTCGGCTTCCACAGCGCCCAGGACAGTGCCCTGCTCTACTACCGGGCGTCCCCGGTGAGA GCTCACCAGGTGTCCCTGCAGCAGGGCCGTGTGAGCCTACAGCTCCTGAGGACTGAAGTGAAAACTCAAGCG GGCTTCGCCGATGGTGCCCCCCATTACGTCGCCTTCTACAGCAATGCCACGGGGGTCTGGCTGTATGTCGAT GACCAGCTCCAGCAGATGAAGCCCCACCGGGGACCACCCCCCGAGCTCCAGCCGCAGCCTGAGGGGCCCCCG AGGCTCCTCCTGGGAGGCCTGCCTGAGTCTGGCACCATTTACAACTTCAGTGGCTGCATCAGCAACGTCTTC GTGCAGCGGCTCCTGGGCCCACAGCGCGTATTTGATCTGCAGCAGAACCTGGGCAGCGTCAATGTGAGCACG
GGCTGTGCACCCGCCCTGCAAGCCCAGACCCCGGGCCTGGGGCCTAGACAGGCCTCCCGCCGCAGCCGTCAG CCCGCCCGGCATCCTGCCTGCATGCTGCCCCCACACCTCAGGACCACCCGAGACTCCTACCAGTTTGGGGGT TCCCTGTCCAGTCACCTGGAGTTTGTGGGCATCCTGGCCCGACATAGGAACGTCTCCGTGCGCTGGGAGAAG AACCGGATCCTGCTGGTGACGGACGGGGCCCGGGCCTGGAGCCAGGAGGGGCCGCACCGGCAGCACCAGGGG GCAGAGCACCCCCAGCCCCACACCCTCTTTGTGGGCGGCCTCCCGGCCAGCAGCCACAGCTCCAAACTTCCG GTGACCGTCGGGTTCAGCGGCTGTGTGAAGAGACTGAGGCTGCACGGGAGGCCCCTGGGGGCCCCCACACGG ATGGCAGGGGTCACACCCTGCATCTTGGGCCCCCTGGAGGCGGGCCTGTTCTTCCCAGGCAGCGGGGGAGTT ATCACTTTAGGTCTGCCAGGAGCTACACTGCCTGATGTGGGCCTGGAACTGGAGGTGCGGCCCCTGGCAGTC ACCGGACTGATCTTCCACTTGGGCCAGGCCCGGACGCCCCCCTACTTGCAGTTGCAGGTGCTACCCCGCCAG GTCCTGCTGCGGGCGGATGACGGAGCAGGGGAGTTCTCCACGTCAGTGACCCGCCCCTCAGTGCTGTGTGAT GGCCAGTGGCACCGGCTAGCGGTGATGAAAAGCGGGAATGTGCTCCGGCTGGAGGTGGACGCGCAGAGCAAC CACACCGTGGGCCCCTTGCTGGCGGCTGCAGCTGGTGCCCCAGCCCCTCTGTACCTCGGGGGCCTGCCTGAG CCCATGGCCGTGCAGCCCTGGCCCCCCGCCTACTGCGGCTGCATGAGGAGGCTGGCGGTGAACCGGTCCCCC GTCGCCATGACTCGCTCTGTGGAGGTCCACGGGGCAGTGGGGGCCAGTGGCTGCCCAGCCGCCTAGAATAAA
In a search of public sequence databases, the NOVlc nucleic acid sequence, located on chromsome 20 has 3800 of 4840 bases (78%) identical to a gb:GENBANE - ID:MMU37501|acc:U37501.1 mRNA from Mus musculus (Mus musculus laminin alpha 5 chain (Lama5) mRNA, partial eds) (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOVlc polypeptide (SEQ ID NO:6) encoded by SEQ ID NO:5 has 3597 amino acid residues and is presented in Table IF using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVlc has a signal peptide and is likely to be localized the mitochondrial matrix space with a certainty of 0.4318. In other embodiments, NOVlc may also be localized to the microbody (peroxisome) with acertamty of 0.3000, the lysosome (lumen) with a certainty of 0.2055 or in the mitochondrial inner membrane with a certainty of 0.1122. The most likely cleavage site for NOVlc is between positions 14 and 15: CVR-GP
Table IF. Encoded NOVlc protein sequence (SEQ ID NO:6). AKRLCAGSALCVRGPRGPAPLLLHPPYFNLAEGARIAASATCGEEAPARGSPRPTEDLYCKLVGGPVAGGD PNQTIQGQYCDICTAANSHKAHPASNAIDGTERWWQSPPLSRGLEYNEVNVTLDLGQVFHVAYVLIKFANSP RPDLWVLERSMDFGRTYQPWQFFAASKRDCLERFGPQTLERITRDDAAICTTEYSRIVPLENGEIWSLVNG PGAMNFSYSPLLREFTKATNVRLRFLRTNTLLGHLMGKALRDPTVTRRYYYSIKDISIGGRCVCHGHADAC DAKDPTDPFRLQCTCQHNTCGGTCDRCCPGFNQQP KPATANSANECQCECYGHATDCYYDPEVDRRRASQS
LDGTYQGGGVCIDCQHHTTGVNCERCLPGFYRSPNHPLDSPHVCRGCNCESDFTDGTCEDLTGRCYCRPNFS GERCDVCAEGFTGFPSCYREHLPGNDTREQVLPAGQIVSCDCSAAGTQGNACRKDPRVGRCLCKPNFQGTHC ELCAPGFYGPGCPASVPALEWPMTAVTLTQAΞAGAEWASRGPHVIAVPPATFTSLSASHPLRSAVCGCSPAG LPEGCDEAGRCLCQPEFAGPHCDRCRPGYHGFPNCAACTCDPRGALDQLCGAGGLCRCRPGYTGTACQECS PGFHGFPSCPATALLKAPCTQPVTPGVGSAAAGPVRGCGVTRVCPVPTTSPTAKLALATLPVWPPVDPALPE QVPCMCRAHVEGPSCDRCKPGF GLSPSNPEGCTRCSCDLRGTLGGVAECQPGTGQCFCKPHVCGQACASC KDGFFGΓDQADYFGCRSCRCDIGGALGQSCEPRTGVCRCRPNTQGPTCSEPARDHYLPDLHHLRLELEEAAT PEGHAVRFGFNPLEFENFSWRGYAQMAPVQPRIVARLNLTSPDLFWLVFRYVNRGAMSVSGRVSVREEGRSA ACANCTAQSQPVAFPPSTEPAFITVPQRGFGEPFVLNPGTWALRVEAEGVLLDYWLLPSAYYEAALLQLRV EACTYRPSAQQSPPSCLLYTHLPLDGFPSAAGLEALCRQDNSLPRPCPTEQLSPSHPPLITCTGSDVDVQL QVAVPQPGRYALWEYANEDARQEVGVAVHTPQRAPQQGLLSLHPCLYSTLCRGTARDTQDHLAVFHLDSEA SVRLTAEQARFFLHGVTLVPIEEFSPEFVEPRVSCISSHGAFGPNSAACLPSRFPKPPQPIILRDCQVIPLP PGLPLTHAQDLTPAMSPAGPRPRPPTAVDPDAEPTLLREPQATWFTTHVPTLGRYAFLLHGYQPAHPTFPV
EVLINAGRVWQGHA ASFCPHGYGCRTLWCEGQALLDVTHSELTVTVRVPKGR L LIDYVLVVPE VYSFG YLREEPLDKSYDFISHCAAQGYHISPSSSSLFCRNAAASLSLFYNNGARPCGCHEVGATGPTCEPFGGQCPC HAHVIGRDCSRCATGY GFPHCRACDCGARLCDELTGQCICPPRTIPPDCIILCQPQTFGCHPLVGCEECMCS
GPGIQELTDPTCDTDSGQCRCRPNVTGRRCDTCSPGFHGYPRCRPCDCHEAGTAPGVCDPLTGQCYCKENVQ
GPKCDQCSLGTFSLDAANPKGCTRCFCFGATERCRSSSYTRQEFVDMEGWVLLSTDRQWPHERQPGTEMLR ADLRHVPEAVPEAFPELYWQAPPSYLGDRVSSYGGTLRYELHSETQRGDVFVP ESRPDWLQGNQMSITFL EPAYPTPGHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASLEQLQIRALFSQISSAVFLRRVALEVASPA GQGALASNVELCLCPASYRGDSCQECAPGFYRDVKGLFLGRCVPCQCHGHSDRCLPGSGVCVCQHNTEGAHC ERCQAGFVSSRDDPSAPCVSCPCP SVPSNRCAPGFFGNPLVLGSSCQPCDCSGNGDPNLLFSDCDPLTGAC RGCLRHTTGPRCEICAPGFYGNALLPGNCTRCDCTPCGTEACDPHSGHCLCKAGVTGRRCDRCQEGHFGFDG CGGCRPCACGPAAEGSECHPQSGQCHCRPGTMGPQCRECAPGYWGLPEQGCRRCQCPGGRCDPHTGRCNCPP GLSGERCDTCSQQHQVPVPGGPVGHSIHCEVCDHCWLLLDDLERAGALLPAIHEQLRGINASSMAWARLHR LNASIADLQVLSVLAFPPQPGPVQAFTFRLPQSQLRSPLGPRHETAQQLEVLEQQSTSLPPQAVGTRDQASQ LAGTEATLGHAKTLLAAIRAVDRTLSELMSQTGHLGLANASAPSGEQLLRTLAEVERLL EMRARDLGAPQ
AAAEAELAAAQRVLARVQEQLSSLWEENQATJATQTRDRLAQHEAGLMDLREALNRAVDATREAQELNSRNQE
RLEEALQR QΞLSRDNATLQATLHAARDTLASVFRLLEGLSPLKFQELERLAASLDGARTPLLQRMQTFSPA
GS KLiRLVEAAEAHAQQLGQLALNLS 11 LDV QDRLTQRAI EASNAYSRI LQAVQAAEDAAGQAIJQQADHTWQ TWRQGLVDRAQQLLANSTALEEAMLQEQQRLGLGEC APMGA RPAGTQIJRDVRAKKDQLEAHIQAAQAMIJ
AMDTGETSKKIAHA AVAAEAQDTATRVQSQLQAMQE VERWQGQYEGLRGQDLGQAVLDAGSAVSTLEKTL PQLLAKLSILENRGVHNASLALSASIGRVRELIAQARGAASKWKVPMKFNGRSGVQLRTPRDLADLAAYTA KFYLQGPEPEPGQGTEDRFVMYMGSRQATGDYMGVΞLRDK VH VYQLGEAGPAVLSIDEDIGEQFAAVSL DRTLQFGH SVTVERQMIQETKGDTVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLLRFPGYRGCIEMDTL
NEEWSLYNFERTFQLDTAVDRPCARSKSTGDP ITDGSYLDGTGFARISFDSQISTTKRFEQELRLVSYSG VLFFLKQQSQFLCLAVQEGSLVLLYDFGAGLKKAVPLQPPPPLTSASKAIQVFLLGGSRKRVLVRVERATVY SVEQDNDLELADAYYLGGVPPDQLPSLRRLFPTGGSVRGCVKGIKALGKYVDLKRLNTTGVSAGCTADLLVG RAMTFHGHGFLRLALSNVAPLTG VYSGFGFHSAQDSALLYYRASPVRPHQVSLQQGRVSLQLLRTEVKTQA GFADGAPHYVAFYSNATGV LYVDDQLQQMKPHRGPPPELQPQPEGPPRLLLGGLPESGTIYNFSGCISNVF VQRLLGPQRVFDLQQMLGSVNVSTGCAPALQAQTPGLGPRQASRRSRQPARHPACMLPPHLRTTRDSYQFGG SLSSHLEFVGILARHR VSVRWEK RILLVTDGARAWSQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSKLP VTVGFSGCV RLRLHGRPLGAPTRMAGVTPCILGPLEAGLFFPGSGGVITLGLPGATLPDVGLETEVRPLAV GLIIFHLGQARTPPYLQLQVLPRQVLLRADDGAGEFSTSVTRPSVLCDGQWHRLAVMKSGNVLRLEVDAQSN HTVGPLLAAAAGAPAPLYLGGLPEPMAVQPWPPAYCGCMRRIIAVNRSPVAMTRSVEVHGAVGASGCPAA
NOVlc is expressed in at least the following tissues: Mammalian Tissue, Small Intestine, Bone Marrow, brain, Prostate, ovary, kidney, melanocyte, heart, uterus, breast, head and neck, stomach, genitourinary tract, pancreas, lung, testis, b-cell, dorsal root ganglia. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55974-02.
NOVld
A disclosed NOVld nucleic acid of 5204 nucleotides (also referred to as 164875783) encoding a novel Human laminin alpha 5-like protein is shown in Table 1 G. An open reading frame was identified beginning with an TGT codon at nucleotides 3-5 and ending with a TAG codon at nucleotides 4923-4925. The start and stop codons are in bold letters and the 5' and 3' untranslated regions are underlined in Table IG. Because the start codon is not a traditional initiation codon, NOVld could be a partial reading frame. NOVld could extend further in the 5' direction.
Table IG. NOVld nucleotide sequence (SEQ ID NO:7).
GCTGTGACCGCTGCCAGGAGGGACATTTTGGTTTCAATGGCTGCGGGGGCTGCCGCCCGTGTGCTTGTGGAC CGGCCGCCGAGGGCTCCGAGTGCCACCCCCAGAGCGGACAGTGCCACTGCCGACCAGGGACCATGGGACCCC AGTGCCGCGAGTGTGCCCCTGGCTACTGGGGGCTCCCTGAGCAGGGCTGCAGGCGCTGCCAGTGCCCTGGGG GCCGCTGTGACCCTCACACGGGCCGCTGCAACTGCCCCCCGGGGCTCAGCGGGGAGCGCTGCGACACCTGCA GCCAGCAGCATCAGGTGCCTGTTCCAGGCGGGCCTGTGGGCCACAGCATCCACTGTGAAGTGTGTGACCACT GTGTGGTCCTGCTCCTGGATGACCTGGAACGGGCCGGCGCCCTCCTCCCCGCCATTCACGAGCAACTGCGTG GCATCAATGCCAGCTCCATGGCCTGGGCCCGTCTGCACAGGCTGAACGCCTCCATCGCTGACCTGCAGAGCC AGCTCCGGAGCCCCCTGGGCCCCCGCCATGAGACGGCACAGCAGCTGGAGGTGCTGGAGCAGCAGAGCACAA GCCTCGGGCAGGACGCACGGCGGCTAGGCGGCCAGGCCGTGGGGACCCGAGACCAGGCGAGCCAATTGCTGG CCGGCACCGAGGCCACACTGGGCCATGCGAAGACGCTGTTGGCGGCCATCCGGGCTGTGGACCGCACCCTGA GCGAGCTCATGTCCCAGACGGGCCACCTGGGGCTGGCCAATGCCTCGGGTCCATCAGGTGAGCAGCTGCTCC GGACACTGGCCGAGGTGGAGCGGCTGCTCTGGGAGATGCGGGCCCGGGACCTGGGGGCCCCGCAGGCAGCAG CTGAGGCTGAGTTGGCTGCAGCACAGAGATTGCTGGCCCGGGTGCAGGAGCAGCTGAGCAGCCTCTGGGAGG AGAACCAGGCACTGGCCACACAAACCCGCGACCGGCTGGCCCAGCACGAGGCCGGCCTCATGGACCTGCGAG AGGCTTTGAACCGGGCAGTGGACGCCACACGGGAGGCCCAGGAGCTCAACAGCCGCAACCAGGAGCGCCTGG AGGAAGCCCTGCAAAGGAAGCAGGAGCTGTCCCGGGACAATGCCACCCTGCAGGCCACTCTGCATGCGGCTA GGGACACCCTGGCCAGCGTCTTCAGATTGCTGCACAGCCTGGACCAGGCTAAGGAGGAGCTGGAGCGCCTCG CCGCCAGCCTGGACGGGGCTCGGACCCCACTGCTGCAGAGGATGCAGACCTTCTCCCCGGCGGGCAGCAAGC TGCGTCTAGTGGAGGCCGCCGAGGCCCACGCACAGCAGCTGGGCCAGCTGGCACTCAATCTGTCCAGCATCA TCCTGGACGTCAACCAGGACCGCCTCACCCAGAGGGCCATCGAGGCCTCCAACGCCTACAGCCGCATCCTGC AGGCCGTGCAGGCTGCCGAGGATGCTGCTGGCCAGGCCCTGCAGCAGGCGGACCACACGTGGGCGACGGTGG TGCGGCAGGGCCTGGTGGACCGAGCCCAGCAGCTCCTGGCCAACAGCACTGCACTAGAAGAGGCCATGCTCC AGGAACAGCAGAGGCTGGGCCTTGTGTGGGCTGCCCTCCAGGGTGCCAGGACCCAGCTCCGAGATGTCCGGG CCAAGAAGGACCAGCTGGAGGCGCACATCCAGGCGGCGCAGGCCATGCTTGCCATGGACACAGACGAGACAA GCAAGAAGATCGCACATGCCAAGGCTGTGGCTGCTGAAGCCCAGGACACCGCCACCCGTGTGCAGTCCCAGC TGCAGGCCATGCAGGAGAATGTGGAGCGGTGGCAGGGCCAGTACGAGGGCCTGCGGGGCCAGGACCTGGGCG AGGCAGTGCTTGACGCAGGCCACTCAGTGTCCACCCTGGAGAAGACGCTGCCCCAGCTGCTGGCCAAGCTGA GCATCCTGGAGAACCGTGGGGTGCACAACGCCAGCCTGGCCCTGTCCGCCAGCATTGGCCGCGTGCGAGAGC TCATTGCCCAGGCCCGGGGGGCTGCCAGTAAGGTCAAGGTGCCCATGAAGTTCAACGGGCGCTCAGGGGTGC AGCTGCGCACCCCACGGGATCTTGCCGACCTTGCTGCCTACACTGCCCTCAAGTTCTACCTGCAGGGCCCAG AGCCTGAGCCTGGGCAGGGTACCGAGGATCGCTTTGTGATGTACATGGGCAGCCGCCAGGCCACTGGGGACT ACATGGGTGTGTCTCTGCGTGACAAGAAGGTGCACTGGGTGTATCAGCTGGGTGAGGCGGGCCCTGCAGTCC TAAGCATCGATGAGGACATTGGGGAGCAGTTCGCAGCTGTCAGCCTGGACAGGACTCTCCAGTTTGGCCACA TGTCCGTCACAGTGGAGAGACAGATGATCCAGGAAACCAAGGGTGACACGGTGGCCCCTGGGGCAGAGGGGC TGCTCAACCTGCGGCCAGACGACTTCGTCTTCTACGTCGGGGGGTACCCCAGTACCTTCACGCCCCCTCCCC TGCTTCGCTTCCCCGGCTACCGGGGCTGCATCGAGATGGACACGCTGAATGAGGAGGTGGTCAGCCTCTACA ACTTCGAGAGGACCTTCCAGCTGGACACGGCTGTGGACAGGCCTTGTGCCCGCTCCAAGTCGACCGGGGACC CGTGGCTCACGGACGGCTCCTACCTGGACGGCACCGGCTTCGCCCGCATCAGCTTCGACAGTCAGATCAGCA CCACCAAGCGCTTCGAGCAGGAGCTGCGGCTCGTGTCCTACAGCGGGGTGCTCTTCTTCCTGAAGCAGCAGA GCCAGTTCCTGTGCTTGGCCGTGCAAGAAGGCAGCCTCGTGCTGTTGTATGACTTTGGGGCTGGCCTGAAAA AGGCCGTCCCACTGCAGCCCCCACCGCCCCTGACCTCGGCCAGCAAGGCGATCCAGGTGTTCCTGCTGGGGG GCAGCCGCAAGCGTGTGCTGGTGCGTGTGGAGCGGGCCACGGTGTACAGCGTGGAGCAGGACAATGATCTGG AGCTGGCCGACGCCTACTACCTGGGGGGCGTGCCGCCCGACCAGCTGCCCCCGAGCCTGCGATGGCTCTTCC CCACCGGAGGCTCAGTCCGTGGCTGCGTCAAAGGCATCAAGGCCCTGGGCAAGTATGTGGACCTCAAGCGGC TGAACACGACAGGCGTGAGCGCCGGCTGCACCGCCGACCTGCTGGTGGGGCGCGCCATGACTTTCCATGGCC ACGGCTTCCTTCGCCTGGCGCTCTCGAACGTGGCACCGCTCACTGGCAACGTCTACTCCGGCTTCGGCTTCC ACAGCGCCCAGGACAGTGCCCTGCTCTACTACCGGGCGTCCCCGGATGGGCTATGCCAGGTGTCCCTGCAGC AGGGCCGTGTGAGCCTACAGCTCCTGAGGACTGAAGTGAAAACTCAAGCGGGCTTCGCCGATGGTGCCCCCC ATTACGTCGCCTTCTACAGCAATGCCACGGGAGTCTGGCTGTATGTCGATGACCAGCTCCAGCAGATGAAGC CCCACCGGGGACCACCCCCCGAGCTCCAGCCGCAGCCTGAGGGGCCCCCGAGGCTCCTCCTGGGAGGCCTGC CTGAGTCTGGCACCATTTACAACTTCAGTGGCTGCATCAGCAACGTCTTCGTGCAGCGGCTCCTGGGCCCAC AGCGCGTATTTGATCTGCAGCAGAACCTGGGCAGCGTCAATGTGAGCACGGGCTGTGCACCCGCCCTGCAAG CCCAGACCCCGGGCCTGGGGCCTAGAGGACTGCAGGCCACCGCCCGGAAGGCCTCCCGCCGCAGCCGTCAGC CCGCCCGGCATCCTGCCTGCATGCTGCCCCCACACCTCAGGACCACCCGAGACTCCTACCAGTTTGGGGGTT CCCTGTCCAGTCACCTGGAGTTTGTGGGCATCCTGGCCCGACATAGGAACTGGCCCAGTCTCTCCATGCACG TCCTCCCGCGAAGCTCCCGAGGCCTCCTCCTCTTCACTGCCCGTCTGAGGCCCGGCAGCCCCTCCCTGGCGC TCTTCCTGAGCAATGGCCACTTCGTTGCACAGATGGAAGGCCTCGGGACTCGGCTCCGCGCCCAGAGCCGCC AGCGCTCCCGGCCTGGCCGCTGGCACAAGGTCTCCGTGCGCTGGGAGAAGAACCGGATCCTGCTGGTGACGG ACGGGGCCCGGGCCTGGAGCCAGGAGGGGCCGCACCGGCAGCACCAGGGGGCAGAGCACCCCCAGCCCCACA CCCTCTTTGTGGGCGGCCTCCCGGCCAGCAGCCACAGCTCCAAACTTCCGGTGACCGTCGGGTTCAGCGGCT GTGTGAAGAGACTGAGGCTGCACGGGAGGCCCCTGGGGGCCCCCACACGGATGGCAGGGGTCACACCCTGCA TCTTGGGCCCCCTGGAGGCGGGCCTGTTCTTCCCAGGCAGCGGGGGAGTTATCACTTTAGACCTCCCAGGAG CTACACTGCCTGATGTGGGCCTGGAACTGGAGGTGCGGCCCCTGGCAGTCACCGGACTGATCTTCCACTTGG GCCAGGCCCGGACGCCCCCCTACTTGCAGTTGCAGGTCCTGCTGCGGGCGGATGACGGAGCAGGGGAGTTCT CCACGTCAGTGACCCGCCCCTCAGTGCTGTGTGATGGCCAGTGGCACCGGCTAGCGGTGATGAAAAGCGGGA ATGTGCTCCGGCTGGAGGTGGACGCGCAGAGCAACCACACCGTGGGCCCCTTGCTGGCGGCTGCAGCTGGTG CCCCAGCCCCTCTGTACCTCGGGGGCCTGCCTGAGCCCATGGCCGTGCAGCCCTGGCCCCCCGCCTACTGCG
GCTGCATGAGGAGGCTGGCGGTGAACCGGTCCCCCGTCGCCATGACTCGCTCTGTGGAGGTCCACGGGGCAG TGGGGGCCAGTGGCTGCCCAGCCGCCTAGGACACAGCCAAGCCCGGCCCCTGGTCAGGCCCCTGCAGCTGCC TCACACCGCCCCTTGTGCTCGCCTCATAGGTGTCTATTTGGACTCTAAGCTCTACGGGTGACAGATCTTGTT TCTGAAGATGGTTTAAGTTATAGCTTCTTAAACGAAAGAATAAAATACTGCAAAATGTTTTTATATTTGGCC CTTCCACCCATTTTTAATTGTGAGAGATTTGTCACCAATCATCACTGGTTCCTCCTTAAAAATTAAAAAGTA ACTTCTGTGTAAAAAAAAAA
In a search of public sequence databases, the NOVld nucleic acid sequence, located on chromsome 20 has 4573 of 4573 bases (100%) identical to a gb:GENBANK- ID: ABOl 1105|acc: AB011105.1 mRNA from Homo sapiens (Homo sapiens mRNA for KIAA0533 protein, partial eds) (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOVld polypeptide (SEQ ID NO:8) encoded by SEQ ID NO:7 has 1640 amino acid residues and is presented in Table 1H using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVld has no signal peptide and is likely to be localized the cytoplasm with a certainty of 0.5050. hi other embodiments, NOVlb may also be localized to the microbody (peroxisome) with acertainty of 0.3000, the lysosome (lumen) with a certainty of 0.2741 or in the mitochondrial matrix space with a certainty of 0.1000.
Table 1H. Encoded NOVld protein sequence (SEQ ID NO:8).
CDRCQEGHFGFNGCGGCRPCACGPAAEGSECHPQSGQCHCRPGTMGPQCRECAPGYWGLPEQGCRRCQCPGG CDPHTGRCNCPPGLSGERCDTCSQQHQVPVPGGPVGHSIHCEVCDHCWLLLDDLERAGALLPAIHEQLRG INASSMAARLHRLNASIADLQSQLRΞPLGPRHETAQQLEVLEQQSTSLGQDARRLGGQAVGTRDQASQLLA GTEATLGHAKTLLAAIRAVDRTLSELMSQTGHLGLAASAPSGEQLLRTLAEVERLLWEMRARDLGAPQAAA EAELAAAQRLLARVQEQLSSL EENQALATQTRDRIIAQHEAGLMDLREALNRAVDATREAQELNSRNQERLE EALQRKQELSRDNATLQATLHAARDTLASVFRLLHSLDQAKEELERLAASLDGARTPLLQRMQTFSPAGSKL RLVEAAEAHAQQLGQLALNLSSIILDVNQDRLTQRAIEASWAYSRILQAVQAAEDAAGQALQQADHT ATVV RQGLVDRAQQLLANSTAIIEEAMLQEQQRLGLVAALQGARTQIJRDVRAKKDQLEAHIQAAQAMLAMDTDETS KKIAHAKAVAAEAQDTATRVQSQLQAMQENVER QGQYEGLRGQDLGQAVLDAGHSVSTLEKTLPQLLAKLS ILENRGVHNASLALSASIGRVRELIAQARGAAS VKVPMKFNGRSGVQLRTPRDLADLAAYTALKFYLQGPE PEPGQGTEDRFVMYMGSRQATGDYMGVSLRDK VHWVYQLGEAGPAVLSIDEDIGEQFAAVSLDRTLQFGHM
SVTVERQMIQETKGDTVAPGAEGLLNIRPDDFVFYVGGYPSTFTPPPLLRFPGYRGCIEMDTIIMEEWSLYN FERTFQLDTAVDRPCARSKSTGDP LTDGSYLDGTGFARISFDSQISTTKRFEQELiRLVSYSGVLFFLKQQS QFLCLAVQEGSLVLLYDFGAGLKKAVPLQPPPPLTSAS AIQVFLLGGSRKRVLVRVERATVYSVEQDNDLE LADAYYLGGVPPDQLPPSLRWLFPTGGSVRGCVKGIKALGKYVDLKRLNTTGVSAGCTADLLVGRA TFHGH GFLRLALSNVAPLTGNVYSGFGFHSAQDSALLYYRASPDGLCQVSLQQGRVSLQLLRTEVKTQAGFADGAPH YVAFYSNATGVWLYVDDQLQQMKPHRGPPPELQPQPEGPPRLLLGGLPESGTIYNFSGCISNVFVQRLLGPQ RVFDLQQNLGSVNVSTGCAPALQAQTPGLGPRGLQATARKASRRSRQPARHPACMLPPHLRTTRDSYQFGGS LSSHL.EFVGILARHRNWPSLSMHVLPRSSRGLLL1FTARLRPGSPSLAI1FLSNGHFVAQMEGLGTRLRAQSRQ RSRPGRWH VSVRWEKNRILLVTDGARAWSQEGPHRQHQGAEHPQPHTLFVGGLPASSHSSKLPVTVGFSGC VKRLRLHGRPLGAPTRMAGVTPCILGPLEAGLFFPGSGGVITLDLPGATLPDVGIJELEVRPIIAVTGLIFHLG QARTPPYLQLQVLLRADDGAGEFSTSVTRPSVLCDGQ HRLAVMKSGNVLRLEVDAQSNHTVGPLLAAAAGA PAPLYLGGLPEPMAVQPWPPAYCGCMRRLAVNRSPVAMTRSVEVHGAVGASGCPAA
A search of sequence databases reveals that the NOVld amino acid sequence has 908 of 913 amino acid residues (99%) identical to, and 1640 of 1645 amino acid residues (99%) identical to, and 1640 of 1645 amino acid residues (99%) similar to, the 1645 amino acid residue ptnr:SWISSNEW-ACC:O15230 protein from Homo sapiens (Human) (Laminin
Alpha-5 Chain) (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
Homologies to any of the above NOVl proteins will be shared by the other NOVl proteins insofar as they are homologous to each other as shown below. Any reference to NOVl is assumed to refer to all four of the NOVl proteins in general, unless otherwise noted.
The disclosed NOVla polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table II.
Table II. BLAST results for NOVla
Gene Index/ Protein/ Organism Length Identity Po Expect Identifier (aa) (%) sitives (%) gι[7459688|pir| | T10 laminin alpha 5 3635 2441/3319 2666/3319 0.0 053 chain - mouse (73%) (79%) ( ragment) gi[2497593 | sp|Q0017 Laminin alpha 3712 793/2179 1106/2179 0.0 4 I LMA DROME chain precursor (36%) (50%) gi I 14786772 I ref | XP_ laminin, alpha 5 1634 1060/1213 1063/1213 0.0 037217. l| [Homo sapiens] (87%) (87%) {XM 037217) gi I 2281044 | em | CAB0 laminin alpha 5 953 571/620 571/620 0.0 9137. ll (Z95636) chain [Homo (92%) (92%) sapiens gi 117136292 I ref |NP_ LanA-Pl; 3712 790/2179 1105/2179 0.0 476617. l| headline; (36%) (50%) (NM 057269) laminin; laminin A; laminin alpha; laminin alpha3 , 5 ; laminin alpha- chain [Drosophila melanogaster]
The homology between these and other sequences is shown graphically in the
ClustalW analysis shown in Table 1J. In the ClustalW alignment of the NOVl proteins, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (t.e., regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 1J. ClustalW Analysis of NOVl
1) Novel NOVla (SEQ ID NO: 2) 2) Novel NOVlb (SEQ ID NO: 4) 3) Novel NOVlc (SEQ ID NO:S) 4) Novel NOVld (SEQ ID NO: 8) 5) gi|7459688|pir| |T10053 laminin alpha 5 chain mouse ( fragment) (SEQ ID NO : 47)
6) gi|2497593 |sp|Q00174 |LMA_DROME Laminin alpha chain precursor (SEQ ID NO:48)
7) gi j 14786772 I ref | XP_037217.11 (XM_037217) laminin, alpha 5 [Homo sapiens] (SEQ ID NO: 49)
8) gi| 2281044 | emb j CAB09137.l| (295636) laminin alpha 5 chain [Homo sapiens (SEQ ID NO : 50 )
9) gi| 17136292|ref |NP_476617.l| (NM_057269) LanA-Pl; headline; laminin; laminin A; laminin alpha; laminin alpha3,5; laminin alpha-chain [Drosophila melanogaster] (SEQ
ID NO: 51)
10 20 30 40 50 60
NOVla MAKRLCAGSALCVRGPRGPAPLLLHPPYFNLAEGARIAASATCGEEAPARGSPRPTΞDLY 60 NOVlb 1 NOVlc MAKRLCAGSALCVRGPRGPAPLLLHPPYFNLAEGARIAASATCGEEAPARGSPRPTEDLY 60 NOVld 1
7459688 |pir I DLy 3 gi 2497593 |sp|Q MGHGVASIGALLVILAISYCQAELTPPYFNLATGRKIYATATCGPDTD GPELY 53 i 14786772 | ref 1 gi 2281044 I emb I ! gi 17136292 I ref MGHGVASIGALLVILAISYCQAELTPPYFNLATGRKIYATATCGQDTD- -GPELY 53
70 80 90 100 110 120
NOVla CKLVGG-PVAGGDPNQTIQGQYCDICTAANSNKAHPAΞNAIDGTER WQΞPPLSRGLEYN 119 NOVlb 1
NOVlc CKLVGG-PVAGGDPNQTIQGQYCDICTAANSNKAHPASNAIDGTER QSPPLSRGLEYN 119
NOVld x gi|7459688|pir| CKLVGG-PVAGGDPNQTIQGQYCDICTAANSNKAHPVSNAIDGTERWWQSPPLSRGLEYN 62 g j 2497593 |sp|Q CKLVGANTEHDHIDYSVIQGQVCDYCDPTVPERNHPPENAIDGTEA QSPPLSRGMKFN 113 gi j 14786772 j ef 1 gi j 2281044 I emb I ! gi 117136292 j ref CKLVGANTEHDHIDYSVIQGQVCDYCDPTVPERNHPPENAIDGTEA QSPPLSRGMKFN 113
130 140 150 160 170 180
NOVla EVNVTLDLGQVFHVAYVLIKFANSPRPDLWVLERSMDFGRTYQP QFFAASKRDCLERFG 179
NOVlb 1
NOVlc EVNVTLDLGQVFHVAYVLIKFANSPRPDL VLERSMDFGRTYQP QFFAASKRDCLERFG 179
NOVld , gi|7459688|pir| EVNVTLDLGQVFHVAYVLIKFANSPRPDLWVLERSTDFGHTYQPWQFFASSKRDCLERFG 122 gil2497593|sp|Q EVNLTINFEQEFHVAYLFIRMGNSPRPGL TLEKSTDYGKT TP QHFSDTPADCETYFG 173 gi j 14786772 I ref ! gi j 2281044 I emb I 1 gi j 17136292 I ef EVNLTINFEQEFHVAYLFIRMGNSPRPGL TLEKSTDYGKT TPWQHFSDTPADCETYFG 173
190 200 210 220 230 240
NOVla PQTLERITRDDAAICTTEYSRIVPLENGEIWSLVNGRPGAMNFSYSPLLREFTKATNVR 239
NOVlb 1
NOVlc PQTLERITRDDAAICTTEYSRIVPLENGEIWSLVNGRPGAMNFSYSPLLREFTKATNVR 239 1
PRTLERITQDDDVICTTEYSRIVPLENGEIWSLVNGRPGALNFSYSPLLRDFTKATNIR 182 KDTYKPITRDDDVICTTEYSKIVPLENGEIPVMLLNERPSSTNYFNSTVLQEWTRATNVR 233
KDTYKPITRDDDVICTTEYSKIVPLENGEIPVMLLNERPSSTNYFNSTVLQE TRATNVR 233
250 260 270 280 290 300
NOVla LRFLRTNTLLGHLMGKALRDPTVTRRYYYSIKDISIGGRCVCHGHADACDAKDPTDPF-R 298
NOVlb 1
NOVlc LRFLRTNTLLGHLMGKALRDPTVTRRYYYSIKDISIGGRCVCHGHADACDAKDPTDPF-R 298
NOVld __ gi|7459688 |pir| LRFLRTNTLLGHLMGKALRDPTVTRRYYYSIKDISIGGRCVCHGHADVCDAKDPLDPF-R 241 gi|2497593|sp|Q IRLLRTKNLLGHLMSVARQDPTVTRRYFYSIKDISIGGRCMCNGHADTCDVKDPKSPVRI 293 gi j 14786772 I ref 1 gi j 2281044 I emb I 1 gi j 17136292 | ref IRLLRTKNLLGHLMSVARQDPTVTRRYFYSIKDISIGGRCMCNGHADTCDVKDPKSPVRI 293
310 320 330 340 350 360
NOVla LQCTCQHNTCGGTCDRCCPGFNQQP KPATANSANECQ-CECYGHATDCYYDPEVDRRRA 357 NOVlb 1 NOVlc LQCTCQHNTCGGTCDRCCPGFNQQPWKPATANSANECQ-CECYGHATDCYYDPEVDRRRA 357 NOVld 1 i 7459688 |pir I LQCACQHNTCGGSCDRCCPGFNQQPWKPATTDSANECQSCNCHGHAYDCYYDPEVDRRNA 301 gi 2497593|sp|Q LACRCQHHTCGIQCNECCPGFEQKK RQNTNARPFNCEPCNCHGHSNECKYDEEVNRKGL 353 gi 14786772 | ref 1 gi 2281044|emb| 1 gi 17136292 I ref LACRCQHHTCGIQCNECCPGFEQKK RQNTNARPFNCEPCNCHGHSNECKYDEEVNRKGL 353
370 380 390 400 410 420
NOVla SQSLDGTYQGGGVCIDCQHHTTGVNCERCLPGFYRSPNHPLDSPHVCRGCNCESDFTDGT 417
NOVlb 1
NOVlc SQSLDGTYQGGGVCIDCQHHTTGVNCERCLPGFYRSPNHPLDSPHVCRGCNCESDFTDGT 417 61 13
13
430 440 450 460 470 480 I
NOVla CEDLTGRCYCRPNFSGERCDVCAEGFTGFPSCY-REHLPGNDTREQVLPAGQIVSCDCSA 476
NOVlb 1
NOVlc CEDLTGRCYCRPNFSGERCDVCAEGFTGFPSCY-REHLPGNDTREQVLPAGQIVSCDCSA 476 1
CEDLTGRCYCRPNFTGELCAACAEGYTDFPHCYPLPSFPHNDTREQVLPAGQIVNCDCNA 421
CEEETGNCECRAAFQPPSCDSCAYGYYGYPNCR ECECNL 452
CEEETGNCECRAAFQPPSCDSCAYGYYGYPNCR- -ECECNL 452
490 500 510 520 530 540
NOVla AGTQGNACRKDPRVGRCLCKPNFQGTHCELCAPGFY-GPGCPASVPALEWPMTAVTLTQA 535 NOVlb NOVlc AGTQGNACRKDPRVGRCLCKPNFQGTHCELCAPGFY-GPGCPASVPALEWPMTAVTLTQA 535 NOVld X gi 7459688 |pir I AGTQGNACRKDPRLGRCVCKPNFRGAHCELCAPGFH-GPSCHPCQCSSPGVANSLCDPES 480 gi 2497593 j sp | Q NGTNGYHCEAESGQ-QCPCKINFAGAYCKQCAEGYYGFPECKACECNKIGSITNDCNVTT 511 gi 14786772 ] ref X gi 2281044 I emb I X gi 17136292 I ref NGTNGYHCEAESGQ-QCPCKINFAGAYCKQCAEGYYGFPECKACECNKIGSITNDCNVTT 511
550 550 570 580 590 600
NOVla SAGAEWASRGPHVIAVPPATFTSLSASHPLRSAVCGCSPAGTLPEGCD-EAGRCLCQPEF 594 NOVlb X NOVlc SAGAEWASRGPHVIAVPPATFTSLSASHPLRSAVCGCSPAGTLPEGCD-EAGRCLCQPEF 594 NOVld X
91 7459688 |pir I GQ CMCRTGFEGDRCDHCALGYFHFPLCQLCGCSPAGTLPEGCD-EAGRCQCRPGF 534 gi 2497593 j sp [ Q G ECKCLTNFGGDNCERCKHGYFNYPTCSYCDCDNQGTESEICNKQSGQCICREGF 566 gi 14786772 I ref 1 i 2281044 I emb I 1 gi 17136292 | ref G ECKCLTNFGGDNCERCKHGYFNYPTCSYCDCDNQGTESEICNKQSGQCICREGF 556
610 620 630 640 650 660
NOVla AGPHCDRCRPGYHGFPNCAACTCDPRGALDQLCGAGGLCRCRPGYTGTACQECSPGFHGF 654
NOVlb X
NOVlc AGPHCDRCRPGYHGFPNCAACTCDPRGALDQLCGAGGLCRCRPGYTGTACQECSPGFHGF 654
NOVld gi|7459688 pi I DGPHCDRCLPGYHGYPDCHACACDPRGALDQQCGVGGLCHCRPGNTGATCQECSPGFYGF 594 gi|2497593 s I Q GGPRCDQCLPGFYNYPDCKPCNCSSTGSSAITCDNTGKCNCLNNFAGKQCTLCTAGYYSY 626 gij 14786772 I ef gij 2281044 I emb I
gi|l7136292 |rβf GGPRCDQCLPGFYNYPDCKPCNCSSTGSSAITCDNTGKCNCLNNFAGKQCTLCTAGYYSY 626
670 680 690 700 710 720
NOVla PSCPATALLKAPCTQPVTPGVGSAAAGPVRGCGVTHVCPVPTTSPTAKPLFTAGSCHPAG 714 NOVlb 1 NOVlc PSCPATALLKAPCTQPVTPGVGSAAAGPVRGCGVTRVCPVPTTSPTAKLALATLPVWP-- 712 NOVld -- gi 7459688|pir| PSCIPCHCSADGSLHTTCDPTTGQCRCRPRVTGLHCDMCVPG--AYNFPYCEAGSCHPAG 652 gi 2497593 jsp I Q PDCLPCHCDSHGSQGVSCN-SDGQCLCQPNFDGRQCDSCKEG--FYNFPSCEDCNCDPAG 683 gi 14786772 |ref X gi 2281044 I emb I X gi 17136292 I ref PDCLPCHCDSHGSQGVSCN-SDGQCLCQPNFDGRQCDSCKEG--FYNFPSCEDCNCDPAG 683
730 740 750 760 770 780
NOVla LAPVDP--ALPEVSPPCMCRAHVEGPSCDRCKPGFWGLSPSNPEGCTRCSCDLRGTLGGV 772
NOVlb X
NOVlc - -PVDP--ALPEAQVPCMCRAHVEGPSCDRCKPGFWGLSPSNPEGCTRCSCDLRGTLGGV 768
NOVld X
LAPANP--ALPETQAPCMCRAHVEGPSCDRCKPGYWGLSASNPEGCTRCSCDPRGTLGGV 710 VIDKFAGCGSVPVGELCKCKERVTGRICNECKPLYWNLNISNTEGCEICDCWTDGTISAL 743
VIDKFAGCGSVPVGELCKCKERVTGRICNECKPLYWNLNISNTEGCEICDCWTDGTISAL 743
790 800 810 820 830 840
NOVla AECQ-GTGQCFCKPHVCGQACASCKDGFFGLDQADYFGCRSCRCDIGGALGQSCEPRTGV 831 NOVlb 1 NOVlc AECQPGTGQCFCKPHVCGQACASCKDGFFGLDQADYFGCRSCRCDIGGALGQSCEPRTGV 828 69 03
03
850 860 870 890 900
NOVla CRCRPNTQGPTCSEPARDHYLPDLHHLRLELEEAATPEGHAVRFGFNPLEFENFSWRGYA 891
NOVlb X
NOVlc CRCRPNTQGPTCSEPARDHYLPDLHHLRLELEEAATPEGHAVRFGFNPLEFENFSWRGYA 888 29 63
63
910 920 930 940 950 960
NOVla QMAPVQPRIVARLNLTSPDLFWLVFRYVNRGAMSVSGRVSVREEGRSATCANCTAQSQPV 951
NOVlb X 48 89 23
23
970 980 990 1000 1010 1020
NOVla AFPPSTEPAFITVPQRGFGEPFVLNPGTWALRVEAEG-VLLDYWLLPSAYYEAALLQLR 1010 NOVlb X NOVlc AFPPSTEPAFITVPQRGFGEPFVLNPGTWALRVEAEG-VLLDYWLLPSAYYEAALLQLR 1007 NOVld X gi 7459688 |pir| AFPPSTEPAFVTVPQRGFGEPFVLNPGIWALLVEAEG-VLLDYWLLPSTYYEAALLQHR 948 gi 2497593 j s | Q SEP QFVTVAGPLGVKPSAIVLDPGRYVFTTKANKNVMLDYFVLLPAAYYEAGILTRH 980
80
1030 1040 1050 1060 1070 1080
NOVla VTEACTYRPSAQQSPPSCLLYTHLPLDGFPSAAGLEALCRQDNSLPRPCPTEQLSPSHPP 1070
NOVlb 1
NOVlc VTEACTYRPSAQQSPPSCLLYTHLPLDGFPSAAGLEALCRQDNSLPRPCPTEQLSPSHPP 1067 008 040
040
1090 1100 1110 1120 1130 1140
NOVla LITCTGSDVDVQLQVAVPQPGRYALWEYANEDAR-QEVGVAVHTPQRAPQQGLLSLHPC 1129 NOVlb 1
NOVlc LITCTGSDVDVQLQVAVPQPGRYALWEYANEDAR-QEVGVAVHTPQRAPQQGLLSLHPC 1126
NOVld 1 gi 7459688 |pir I LATCFGSDVDIQLEMAVPQPGQYVLWEYVGEDSH-QEMGVAVHTPQRAPQQGVLNLHPC 1067 gi 2497593 I sp I Q IPVLSGSQNELHYIVDVPRSGRYIFVIDYISDRNFPDSYYINLKLKDNPDSETSVLLYPC 1100 gi 14786772|ref 1 gi 2281044|emb| . 1 gi 17136292 |ref IPVLSGSQNELHYIVDVPRSGRYIFVIDYISDRNFPDSYYINLKLKDNPDSETSVLLYPC 1100
1150 1160 1170 1180 1190 1200
NOVla LYSTLCRGTARDTQDHLAVFHLDSEASVRLT AEQARFFLHGVTLVPIEEFSPEFVE 1185
NOVlb 1
NOVlc LYSTLCRGTARDTQDHLAVFHLDSEASVRLT AEQARFFLHGVTLVPIEEFSPEFVE 1182
NOVld 1 123 160
160
1210 1220 1230 1240 1250 1260
NOVla PRVSCISSHGAFGPNSAACLPSRFPKPPQPIILRDCQVIPLPPGLPLTHAQDLTPAMSPA 1245
NOVlb 1 NOVlc PRVSCISSHGAFGPNSAACLPSRFPKPPQPIILRDCQVIPLPPGLPLTHAQDLTPAMSPA 1242
NOVld 1 183 203
203
1270 1280 1290 1300 1310 1320 NOVla GPRPRPPTAVDPDAEPTLLREPQATWFTTHVPTLGRYAFLLHGYQPAHPTFPVEVLINA 1305
NOVlb 1
NOVlc GPRPRPPTAVDPDAEPTLLREPQATWFTTHVPTLGRYAFLLHGYQPAHPTFPVEVLINA 1302
NOVld 1 gi 7459588 pir | GPQPRPPTAVDPNAEPTLLRHPQGTWFTTQVPTLGRYAFLLHGYQPVHPSFPVEVLING 1243 g 2497593 sp | Q ASLDERVKLVHLDSQ NEATIVIESKVDATKPNLFVILVKYYQPSHPKYQVYYTLTA 1259 gi 14786772 j ref 1 gi 2281044 I emb I 1 gi 17136292 I ref ASLDERVKLVHLDSQ NEATIVIESKVDATKPNLFVILVKYYQPSHPKYQVYYTLTA 1259 1330 1340 1350 1360 1370 1380
NOVla GRV-WQGHANASFCPHGYGCRTLWCEGQALLDVTHSELTVTVRVPKGRWLWLDYVLWP 1364
NOVlb 1
NOVlc GRV-WQGHANASFCPHGYGCRTLWCEGQALLDVTHSELTVTVRVPKGRWLWLDYVLWP 1361 NOVld 1
302 318
318
1390 1400 1410 1420 1430 1440
NOVla ENVYSFGYLREEPLDKSYDFISHCAAQGYHISPSSSSLFCRNAAASLSLFYNNGARPCGC 1424 NOVlb 1
NOVlc ENVYSFGYLREEPLDKSYDFISHCAAQGYHISPSSSSLFCRNAAASLSLFYNNGARPCGC 1421
NOVld 1 gi 7459688 |pir| EDAYSSSYLQEEPLDKSYDFISHCATQGYHISPSSSSPFCRNAATSLSLFYNNGALPCGC 1362 gi 2497593 I sp I Q LKQYNDDLLVEETFDQTKEFIQNCGHDHFHITHN-ASDFCKKSVFSLTADYNSGALPCNC 1377 gi 14786772|ref 1 gi 2281044|emb| 1 gi 17136292 I ref LKQYNDDLLVEETFDQTKEFIQNCGHDHFHITHN-ASDFCKKSVFSLTADYNSGALPCNC 1377
1450 1460 1470 1480 1490 1500
....I....I....J....I....I....I....I....I....I....I....I....I
NOVla HEVGATGPTCEPFGGQCPCHAHVIGRDCSRCATGYWGFPNCRACDCG-ARLCDELTGQCI 1483
NOVlb 1
NOVlc HEVGATGPTCEPFGGQCPCHAHVIGRDCSRCATGYWGFPNCRACDCG-ARLCDELTGQCI 1480 421 437
437
1510 1520 1530 1540 1550 1560
NOVla CPPRTIPPDCLLCQPQTFGCHPLVGCEECNCSGPGIQELTDPTCDTDSGQCRCRPNVTGR 1543
NOVlb X NOVIC CPPRTIPPDCLLCQPQTFGCHPLVGCEECNCSGPGIQELTDPTCDTDSGQCRCRPNVTGR 1540
NOVld X 481 496
496
1570 1580 1590 1600 1610 1620 NOVla RCDTCSPGFHGYPRCRPCDCHEAGTAPGVCDPLTGQCYCKENVQGPKCDQCSLGTFSLDA 1603
NOVlb 1
NOVlc RCDTCSPGFHGYPRCRPCDCHEAGTAPGVCDPLTGQCYCKENVQGPKCDQCSLGTFSLDA 1600 541 556
556 1630 1640 1650 1660 1670 1680
NOVla ANPKGCTRCFCFGATERCRSSSYTRQEFVDMEGWVLLSTDRQWPHERQPGTEMLRADLR 1663
NOVlb 1
NOVlc ANPKGCTRCFCFGATERCRSSSYTRQEFVDMEGWVLLSTDRQWPHERQPGTEMLRADLR 1660 601 616
616
1690 1700 1710 1720 1730 1740
NOVla HVPEAVPEAFPELYWQAPPSYL GDRVSSYGGTLRYELHSETQRGDVFVPME 1714 NOVlb 1
NOVlc HVPEAVPEAFPELYWQAPPSYL- GDRVSSYGGTLRYELHSETQRGDVFVPME 1711
NOVld X gi 7459688|pir| SVADTFSELYWQAPPSYL GDRVSSYGGTLHYELHΞETQRGDIFIPYE 16 8 gi 2497593 |sp|Q NETTLKADFTLREVNDERPAYFGVLDYLLNQNNHISAYGGDLAYTLHFTSGFDG KYI 1673 gi 14786772 | ref gi 2281044|emb| gi 17136292 | ref NETTLKADFTLREVNDERPAYFGVLDYLLNQNNHISAYGGDLAYTLHFTSGFDG- -KYI 1673
1750 1760 1770 1780 1790 1800
NOVla SRPDWLQGNQMSI FLEPAYPTPGHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASL 1774
NOVlb X
NOVlc SRPDWLQGNQMSITFLEPAYPTPGHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASL 1771
NOVld X gi 7459688 pir| SRPDWLQGNQMSIAFLELAYPPPGQVHRGQLQLVEGNFRHLETHNPVSREELMMVLAGL 1708 i 2497593 sp|Q VAPDVILFSEHNALVHTSYEQPSRNEPFTNRVNIVESNFQTISGK-PVΞRADFMMVLRDL 1732 gi 14786772] ef X gi 2281044|emb| gi 17136292 | ref VAPDVILFSEHNALVHTSYEQPSRNEPFTNRVNIVESNFQTISGK-PVSRADFMMVLRDL 1732
1810 1820 1830 1840 1850 1860
NOVla EQLQIRALFSQISSAVFLRRVALEVASPAGQGA LASNVELCLCPASYRGDSCQECAP 1831
NOVlb X
NOVlc EQLQIRALFSQISSAVFLRRVALEVASPAGQGA LASNVELCLCPASYRGDSCQECAP 1828
NOVld X gi|7459688|pir| EQLQIRALFSQTSSSVSLRRWLEVASEAGRGP PASNVELCMCPANYRGDSCQECAP 1765 gi|2497593 | sp | Q KVIFIRANYWEQTLVTHLSDVYLTLADEDADGTGEYQFLAVERCSCPPGYSGHSCEDCAP 1792 gi| 14786772 | ref gi| 228104 | emb | gi| 17136292 | ref KVIFIRANYWEQTLVTHLSDVYLTLADEDADGTGEYQFLAVERCSCPPGYSGHSCEDCAP 1792
1870 1890 1900 1910 1920
NOVla GFYRDVKGLFLGRCVPCQCHGHSDRCLPGSGVCV-CQHNTEGAHCERCQAGFV-SSRDDP 1889
NOVlb X
NOVlc GFYRDVKGLFLGRCVPCQCHGHSDRCLPGSGVCV-CQHNTEGAHCERCQAGFV-SSRDDP 1886
NOVld gi|7459688|pir| GYYRDTKGLFLGRCVPCQCHGHSDRCLPGSGICVGCQHNTEGDQCERCRPGFVSSDPSNP 1825 gi|2497593|sp|Q GYYRDPSGPYGGYCIPCECNGHSETCDCATGICSKCQHGTEGDHCERCVSGYYGNATNGT 1852 gi| 14786772 | ref gi| 2281044] emb | gi| 17136292 |ref GYYRDPSGPYGGYCIPCECNGHSETCDCATGICSKCQHGTEGDHCERCVSGYYGNATNGT 1852
1930 1940 1950 1960 1970 1980
NOVla SAPCVSCPCPLSVPSN RCAPGFFGNPLVLGS 1920
NOVlb X
NOVlc SAPCVSCPCPLSVPSN RCAPGFFGNPLVLGS 1917
NOVld __, X gi|7459688|pir| ASPCVSCPCPLAVPSNNFADGCVLRNG- -RTQCLCRPGYAGASCERCAPGFFGNPLVLGS 1883 gi| 2497593 |sp|Q PGDCMICACPLPFDSNNFATSCEISESGDQIHCECKPGYTGPRCESCANGFYGΞPEΞIGQ 1912 gi ] I 1144778866777722 |I rreeff 1 gi| 228104 | emb | X gi| 17136292] ef PGDCMICACPLPFDSNNFATSCEISESGDQIHCECKPGYTGPRCESCANGFYGEPESIGQ 1912
1990 2000 2010 2020 2030 2040
NOVla SCQPCDCSGNGDPNLLFSDCDPLTGACRGCLRHTTGPRCEICAPGFYGNALLPGNCTRCD 1980
NOVlb 1
NOVlc SCQPCDCSGNGDPNLLFSDCDPLTGACRGCLRHTTGPRCEICAPGFYGNALLPGNCTRCD 1977
NOVld 1 gi 7459688|pir| SCQPCDCSGNGDPNMIFΞDCDPLTGACRGCLRHTTGPHCERCAPGFYGNALLPGNCTRCD 1943 gi 2497593 |sp|Q VCKPCECSGNINPEDQGS-CDTRTGECLRCLNNTFGAACNLCAPGFYGDAIKLKNCQSCD 1971 gi 14786772 | ef 1 gi 2281044 ! emb | 1 gi 17136292 ) ref VCKPCECSGNINPEDQGS-CDTRTGECLRCLNNTFGAACNLCAPGFYGDAIKLKNCQSCD 1971
2050 2060 2070 2080 2090 2100
2170 2180 2190 2200 2210 2220
NOVla
2155
NOVlb X
2290 2300 2310 2320 2330 2340
, .| | ....l ...I ..
NOVla bqQsτs[Jpp gAVG0RDQgSQLtAGΪEAggHAKTLLAAIRAVDRTLS|LMSQT 2268
NOVlb * X
2350 2360 2370 2380 2390 2400
NOVla GHJJG Alj^SJgPSGEQLLRTBAE ERLΪ^^^ 2328 NOVlb
2530 2540 2550 2560 2570 2580
NOVla TFSP@GSK RJ3 føjϊ^AHgQCJJGQ: ^ 2505
NOVlb 1
2590 2500 2610 2620 2630 2640
NOVla ^EDAAGQgLQQ^TWQø VRQgL ^QQ LANgj ljES MLiEQg LGLGECWAPMG 2565
NOVlb 1
2650 2660 2670 2680 2690 2700
NOVla AiJRPAGTQLRDyRgKKDQLgAHIQAAQAMliAMDTGgf S - KKI AH Kgvg EgQDTATRgQ 2624
NOVlb
gi 117136292 | ref El[J5EP^SVQ PKE EI H@ώ^DLiSTN^SSQ^KQ£DD|^GS SKgSE AEDli EQQH 2641
2890 2900 2910 2920 2930 2940
2950 2960 2970 2980 2990 3000
NOVla NOVlb NOVlc NOVld
3070 3080 3090 3100 3110 3120
.... I .... I .... I .... I .... I .... I .... I .... I .... I .... I .... I ....i
NOVla LAVQEGSLVLLYDPGAGLKKAVPLQPPPPLTSASKAIQVFLLGGSRKRVLVRVERATVYS 3028
NOVlb LAVQEGSLVLLYDPGAGLKKAVPLQPPPPLTSAΞKAIQVFLLGGSRKRVLVRVERATVYS 268
NOVlc LAVQEGSLVLLYDFGAGLKKAVPLQPPPPLTSASKAIQVFLLGGSRKRVLVRVERATVYS 3025
NOVld LAVQEGSLVLLYDFGAGLKKAVPLQPPPPLTSASKAIQVFLLGGSRKRVLVRVERATVYS 1000 gi|7459688|pir| 2971 gi j 2497593 jsp I Q l FFNISLgEgGGVQSGS@DRYNDNQWHJgVQAERENRNGLL3K3DDIfflISR0NAP 2987
gi 14786772 |ref 989 gi 2281044 I emb I 308 gi 17136292 ref IIEMipgAIFFNISL@EgGGVQSGS@DRYNDNQWHgVQAΞRENRNGLL gDDI|jISRjNAP 2987
3250 3260 3270 3280 3290 3300
NOVla AAQVSLQQGRVSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVWLYVDDQLQQMKPH 3204 NOVlb HQVSLQQGRVSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVWLYVDDQLQQMKPH 445 NOVlc EQVSLQQGRVSLQLLRTEVKTQAGFADGAPHYVAFYSNATGVWLYVDDQLQQMKPH 3201 NOVld 3LCBB 1177 i 7459688|pir| -GPY18 lRE@HffiTfeFJWQ!jffiEl3g T/ 3148 gi 2497593 I sp J Q OSSTIGLg^DgLLKgNSMGSQLyiDDRILNDGED: @ELRLTVJgEiVDNKRLG 3159 gi 14786772 I ref --GL 1166 gi 2281044|emb| --GL< 485 gi 17136292 [ref QSSTIGLg^DgL KgNSMGSQpVIDDRILNDGEDHgVTVQBTQgELRLTVjgDVDNKRLG 3159
3310 3320 3330 3340 3350 3360
NOVla NOVlb NOVlc NOVld
3490 3500 3510 3520 3530 3540
3550 3560 3570 3580 3590 3600
3610 3620 3630 3640 3650 3660
3570 3680 3690 3700 3710 3720
3730 3740 3750 3760 3770 3780
NOVla
NOVlb
NOVlc
NOVld
0
NOVla 3583
NOVlb 891
The presence of identifiable domains in NOVl, as well as all other NOVX proteins, was determined by searches using software algorithms such as PROSITE, DOMAIN, Blocks, Pfam, ProDomain, and Prints, and then determining the Interpro number by crossing the domain match (or numbers) using the Interpro website (http:www.ebi.ac.uk/ interpro).
DOMAIN results for NOVl as disclosed in Tables 1K-1L, were collected from the Conserved Domain Database (CDD) with Reverse Position Specific BLAST analyses. This BLAST analysis software samples domains found in the Smart and Pfam collections. For Table IK and all successive DOMAIN sequence alignments, fully conserved single residues are indicated by black shading or by the sign (|) and "strong" semi-conserved residues are indicated by grey shading or by the sign (+). The "strong" group of conserved amino acid residues maybe any one of the following groups of amino acids: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MTLF, HY, FYW.
Tables 1K-S list the domain descriptions from DOMAIN analysis results against NOVla. This indicates that the NOVla sequence has properties similar to those of other proteins known to contain this domain. Below are representative domain results. There are additional areas on NOVla that also have homology to these Domains.
Table IK. Domain Analysis of NOVla gnl I Smart I smart00136, LamNT, Laminin N-terminal domain (domain VI); N- terminal domain of laminins and laminin-related protein such as Unc-6/ netrins. (SEQ ID NO: 52)
CD-Length = 239 residues, 96.7% aligned
Score = 271 bits (692) , Expect = 6e-73
Query: 26 PPYFNLAEGARIAASATCGEEAPARGSPRPTEDLYCKLVGGPVAGGDPNQTIQGQYCDIC 85 i ÷ u i i + I I + I I H+ i i n u n i n i
Sbjct: 9 PEFVNLAFGRPVTASSTCGEQGPER YCKLVGR TEQGKKCDYC 50
Query : 86 TAANSNKAHPASNAIDGTE RWWQSPPLSRGLEYNEVNVTLDLGQVFHVAYVLIKFA 141 i + mil i II IIII in i + 11+11111+ 11+ 11++11
Sbjct: 51 DARDPRRSHPAENLTDGNNPGNPTWWQSEPLSNGPQ- -NVNLTLDLGKEFHLTYVILKFC 108
Query: 142 NSPRPDLWVLERSMDFGRTYQPWQFFAASKRDCLERFGPQTLERITR- -DDAAICTTEYS 199
IIII i mn 111+1+11+1+1++ n n ιι+ + +11+111
Sbjct: 109 -SPRPSLAILERS-DFGKTWQPYQYFSS DCRRTFGRPPRGPITKGNEQEVLCTSEYS 163
Query: 200 RIVPLENGEIWSLVNGRPGAMNFSYSPLLREFTKATNVRLRFLRTNTLLGHLMGKALRD 259
164 DI I : VIPILIEI
Sbjct GG uEIiAFS iT mEGnPSA iTD +FιDNS 1P1V+L1+QE1W+VTA 1T1N1+IR1V+R1LTR 1N iTnLGDDL 1M1DK 1-- 1D1 221
Query : 260 PTVTRRYYYSIKDISIGG 277 i
Sbjct: 222 PEV uTRiSY nYYmAISD 1I1A+V+G1G1 239
Table IL. Domain Analysis of NOVla gnl I Pfam|pfam00055, laminin_Nterm, Laminin N-terminal (Domain VI). (SEQ ID NO: 53)
CD-Length = 237 residues, 100.0% aligned Score = 219 bits (559) , Expect = 2e-57
Query: 24 LHPPYFNLAEGARIAASATCGEEAPARGSPRPTEDLYCKLVGGPVAGGDPNQTIQGQYCD 83
+ι III I mm 11 +ι mi i + i i
Sbjct: 1 CYPATGNLAIGRALSATSTCGLHSP EPYCILSH- -LQPRDKK CF 42
Query: 84 137
Sbjct: 43
102
Query: 138 IKFANSPRPDLWVLERSMDFGRTYQPWQFFAASKRDCLERFG- - PQTLERITRDDA-AIC 194
1 1 + 11 + 111 III 1+ I+I++I II + 1+ I I + +1
Sbjct: 103 ITFK-TFRPAAMIYERSSDFG-TWIPYQYYAY DCEATYPGIPRRPIRTGRAEDDVLC 157
Query: 195 TTEYSRIVPLENGEIWSLVNGRPGAMNFSYSPLLREFTKATNVRLRFLRTNTLLGHLMG 254
1+ II I II II++ I + III I II II 1+1+ IIII+I+ I +11 +1+
Sbjct: 158 TSRYSDIEPLTEGEVIFΞTLEGRPSADNFDPSPRLQEWLKATNIRITLTRLHTLGDNLLD 217
Query: 255 KALRDPTVTRRYYYSIKDISIGG 277
II I +III+I II +11
Sbjct: 218 SDPEVLEKYYYAISDIWGG 237
Table IM. Domain Analysis of NOVla gnl|Smart I smart00281, LamB, Laminin B domain (SEQ ID NO:54) CD-Length = 127 residues, 98.4% aligned Score = 152 bits (385) , Expect = 2e-37
Query: 1674 PELYWQAPPSYLGDRVSSYGGTLRYELHSETQRGDVFVPMESRPDWLQGNQMSITFLEP 1733
Sbjct: EPVYWVAPEQFLGDKVTSYGGKLRYTLSFDGREGGTTL SAPDVILEGNGLRLSHPAQ 59
Query: 1734 AYPTPGHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASLEQLQIRALFSQISSAVFLR 1793
Sbjct: 60 GPPLPDEETTNEVRFREENWQYFGGR-PVTREDLMMVLANLTAILIRATYSEQQLASRLS 118
Query : 1794 RVALEVASP 1802 Mill I
Sbjct: 119 DVSLEVAVP 127
Table IN. Domain Analysis of NOVla gnl|Pfam|pfam00052, laminin_B, Laminin B (Domain IV) (SEQ ID
WO: 55)
CD-Length = 135 residues, 100.0% aligned
Score = 92.4 bits (228), Expect = 4e-19
Query: 1677 YWQAPPSYLGDRVSSYGGTLRYELHSETQRGDVFVPMESRPDWLQGNQMSITFLEPAYP 1736 ιι+ i +ιιι+ι+nιι ι+ι + i i iii+i+n + ++ i
Sbjct: 1 YWRLPERFLGDQVTSYGGKLKYSV- - FDGVGTSNSEPDVILKGNGLRLSVPYMAQG 55
Query: 1737 TP GHVHRGQLQLVEGNFRHTETRNTVSREELMMVLASLEQLQIRALFSQISSAVFLR 1793
+ ++I I I +++ I + II+ + III + I + III +I + I
Sbjct: 56 NSYPSEVRVKYTVRLHE-TFWDFQSQPAVTREDFLSVLANLTAILIRATYSAGQAQSRLD 114
Query: 1794 RVALEVASPAGQGA-LASNVE 1813
MM I I 1+ II
Sbjct: 115 DVSLEIARPGAAGPVPATWVE 135
Table lO. Domain Analysis of NOVla gnl|Smart I smart00282, LamG, Laminin G domain (SEQ ID NO: 56) CD-Length = 135 residues, 88.1% aligned Score = 75.6 bits (187), Expect = 2e-14
Query: 2759 FVMYMGSRQATGDYMGVSLRDKKVHWVYQLGEAGPAVLSIDEDI--GEQFAAVSLDRTLQ 2816
++I 11+ II ++ + II I ++ I II +1 II 1+ I 1+ I I++I +
Sbjct: 17 LLLYAGSKG-GGDFLALELRDGRLVLRYDLG-SGPARLTSDPTPLNDGQWHRVSVERNGR 74 Query: 2817 FGHMSVTVERQMIQETKGDTVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLLRFPGYRG 2876
+ 11 ++ 1+ II +1 + 1 I Ml I I 1 11 + 11
Sbjct: 75 RVTLSVDGGNRVSGES PGGSTILDL DGPLYLGGLPEDLKLPGLPVTPGFRG 125
Query: 2877 CIEMDTLNEE 2886
II • +1 + Sbjct: 126 CIRNLKVNGK 135
Table IP. Domain Analysis of NOVla gnl |Pfam|pfam00053, laminin_EGF, Laminin EGF-li e (Domains III and V).
This family is like pfam00008 but has 8 conserved cysteines instead of
6. (SEQ ID NO:57)
CD-Length = 49 residues, 100.0% aligned
Score = 59.3 bits (142), Expect = 4e-09
Query: 1561 CDCHEAGTAPGVCDPLTGQCYCKENVQGPKCDQCSLGTFSLDAANPKGC 1609
111+ 1+ III llll II I I +11+1 I + I + +11
Sbjct: 1 CDCNPHGSLSDTCDPETGQCLCKPGVTGRRCDRCKPGYYGLPSDPGQGC 49
Table 1Q. Domain Analysis of NOVla gnl|Smart I smart00180, EGF_Lam, Laminin-type epidermal growth factor- like domai (SEQ ID NO.58) CD-Length = 47 residues, 87.2% aligned Score = 55 8 bits (133) , Expect = 4e-08
Query 1979 CDCTPCGT-EACDPHSGHCLCKAGVTGRRCDRCQEGHFGFD 2018 ui i ι+ ui +ι i II ilium ι++ι
Sbjct 1 CDCDPGGSASTCDPETGQCECKPNTTGRRCDRCAPGYYGLP 41
Table 1R. Domain Analysis of NOVla gnl I Pfam|pfam01576, Myosιn_taιl, Myosm tail The myosm molecule is a multi- subunit complex made up of two heavy chains and four light chains it is a fundamental contractile protein found m all eukaryote cell types. This family consists of the coiled-coil myosm heavy chain tail region. The coiled-coil is composed of the tail from two molecules of myosm These can then assemble into the macromolecular thick filament The coiled-coil region provides the structural backbone the thick filament. (SEQ ID NO: 59) CD-Length = 860 residues, 60 6% aligned Score = 53.1 bits (126), Expect = 3e-07
Query 2205 RHETAQQLEVLEQQSTSLPPQAVGTRDQASQLLAGTEATLGHAKTLLA-AIRAVDRTLSE 2263
I + +++II I ++ +1 1 +1 II I + I I + 1+
Sbjct 69 RADLSRELEELSERLE EAGGATAAQIELNKKREAELAKLRKDLEEANLQHEEALAT 124
Query 2264 LMSQTGHLGLANASAPSGEQL LRTLAEVERLLWEMRARDLGAP QAAAEAELAAAQ 2318
I + I +1 11+ + 11 1+ + II I + 1+
Sbjct 125 LRKK--H QDAINELSEQIEQLQKQKAKAEKEKSQLQAEVDDLLAQLDSITKAKLNAE 179
Query 2319 RVLARVQEQLSSLW EENQALA--TQTRDRLAQHEAGLM-DLREALNRAVDATREAQ 2371
+ +++ II I I I + I I + 11 + 1 I 11 + + ++
Sbjct 180 KKAKQLESQLSELQVKLDELQRQLNDLTSQKSRLQSENSDLTRQLEEAEAQVSNLΞKLKS 239
Query 2372 ELNSRNQERLEEALQRKQELSRDNATLQATLHAARDTLASVFRLLEGLSPLK FQELE 2428
+1 1+ llll + +1 11+ I III I 1 1+ ll l l ++I
Sbjct 240 QLESQ LEEAKRSLEEESRERANLQAQLRQLEHDLDSLREQLEEESEAKAELERQLS 295
Query 2429 RLAASLDGARTPL LQRMQTFSPAGSKL RLVEAAEAHAQQLGQLALNLS 2476
+ 1 + 1+ I + II III I I + I
Sbjct 296 KANAEIQQWRSKFESEGALRAEELEELKKKLNQKISELEEAAEAANAKCDSLEKTKSRLQ 355
Query 2477 IILDVNQDRLTQRAIEASNAYSRILQAVOAAEDAAGQALQOADHTWQTWR- -QGLVDRA 2534
1+ I +1 +11 + 1+ I I 1+ I I +1 I
Sbjct 356 SELEDL QIELERANAAASELEKKQKNFDKILAE WKRKVDELQAELDTA 403
Query 2535 QQ LLANSTALEEAMLQ EQQRLGLGECWAPMGALRPAGTQLRDVRAK 2580
1+ 1 lll l 1 + I I 1 I + ++
Sbjct 404 QREARNLSTELFRLKNELEELKDQVEALRRENKNLQD-EIHDLTDQLGEGGRNVHELEKA 462
Query 2581 KDQLEAHIQAAQAMLAMDTGETSKKJAHAKAVAABAQDTATRVQSQLQAMQENVER 2636
+ +111 11 I++ I + + I I +1 ++ +11
Sbjct 463 RRRLEAEKDELQA--ALEEAEAA LELEESKVLRAQVELSQIRSEIERRLAE 511
Query 2637 WQGQYEGLRGQ DLGQAVLDA GSAVSTLEKTLPQLLAKLSI-LE--NRGVHN 2684
+ ++I I + II l+l + 1 1+1 1 + +1 I 1+ 1+
Sbjct 512 KEEEFENTRKNHQRAIESLQATLEAETKGKAEASRLKKKLEGDINELEIALDHANKANAE 571
Query 2685 ASLALSASIGRVRELIAQ 2702
I + +1+11 I
Sbjct 572 AQKNVKKYQQQVKELQTQ 589
Table IS. Domain Analysis of NOVla gnl|pfam|pfam00054, laminin_G, Laminin G domain. (SEQ ID NO:60) CD-Length = 134 residues, 89.6% aligned Score = 47.8 bits (112), Expect = le-05
Query: 2760 VMYMGSRQATGDYMGVSLRDKKVHWVYQLGEAGPAVLSIDEDIGE-QFAAVSLDRTLQFG 2818
++I 1+ I++ + III ++ I II +1111+ + + + ++ I l+l + I
Sbj ct : 10 LLYGGT-NTDRDFLALELRDGRLEVSYDLG-SGPAWRSGDRLNDGKWHRVELERNGRKG 67
Query : 2819 HMSVTVERQMIQETKGDTVAPGAEGLLNLRPDDFVFYVGGYPSTFTPPPLLRF-PGYRGC 2877
+ 1 1 1 + 1 + I l + l I l l l l I I ++ I I
Sbjct: 68 TLSVDGEESVDGESPSGPDVPHE--NLDL DTPLYVGGLPELSVKRLLAAISTSFKGC 122
Query: 2878 IEMDTLN 2884
I + 1
Sbj ct : 123 IRDVIVN 129
Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth, migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consist of a coiled coil structure contributed by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module. It is known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the LE domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found (1). Miner et al (1) identified a fifth member of the alpha subfamily of vertebrate laminin chains. Consistent with the trimeric structure of laminin, all basal laminae characterized to that time contained at least 1 beta and at least 1 gamma chain. For the alpha chains, on the other hand, the situation was less clear. Using PCR, Miner et al. identified a novel murine alpha chain called alpha-5. Sequence analysis revealed a close relationship to the only known Drosophila alpha chain, suggesting that the ancestral alpha laminin gene is more similar to laminin alpha-5 than it is to laminin alpha-1, alpha-2, alpha-3, or alpha-4. Analysis of RNA expression showed that alpha-5 is widely expressed in adult tissues, with highest levels in lung, heart, and kidney. It is speculated that the Laminin alpha 5 may be a major laminin chain of adult basal laminae. Dirkin et al (2) mapped the LAMA5 gene to 20ql3.2-ql3.3; the mouse gene (Lama5) was mapped by linkage analysis to a syntenic region of distal chromosome 2.
The novel sequence described here is a human homolog of mouse laminin alpha 5.
Because of its expression pattern (3-4), it is suggested that laminin laminin alρha5 plays role
in the development of the human lung and skin morphogenesis. In addition, there is distinct temporal and spatial expression of these chains during proliferative and differentiation stages, possibly reflecting different functions (4).
The disclosed NOVl nucleic acid of the invention encoding a Human laminin alpha 5 - like protein includes the nucleic acid whose sequence is provided in Table 1A ,1C, IE, IG, or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases maybe changed from the corresponding base shown in Table 1A, IC, IE, or IG while still encoding a protein that maintains its Human laminin alpha 5-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 31% percent of the bases maybe so changed. The disclosed NOVl protein of the invention includes the Human laminin alpha 5-like protein whose sequence is provided in Table IB, ID, IF, or 1H. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table IB, ID, IF, or 1H while still encoding a protein that maintains its Human laminin alpha 5-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 54% percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fab or (Fab)2, that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Human laminin alpha 5-like protein (NOVl) may function as a member of a "Human laminin alpha 5 family". Therefore, the NOVl nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic,
diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOVl nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in cancer including but not limited to various pathologies and disorders as indicated below. For example, a cDNA encoding the Human laminin alpha 5- like protein (NOVl) may be useful in gene therapy, and the Human laminin alpha 5 -like protein (NOVl) may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, TMel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of;
SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, neuroprotection, fertility, diabetes, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonepliritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy, cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, ulcers, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, or other pathologies or conditions. The NOVl nucleic acid encoding the Human laminin alpha 5-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
NOVl nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVl substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOVl proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for
functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV2
NOV2 includes three novel Human Hurpin/PI 13-like proteins disclosed below. The disclosed sequences have been named NOV2a, NOV2b, and NOV2c. NOV2a
A disclosed NOV2a nucleic acid of 3105 nucleotides (also referred to as CG55999-01) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 38-40 and ending with a TAA codon at nucleotides 1238-1240. A The start and stop codons are in bold letters in Table 2A.
Table 2A. NOV2a nucleotide sequence (SEQ ID NO:9).
TGTTGTTCTTGCTATTCTAGGTCTCGCTAAAATCATCATGGATTCACTTGGCGCCGTCAGCACTCGACTTGG GTTTGATCTTTTCAAAGAGCTGAAGAAAACAAATGATGGCAACATCTTCTTTTCCCCTGTGGGCATCTTAAC TGCAATTGGCATGGTCCTCCTGGGGACCCGAGGAGCCACCGCTTCCCAGTTGGAGGAGGTGTTTCACTCTGA AAAAGAGACGAAGAGCTCAAGAATAAAGGCTGAAGAAAAAGAGGTGGTAAGAATAAAGGCTGAAGGAAAAGA GATTGAGAACACAGAAGCAGTACATCAACAATTCCAAAAGTTTTTGACTGAAATAAGCAAACTCACTAATGA TTATGAACTGAACATAACCAACAGGCTGTTTGGAGAAAAAACATACCTCTTCCTTCAAAAATACTTAGATTA TGTTGAAAAATATTATCATGCATCTCTGGAACCTGTTGATTTTGTAAATGCAGCCGATGAAAGTCGAAAGAA GATTAATTCCTGGGTTGAAAGCAAAACAAATGAAAAAATCAAGGACTTGTTCCCAGATGGCTCTATTAGTAG CTCTACCAAGCTGGTGCTGGTGAACATGGTTTATTTTAAAGGGCAATGGGACAGGGAGTTTAAGAAAGAAAA TACTAAGGAAGAGAAATTTTGGATGAATAAGAGCACAAGTAAATCTGTACAGATGATGACACAGAGCCATTC CTTTAGCTTCACTTTCCTGGAGGACTTGCAGGCCAAAATTCTAGGGATTCCATATAAAAACAACGACCTAAG CATGTTTGTGCTTCTGCCCAACGACATCGATGGCCTGGAGAAGATAATAGATAAAATAAGTCCTGAGAAATT GGTAGAGTGGACTAGTCCAGGGCATATGGAAGAAAGAAAGGTGAATCTGCACTTGCCCCGGTTTGAGGTGGA GGACGGTTACGATCTAGAGGCGGTCCTGGCTGCCATGGGGATGGGCGATGCCTTCAGTGAGCACAAAGCCGA CTACTCGGGAATGTCGTCAGGCTCCGGGTTGTACGCCCAGAAGTTCCTGCACAGTTCCTTTGTGGCAGTAAC TGAGGAAGGCACCGAGGCTGCAGCTGCCACCGGCATAGGCTTTACTGTCACATCCGCCCCAGGTCATGAAAA TGTTCACTGCAATCATCCCTTCCTGTTCTTCATCAGGCACAATGAATCCAACAGCATCCTCTTCTTCGGCAG ATTTTCTTCTCCTTAAGATGATCGTTGCCATGGCATTGCTGCTTTTAGCAAAAAACAACTACCAGTGTTACT CATATGATTATGAAAATCGTCCATTCTTTTAAATGTTGTCTCACTTGCATTTCCAGTCTTGGCCATCAAATC AATGATTTAATGACTCCAATAATGTGTGTGTTTATAACCATCCTCGAAAGTGAAATGTCCTTTTTTTTGTGC CATGCGTAAGGTGAGTCAAACCAAACCTCATTGATAATCTCCCCTTTGGTTTCCTTTGAAAGTAAATTGGTA TCTTGTAGTTTTGTGCACACGAAAGGAGAGAAAGTTTCTCCAGTAAAGAGTACGAACTAGTAATTTTGGGGG GTCTCTCTAATTCTGGTATTTTGACATGTTATAATACGCAAGTAAAATAAAACAATAGTTTACTCAGCTCAT GTTACTATTCCCCAACAGATATTGTGGCAAATCACACATAGGAAAGAGGATTTGGGAATACAGTAGCAAAAC ATAAATTAAAACTCAAATGCCCAGGACAAAATAAAACAATATACCAGATGGAGAGGATGCCCGTATTTTCAT CTTCCATTCTAACATTATCCATTGTTAGATGCATAAGCATTTTGATATTGTGTAATAAATGTGGTATTTGAG AAGATAAATGATGTAGTTGATCAGTAATCCTCCTCTATCACCTTTTTAGACTTTGTAAGGTAAATATTTGGA CTAACTTTTAGAAAAGTTTCCCTTTTTTTCTCCATTTACATTTTTCTGGTTTTTTTTTTTTTTTTTGAGTGA GGTACGAGTATTACCAAATGATATTTTCTGAAGATGCTTTTTGGAAAGCTCTGAATCTATACCTAATGCTCT TAATTATTGGCTTGTTTCATTTTTTTCCTCCAGTTTTTAACAAGATCACATAACTGGCTTATTTTTAACAGC TTTGTCAAACTACAATTTACATGCCGTAAAATGTACACACTGTAATTTTATAATTCATTGACTTTTAGTAAA TTTTCTAGCGTTATGCATCGCCACAATCCAGTTTTAGAATATTTCCATGACCCTAAGAAGTTTCCTCATGTC TATTAATATTCCCAATCCTAGGCACCACTGAGTTGTTTTCTGTCTTTATAAGTTTTTCTTTCTACATCTTAT ATAAATGGAATCATAATACATGTAGTATTTTGTGTCTGGCGTCTTGCACTTAGCATGGTGTTCTTGAGGTTC ATCTGTTGTAGTATGTATTGATACTTAGGATTTTTTTATTGCCGAATACTATTCCATTGCATGGAAAAGACC TATTTTATTTCTAGGTTCACCAGTTGAGGGACATTTGGATTGTTCCCACTTCTTGGGCTGTTAGGAATAATG TTGCTCTGAACATGTAAATAAAGATCTTTGTGTTCACATATGTTTTTCATTTTCTGTTGGGGAGATTCCCTA GGCTAGAAATTGCTGGGCCATATGAAAAATCAATAGTTAGCTTTGTAAGAAACAGTCAAACTGTTTTCCCAA CGTGACATTTTATATTCCCACCAGGAATGTTTAAAACTAGTGTCTTCAAATCCTCACCAACATCCAGGATTG TGTCTTTATGATTATAGCCATTTTTGTAGGTACAAAGTGGCATCTCATGGTGGTTTTAATTTGCATTTCCAT AATATCTAATTAGGTTGAGCTTTTTTTATGTGCTTATTGGCCATTTGTTTGACTTTGTTTGGTGAAATGTAT ACAAATCATTTGCTCATTTTTAATTTGGGTTGTCTGTCTTGTCTTCTCATTTTATTGAGTTAAATGAGTTCT TAATAATCTCTGGCTTACAAGTCCTTAATTTATCAAATATATGATACGTGGACATTTCCTCATAAAAAAAAA AAAAAAAAA
The disclosed NOV2a nucleic acid sequence, localized to the q21.3-22 region of chromsome 18, has 2854 of 2866 bases (99%) identical to a gb:GENBANK- BD:HSPI1371 l|acc:AJ001696.2 mRNA from Homo sapiens (Homo sapiens mRNA for hurpin, clone R7-1.1) (E = 0.0).
A NOV2a polypeptide (SEQ ID NO: 10) encoded by SEQ ID NO:9 has 400 amino acid residues and is presented using the one-letter code in Table 2B. Signal P, Psort and/or Hydropathy results predict that NOV2a contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900. In other embodiments, NOV2a may also be localized to the microbody (peroxisome) with a certainty of 0.7106, the Golgi body with a
certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000. The most likely cleavage site for NOV2a is between positions 50 and 51 : ATA-SQ.
Table 2B. Encoded NOV2a protein sequence (SEQ ID NO:10).
MDSLGAVSTRLGFDLFKELKKTNDGNIFFSPVGILTAIGMVLLGTRGATASQLEEVFHΞEKETKSSRIKAEE KEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEKTYLFLQKYLDYVEKYYHASLEPV DFVNAADESRKKINSWVESKTNEKIKDLFPDGSISSSTKLVLVNMVYFKGQWDREFKKENTKEEKFWMNKST SKSVQMMTQSHSFSFTFLEDLQAKILGIPYKNNDLSMFVLLPNDIDGLEKIIDKISPΞKLVEWTSPGHMEER KVNLHLPRFEVEDGYDLEAVLAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATGI GFTVTSAPGHENVHCNHPFLFFIRHNESNSILFFGRFSSP
The disclosed NOV2a amino acid sequence has 391 of 400 amino acid residues (97%) identical to, and 391 of 400 amino acid residues (97%) similar to, the 391 amino acid residue ptnr:SWISSNEW-ACC:Q9UrV8 protein from Homo sapiens (Human) (Hurpin (HACAT UV- Repressible Serpin) (Protease Inhibitor 13) (Headpin) (E = 5.8e"206).
NOV2a is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, and/or RACE sources.
In addition, the sequence is predicted to be expressed in keratinocytes because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSPI13711|acc:AJ001696.2) a closely related Homo sapiens mRNA for hurpin, clone R7-1.1 homolog. NOV2b
In the present invention, the target sequence identified previously, NOV2a, was subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species. These primers were then employed in
PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported below, which is designated NOV2b. This differs from the previously identified sequence (NOV2a) in having 2 different aminoacids.
A disclosed NOV2b nucleic acid of 1238 nucleotides (also referred to as CG55999-02) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 24-26 and ending with a TAA codon at nucleotides 1224-1226. A The start and stop codons are in bold letters in Table 2C and the 5' and 3' untranslated regions are underlined.
Table 2C. NOV2b nucleotide sequence (SEQ ID NO:ll).
TTCTAGGTCTCGCTAAAATCATCATGGATTCACTTGGCGCCGTCAGCACTCGACTTGGGTTTGATCTTTTCA
AAGAGCTGAAGAAAACAAATGATGGCAACATCTTCTTTTCCCCTGTGGGCATCTTGACTGCAATTGGCATGG
TCCTCCTGGGGACCCGAGGAGCCACCGCTTCCCAGTTGGAGGAGGTGTTTCACTCTGAAAAAGAGACGAAGA
GCTCAAGAATAAAGGCTGAAGAAAAAGAGGTGGTAAGAATAAAGGCTGAAGGAAAAGAGATTGAGAACACAG
AAGCAGTACATCAACAATTCCAAAAGTTTTTGACTGAAATAAGCAAACTCACTAATGATTATGAACTGAACA
TAACCAACAGGCTGTTTGGAGAAAAAACATACCTCTTCCTTCAAAAATACTTAGATTATGTTGAAAAATATT
ATCATGCATCTCTGGAACCTGTTGATTTTGTAAATGCAGCCGATGAAAGTCGAAAGAAGATTAATTCCTGGG
TTGAAAGCAAAACAAATGAAAAAATCAAGGACTTGTTCCCAGATGGCTCTATTAGTAGCTCTACCAAGCTGG
TGCTGGTGAACATGGTTTATTTTAAAGGGCAATGGGACAGGGGGTTTAAGAAAGAAAATACTAAGGAAGAGA AATTTTGGATGAATAAGAGCACAAGTAAATCTGTACAGATGATGACACAGAGCCATTCCTTTAGCTTCACTT
TCCTGGAGGACTTGCAGGCCAAAATTCTAGGGATTCCATATAAAAACAACGACCTAAGCATGTTTGTGCTTC TGCCCAACGACATCGATGGCCTGGAGAAGATAATAGATAAAATAAGTCCTGAGAAATTGGTAGAGTGGACTA GTCCAGGGCATATGGAAGAAAGAAAGGTGAATCTGCACTTGCCCCGGTTTGAGGTGGAGGACAGTTACGATC TAGAGGCGGTCCTGGCTGCCATGGGGATGGGCGATGCCTTCAGTGAGCACAAAGCCGACTACTCGGGAATGT CGTCAGGCTCCGGGTTGTACGCCCAGAAGTTCCTGCACAGTTCCTTTGTGGCAGTAACTGAGGAAGGCACCG AGGCTGCAGCTGCCACTGGCATAGGCTTTACTGTCACATCCGCCCCAGGTCATGAAAATGTTCACTGCAATC ATCCCTTCCTGTTCTTCATCAGGCACAATGAATCCAACAGCATCCTCTTCTTCGGCAGATTTTCTTCTCCTT AAGATGATCGTTGC
The disclosed NOV2b nucleic acid sequence, localized to the q21.3 region of chromsome 18, has 999 of 1013 bases (98%) identical to a gb:GENBANK- ID:AF169949|acc:AFl 69949.1 mRNA from Homo sapiens (Homo sapiens headpin mRNA, complete eds) (E = 1.4e"215).
A NOV2b polypeptide (SEQ ID NO: 12) encoded by SEQ LD NO:l 1 has 400 amino acid residues and is presented using the one-letter code in Table 2D. Signal P, Psort and/or Hydropathy results predict that NOV2b contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900. In other embodiments, NOV2b may also be localized to the microbody (peroxisome) with a certainty of 0.7147, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000. The most likely cleavage site for NOV2b is between positions 50 and 51 : ATA-SQ.
Table 2D. Encoded NOV2b protein sequence (SEQ ID NO:12).
MDSLGAVSTRLGFDLFKELKKTNDGNIFFSPVGILTAIGMVLLGTRGATASQLEEVFHSEKETKSSRIKAEE KEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEKTYLFLQKYLDYVEKYYHAΞLEPV DFVNAADESRKKINSWVESKTNEKIKDLFPDGSISSSTKLVLVNMVYFKGQWDRGFKKENTKEEKFWMNKST SKSVQMMTQSHSFSFTFLEDLQAKILGIPYKNNDLSMFVLLPNDIDGLEKIIDKISPEKLVEWTSPGHMEER KVNLHLPRFEVEDSYDLEAVLAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATGI GFTVTSAPGHENVHCNHPFLFFIRHNESNSILFFGRFSSP
The disclosed NOV2b amino acid sequence has 390 of 400 amino acid residues (97%) identical to, and 390 of 400 amino acid residues (97%) similar to, the 391 amino acid residue ptπr:SPTREMBL-ACC:Q9UKG0 protein from Homo sapiens (Human) (HEADPIN) (E = 5.3e-205).
NOV2b is expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus, Buccal mucosa, Cervix, Coronary Artery, Skin, Vulva. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55999-02.
The sequence is predicted to be expressed in keratinocytes because of the expression pattern of (GENBANK-ID: gb:GENBANK-LO:AF169949|acc:AF169949.1) a closely related Homo sapiens headpin mRNA, complete eds homolog in species Homo sapiens. NOV2c
A disclosed NOV2c nucleic acid of 1559 nucleotides (also referred to as CG55999-05) encoding a novel Human Hurpin PI 13-like protein is shown in Table 2E. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 353-355 and ending with a TAA codon at nucleotides 1553-1555. A The start and stop codons are in bold letters in Table 2E and the 5' and 3' untranslated regions are underlined.
Table 2E. NOV2c nucleotide sequence (SEQ ID NO:13).
AAGCTTCCATGAAGAGGAGGCTGTGGAGAGGCAGAGACAGGCAGGGTCAGACAGAGAGCAAGAGAATAAAGC CATTAAAACATTAACCCTGCTCCGCGGGGAAATAAGAACTGAGCACCACCGGATGACGGAAGACTCCAGTAG ATTGATGGATGTCTCCCAGCAAGAGAAGGCCAAGAGAGGACGTGAGAAGCAGGCAGCAGCGACCTTTCACCA AAAGGGTGGAAATCCCTGTATTCCGGATCGATGCAAGAAGAGGAATAGAAGCAGAAAGGATTCCCCTGACAC AGAGTAATTCAAATGTTCAGTTTTGATTGTTGTTCTTGCTATTCTAGGTCTCGCTAAAATCATCATGGATTC ACTTGGCGCCGTCAGCACTCGACTTGGGTTTGATCTTTTCAAAGAGCTGAAGAAAACAAATGATGGCAACAT CTTCTTTTCCCCTGTGGGCATCTTGACTGCAATTGGCATGGTCCTCCTGGGGACCCGAGGAGCCACCGCTTC CCAGTTGGAGGAGGTGTTTCACTCTGAAAAAGAGACGAAGAGCTCAAGAATAAAGGCTGAAGAAAAAGAGGT GGTAAGAATAAAGGCTGAAGGAAAAGAGATTGAGAACACAGAAGCAGTACATCAACAATTCCAAAAGTTTTT GACTGAAATAAGCAAACTCACTAATGATTATGAACTGAACATAACCAACAGGCTGTTTGGAGAAAAAACATA CCTCTTCCTTCAAAAATACTTAGATTATGTTGAAAAATATTATCATGCATCTCTGGAACCTGTTGATTTTGT AAATGCAGCCGATGAAAGTCGAAAGAAGATTAATTCCTGGGTTGAAAGCAAAACAAATGAAAAAATCAAGGA CTTGTTCCCAGATGGCTCTATTAGTAGCTCTACCAAGCTGGTGCTGGTGAACATGGTTTATTTTAAAGGGCA ATGGGACAGGGAGTTTAAGAAAGAAAATACTAAGGAAGAGAAATTTTGGATGAATAAGAGCACAAGTAAATC TGTACAGATGATGACACAGAGCCATTCCTTTAGCTTCACTTTCCTGGAGGACTTGCAGGCCAAAATTCTAGG GATTCCATATAAAAACAACGACCTAAGCATGTTTGTGCTTCTGCCCAACGACATCGATGGCCTGGAGAAGAT AATAGATAAAATAAGTCCTGAGAAATTGGTAGAGTGGACTAGTCCAGGGCATATGGAAGAAAGAAAGGTGAA TCTGCACTTGCCCCGGTTTGAGGTGGAGGACAGTTACGATCTAGAGGCGGTCCTGGCTGCCATGGGGATGGG CGATGCCTTCAGTGAGCACAAAGCCGACTACTCGGGAATGTCGTCAGGCTCCGGGTTGTACGCCCAGAAGTT CCTGCACAGTTCCTTTGTGGCAGTAACTGAGGAAGGCACCGAGGCTGCAGCTGCCACTGGCATAGGCTTTAC TGTCACATCCGCCCCAGGTCATGAAAATGTTCACTGCAATCATCCCTTCCTGTTCTTCATCAGGCACAATGA ATCCAACAGCATCCTCTTCTTCGGCAGATTTTCTTCTCCTTAAGATG
The disclosed NOV2c nucleic acid sequence, localized to the q21.3-22 region of chromsome 18, has 519 of 519 bases (100%) identical to a gb:GENBANK- ID:AF216854|acc:AF216854.1 mRNA from. Homo sapiens (Homo sapiens headpin gene, complete eds) (E = 2.3e"303).
A NOV2c polypeptide (SEQ ID NO: 14) encoded by SEQ ID NO:13 has 400 amino acid residues and is presented using the one-letter code in Table 2F. Signal P, Psort and/or Hydropathy results predict that NOV2c contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900. hi other embodiments, NOV2c may also be localized to the microbody (peroxisome) with a certainty of 0.7024, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000. The most likely cleavage site for NOV2c is between positions 50 and 51 : ATA-SQ.
Table 2F. Encoded NOV2c protein sequence (SEQ ID NO:14).
MDSLGAVSTRLGFDLFKELKKTNDGNIFFSPVGILTAIGMVLLGTRGATASQLEEVPHSEKETKSSRIKAEE KEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEKTYLFLQKYLDYVEKYYHASLEPV DFVNAADESRKKINSWVESKTNEKIKDLFPDGSISSSTKLVLVNMVYFKGQWDREFKKENTKEEKFWMNKST SKSVQMMTQSHSFSFTFLEDLQAKILGIPYKNNDLSMFVLLPNDIDGLEKIIDKISPEKLVEWTSPGHMEER KVNLHLPRFEVEDSYDLEAVLAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATGI GFTVTSAPGHENVHCNHPFLFFIRHNΞSNSILFFGRFSSP
The disclosed NO V2c amino acid sequence has 391 of 400 amino acid residues (97%) identical to, and 391 of 400 amino acid residues (97%) similar to, the 391 amino acid residue
ptnr:SPTREMBL-ACC:Q9UKG0 protein from Homo sapiens (Human) (Headpin) (E = ie"
205
NOV2d
A disclosed NOV2d nucleic acid of 818 nucleotides (also referred to as CG55999-06) encoding a novel Human Hurpin/PI 13-like protein is shown in Table 2G. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 40-42 and ending with a TAA codon at nucleotides 565-567. A The start and stop codons are in bold letters in Table 2G and the 5' and 3' untranslated regions are underlined.
Table 2G. NOV2d nucleotide sequence (SEQ ID NO:15).
ACCGTCTCTCCAAAAACCCGAGGTCTCGCTAAAATCATCATGGATTCACTTGGCGCCGTCAGCACTCGACTT GGGTTTGATCTTTTCAAAGAGCTGAAGAAAACAAATGATGGCAACATCTTCTTTTCCCCTGTGGGCATCTTG ACTGCAATTGGCATGGTCCTCCTGGGGACCCGAGGAGCCACCGCTTCCCAGTTGGAGGAGGTGTTTCACTCT GAAAAAGAGACGAAGAGCTCAAGAATAAAGGCTGAAGAAAAAGAGGTGGTAAGAATAAAGGCTGAAGGAAAA GAGATTGAGAACACAGAAGCAGTACATCAACAATTCCAAAAGTTTTTGACTGAAATAAGCAAACTCACTAAT GATTATGAACTGAACATAACCAACAGGCTGTTTGGAGAAAAAACATACCTCTTCCTTCAAAAATACTTAGAT TATGTTGAAAAATATTATCATGCATCTCTGGAACCTGTTGATTTTGTAAATGCAGCCGATGAAAGTCGAAAG AAGATTAATTCCTGGGTTGAAAGCAAAACAAATGATGTGGAAACTGAGGCACAGAGAGTTTAAATAACTTGC CCAAGATTCCTCAGCTGATAAGAGGCAAACTGGATGCTAACAGAGGCATCTGACCCCAGAGTCTGGACTCTT AACCATGAACCTTAATTTATCCACTGGGATAAATAGGCGATGGGCAAAATGAGAACCTCCCCGTCGATTCTG CCAGCAAACCCTTTGTCAGCAAGGCCCTCAGAAAAAATCAAGGACTTGTTCCCAGATGGCTCTATTAGTAGC TCTACCAAGCTGGTGCTGGTGACATG
The disclosed NOV2d nucleic acid sequence, localized to the q21.3-22 region of chromsome 18, has 214 of 214 bases (100%) identical to a gb:GENBANK- ID:AF216854|acc:AF216854.1 mRNA from Homo sapiens (Homo sapiens headpin gene, complete eds) (E = 1.3e"134).
ANOV2d polypeptide (SEQ ID NO: 16) encoded by SEQ ID NO: 15 has 175 amino acid residues and is presented using the one-letter code in Table 2H. Signal P, Psort and/or Hydropathy results predict that NOV2d contains a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.7900. hi other embodiments, NOV2d may also be localized to the microbody (peroxisome) with a certainty of 0.3878, the Golgi body with a certainty of 0.3000, or the endoplasmic reticulum (membrane) with a certainty of 0.2000. The most likely cleavage site for NOV2d is between positions 50 and 51 : ATA-SQ.
Table 2H. Encoded NOV2d protein sequence (SEQ ID NO:1 ).
MDSLGAVSTRLGFDLFKELKKTNDGNIFFSPVGILTAIGMVLLGTRGATASQLEEVFHSEKETKSSRIKAEE KEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEKTYLFLQKYLDYVEKYYHASLEPV DFVNAADESRKKINSWVESKTNDVETEAQRV
The disclosed NOV2d amino acid sequence has 157 of 167 amino acid residues (94%) identical to, and 158 of 167 amino acid residues (94%) similar to, the 391 amino acid residue ptnr:SWISSNEW-ACC:Q9UIV8 protein from Homo sapiens (Human) (HURPIN (HACAT UV-Repressible Serpin) (Protease Inhibitor 13) (Headpin)) (E = 2.2e"76).
NOV2d is expressed in at least the following tissues: Mammalian Tissue, Coronary Artery, Buccal mucosa, Pituitary Gland, Cervix, Uterus, Vulva, Skin. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG55999-06.
NOV2e
A disclosed NOV2e nucleic acid of 1062 nucleotides (also referred to as 166485357) encoding a novel Human Hurpin PI 13-like protein is shown in Table 21. An open reading frame was identified beginning with an GGA initiation codon at nucleotides 1-3 and ending with a GAG codon at nucleotides 1060-1062. A The start and stop codons are in bold letters in Table 21. Since the start and stop codons are not traditional initiation and termination codons, NOV2e may be a partial reading frame that extends further in the 5' and 3' directions.
Table 21. NOV2e nucleotide sequence (SEQ ID NO: 197).
GGATCCTCCCAGTTGGAGGAGGTGTTTCACTCTGAAAAAGAGACGAAGAGCTCAAGAATAAAGGCTGAAGAA AAAGAGGTGGTAAGAATAAAGGCTGAAGGAAAAGAGATTGAGAACACAGAAGCAGTACATCAACAATTCCAA AAGTTTTTGACTGAAATAAGCAAACTCACTAATGATTATGAACTGAACATAACCAACAGGCTGTTTGGAGAA AAAACATACCTCTTCCTTCAAAAATACTTAGATTATGTTGAAAAATATTATCATGCATCTCTGGAACCTGTT GATTTTGTAAATGCAGCCGATGAAAGTCGAAAGAAGATTAATTCCTGGGTTGAAAGCAAAACAAATGAAAAA ATCAAGGACTTGTTCCCAGATGGCTCTATTAGTAGCTCTACCAAGCTGGTGCTGGTGAACATGGTTTATTTT AAAGGGCAATGGGACAGGGAGTTTAAGAAAGAAAATACTAAGGAAGAGAAATTTTGGATGAATAAGAGCACA AGTAAATCTGTACAGATGATGACACAGAGCCATTCCTTTAGCTTCACTTTCCTGGAGGACTTGCAGGCCAAA ATTCTAGGGATTCCATATAAAAACAACGACCTAAGCATGTTTGTGCTTCTGCCCAACGACATCGATGGCCTG GAGAAGATAATAGATAAAATAAGTCCTGAGAAATTGGTAGAGTGGACTAGTCCAGGGCATATGGAAGAAAGA AAGGTGAATCTGCACTTGCCCCGGTTTGAGGTGGAGGACAGTTACGATCTAGAGGCGGTCCTGGCTGCCATG GGGATGGGCGATGCCTTCAGTGAGCACAAAGCCGACTACTCGGGAATGTCGTCAGGCTCCGGGTTGTACGCC CAGAAGTTCCTGCACAGTTCCTTTGTGGCAGTAACTGAGGAAGGCACCGAGGCTGCAGCTGCCACTGGCATA GGCTTTACTGTCACATCCGCCCCAGGTCATGAAAATGTTCACTGCAATCATCCCTTCCTGTTCTTCATCAGG CACAATGAATCCAACAGCATCCTCTTCTTCGGCAGATTTTCTTCTCCTCTCGAG
A NOV2e polypeptide (SEQ ID NO:14) encoded by SEQ ID NO:13 has 354 amino acid residues and is presented using the one-letter code in Table 2J.
Table 2J. Encoded NOV2e protein sequence (SEQ ID NO:198).
GSSQLEEVFHSEKETKSSRIKAEEKEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGE KTYLFLQKYLDYVEKYYHASLEPVDFVNAADESRKKINSWVESKTNEKIKDLFPDGSISSSTKLVLVNMVYF KGQWDREFKKENTKEEKFWMNKSTSKSVQMMTQSHSFSFTFLEDLQAKILGIPYKNNDLSMFVLLPNDIDGL EKIIDKISPEKLVEWTSPGHMEERKVNLHLPRFEVEDSYDLEAVLAAMGMGDAFSEHKADYSGMSSGSGLYA QKFLHSSFVAVTEEGTEAAAATGIGFTVTSAPGHENVHCNHPFLFFIRHNESNSILFFGRFSSPLE
NOV2a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 21.
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 2L.
Table 2L. ClustalW Analysis of NOV2
1) NOV2a (SEQ ID NO: 10)
2) NOV2b (SEQ ID NO: 12)
3) NOV2c (SEQ ID NO: 14)
4) NOV2d (SEQ ID NO: 16)
5) NOV23 (SEQ ID NO: 198)
6) gi| 8393956|ref |NP_036529.l| (NM_012397) serine (or cysteine) proteinase inhibitor, clade B (SEQ ID NO: 61)
7) gi|6018510 emb|CAA04937.l| (AJ001698) hurpin [Homo sapiens] (SEQ ID N0:62)
8) giJ7522623 pir|| C7118 headpin serine proteinase inhibitor - human (SEQ ID NO : 63 )
9) gi|9801227|emb|CAC03569.l| (AJ278717) hurpin [Homo sapiens] (SEQ ID N0-.64)
10) gi I 266995 j sp| P29508 j SCC1_HUMAN SQUAMOUS CELL CARCINOMA ANTIGEN 1 (SCCA-1) (PROTEIN T4-A) (SEQ ID NO: 65)
250 260 270 280 290 300
NOV2a 300 NOV2b ILGIPYK NDLSMFVLLPNDIDGLEKIIDKISPE LVEWTSPGHMEERKVWLHLPRFEVi 300 NOV2c I GIPYKNNDLSMFVL PNDIDGLEKIIDKISPEK VE TSPGHMEERKVNLHLPRFEVI 300 NOV2d 175 NOV2e GIPYKNNDLSMFVLLPNDIDGLEKIIDKISPEK VEWTSPGHMEERKVNLHLPRFEV 252 gi 8393956 ref ILGIPYKNNDLSMFV PNDIDG E IIDKISPEKLVEWTSPGHMEERKVN HLPRFEV; 291 gi 6018510 emb 290 g 7522623 pir 291 gi 9801227 emb A'MΛ-MIΛIύiAM ■i'ΛwmitmansnLVB 239 gi 266995' sp|P2 ! mm 290
310 320 330 340 350 360
I ..I..
NOV2a uwjϊUUisavijftΛMGMGDAFSEHKADYSGMSSGSGLYAQKFIjHSSFVAVTEEGTEAAAATG 360
NOV2b DHYDLEAVIAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATG 360
NOV2c nBγD EAV AAMGMGDAFSEH ADYSGMSSGSGLYAOKF HSSFVAVTEΞGTΞAAAATG 360
NOV2d 175
NOV2e YD EAVLAAMGMGDAFSEH1ADYSGMSSGSGLYAQKF HΞSFVAVTEEGTEAAAATGI 312 gi 8393956 ref I YDLEAVLAAMGMGDAFΞEHKADYSGMSSGSGLYAQKFLHSΞFVAVTEEGTEAAAATGI 351 gi 6018510 embj YDL|AV AAMGMGDAFSEHKADYSGMSSGSG YAQKFLHSSFVAVTEEGTEAAAATGI 350 gi 7522623 pir| YDLEAVAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATGI 351
9801227 emb| YDLEAV AΑMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAΛ 299 g 266995 |j 3p|P2 JKDTg |SHViJlI j G - fGS alv SG iiiaKaiaBJEE Λl 349
370 380 390 400
.|....|....L..J...._L_..
NOV2a MVttCNHPFLFFIRHNESNSI FFGRFSS - 400
NOV2b TVTSAPGHENVHCNHPFLFFIRHWESMSILFFGRFSS - 400
NOV2c ϋiiiαa»ιa3Ha;iBia«iBCT»naa«a3Bwιa-- 400
NOV2d 175
NOV2e ΓTVTSAPGHENVHCISIHPF FFIRHNESNSI FFGRFSSI |LE 354 gi 8393956 ref | ?TVTSAPGHENVHCNHPF FFIRHNESWSILFFGRFSSΪ 391 gi 6018510 emb| "TVTSAPGHEKVHCNHPF FFIRHHESMSILFFGRFSSΪ 390 gi 7522623 pir| 391 gi 9801227 emb| 'TVTSAPGHENVHCNHPS -- 339 gi 266995|ϊ 3p|P2 pUjja'iiJiuaal'-aaaiBJ- - 390
Tables 2M-N lists the domain description from DOMAIN analysis results against NOV2a. This indicates that the NOV2a sequence has properties similar to those of other proteins known to contain this domain.
Table 2M Domain Analysis of NOV2 gnl] Pf m|pfam00079, serpin, Serpin (S protease inhibitor). Structure is a multi-domain fold containing a bundle of helices and a beta sandwich. (SEQ ID NO: 66)
CD-Length = 377 residues, 98.4% aligned
Score = 318 bits (816) , Expect = 3e-88
Query: 3 SLGAVSTRLGFDLFKEL-KKTNDGNIFFSPVGILTAIGMVLLGTRGATASQLEEVFHSEK 61
I + + I Mil ++ I Mil l I + 1 + 1+ II +1 11 + 1 + II
Sbjct: 7 KLASANADFAFSLYKELVEQNPDKNIFFSPVSISSALAMLSLGAKGNTATQILEVLGFNL 66
Query: 62 ETKSSRIKAEEKEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEK 121
I +11 II I I+++ +1 I II +1
Sbjct: 67 TETSE AEIHQGFQHLLQELNRPDTGLQLTTGNALFVDK 104
Query: 122 TYLFLQKYLDYVEKYYHASLEPVDFVNAADESRKKINSWVESKTNEKIKDLFPDGSISSS 181
+ I ++|+ ++ I + + I)] + +|++|+ || in II ||||| I + I
Sbjct: 105 SLKLLDEFLEDSKRLYQSEVFSVDF-SDPEEAKKQINDWVEKKTQGKIKDLLKD--LDSD 161 Query: 182 TKLVLVNMVYFKGQ DREFJJSWTKEEifF MNKSTSKSVQMMTQSHSFSFTFLEDLQAKI 241
I lllll +IIII+I + I I l+ll I ++I 1+ l ll l + 1 + l+l 1+
Sbjct: 162 TVLVLVNYIYFKGK KKPFDPELTEEEDFHVDKKTTVKVPMMNQLGTFYYFRDEELNCKV 221 Query: 242 LGIPYKNNDLSMFVLLPNDIDGLEKIIDKISPEKLVE TSPGHMEERKVNLHLPRFEVED 301
I +111 I II +II+++ II++ +111 I +1 +11 l+l l+l l+l +1
Sbjct: 222 LELPYKGNATSMLFILPDEVGKLEQVEAALSPETLRKWLE--NMEPREVELYLPKFSIEG 279 Query: 302 GYDLEAVLAAMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVTEEGTEAAAATGIG 361
111+ III +1+ I II +11 ll+l I I +1 + + I
Sbjct: 280 TYDLKDVLAKLGITDLFSN-QADLSGISEDEDLKVSKAVHKAVLEVDEEGTEAAAATGAI 338 Query: 362 FTVTSAPGHENVHCNHPFLFFIRHNESNSILFFGRFSSP 400
I I + llll I + + llll 1+ +1
Sbjct: 339 IVPRSLPPELEFTADRPFLFLIYDDPTGSILFMGKWNP 377
Table 2N Domain Analysis of NOV2 gnl | Smart] smart 00093, SERPIN, SERine Proteinase INhibitors (SEQ ID
NO: 67)
CD-Length = 360 residues, 100.0% aligned
Score = 312 bits (800) , Expect = 2e-86
Query: 13 FDLFKELKKTN-DGNIFFSPVGILTAIGMVLLGTRGATASQLEEVFHSEKETKSSRIKAE 71 lll+lll I + I III I +1+ 1+ II +I+II+I+ II I
Sbjct: 1 FDLYKELAKESPDKNIFFSPVSISSALAMLSLGAKGSTATQILEVLGFNLTΞTSE 55
Query: 72 EKEWRIKAEGKEIENTEAVHQQFQKFLTEISKLTNDYELNITNRLFGEKTYLFLQKYLD 131
+11 II I +++ l +l I II +1+ I +1+
Sbjct: 56 ADIHQGFQHLLHLLNRPDNKLQLKTANALFVDKSLKLLDSFLE 98
Query: 132 YVEKYYHASLEPVDFVNAADESRKKINS VESKTNEKIKDLFPDGSISSSTKLVLVNMVY 191 | + | I I ++ III + μμ+i + ii ||+ II lllll I + l + lllll +1
Sbjct: 99 DVKKLYGAEVQSVDFSDPAEEAKKQIND VKKKTQGKIKDLLSD--LDPDTRLVLVNAIY 156
Query : 192 FKGQWDREFKKEIOT EEKFWMNKSTSKSVQIv TQ-SHSFSFTFLEDLQAKILGIPYKNND 250 lll+l I lll+ll I+++++I+ I ll+l +1 + l+l ++I +111 I
Sbjct: 157 FKGKWKTPFDPENTREEDFYVDETTTVKVPMMSQTGRTFRYGRDEELNCQVLELPYKGN- 215
Query: 251 LSMFVLLPNDIDGLEKIIDKISPEKLVE TSPGHMEERKVNLHLPRFEVEDGYDLEAVLA 310
II ++II++ III + ++II I +11 + +1 I I+II+I++I 111+ II
Sbjct: 216 ASMLIILPDEG-GLETVEKALTPETLKK TK--SLTKRSVELYLPKFKLEISYDLKDVLE 272 Query: 311 AMGMGDAFSEHKADYSGMSSGSGLYAQKFLHSSFVAVrSEGTEAAAATGIGFTVTSAPGH 370
+1+ I II III ll+l I I +1 +1+ I 11111111111+ I I
Sbjct: 273 KLGITDLFSN-KADLSGISEDKDLKVSKWHKAFLEVNEEGTEAAAATGVIIVPRSLP-P 330
Query: 371 ENVHCNHPFLFFIRHNESNSILFFGRFSSP 400
I llll II I + llll 1+ +1
Sbjct: 331 PEFKANRPFLFLIRDNPTGSILFMGKWNP 360
Proteolysis is the key feature of programmed cell death. Extracellular proteinases can activate cell surface receptors which trigger apoptosis, and the effector machinery requires the activation and activity of numerous intracellular proteinases (primarily caspases). Effective control of proteolysis is essential for homeostasis and can occur at two levels: regulation of proteinase activation, and regulation of the activated proteinase. The serpins, a family of proteins that inhibit chymotrypsin-like serine proteinases, control activated proteinases and several have been imphcated in the regulation of cell death. Hurpin is a novel serine proteinase inhibitor recently cloned by Abts HF et al. (1999, J. Mol. Biol, Vol. 293 :29-39). It has nearly 59%) amino acid identity with the squamous cell carinoma antigenl (SCCA1) and squamous cell carcinoma antigen 2 (SCCA2). Expression of hurpin appears to be related to the activation or proliferation state of keratinocytes.
The disclosed NOV2 nucleic acid of the invention encoding a Human Hurpin/Pi 13- like protein includes the nucleic acid whose sequence is provided in Tables 2 A, 2C, 2E, 2G or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Tables 2A, 2C, 2E, or, 2G while still encoding a protein that maintains its Human Hurpin/Pi 13 -like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject, hi the mutant or
variant nucleic acids, and their complements, up to about 3 percent of the bases may be so changed.
The disclosed NOV2 protein of the invention includes the Human Hurpin/PI 13 -like protein whose sequence is provided in Tables 2B, 2D, 2F, or 2H. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2B, 2D, 2F, or 2H while still encoding a protein that maintains its Human Hurpin/PI 13-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 48 percent of the residues may be so changed. The NOV2 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in Colorectal cancer; Combined factor V and VIII deficiency; Cone-rod retinal dystrophy- 1; Leukemia/lymphoma, B-cell, 2; Lymphomaleukemia, B-cell, variant; Protoporphyria, erythropoietic; Protoporphyria, erythropoietic, recessive, with liver failure; Obesity, autosomal dominant; Osteosarcoma; cancer, skin psoriasis, and/or other pathologies and disorders.
NOV2 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV2 protein has multiple hydrophilic regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which are useful in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV3
NOV3 includes three novel Set Binding Factor (SBFl)-like proteins disclosed below. The disclosed sequences have been named NOV3a and NOV3b.
NOV3a
A disclosed NOV3a nucleic acid of 5316 nucleotides (also referred to as CG56019-01) encoding a novel Set Binding Factor (SBFl)-like protein is shown in Table 3A. An open reading frame was identified beginning with a ATT initiation codon at nucleotides 3-5 and ending with a TGA codon at nucleotides 5172-5174. The start and stop codons are in bold letters, and the 5' and 3' untranslated regions are underlined. Because the start codon is not a
traditional initiation codon, NOV3 could be a partial open reading frame that extends further in the 5' direction.
Table 3A. NOV3a Nucleotide Sequence (SEQ ID NO:17)
GAATTCGGCACGAGGTCTTCCTGTCCCGGAGCTACCAGCGGCTCGCCGATGCCTGTAGGGGCCTCCTGGCA CTGCTGTTTCCTCTCAGATACAGCTTCACCTATGTGCCCATCCTGCCGGCTCAGCTGCTGGAGGTCCTCAG CACACCCACGCCCTTCATCATTGGGGTCAACGCGGCCTTCCAGGCAGAGACCCAGGAGCTGCTCGATGTGA TTGTTGCTGATCTGGATGGAGGGACGGTCACCATTCCTGAGTGTGTGCACATTCCACCCTTGCCAGAGCCA CTGCAGAGTCAGACGCACAGTGTGCTGAGCATGGTCCTGGACCCGGAGCTGGAGTTGGCTGACCTCGCCTT CCCTCCGCCCACGACATCCACCTCCTCCCTGAAGATGCAGGACAAGGAGCTGCGCGCGGTCTTCCTGCGGC TGTTCGCTCAGCTGCTGCAGGGCTATCGCTGGTGCCTGCACGTCGTGCGCATCCACCCGGAGCCTGTCATC CGCTTCCATAAGGCAGCCTTCCTGGGGCAGCGTGGGCTGGTAGAGGACGATTTCCTGATGAAGGTGCTGGA GGGCATGGCCTTTGCTGGCTTTGTGTCAGAGCGTGGGGTCCCATACCGCCCTACGGACCTGTTCGATGAGC TGGTGGCCCACGAGGTGGCAAGGATGCGGGCGGATGAGAACCACCCCCAGCGTGTCCTGCGTCACGTCCAG GAACTGGCAGAGCAGCTCTACAAGAACGAGAACCCGTACCCAGCCGTGGCGATGCACAAGGTACAGAGGCC CGGTGAGAGCAGCCACCTGCGACGGGTGCCCCGACCCTTCCCCCGGCTGGATGAGGGCACCGTGCAGTGGA TCGTGGACCAGGCTGCAGCCAAGATGCAGGGTGCACCCCCAGCTGTGAAGGCCGAGAGGAGGACCACCGTG CCCTCAGGGCCCCCCATGACTGCCATACTGGAGCGGTGCAGTGGGCTGCATGTCAACAGCGCCCGGCGGCT GGAGGTTGTGCGCAACTGCATCTCCTACGTGTTTGAGGGGAAAATGCTTGAGGCCAAGAAGCTGCTCCCAG CCGTGTTGAGGGCCCTGAAGGGGCGAGTTGCCCGCCGCTGCCTCGCCCAGGAGCTGCACCTGCATGTGCAG CAGAACCGTGCGGTCCTGGACCACCAGCAGTTTGACTTTGTCGTCCGTATGATGAACTGCTGCCTGCAGGA CTGCACTTCTCTGGACGAGCATGGCATTGCGGCGGCTCTGCTGCCTCTGGTCACAGCCTTCTGCCGGAAGC TGAGCCCGGGGGTGACGCAGTTTGCATACAGCTGTGTGCAGGAGCACGTGGTGTGGAGCACGCCACAGTTC TGGGAGGCCATGTTCTATGGGGATGTGCAGACTCACATCCGGGCCCTCTACCTGGAGCCCACGGAGGACCT GGCCCCCGCCCAGGAGGTTGGGGAGGCACCTTCCCAGGAGGACGAGCGCTCTGCCCTAGACGTGGCTTCTG AGCAGCGGCGCTTGTGGCCAACTCTGAGTCGTGAGAAGCAGCAGGAGCTGGTGCAGAAGGAGGAGAGCACG GTGTTCAGCCAGGCCATCCACTATGCCAACCGCATGAGCTACCTCCTCCTGCCCCTGGACAGCAGCAAGAG CCGCCTACTTCGGGAGCGTGCCGGGCTGGGCGACCTGGAGAGCGCCAGCAACAGCCTGGTCACCAACAGCA TGGCTGGCAGTGTGGCCGAGAGCTATGACACGGAGAGCGGCTTCGAGGATGCAGAGACCTGCGACGTAGCT GGGGCTGTGGTCCGCTTCATCAACCGCTTTGTGGACAAGGTCTGCACGGAGAGTGGGGTCACCAGCGACCA CCTCAAGGGGCTGCATGTCATGGTGCCAGACATTGTCCAGATGCACATCGAGACCCTGGAGGCCGTGCAGC GGGAGAGCCGGAGGCTGCCGCCCATCCAGAAGCCCAAGCTGCTGCGGCCGCGCCTGCTGCCGGGTGAGGAG TGTGTGCTGGACGGCCTGCGCGTCTACCTGCTGCCGGATGGGCGTGAGGAGGGCGCGGGGGGCAGTGCTGG GGGACCAGCATTGCTCCCAGCTGAGGGCGCCGTCTTCCTCACCACGTACCGGGTCATCTTCACGGGGATGC CCACGGACCCCCTGGTTGGGGAGCAGGTGGTGGTCCGCTCCTTCCCGGTGGCTGCGCTGACCAAGGAGAAG CGCATCAGCGTCCAGACCCCTGTGGACCAGCTCCTGCAGGACGGGCTCCAGCTGCGCTCCTGCACATTCCA GCTGCTGAAAATGGCCTTTGACGAGGAGGTGGGGTCTGACAGCGCCGAGCTCTTCCGTAAGCAGCTGCATA AGCTGCGGTACCCGCCGGACATCAGGGCCACCTTTGCGTTCACCTTGGGCTCTGCCCACACACCTGGCCGG CCACCGCGAGTCACCAAGGACAAGGGTCCTTCCCTCAGAACCCTGTCCCGGAACCTGGTCAAGAACGCCAA GAAGACCATCGGGCGGCAGCATGTCACTCGCAAGAAGTACAACCCCCCCAGCTGGGAGCACCGGGGCCAGC CGCCCCCTGAGGACCAGGAGGACGAGATCTCAGTGTCGGAGGAGCTGGAGCCCAGCACGCTGACCCCGTCC TCAGCCCTGAAGCCCTCCGACCGCATGACCATGAGCAGCCTGGTGGAAAGGGCTTGCTGTCGCGACTACCA GCGCCTCGGTCTGGGCACCCTGAGCAGCAGCCTGAGCCGGGCCAAGTCTGAGCCCTTCCGCATTTCTCCGG TCAACCGCATGTATGCCATCTGCCGCAGCTACCCAGGGCTGCTGATCGTGCCCCAGAGTGTCCAGGACAAC GCCCTGCAGCGCGTGTCCCGCTGCTATCGCCAGAACCGCTTCCCCGTGGTCTGCTGGCGCAGCGAGCGGTC CAAGGCGGTGCTGCTGCGCTCTGGAGGCCTGCATGGCAAAGGTGTCGTCGGCCTCTTCAAGGCCCAGAACG CACCTTCTCCAGGCCAGTCCCAGGCGGACTCGAGTAGCCTGGAGCAGGAGAAGTACCTGCAGGCTGTGGTC AGCTCCATGCCCCGCTACGCCGACGCGTCGGGACGCAACACGCTTAGCGGCTTCTCCTCAGCCCACATGGG CAGTCACGTTCCCAGCCCCAGAGCCAGGGTCACCACGCTGTCCAACCCCATGGCGGCCTCGGCCTCCAGAC GGACCGCACCCCGAGGTAAGTGGGGCAGTGTCCGGACCAGTGGACGCAGCAGTGGCCTTGGCACCGATGTG GGCTCCCGGCTAGCTGGCAGAGACGCGCTGGCCCCACCCCAGGCCAACGGGGGCCCTCCCGACCCGGGCTT CCTGCGTCCGCAGCGAGCAGCCCTCTATATCCTTGGGGACAAAGCCCAGCTCAAGGGTGTGCGGTCAGACC CCCTGCAGCAGTGGGAGCTGGTGCCCATTGAGGTATTCGAGGCACGGCAGGTGAAGGCTAGCTTCAAGAAG CTGCTGAAAGCATGTGTCCCAGGCTGCCCCGCTGCTGAGCCCAGCCCAGCCTCCTTCCTGCGCTCACTGGA GGACTCAGAGTGGCTGATCCAGATCCACAAGCTGCTGCAGGTGTCTGTGCTGGTGGTGGAGCTCCTGGATT CAGGCTCCTCCGTGCTGGTGGGCCTGGAGGATGGCTGGGACATCACCACCCAGGTGGTATCCTTGGTGCAG CTGCTCTCAGACCCCTTCTACCGCACGCTGGAGGGCTTTCGCCTGCTGGTGGAGAAGGAGTGGCTGTCCTT CGGCCATCGCTTCAGCCACCGTGGAGCTCACACCCTGGCCGGGCAGAGCAGCGGCTTCACACCCGTCTTCC TGCAGTTCCTGGACTGCGTACACCAGGTCCACCTGCAGTTCCCCATGGAGTTTGAGTTCAGCCAGTTCTAC CTCAAGTTCCTCGGCTACCACCATGTGTCCCGCCGTTTCCGGACCTTCCTGCTCGACTCTGACTATGAGCG CATTGAGCTGGGGCTGCTGTATGAGGAGAAGGGGGAACGCAGGGGCCAGGTGCCGTGCAGGTCTGTGTGGG AGTATGTGGACCGGCTGAGCAAGAGGACGCCTGTGTTCCACAATTACATGTATGCGCCCGAGGACGCAGAG GTCCTGCGGCCCTACAGCAACGTGTCCAACCTGAAGGTGTGGGACTTCTACACTGAGGAGACGCTGGCCGA GGCCCTCCCTATGACTGGGAACTGGCCCAGGGGCCCCCTGAACCCCCAGAGGAAGAACGGTCTGATGGAGG CGTCCCCAGAGCAGCGCCGCGTGGTGTGGCCCTGTTACGACAGCTGCCCGCGGGCCCAGCCTGACGCCATC
TCACGCCTGCTGGAGGAGCTGCAGAGGCTGGAGACAGAGTTGGGCCAACCCGCTGAGCGCTGGAAGGACAC CTGGGACCGGGTGAAGGCTGCACAGCGCCTCGAGGGCCGGCCAGACGGCCGTGGCACCCCTAGCTCCCTCC TTGTGTCCACCGCACCCCACCACCGTCGCTCGCTGGGTGTGTACCTGCAGGAGGGGCCCGTGGGCTCCACC CTGAGCCTCAGCCTGGACAGCGACCAGAGTAGTGGCTCAACCACATCCGGCTCCCGTCAGGCTGCCCGCCG CAGCACCAGCACCCTGTACAGCCAGTTCCAGACAGCAGAGAGTGAGAACAGGTCCTACGAGGGCACTCTGT ACAAGAAGGGGGCCTTCATGAAGCCTTGGAAGGCCCGCTGGTTCGTGCTGGACAAGACCAAGCACCAGCTG CGCTACTACGACCACCGTGTGGACACAGAGTGCAAGGGTGTCATCGACTTGGCGGAGGTGGAGGCTGTGGC ACCTGGCACGCCCACTATGGGTGCCCCTAAGACTGTGGACGAGAAGGCCTTCTTTGACGTGAAGACAACGC GTCGCGTTTACAACTTCTGTGCCCAGGACGTGCCCTCGGCCCAGCAGTGGGTGGACCGGATCCAGAGCTGC TGTCGGACGCCTGAGCCTCCCAGCCCTGCCCGGCTGCTCTGCTCTCGTTACCGACCACTAGGGGTGGCAGG GCCGCCCCGGCCATGTTTACAGCCCCGGCCCTCGACAGTACTGAGCCCCGAGCCCCCAGCACTTGTGTGTA CAGCCCCCGTCCCCGCCCCGCCCCGCCCGGCCGGCCCTAACTTATTTTGGCGTCACAGCTGAGCACCGTGC CGGGAGGTGGCCAAGGTACAGCCCGCAATGGGCCTGTAAATAGTCCGGCCCCGTCAGCGTGTGCTGGTCCA CGGGCTCAGGCGAGTTTCTAGAAAGAGTCTATATAAAGAGAGAACTAACGCCAAAAAAAAAA
The disclosed NOV3a nucleic acid sequence maps to the ql3.3 region of chromosome 22 and has 3553 of 3902 bases (91%) identical to a gb:GENBANK- 1D:HSU9318 l]acc:U93181.1 mRNA from. Homo sapiens (Homo sapiens nuclear dual- specificity phosphatase (SBF1) mRNA, partial eds) (E = 0.0).
A disclosed NOV3a protein (SEQ ID NO:18) encoded by SEQ LO NO:17 has 1723 amino acid residues, and is presented using the one-letter code in Table 3B. Signal P, Psort and or Hydropathy results predict that NOV3a does have a signal peptide, and is likely to be localized to the mitochondrial membrane space with a certainty of 0.5000. In other embodiments NOV3a is also likely to be localized to the microbody (peroxisome) with a certainty of 0.3000, to mitochondrial imier membrane with a certainty of 0.2187, or to the mitochondrial intermembrane space with a certainty of 0.2187. The most likely cleavage site for NOV3a is between positions 33 and 34, (SFT-YV).
Table 3B. Encoded NOV3a protein sequence (SEQ ID NO: 18).
IRHEVFLSRSYQRLADACRGLLALLFPLRYSFTYVPILPAQLLEVLSTPTPFIIGVNAAFQAETQELLDVI VAϋLDGGTVTIPECVHIPPLPEPLQSQTHSVLSMVLDPELELADLAFPPPTTSTSΞLKMQDKELRAVFLRL FAQLLQGYR CLHWRIHPEPVIRFHKAAFLGQRGLVEDDFLMKVLEGMAFAGFVSERGVPYRPTDLFDEL VAHEVARMRADENHPQRVLRHVQELAEQLYKNENPYPAVAMHKVQRPGESSHLRRVPRPFPRLDEGTVQWI VDQAAAKMQGAPPAVKAERRTTVPSGPPMTAILERCSGLHVKSARRLEWRNCISYVFEGKMLEAKKLLPA VLRALKGRVARRCLAQELHLHVQQNRAVLDHQQFDFWRMMNCCLQDCTSLDEHGIAAALLPLVTAFCRKL SPGVTQFAYSCVQEHWWSTPQFWEAMFYGDVQTHIRALYLEPTEDLAPAQEVGEAPSQEDERSALDVASE QRRL PTLSREKQQELVQKEESTVFSQAIHYANRMSYLLLPLDSSKSRLLRERAGLGDLESASNSLVTNSM AGSVAESYDTEΞGFEDAETCDVAGAWRFINRFVDKVCTESGVTSDHLKGLHVMVPDIVQMHIETLEAVQR ESRRLPPIQKPKLLRPRLLPGEECVLDGLRVYLLPDGREEGAGGSAGGPALLPAEGAVFLTTYRVIFTGMP TDPLVGEQVWRSFPVAALTKEKRISVQTPVDQLLQDGLQLRSCTFQLLKMAFDEEVGSDSAELFRKQLHK LRYPPDIRATFAFTLGSAHTPGRPPRVTKDKGPSLRTLSRNLVKNAKKTIGRQHVTRKKYNPPS EHRGQP PPEDQEDEISVSEELEPSTLTPSSALKPSDRMTMSSLVERACCRDYQRLGLGTLSSSLSRAKSEPFRISPV NRMYAICRSYPGLLIVPQSVQDNALQRVSRCYRQNRFPWCWRSERSKAVLLRSGGLHGKGWGLFKAQNA PSPGQSQADSSSLEQEKYLQAWSSMPRYADASGRNTLSGFSSAHMGSHVPSPRARVTTLSNPMAASASRR TAPRGK GSVRTSGRSSGLGTDVGSRLAGRDALAPPQANGGPPDPGFLRPQRAALYILGDKAQLKGVRSDP LQQWELVPIEVFEARQVKASFKKLLKACVPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLWELLDS GSSVLVGLEDG DITTQWSLVQLLSDPFYRTLEGFRLLVEKE LSFGHRFSHRGAHTLAGQSSGFTPVFL QFLDCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEKGERRGQVPCRSVWE YVDRLSKRTPVFHNYMYAPEDAEVLRPYSNVSNLKVWDFYTEETLAEALPMTGNWPRGPLNPQRKNGLMEA SPEQRRWWPCYDSCPRAQPDAISRLLEELQRLETELGQPAERWKDTWDRVKAAQRLEGRPDGRGTPSSLL VSTAPHHRRSLGVYLQEGPVGSTLSLSLDSDQSSGSTTSGSRQAARRSTSTLYSQFQTAESENRSYEGTLY KKGAFMKPWKARWFVLDKTKHQLRYYDHRVDTECKGVIDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTR
RVYNFCAQDVPSAQQ VDRIQSCCRTPEPPSPARLLCSRYRPLGVAGPPRPCLQPRPSTVLSPEPPALVCT APVPAPPRPAGPNLF RHS
The disclosed NOV3a amino acid has 1047 of 1079 amino acid residues (97%) identical to, and 1052 of 1079 amino acid residues (97%) similar to, the 1697 amino acid residue ptnr:SPTREMBL-ACC:O60228 protein from Homo sapiens (Human) (Nuclear Dual- Specificity Phosphatase) (E= 0.0).
NOV3 is expressed in at least the following tissues: Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, and or RACE sources.
NOV3b hi the present invention, the target sequence identified previously, NOV3a, was subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with
another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported below, which is designated NOV3b. This differs from the previously identified sequence (NOV3a) by coding for 50 additional bases at 5' end that includes a signal peptide.
A disclosed NOV3b nucleic acid of 5740 nucleotides (also referred to as Curagen Accession No. CG56019-02) encoding a novel Set Binding Factor 1 -like protein is shown in Table 3C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 396-398 and ending with a TGA codon at nucleotides 2439-2441. A putative untranslated region downstream from the termination codon are underlined in Table 3C. The start and stop codons are in bold letters.
Table 3C. NOV3b nucleotide sequence (SEQ ID NO:19).
ACGCGTGTGGAGGATGCCACAGAGAGGGAGGAAGAGGGGGATGAGGGAGGCCAGACCCACCTGTCTCCCACA GCACCTGCCCCATCTGCCCAGCTGTTTGCACCGAAGACGCTGGTACTGGTGTCGCGACTCGACCACACGGGG GGGTTCAGGACCAGCCTTGGCCTCATCTATGCCATCCACGTGGAGGGCCTGAATGTGTGCCTGGAGAACGTG ATTGGGAACCTGCTGACGTGCACTGTGCCCCTGGCTGGGGGCTCGCAGAGGACGATCTCTTTGGGGGCTGGT GACCGGCAGGTCATCCAGACTCCACTGGCCGACTCGCTGCCCGTCAGCCGCTGCAGCGTGGCCCTGCTCTTC CGCCAGCTAGGTGAGCCTGTCTGTCCCACCCCCGCATGGCTTCCCCTCGGGGACTGGTAGTTAGGGATGTGG GTTCTCACTCTGCCTGGGTGGGGGCCCAGGGTCCTCTCCAAGCTTCTCTTCTTCCTTTAGGCATCACCAACG TGCTGTCTTTGTTCTGTGCCGCCCTCACGGAGCACAAGGTTCTCTTCCTGTCCCGGAGCTACCAGCGGCTCG CCGATGCCTGTAGGGGCCTCCTGGCACTGCTGTTTCCTCTCAGATACAGCTTCACCTATGTGCCCATCCTGC CGGCTCAGCTGCTGGAGGTCCTCAGCACACCCACGCCCTTCATCATTGGGGTCAACGCGGCCTTCCAGGCAG AGACCCAGGAGCTGCTCGATGTGATTGTTGCTGATCTGGATGGAGGGACGGTCACCATTCCTGAGTGTGTGC ACATTCCACCCTTGCCAGAGCCACTGCAGAGTCAGACGCACAGTGTGCTGAGCATGGTCCTGGACCCGGAGC TGGAGTTGGCTGACCTCGCCTTCCCTCCGCCCACGACATCCACCTCCTCCCTGAAGATGCAGGACAAGGAGC TGCGCGCGGTCTTCCTGCGGCTGTTCGCTCAGCTGCTGCAGGGCTATCGCTGGTGCCTGCACGTCGTGCGCA TCCACCCGGAGCCTGTCATCCGCTTCCATAAGGCAGCCTTCCTGGGCCAGCGTGGGCTGGTAGAGGACGATT TCCTGATGAAGGTGCTGGAGGGCATGGCCTTTGCTGGCTTTGTGTCAGAGCGTGGGGTCCCATACCGCCCTA CGGACCTGTTCGATGAGCTGGTGGCCCACGAGGTGGCAAGGATGCGGGCGGATGAGAACCACCCCCAGCGTG TCCTGCGTCACGTCCAGGAACTGGCAGAGCAGCTCTACAAGAACGAGAACCCGTACCCAGCCGTGGCGATGC ACAAGGTACAGAGGCCCGGTGAGAGCAGCCACCTGCGACGGGTGCCCCGACCCTTCCCCCGGCTGGATGAGG GCACCGTGCAGTGGATCGTGGACCAGGCTGCAGCCAAGATGCAGGGTGCACCCCCAGCTGTGAAGGCCGAGA GGAGGACCACCGTGCCCTCAGGGCCCCCCATGACTGCCATACTGGAGCGGTGCAGTGGGCTGCATGTCAACA GCGCCCGGCGGCTGGAGGTTGTGCGCAACTGCATCTCCTACGTGTTTGAGGGGAAAATGCTTGAGGCCAAGA AGCTGCTCCCAGCCGTGTTGAGGGCCCTGAAGGGGCGAGCTGCCCGCCGCTGCCTCGCCCAGGAGCTGCACC TGCATGTGCAGCAGAACCGTGCGGTCCTGGACCACCAGCAGTTTGACTTTGTCGTCCGTATGATGAACTGCT GCCTGCAGGACTGCACTTCTCTGGACGAGCATGGCATTGCGGCGGCTCTGCTGCCTCTGGTCACAGCCTTCT GCCGGAAGCTGAGCCCGGGGGTGACGCAGTTTGCATACAGCTGTGTGCAGGAGCACGTGGTGTGGAGCACGC CACAGTTCTGGGAGGCCATGTTCTATGGGGATGTGCAGACTCACATCCGGGCCCTCTACCTGGAGCCCACGG AGGACCTGGCCCCCGCCCAGGAGGTTGGGGAGGCACCTTCCCAGGAGGACGAGCGCTCTGCCCTAGACGTGG CTTCTGAGCAGCGGCGCTTGTGGCCAACTCTGAGTCGTGAGAAGCAGCAGGAGCTGGTGCAGAAGGAGGAGA GCACGGTGTTCAGCCAGGCCATCCACTATGCCAACCGCATGAGCTACCTCCTCCTGCCCCTGGACAGCAGCA AGAGCCGCCTACTTCGGGAGCGTGCCGGGCTGGGCGACCTGGAGAGCGCCAGCAACAGCCTGGTCACCAACA GCATGGCTGGCAGTGTGGCCGAGAGCTATGACACGGAGAGCGGCTTCGAGGATGCAGAGACCTGCGACGTAG CTGGGGCTGTGGTCCGCTTCATCAACCGCTTTGTGGACAAGGTCTGCACGGAGAGTGGGGTCACCAGCGACC ACCTCAAGGGGCTGCATGTCATGGTGCCAGACATTGTCCAGATGCACATCGAGACCCTGGAGGCCGTGCAGC GGGAGAGCCGGAGGCTGCCGCCCATCCAGAAGCCCAAGCTGCTGCGGCCGCGCCTGCTGCCGGGTGAGGAGT GTGTGCTGGACGGCCTGCGCGTCTACCTGCTGCCGGATGGGCGTGAGGAGGGCGCGGGGGGCAGTGCTGGGG GACCAGCATTGCTCCCAGCTGAGGGCGCCGTCTTCCTCACCACGTACCGGGTCATCTTCACGGGGATGCCCA CGGACCCCCTGGTTGGGGAGCAGGTGGTGGTCCGCTCCTTCCCGGTGGCTGCGCTGACCAAGGAGAAGCGCA TCAGCGTCCAGACCCCTGTGGACCAGCTCCTGCAGGACGGGCTCCAGCTGCGCTCCTGCACATTCCAGCTGC TGAAAATGGCCTTTGACGAGGAGGTGGGGTCTGACAGCGCCGAGCTCTTCCGTAAGCAGCTGCATAAGCTGC GGTACCCGCCGGACATCAGGGCCACCTTTGCGTTCACCTTGGGCTCTGCCCACACACCTGGCCGGCCACCGC GAGTCACCAAGGACAAGGGTCCTTCCCTCAGAACCCTGTCCCGGAACCTGGTCAAGAACGCCAAGAAGACCA
TCGGGCGGCAGCATGTCACTCGCAAGAAGTACAACCCCCCCAGCTGGGAGCACCGGGGCCAGCCGCCCCCTG AGGACCAGGAGGACGAGATCTCAGTGTCGGAGGAGCTGGAGCCCAGCACGCTGACCCCGTCCTCAGCCCTGA AGCCCTCCGACCGCATGACCATGAGCAGCCTGGTGGAAAGGGCTTGCTGTCGCGACTACCAGCGCCTCGGTC TGGGCACCCTGAGCAGCAGCCTGAGCCGGGCCAAGTCTGAGCCCTTCCGCATTTCTCCGGTCAACCGCATGT ATGCCATCTGCCGCAGCTACCCAGGGCTGCTGATCGTGCCCCAGAGTGTCCAGGACAACGCCCTGCAGCGCG TGTCCCGCTGCTACCGCCAGAACCGCTTCCCCGTGGTCTGCTGGCGCAGCGGGCGGTCCAAGGCGGTGCTGC TGCGCTCTGGAGGCCTGCATGGCAAAGGTGTCGTCGGCCTCTTCAAGGCCCAGAACGCACCTTCTCCAGGCC AGTCCCAGGCGGACTCGAGTAGCCTGGAGCAGGAGAAGTACCTGCAGGCTGTGGTCAGCTCCATGCCCCGCT ACGCCGACGCGTCGGGACGCAACACGCTTAGCGGCTTCTCCTCAGCCCACATGGGCAGTCACGGTAAGTGGG GCAGTGTCCGGACCAGTGGACGCAGCAGTGGCCTTGGCACCGATGTGGGCTCCCGGCTAGCTGGCAGAGACG CGCTGGCCCCACCCCAGGCCAACGGGGGCCCTCCCGACCCGGGCTTCCTGCGTCCGCAGCGAGCAGCCCTCT ATATCCTTGGGGACAAAGCCCAGCTCAAGGGTGTGCGGTCAGACCCCCTGCAGCAGTGGGAGCTGGTGCCCA TTGAGGTATTCGAGGCACGGCAGGTGAAGGCTAGCTTCAAGAAGCTGCTGAAAGCATGTGTCCCAGGCTGCC CCGCTGCTGAGCCCAGCCCAGCCTCCTTCCTGCGCTCACTGGAGGACTCAGAGTGGCTGATCCAGATCCACA AGCTGCTGCAGGTGTCTGTGCTGGTGGTGGAGCTCCTGGATTCAGGCTCCTCCGTGCTGGTGGGCCTGGAGG ATGGCTGGGACATCACCACCCAGGTGGTATCCTTGGTGCAGCTGCTCTCAGACCCCTTCTACCGCACGCTGG AGGGCTTTCGCCTGCTGGTGGAGAAGGAGTGGCTGTCCTTCGGCCATCGCTTCAGCCACCGTGGAGCTCACA CCCTGGCCGGGCAGAGCAGCGGCTTCACACCCGTCTTCCTGCAGTTCCTGGACTGCGTACACCAGGTCCACC TGCAGTTCCCCATGGAGTTTGAGTTCAGCCAGTTCTACCTCAAGTTCCTCGGCTACCACCATGTGTCCCGCC GTTTCCGGACCTTCCTGCTCGACTCTGACTATGAGCGCATTGAGCTGGGGCTGCTGTATGAGGAGAAGGGGG AACGCAGGGGCCAGGTGCCGTGCAGGTCTGTGTGGGAGTATGTGGACCGGCTGAGCAAGAGGACGCCTGTGT TCCACAATTACATGTATGCGCCCGAGGACGCAGAGGTCCTGCGGCCCTACAGCAACGTGTCCAACCTGAAGG TGTGGGACTTCTACACTGAGGAGACGCTGGCCGAGGGCCCTCCCTATGACTGGGAACTGGCCCAGGGGCCCC CTGAACCCCCAGAGGAAGAACGGTCTGATGGAGGCGCTCCCCAGAGCAGGCGCCGCGTGGTGTGGCCCTGTT ACGACAGCTGCCCGCGGGCCCAGCCTGACGCCATCTCACGCCTGCTGGAGGAGCTGCAGAGGCTGGAGACAG AGTTGGGCCAACCCGCTGAGCGCTGGAAGGACACCTGGGACCGGGTGAAGGCTGCACAGCGCCTCGAGGGCC GGCCAGACGGCCGTGGCACCCCTAGCTCCCTCCTTGTGTCCACCGCACCCCACCACCGTCGCTCGCTGGGTG TGTACCTGCAGGAGGGGCCCGTGGGCTCCACCCTGAGCCTCAGCCTGGACAGCGACCAGAGTAGTGGCTCAA CCACATCCGGCTCCCGTCAGGCTGCCCGCCGCAGCACCAGCACCCTGTACAGCCAGTTCCAGACAGCAGAGA GTGAGAACAGGTCCTACGAGGGCACTCTGTACAAGAAGGGGGCCTTCATGAAGCCTTGGAAGGCCCGCTGGT TCGTGCTGGACAAGACCAAGCACCAGCTGCGCTACTACGACCACCGTGTGGACACAGAGTGCAAGGGTGTCA TCGACTTGGCGGAGGTGGAGGCTGTGGCACCTGGCACGCCCACTATGGGTGCCCCTAAGACCGTGGACGAGA AGGCCTTCTTTGACGTGAAGACAACGCGTCGCGTTTACAACTTCTGTGCCCAGGACGTGCCCTCGGCCCAGC AGTGGGTGGACCGGATCCAGAGCTGCCTGTCGGACGCCTGAGCCTCCCAGCCCTGCCCGGCTGCTCTGCTTC CGGTCGTTACCGACCACTAGGGGTGGTGTTGGGACACCTGGGCGAGATGTGAGGGTGGGCTCACTTGAGCCA CTGAAACCAGCCAGGTCTTCCCTCAGGCCGGACAGATGGCGCCTGACCAAAGTTCCTGGCACCTGGAAAACC CACAGCAGGGCACGAGTGACCTGAGAGGCCCACTCAGGCAGAAGAGACGCAAGCTGGGCCGTCCAACTGGTT TCAACTGCCAGCTTTACCAATGCAGCATTTATTTTAAAATTAAATTAAATTA
In a search of public sequence databases, the NOV3b nucleic acid sequence, located on chromosome 11, has 4947 of 4963 bases (99%) identical to a gb:GENBANK- ID:HSU93181 |acc:U93181.1 mRNA from Homo sapiens (Homo sapiens nuclear dual- specificity phosphatase (SBFl) mRNA, partial eds) (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOV3b polypeptide (SEQ ID NO:20) encoded by SEQ ID NO: 19 has 1681 amino acid residues and is presented in Table 3B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV3b has a signal peptide and is likely to be localized to the Golgi body with a certainty of 0.9000. hi other embodiments, NOV3b may also be localized to the plasma membrane with a certainty of 0.7900, in the microbody (peroxisome) with a certainty of 0.3525, or in the endoplasmic reticulum (membrane) with a certainty of 0.2000. The most likely cleavage site for NOV3b is between positions 46 and 47, ALT-EH.
Table 3D. Encoded NOV3b protein sequence (SEQ ID NO:20).
MASPRGLWRDVGSHSAVJVGAQGPLQASLLPLGITNVLSLFCAALTEHKVLFLSRSYQRLADACRGLLALLF PLRYSFTYVPILPAQLLΞVLSTPTPFIIGVNAAFQAETQELLDVIVADLDGGTVTIPECVHIPPLPEPLQSQ THSVLSMVLDPELELADLAFPPPTTSTSSLKMQDKELRAVFLRLFAQLLQGYR CLHWRIHPEPVIRFHKA AFLGQRGLVEDDFLMKVLEGMAFAGFVSERGVPYRPTDLFDELVAHEVARMRADENHPQRVLRHVQELAEQL YKNENPYPAVAMHKVQRPGESSHLRRVPRPFPRLDEGTVQ IVDQAAAKMQGAPPAVKAERRTTVPSGPPMT AILERCSGLHVNSARRLEWRNCISYVFEGKMLEAKKLLPAVLRALKGRAARRCLAQELHLHVQQNRAVLDH QQFDFWRMMNCCLQDCTSLDEHGIAAALLPLVTAFCRKLSPGVTQFAYSCVQEHW STPQF EAMFYGDV QTHIRALYLEPTEDLAPAQEVGEAPSQEDERSALDVASEQRRL PTLSREKQQELVQKEESTVFSQAIHYAN RMSYLLLPLDSSKSRLLRERAGLGDLESASNSLVTNSMAGSVAESYDTESGFEDAETCDVAGAWRFINRFV DKVCTESGVTSDHLKGLHVMVPDIVQMHIETLEAVQRESRRLPPIQKPKLLRPRLLPGEECVLDGLRVYLLP DGREEGAGGSAGGPALLPAEGAVFLTTYRVIFTGMPTDPLVGEQVWRSFPVAALTKEKRISVQTPVDQLLQ DGLQLRSCTFQLLKMAFDEEVGSDSAELFRKQLHKLRYPPDIRATFAFTLGSAHTPGRPPRVTKDKGPSLRT LSRNLVKNAKKTIGRQHVTRKKYNPPS EHRGQPPPEDQEDEISVSEELEPSTLTPSSALKPSDRMTMSSLV ERACCRDYQRLGLGTLSSSLSRAKSEPFRISPVNRMYAICRSYPGLLIVPQSVQDNALQRVSRCYRQNRFPV VCWRSGRSKAVLLRSGGLHGKGWGLFKAQNAPSPGQSQADSSSLEQEKYLQAWSSMPRYADASGRNTLSG FSSAHMGSHGK GSVRTSGRSSGLGTDVGSRLAGRDALAPPQANGGPPDPGFLRPQRAALYILGDKAQLKGV RSDPLQQ ELVPIEVFEARQVKASFKKLLKACVPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLWEL LDSGSSVLVGLEDG DITTQWSLVQLLSDPFYRTLEGFRLLVEKEWLSFGHRFSHRGAHTLAGQSSGFTPV FLQFLDCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEKGERRGQVPCRSVW EYVDRLSKRTPVFHNYMYAPEDAEVLRPYSNVSNLKVWDFYTEETLAEGPPYD ELAQGPPEPPEEERSDGG APQSRRRWWPCYDSCPRAQPDAISRLLEELQRLETELGQPAER KDTWDRVKAAQRLEGRPDGRGTPSSLL VSTAPHHRRSLGVYLQEGPVGSTLSLSLDSDQSSGSTTSGΞRQAARRSTSTLYSQFQTAESENRSYEGTLYK KGAFMKP KAR FVLDKTKHQLRYYDHRVDTECKGVIDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTRRV YNFCAQDVPSAQQ VDRIQSCLSDA
A search of sequence databases reveals that the NOV3b amino acid sequence has 1631 of 1631 amino acid residues (100%) identical to, and 1631 of 1631 amino acid residues (100%) similar to, the 1631 amino acid residue ρtnr:SPTREMBL-ACC:Q9UGB8 protein from Homo sapiens (Human) (DJ579N16.2 (Set Binding Factor 1)) (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
NOV3b is expressed in at least the following tissues: Adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, maimnary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG56019-02.The sequence is predicted to be expressed with a similar pattern to (GENBANK-ID: gb:GENBANK- ID :HSU93181 |acc:U93181.1) a closely related Homo sapiens nuclear dual-specificity phosphatase (SBFl) mRNA, partial eds homolog.
NOV3a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 3E.
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3F.
Table 3F. ClustalW Analysis of NO 3
1) NOV3a (SEQ ID NO : 18 )
2) NOV3b (SEQ ID NO . 20)
3) gι|3015538|gb|AAC39675.l| (U93181) nuclear dual -specificity phosphatase [Homo sapiens] (SEQ ID NO: 68) 4) gι|6572379|emb|CAB63063.l| (AL096767) dJ579Nl6.2 (SET binding factor 1) [Homo sapiens] (SEQ ID NO: 69)
5) gι|l7485528|ref |XP_037447. | (XM_037447) SET binding factor 1 [Homo sapiens] (SEQ ID NO: 70)
6) gι|l2698077|dbj |BAB21857.l| (AB051553) KIAA1766 protein [Homo sapiens] (SEQ ID NO:71)
7) gi|l5292603|gb|AAK93570.l| (AY052146) SD10541p [Drosophila melanogaster] (SEQ ID NO: 72)
10 20 30 40 50 60
NOV3a
NOV3b gi|3015538|gb|A gi j 6572379 j emb I gi j 17485528 | ref MSAPSSSPRAAEPARAPRAAPRPSPWRGSRTTSCWWRSGRTRAGSGEGQGQILQRFPEKD 60 gi|l2698077 | bj -RFPQKD 6 gi|l5292603|gb| 1
70 90 100 110 120
N0V3a 1
NOV3b 1 gi 3015538 I gb I A 1 gi 6572379 j em I -- 1 gi 17485528 |rβ£ EDNPFPQGIELFCQPSG QLCPERNPPTFFVAVLTDINSERHYCACLTFWEPAEPSQET 120
6
130 140 150 160 170 180
N0V3 1
80 14
190 200 210 220 230 240
gi|12698077|dbj EJglK EgJNgVKMΪΪ gijl5292603 jgb| ELLKSEAQNRNLl2τι*pgjj
1030 1040 1050 1060 1070 1080
1150 1160 1170 1180 1190 1200
1210 1220 1230 1240 1250 1260
1270 1280 1290 1300 1310 1320
1330 1340 1350 1360 1370 1380
NOV3a PSPRARVTTLSNPMAASASRRTAPRGKWGSVRTSGRSSGLGTDVGSRLAGRDALAPPQAN 1104
NOV3b KWGSVRTSGRSSGLGTDVGSRLAGRDALAPPQAN 1124 gi | 3015538 | gb | A KWGSVRTSGRSSGLGTDVGSRLAGRDALAPPQAN 1078 gi j 6572379 I emb I 552 gi j 17485528 I ref P SPRARVTTLSNPMAASASRRTAPRG 1327
gi 12698077 |dbj H23 gi 15292603 |gb| SSD- -DRQPLTPELSRKHKNNLDISDGNKSSQGGKGGTMK 1078
1390 1400 1410 1420 1430 1440
NOV3a GGPPDPGFLRPQRAALYILGDKAQLKGVRSDPLQQWELVPIEVFEARQVKASFKKLLKAC 116
NOV3b GGPPDPGFLRPQRAALYILGDKAQLKGVRSDPLQQWELVPIEVFEARQVKASFKKLLKAC 1184 gi 3015538 gb|A GGPPDPGFLRPQRAALYILGDKAQLKGVRSDPLQQWELVPIEVFEARQVKASFKKLLKAC 1138 gi 6572379 embj 552 gi 17485528 | ref 1327 gi 12698077 |dbj 1123 g 15292603 jgbj GNPKNSLAHPFRKMRLYALGEKSQAKSN-MNVDFCADFIPVDYPDIRQSRPAFKKLIRAC 1137
1450 1460 1470 1480 1490 1500
NOV3 VPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLWELLDSG-SSVLVGLEDGWDITT 1223
N0V3b VPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLWELLDSG-SSVLVGLEDGWDITT 1243 gi 3015538|gb|A VPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLWELLDSG-SSVLVGLEDGWDITT 1197 gi 6572379 | emb | 55 gi 17485528 ref . 13 i 12698077 dbj 1123 gi 15292603 gb| MPΞHNTNEADGQΞFAKMVEQSDWLQQISSLMQLSGAWDLIDLQESSVMLSLEDGSDVTA 1197
1510 1520 1530 1540 1550 1560
N0V3a QWSLVQLLSDPFYRTLEGFRLLVEKEWLSFGHRFSHRG- -AHTLAGQSSGFTPVFLQFL 1281
1570 1580 1590 1600 1610 1620
NOV3a DCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEK- -- 1335
NOV3b DCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEK- -- 1355 gi|3015538|gb|A DCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEK- -- 1309 gi| 6572379] emb | 552 gi| 17485528 | ref 1327 gi| 12698077 | dbj 1123 gi|l5292603|gb| DWHQLQRQFPMAFEFNDFYLRFLAYHSVSCRFRTFLFDCELERSDSGIAAMEDKRGSLN 1317
1630 1640 1650 1660 1670 1680
NOV3a -GERRGQVPCR SVWEYVDRLSKRTPVFHNYM 1365
NOV3b -GERRGQVPCR SVWEYVDRLSKRTPVFHNYM 1385
S 3015538|gb|A -GERRGQVPCR SVWEYVDRLSKRTPVFHNYM 1339 gi 6572379 emb | 552 gi 1 177448855552288 |I eeff 1327 gi 12698077 | dbj 1123 gi 15292603 | gb | AKHMFGAGGMATNGSDDECSVYPLDIRSQRAPAPLNRIGHSIFDYIERQHNKTPIFYNFL 1377
1690 1700 1710 1720 1730 1740
NOV3a YAPEDAEVLRPYSNVSNLKVWDFYTEETLAEALPMTGNWPRGPLNPQRKNGLMEASPE-Q 1424
NOV3b YAPEDAEVLRPYSNVSNLKVWDFYTEETLAEGPPYDWELAQGPPEPPEEERSDGGAPQSR 1445 gi|3015538|gb|A YAPEDAEVLRPYSNVSNLKVWDFYTEETLAEALPMTGNWPRGPLNPQRKNGLMEASPE-Q 1398 gi| 6572379 | emb | 552 gi 17485528 | ref 1327 gi| 12698077 | bj 1123 gi 15292603 |gb| YSGDKSVTLRPQNNVAALDLWCYYTNEELAQGAPYDLEVT TVDDEIDLSΞTKGK 1431
1750 1760 1770 1780 1790 1800
NOV3a RRWWPCYDSCPRAQPDAISRLLEELQRLETELGQPAERWKDTWDRVKAAQRLEGRPDGR 1484
1810 1820 1830 1840 1850 1860
N0V3a GTPSSLLVSTAPHHRRSLGVYLQEGPVG 1512
N0V3b GTPSSLLVSTAPHHRRSLGVYLQEGPVG 1533
1930 1940 1950 1960 1970 1980
N0V3a TSTLYSQFQTAESENRSYEGTLYKKGAFMKPWKARWFVLDKTKHQLRYYDHRVDTECKGV 1599
1990 2000 2010 2020 2030 2040
N0V3a IDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTRRVYNFCAQDVPSAQQWVDRIQSCCRT 1659 N0V3b IDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTRRVYNFCAQDVPSAQQWVDRIQSCLSD 1680 i 3015538|gb|A IDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTRRVYNFCAQDVPSAQQWVDRIQSCCRT 1633 gi 6572379 j emb | 552 gi 17485528 I ref 1327 gi 12698077 | dbj 1123 gi 15292603 jgbj IELAEVQSVTAAQPAQIGAKGVDEKGFFDLKTSKRIYNFYAINANLAQEWIEKLQACLQ- 1728
N0V3a WRHS 1723 N0V3b 1681 gi 3015538|gb|A WRHS 1697 gi 6572379 emb I 552 g 17485528 ref 1327 gi 12698077 dbj 1123 gi 15292603 gb| 1728
Tables 3G-3I list the domain descnptions from DOMAIN analysis results against NOV3a. This indicates that the NOV3a sequence has properties similar to those of other proteins known to contain this domain.
Table 3G Domain Analysis of NOV3a gnl|pfam|pfam02141, DENN, DENN (AEX-3) domain (SEQ ID NO: 73) CD-Length = 146 residues, 51 4% aligned Score = 69 3 bits (168), Expect = 2e-12
Query: VFLSRSYQRLADACRGLLALLFPLRYSFTYVPILPAQLLEVLSTPTPFIIGVNAAFQAET 64
+1 II 1+ I ++III+I + l+l+lll I +11 III++III ++I Sbjct 70 LFHSRKLSTLSSCCEAWALLYPFEWQCPYIPLLPASLADVLLAPTPYLIGVPSSFFDNK 129 Query: 65 QELL DVIVADLD 76
I III III Sbjct 130 LLELPPSDVICVDLD 144
Table 3H Domain Analysis of NOV3a gnl I Smart I smart00233 , PH, Pleckstr homology domain.; Domain commonly found in eukaryotic signalling proteins. The domain family possesses multiple functions including the abilities to bind ositol phosphates , and various proteins . PH domains have been found to possess inserted domains (such as PLC gamma, syntrophms) and to be inserted within other domains. Mutations m Brutons tyrosine kinase (Btk) within its PH domain cause X-linked agammaglobulmaemia (XLA) in patients. Point mutations cluster into the positively charged end of the molecule around the predicted binding site for phosphatidylmositol lipids (SEQ ID NO: 74) CD-Length = 104 residues, 96.2% aligned Score = 63 5 bits (153), Expect = 9e-ll
Query 1557 YEGTLYKKGA-FMKPWKAR FVLDKTKHQLRYYDHR---VDTECKGVIDLAEVEAVAPGT 1612
II I II + I II kill 1 11 + ++ II I 1+
Sbjct: 3 KEGWLLKKSSGGKKSWKKRYFVL--FNGVLLYYKSKKKKSSSKPKGSIPLSGCTVREAPD 60 Query 1613 PTMGAPKTVDEKAFFDVKT-TRRVYNFCAQDVPSAQQWVDRIQSCCR 1658 + +| |++ I I + I + ++II+ ++
Sbjct. 61 S DSDKKKNCFEIVTPDRKTLLLQAESEEERKEWVEALRKAIA 102
Table 31 Domain Analysis of NOV3a gnl I Pfam|pfam00169, PH, PH domain PH stands for pleckstrm homology (SEQ ID NO: 75)
CD-Length = 100 residues, 97.0% aligned Score = 53 1 bits (126), Expect = le-07
Query 1558 EGTLYKKGAFMKP-WKARWFVLDKTKHQLRYYDHRV-DTECKGVIDLAEVEAVAPGTPTM 1615 II I II I II l+l I 1 11 + l ll l 1+
Sbjct. 4 EGWLLKKΞTVKKKRWKKRYFFL--FNDVLIYYKDKKKSYEPKGSIPLSGCSVEDVPDSEF 61 Query: 1616 GAPKTVDEKAFFDVKTTRR--VYNFCAQDVPSAQQWVDRIQSCCR 1658
I I +++ + 1+ I 1+ 111 I Sbjct- 62 KRPNC FQLRSRDGKETFILQAESEEERQDWIKAIQSAIR 100
Mammalian SET domain-containing proteins define a distinctive class of chromatin- associated factors that are targets for growth control signals and oncogenic activation. By yeast two-hybrid screening, Cui X et. al. (1998,Nat. Genet. Vol. 18: 331-337) identified Sbfl (also known as nuclear dual-specificity phosphatase)as a protein interacting with the SET domain in the protooncoprotein homolog of Drosophila trithorax, Hrx. Sbfl, shares extensive sequence similarity with myotubularm, a dual specificity phosphatase (dsPTPase) that is mutated in a subset of patients with inherited myopathies. Both Sbfl and myotubularin interact with the SET domains of Hrx and other epigenetic regulatory proteins, but Sbfl lacks phosphatase activity due to several evolutionarily conserved amino acid changes in its structurally preserved catalytic pocket. Sbfl has shown to prevent myoblast differentiation in vitro and induce oncogenic changes in NTH 3T3 fibroblasts. Furthermore, it also functions as SET domain-dependent positive regulator of growth-inducing kinase signaling pathways (hnmaculataDe Vivo et al., 1998, Proc. Natl. Acad. Sci. USA, vol 95: 9471-9476).
The disclosed NOV3 nucleic acid of the invention encoding a Set Binding Factor (SBFl)-like protein includes the nucleic acid whose sequence is provided in Table 3A, 3C, or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 3A, or 3C while still encoding a protein that maintains its Set Binding Factor (SBFl)-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject, hi the mutant or variant nucleic acids, and their complements, up to about 9 percent of the bases may be so changed. The disclosed NOV3 protein of the invention includes the Set Binding Factor (SBF1)- like protein whose sequence is provided in Table 3B, or 3D. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 3B, or 3D while still encoding a protein that maintains its Set Binding
Factor (SBFl)-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 63 percent of the residues maybe so changed.
The pfotein similarity information, expression pattern, and map location for the Set Binding Factor (SBFl)-like protein and nucleic acid (NOV3) disclosed herein suggest that NOV3 may have important structural and/or physiological functions characteristic of the citron kinase-like family. Therefore, the NOV3 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.
The NOV3 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neurodegeneration; Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, and/or other pathologies.
NOV3 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. For example the disclosed NOV3 protein have multiple hydrophilic regions, each of which can be used as an immunogen. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV4
A disclosed NOV4 nucleic acid of 762 nucleotides (designated CuraGen Ace. No. CG55692-01) encoding a novel TSPAN-1-like protein is shown in Table 4A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 9-11 and ending with a TAA codon at nucleotides 732-734. A putative untranslated region downstream from the termination codon is underlined in Table 4A, and the start and stop codons are in bold letters.
Table 4A. NOV4 Nucleotide Sequence (SEQ ID NO:21)
GACACACCATGCAGTGCTTCAAATTCATTAAGGTCATGATGTTCCTCTTCAATCAACTCATCTTTCTCTG TGGTGCAGCCCTGTTGGCTGTGGGAATATGGGTAACCGTCGATGGGACATCTTTCCTGAAGGTCTTCGGA TCACTATCATCCAGTGCCATGCAGTTTGTCAACGTGGGCTACTTCCTCATCGCCGCTGGTGCTGTGCTCT TCATTTTTGGTTTCCTGGGCTGCTATGGTGCTCCCTCTGAGAAACAAGTGTGTGCTCTGGTGATGTTCTT TTCCATCCTCCTCATCATCTTCATCGCTGAGATTGCAGGTGCTGTGGTTGCTTTGGTGTACACCACATTG GCTGAACAATTCCTGACACTCCTGGTGGTGCCTGCTATCGAAAAAGACTATGGTTACCAGACTGATTTCA CCCAAGTATGGAACACTACAATGGAAGAGTTGCATTGCTGTGGCTTTAACAACTACACAGATTTTAATGC CTCACGTTTCGTCAAAGAGAATAAAGTCTTCCCCCCACCCTGTTGTGCCAACCCTGGCAACCATACAGTT GAACCATGCACCGAGGAGAAGGCCAAAAGTATGAAAGTACAGGGTTGTTTCAAAGAGATTCTGCATAGAA TCAGAAACAATGCAGTCACTGTGGGTGGTGTGGCAGTTGGAGTTGCGGCCCTAGAGCTGGCTGCCATGGT TGTATCCATGTATCTATACTGCAATCTGAAATAAGACTACTACTTCCTCCTGACTTGCTGCC
The nucleic acid sequence, localized to chromosome 12, has 616 of 765 bases (80%) identical to a gb:GENBANK-ID:AF065388|acc:AF065388.1 mRNA from Homo sapiens (Homo sapiens tetraspan NET-1 mRNA, complete eds) (E = 1.8e" ).
A NOV4 polypeptide (SEQ ID NO:22) encoded by SEQ ID NO:21 is 241 amino acid residues and is presented using the one letter code in Table 4B. Signal P, Psort and/or Hydropathy results predict that NOV4 has no signal peptide and is likely to be localized at the plasma membrane with a certainty of 0.6400. h other embodiments, NOV4 may also be localized to the Golgi body with a certainty of 0.4600, the endoplasmic reticulum (membrane) with a certainty of 0.3700, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The most likely cleavage site for NOV4 is between positions 36 and 37: VDG-TS.
Table 4B. NOV4 protein sequence (SEQ ID NO:22)
MQCFKFIKVMMFLFNQLIFLCGAALLAVGIWVTVDGTSFLKVFGSLSSSAMQFVNVGYFLIAAGAVLFIFGFLG CYGAPSEKQVCALVMFFSILLIIFIAEIAGAWALVYTTLAEQFLTLLWPAIEKDYGYQTDFTQVWNTTMEEL HCCGFNNYTDFNASRFVKENKVFPPPCCANPGNHTVEPCTEEKAKSMKVQGCFKEILHRIRNNAVTVGGVAVGV AALELAAMWSMYLYCNLK
The full amino acid sequence of the protein of the invention was found to have 177 of 241 amino acid residues (73%) identical to, and 197 of 241 amino acid residues (81%>) similar
to, the 241 amino acid residue ptnr:SPTREMBL-ACC:O60635 protein from Homo sapiens (Human) (TSPAN-1) (E = 6.1e"92).
NOV4 is expressed in at least Colon, Testis, prostate, melanocyte, heart, uterus, kidney, stomach because of the expression pattern of (GENBANK- ID:AF065388|acc:AF065388.1) a closely related Homo sapiens tetraspan NET-1 mRNA, complete eds homolog in species Homo sapiens :
NOV4 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 4C.
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 4D.
Table 4D ClustalW Analysis of NOV4
1) NOV4 (SEQ ID NO: 22)
4) gi|l3097420|gb|AAH03448.l|AAH03448 (BC003448) Similar to tetraspan 1 [Mus musculus] (SEQ ID NO: 76)
5) gi|5032197|ref |NP_005718.l| (NM_005727) tetraspan 1 [Homo sapiens] (SEQ ID NO -.77)
6) gi I 12643622 I sp I 050635 ]TSN1_HUMAN TETRASPANIN 1 (TSPAN-1) (TETRASPAN NET-1) (TETRASPANIN TM4-C) (SEQ ID N0:78)
7) gi|660156l|gb|AAF19031.l|AF2066Sl_l (AF206661) neuronal tetraspanin [Gallus gallus] (SEQ ID NO: 79)
8) gi 117570135 I ref | NP_510445.11 (NM_078044) tetraspanin [Caenorhabditis elegans] (SEQ ID NO: 80)
Table 4E lists the domain description from DOMAIN analysis results against N0V4. This indicates that the N0V4 sequence has properties similar to those of other proteins known to contain this domain.
Table 4E Domain Analysis of NO 4 gnl I Pfam|pfam00335, transmembrane4 , Tetraspanin family. (SΞQ ID
NO: 81)
CD-Length = 222 residues, 100.0% aligned
Score = 126 bits (316) , Expect = 2e-30
Query : 8 KVMMFLFNQLIFLCGAALLAVGIWVTVDGTSFLKVFGSLSSSAMQFVNVGYFLIAAGAVL 67
I ++II I I +111 II +11 ++ lllll I III ll+l Sbjct: 1 KYLLFLLNLLFWLCGILLLAVGIWLLVDLSSFSELLGSLSSLV AAYVLIAVGAIL 55 Query: 68 FIFGFLGCYGAPSEKQVCALVMFFSILLIIFIAEIAGAWALVYTTLAEQFLTLLWPAI 127
1+ lllll II I + I I ++I ll+lll l+l ++I 1+ 1 1 + 11 Sbjct: 56 FLVGFLGCCGAIRESR-CLLGLYFVFLLLIFILEVAAGILAFVFRDKLESSLNESLKNAI 114 Query: 128 EKDYGYQTDFTQVWNTTMEELHCCGFNNYTDFNASRFVKENKVFPPPCCANPGNHTVEPC 187
+ 1 I 1+ 1+ III I Ilk I++ + 1 11 + Sbjct: 115 KNYYDTDPDERNAWDKLQEQFKCCGVNGYTDWFDΞQW--FSNGVPFSCCNPSVS CNS 169 Query : 188 TEEKAKSMKVQGCFKEILHRIRNNAVTVGGVAVGVAALBLAAMWSMYLYCNL 240 +++ ++ +|| +++| + I + I I I I l+ l +l ++| |++| I |++
Sbj ct : 170 AQDEEDTIYQEGCLEKLLEWLEENLLIVGGVALGIALIQLLGMILSCCLCCSI 222
Members of the 'transmembrane 4 superfamily' (TM4SF) are cell-surface proteins presumed to have 4 transmembrane domains. TM4SF proteins form complexes with integrins and other cell-surface proteins. A number of eukaryotic cell surface antigens have been shown to be related, including mammalian leukocyte antigen CD37, mammalian lysosomal membrane protein CD63, human tumour-associated antigen CD-029, and several others. These proteins are all type II membrane proteins: they contain an N-terminal transmembrane (TM) domain, which acts both as a signal sequence and a membrane anchor, and 3 additional TM regions (hence the name 'TM4'). The sequences contain a number of conserved cysteine residues.
The disclosed NOV4 nucleic acid of the invention encodmg a TSPAN-1 -like protein includes the nucleic acid whose sequence is provided in Table 4A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 4A while still encodmg a protein that maintains its TSPAN-1 -like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 20 percent of the bases may be so changed.
The disclosed NOV4 protein of the invention includes the TSPAN-1 -like protein whose sequence is provided in Table 4B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 4B while still encoding a protein that maintains its TSPAN-1 -like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 69 percent of the residues may be so changed.
The protein similarity information, expression pattern, and map location for the TSPAN-1 -like protein and nucleic acid (NOV4) disclosed herein suggest that this NOV4 protein may have important structural and/or physiological functions characteristic of the
TSPAN-1 family. Therefore, the NOV4 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. These include serving as a specific or selective nucleic acid or protein diagnostic and or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo.
The NOV4 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from Hypercalceimia, Ulcers, Inflammatory bowel disease, Diverticular disease, Hirschsprung's disease , Crohn's Disease, Appendicitis, Fertility, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomeralonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy,
Hypercalceimia, Lesch-Nyhan syndrome, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD),Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, and/or other pathologies. The NOV4 nucleic acids, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
NOV4 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV5
A disclosed NOV5 nucleic acid of 469 nucleotides (also referred to as CG56073-01) encoding a novel Fatty Acid-Binding Protein, Epidermal-like protein is shown in Table 5A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides
148-150 and ending with a TGA codon at nucleotides 395-397. Putative untranslated regions upstream from the initiation codon and downstream from the termination codon are underlined in Table 5 A, and the start and stop codons are in bold letters.
Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:23)
GCCATCTGCCAACCATGGTCACCACTCAGCAGCTGCTAGGAAGATGGCGCCCAGCAGAGAGG AAATACCTCAAAGAAACAGGGATGAGAATGGCCCTGCAAAAAATTGGTGCAATGACTAAACC AGATGGTGCCATCTCTGATGGCAAAAGCTTCACTATAAAAACCAAGAGCACTCTGAAAACAA CACGGTTTTCTTCTAAACTTGGAGAGAAGTATGAAAGAACTACAGGTGATGGCAGAAAAAAC TCACTATTTGTCTGCAACTTTACAAAGCGTGCATTGGTTCAACACTGGGAATGGGATGAGGA AAGAAAAACGAGAAGAAGAAAAGTGGGAGACAAAAAAGCAGGGATGGAATGCATTATGAACA ATGTCACCTGTACTCAGATCTGTGAAAATAAAAAAAGCAGAATAAAAATTTCCTTACTGCTT TGGAGAGCAATTAGCTGAGAGAAGGAACAATTTCA
The NOV5 nucleic acid was identified on chromosome 2 and has 313 of 411 bases (76%) identical to a gb:GENBANK-ID:AF059507|acc:AF059507.1 mRNA from Bos taurus (Bos taurus epidermal fatty acid-binding protein (E-FABP) mRNA, complete eds) (E = 4.5e"
41). A disclosed NOV5 polypeptide (SEQ ID NO:24) encoded by SEQ ID NO:23 is 145 amino acid residues and is presented using the one-letter code in Table 5B. Signal P, Psort and or Hydropathy results predict that NOV5 has no signal peptide and is likely to be localized in the nucleus with a certainty of 0.9775. In other embodiments, NOV5 may also be localized to the microbody (peroxisome) with acertainty of 0.3925, the mitochondrial matrix space with a certainty of 0.3600, or the lysosome (lumen) with a certainty of 0.1000.
Table 5B. Encoded NOV5 protein sequence (SEQ ID NO:24)
MVTTQQLLGRWRPAERKYLKETGMRMALQKIGAMTKPDGAISDGKSFTIKTKSTLKTTRFSSKLGEKYERTT GDGRKNSLFVCNFTKRALVQHWEWDEERKTRRRKVGDKKAGMECIMNNVTCTQICENKKSRIKISLLLWRAI S
The disclosed NOV5 amino acid sequence has 80 of 132 amino acid residues (60%) identical to, and 96 of 132 amino acid residues (72%) similar to, the 135 amino acid residue ptnr:SWISSPROT-ACC:P55052 protein from Bos taurus (Bovine) (Fatty Acid-Binding
Protein, Epidermal (E-FABP) (Differentiation- Associated Lipid Binding Protein LP2)) (E = 0.0).
NOV5 is expressed in at least retina. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and or RACE sources.
NOV5 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 5D.
Table 5D Clustal W Sequence Alignment
1) NOV5 (SEQ ID NO: 24)
2) gi I 66480711 sp I 55052 I FABE_BOVIN FATTY ACID-BINDING PROTEIN, EPIDERMAL (E-FABP) (SEQ ID NO: 82)
3) gi|l293786|gb|AAB41297.l| (U55188) LP2 [Bos taurus] (SEQ ID NO:83)
4) gii455758ljref|NP_001435.l| (NM_001444) fatty acid binding protein 5 (psoriasis- associated) ; E-FABP [Homo sapiens] (SEQ ID NO:84)
5) gi 113651882 I re |XP_011655.Ξ| (XM_011655) similar to fatty acid binding protein 5 (psoriasis-associated); E-FABP (H. sapiens) [Homo sapiens] (SEQ ID NO:85)
6) gi|l836058|gb|AAB46848.l| (S83247) DA11 [Rattus s . ] (SEQ ID NO:86)
The fatty acid-binding protein (FABP) family consists of small, cytosolic proteins believed to be involved in the uptake, transport, and solubilization of their hydrophobic ligands. Members of this family have highly conserved sequences and tertiary structures. Using an antibody against testis lipid-binding protein, a member of the FABP family, a protein was identified from bovine retina and testis that coeluted with exogenously added docosahexaenoic acid during purification. Amino acid sequencing and subsequent isolation of its cDNA revealed it to be nearly identical to a bovine protein expressed in the differentiating lens and to be the likely bovine homologue of the human epidermal fatty acid-binding protein (E-FABP). From quantitative Western blot analysis, it was estimated that bovine E-FABP comprised 0.9%, 0.1%, and 2.4%> of retina, testis, and lens cytosolic proteins, respectively. Binding studies using the fluorescent probe ADIFAB indicated that this protein bound fatty acids of differing levels of saturation with relatively high affinities. Kd values ranged from 27 to 97 nM. fn addition, the protein was immunolocalized to the MuUer cells in the retina as well as to Sertoli cells in the testis. The location of bovine E-FABP in cells known to be supportive to other cell types in their tissues and the ability of E-FABP to bind a variety of fatty acids with similar affinities indicate that it may be involved in the uptake and transport of fatty acids essential for the nourishment of the surrounding cell types.
The disclosed NOV5 nucleic acid of the invention encoding a Fatty Acid-Binding Protein, Epidermal -like protein includes the nucleic acid whose sequence is provided in Table 5A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 5A while still encoding a protein that maintains its Fatty Acid-Binding Protein, Epidermal -like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the
chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 24 percent of the bases may be so changed. The disclosed NOV5 protein of the invention includes the Fatty Acid-Binding Protein,
Epidermal -like protein whose sequence is provided in Table 5B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 5B while still encoding a protein that maintains its Fatty Acid-Binding Protein, Epidermal-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 52 percent of the residues may be so changed.
The NOV5 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in psoriasis, basal and squamous cell carcinomas, obesity, diabetis, and/or other pathologies and disorders involving fatty acid transport of skin, oral mucosa, and or other diseases, disorders and conditions of the like. The NOV5 nucleic acid, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
NOV5 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. For example the disclosed NOV5 protein have multiple hydrophilic regions, each of which can be used as an immunogen. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV6
A disclosed NOV6 nucleic acid of 816 nucleotides (also referred to as CG50261-02) encoding a novel Uncoupling Protein 1-like protein is shown in Table 6 A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TAA codon at nucleotides 814-816. The start and stop codons are in bold letters in Table 6A.
Table 6A. NOV6 Nucleotide Sequence (SEQ ID NO:25)
ATGGGGGGCCTGACAGCCTCGGACGTACACCCGACCCTGGGGGTCCAGCTCTTCTCAGCTGGAATAGCGG CGTGCTTGGCGGACGTGATCACCTTCCCGCTGGACACGGCCAAAGTCCGGCTCCAGGTCCAAGGTGAATG CCCGACGTCCAGTGTTATTAGGTATAAAGGTGTCCTGGGAACAATCACCGCTGTGGTAAAAACAGAAGGG CGGATGAAACTCTACAGCGGGCTGCCTGCGGGGCTTCAGCGGCAAATCAGCTCCGCCTCTCTCAGGATCG GCCTCTACGACACGGTCCAGGAGTTCCTCACCGCAGGGAAAGAAACAGCACCTAGTTTAGGAAGCAAGAT TTTAGCTGGTCTAACGACTGGAGGAGTGGCAGTATTCATTGGGCAACCCACAGAGGTCGTGAAAGTCAGA CTTCAAGCACAGAGCCATCTCCACGGAATCAAACCTCGCTACACGGGGACTTATAATGCGTACAGAATAA TAGCAACAACCGAAGGCTTGACGGGTCTTTGGAAAGGGACTACTCCCAATCTGATGAGAAGTGTCATCAT CAATTGTACAGAGCTAGTAACATATGATCTAATGAAGGAGGCCTTTGTGAAAAACAACATATTAGCAGGA CAGTACAAAAGTGTGCCCAACTGTGCAATGAAAGTGTTCACTAACGAAGGACCAACGGCTTTCTTCAAGG GGTTGGTACCTTCCTTCTTGCGACTTGGATCCTGGAACGTCATTATGTTTGTGTGCTTTGAACAACTGAA ACGAGAACTGTCAAAGTCAAGGCAGACTATGGACTGTGCCACATAA
The disclosed NOV6 nucleic acid sequence , located on chromosome 4, has 628 of 628 bases (100%) identical to a gb:GENBANK-LO:HSU28480|acc:U28480.1 mRNA from Homo sapiens (Human uncoupling protein (UCP) mRNA, complete eds) (E = Lie"176).
A disclosed NOV6 polypeptide (SEQ ID NO:26) encoded by SEQ LO NO:25 is 271 amino acid residues and is presented using the one-letter amino acid code in Table 6B. Signal P, Psort and/or Hydropathy results predict that NOV6 contains no signal peptide and is likely to be localized extracellularly with a certainty of 0.4753. hi other embodiments, NOV6 is also likely to be localized to the plasma membrane with a certainty of 0.1900, to the microbody (peroxisome) with a certainty of 0.1544, or to the endoplasmic reticulum (membrane) with a certainty of 0.1000
Table 6B. Encoded NOV6 protein sequence (SEQ ID NO:26).
MGGLTASDVHPTLGVQLFSAGIAACLADVITFPLDTAKVRLQVQGECPTSSVIRYKGVLGTITAWKTEGRMKLY SGLPAGLQRQISSASLRIGLYDTVQEFLTAGKETAPSLGSKILAGLTTGGVAVFIGQPTEWKVRLQAQSHLHGI KPRYTGTYNAYRIIATTEGLTGLWKGTTPNLMRSVIINCTELVTYDLMKEAFVKNNILAGQYKSVPNCAMKVFTN EGPTAFFKGLVPSFLRLGSWNVIMFVCFEQLKRELSKSRQTMDCAT
The disclosed NOV6 amino acid sequence has 209 of 209 amino acid residues (100%) identical to, and 209 of 209 amino acid residues (100%) similar to, the 307 amino acid residue ptnr:pir-id:G01858 protein from human (uncoupling protein 1, mitochondrial) (E = 4.8e"140). NOV6 is expressed in at least the following tissues: Adrenal Gland/Suprarenal gland and Brown adipose. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
NOV6 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 6C.
Table 6C. BLAST results for NOV6
Gene Index/ Protein/ Organism Length Identity Positives Expect
Identifier (aa) (%) (%) gi I 11225256 I ref |NP_ uncoupling 307 271/307 271/307 e-144 068605.1 j protein 1; (88%) (88%) (NM 021833) thermogenin,- mitochondrial brown fat uncoupling protein [Homo sapiens] gi|1351353|sp|P2587 MITOCHONDRIAL 307 270/307 270/307 e-143 4 I UCPl HUMAN BROWN FAT (87%) (87%) UNCOUPLING PROTEIN 1 (UCP 1) (THERMOGENIN) gi|l36689|sp|P14271 MITOCHONDRIAL 305 226/307 245/307 e-117 I UCPl RABIT BROWN FAT (73%) (79%) UNCOUPLING PROTEIN 1 (UCP 1) (THERMOGENIN) gι|109392|pir| A324 uncoupling 305 225/307 245/307 e-117 46 protein - rabbit (73%) (79%) gι|1351354|sp|P0457 MITOCHONDRIAL 307 216/303 238/303 e-115 5 I UCPl MESAU BROWN FAT (71%) (78%) UNCOUPLING PROTEIN 1 (UCP 1) (THERMOGENIN)
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 6D.
Table 6D Information for the ClustalW proteins
1) NOV6 (SEQ ID NO: 26)
4) gi 111225256 I ref | NP_068605.11 (NM_021833) uncoupling protein 1; thermogenin; mitochondrial brown fat uncoupling protein [Homo sapiens] (SEQ ID NO: 87)
5) gi| 1351353 | sp | P25874 |UCP1_HUMAN MITOCHONDRIAL BROWN FAT UNCOUPLING PROTEIN 1 (UCP 1) (THERMOGENIN) (SEQ ID NO: 88)
6) gi|l36689|sp|P1427l|UCPl_RABIT MITOCHONDRIAL BROWN FAT UNCOUPLING PROTEIN 1 (UCP 1) (THERMOGENIN) (SEQ ID NO: 89)
7) gi| 109392 |pir| |A32446 uncoupling protein - rabbit (SEQ ID NO:90)
6. gijl351354|s jp04575|UCPl_MESAU MITOCHONDRIAL BROWN FAT UNCOUPLING PROTEIN 1 (UCP
1) (THERMOGENIN) (SEQ ID NO: 91)
10 20 30 40 50 60 0
70 80 90 100 110 120
NOV6 SASQPFAFNCTFPPITSGEVSVTWYKNSSKIPVSKIIQSRIHQDETWILFLPMEWGDSGV 120 g 11225256 I ef 1 gi 1351353 I s I P 1 gi 136689 sp|Pl gi 109392 pir| I gi 1351354 I sp P
130 140 150 160 170 180
Tables 6E-F list the domain description from DOMAIN analysis results against NOV6. This indicates that the NOV6 sequence has properties similar to those of other proteins known to contain this domain.
Table 6E. Domain Analysis of NOV6 gnl |Pfam|pfam00153 , mito_carr, Mitochondrial carrier protein. (SEQ ID
NO: 92)
CD-Length = 96 residues, 95.8% aligned
Score = 81.6 bits (200), Expect = 5e-17
Query: 111 PSLGSKILAGLTTGGVAVFIGQPTEWKVRLQAQSHLHGIKPRYTGTYNAYRIIATTEGL 170
I + + 1 1 1 I + 1 + I + 1 1 1 M l I + 1 1 + ++ I I I
Sbjct: 3 LSFLASLLAGGIAGAIAALVTYPLDWKTRLQVQGS SSKYKGILDCFKKIVKEEGR 58 Query: 171 TGLWKGTTPNLMRSVIINCTELVTYDLMKEAFVKNN 206
II + 11 I l+ l Ik +k I
Sbjct: 59 AGLYKGLGPTLLRVAPYAAIYFGTYEQLKKLLGKKL 94
Table 6F. Domain Analysis of NOV6 gnl | Pf am| pf am00153 , mito_carr, Mitochondrial carrier protein . ( SEQ ID
NO : 93 )
CD-Length = 95 residues , 99 .0% aligned
Score = 79 .3 bits ( 194 ) , Expect = 3e-16
Query: 10 HPTLGVQLFSAGIAACLADVr FPLDTAKVRLQVQGECPTSSVIRYKGVLGTITAWKTE 69
I + III +1 ++I+III I M i +III+I +11 I
Sbj Ct : 2 PLSFLASLLAGGIAGAIAALVTYPLDWKTRLQVQGSSS- -KYKGILDCFKKIVKEE 56
Query: 70 GRMKLYSGLPAGLQRQISSASLRIGLYDTVQEFLTAGKET 109
II II II I I k+ I k +++ I
Sbjct: 57 GRAGLYKGLGPTLLRVAPYAAIYFGTYEQLKKLLGKKLGE 96
The uncoupling protein (UCP) of mitochondria in brown adipose tissue is a specific component unique to mammalian cells. Complementary DNAs for rat and mouse UCP were isolated in several laboratories (Jacobson et al., 1985; Bouillaud et al., 1986; Ridley et al., 1986). The cDNAs have been used to determine the sequence of rat UCP and to monitor changes in UCP mRNA levels under various physiologic, pathologic, and pharmacologic circumstances. A controversy exists concerning the physiologic significance of brown adipose tissue in humans and its possible contribution to resistance to obesity (see 601665). There is, however, a large amount of evidence that this tissue is present in young infants and also in human adults in certain pathologic and nonpathologic situations.
Bouillaud et al. (1988) screened a human genomic library with a cDNA corresponding to the UCP of rat brown adipose tissue mitochondria. They succeeded in cloning a 0.5-kb
fragment containing 2 intronic regions and 2 exonic regions. The exonic regions encode a sequence of 84 amino acids with a strong homology to the central domain of rat UCP. Southern analysis experiments suggested that there is 1 copy of the gene in the human, as there is in rodents, hi Northern analysis experiments, the probe detected a specific 1.8-kb mRNA in human brown adipose tissue obtained from 6 patients with pheochromocytoma and from 1 patient with a hibernoma.
Cassard et al. (1990) found that the human UCP gene spans 13 kb and contains a transcribed region that covers 9 kb. It has 6 exons. The uncoupling protein has 305 amino acids and a molecular weight of 32,786. Fletcher et al. (1991) mapped the Ucp gene to mouse chiOmosome 8 in a location between a segment that carries genes homologous to genes on human 8p, on the centromeric side, and a segment that carries genes homologous to human genes on 16q, in the telomeric direction. Thus, the human homolog of Ucp is probably on either 8p or 16q. Using in situ hybridization, Cassard et al. (1990) assigned the human UCP gene to 4q31. They found that the primary structure of UCP is similar to that of ADP/ATP translocator of skeletal muscle (103220), the gene for which is also located on chromosome 4. Thus, the prediction from homology to the mouse did not hold up.
Brown adipose tissue, because of its capacity for uncoupled mitochondrial respiration, is an important site of facultative energy expenditure. It has been speculated that this tissue normally functions to prevent obesity. Surgical efforts to ablate or denervate the brown adipose tissue have been unsuccessful because of the diffuse deposits and substantial capacity for regeneration and hypertrophy. Lowell et al. (1993) used a transgenic toxigene approach to create 2 lines of transgenic mice with primary deficiency of brown adipose tissue. In constructing these transgenic mice, Lowell et al. (1993) used the regulatory elements of the gene for uncoupling protein to drive expression of the diphtheria toxin A chain (UCP-DTA) or an attenuated mutant. At 16 days, both lines had deficient brown fat and obesity. In one line, brown fat subsequently regenerated and obesity resolved. In the other line, the deficiency persisted and obesity, with its morbid complications, advanced. Obesity developed in the absence of hyperphagia, indicating that brown fat deficient mice have increased metabolic efficiency. As obesity progressed, transgenic animals developed hyperphagia. See also UCP2 (601693).
Uncoupling protein is a mitochondrial proton channel that is not coupled to oxidative phosphorylation. Therefore, when a proton gradient is established across the inner mitochondrial membrane, activation of the uncoupling protein leads to the uncoupled passage
of protons through the channel and the generation of heat. Expression and activation of uncoupling proteins is usually mediated by the sympathetic nervous system and is directly controlled by norepinephrine. This mechanism is part of the adaptive response to cold temperatures. It also regulates energy balance. Manipulation of thermogenesis could be an effective strategy against obesity (Lowell et al., 1993). Enerback et al. (1997) determined the role of UCP in the regulation of body mass by targeted inactivation of the UCP gene in mice. They found that UCP-deficient mice consumed less oxygen after treatment with a beta-3- adrenergic receptor agonist and that they were sensitive to cold, indicating that thermoregulation was defective. However, this deficiency caused neither hyperphagia nor obesity in mice fed on either a standard or a high-fat diet. Enerback et al. (1997) proposed that the loss of UCP may be compensated by UCP2, a homolog of UCP that is ubiquitously expressed and is induced in the brown fat of UCP-deficient mice.
Adrenaline and noradrenaline, the main effectors of the sympathetic nervous system and adrenal medulla, respectively, are thought to control adiposity and energy balance through several mechanisms. They promote catabolism of triglycerides and glycogen, stimulate food intake when injected into the central nervous system, activate thermogenesis in brown adipose tissue, and regulate heat loss through modulation of peripheral vasoconstriction and piloerection. Thermogenesis in brown adipose occurs in response to cold and overeating, and there is an inverse relationship between diet-induced thermogenesis and obesity both in humans and animalmodels. As a potential model for obesity, Thomas and Palmiter (1997) generated mice that could not synthesize noradrenaline or adrenaline by inactivating the gene that encodes dopamine beta-hydroxylase (DBH; 223360). These mice were cold intolerant because they had impaired peripheral vasoconstriction and were unable to induce thermogenesis in brown adipose tissue through uncoupling protein (UCPl). The mutants had increased food intake but did not become obese because their basal metabolic rate (BMR) was also elevated. The unexpected increase in BMR was not due to hyperthyroidism, compensation by the widely expressed UCP2, or shivering.
The failure of UCPl expressed in E. coli inclusion bodies to carry out fatty acid- dependent H(+) transport activity inclusion bodies made Echtay et al. (2000) seek a native UCP cofactor. They identified coenzyme Q (CoQ, or ubiquinone) as such a cofactor. On addition of CoQ(10) to reconstituted UCPl from inclusion bodies, fatty acid-dependent proton transport reached the same rate as with native UCPl. The proton transport was highly sensitive to purine nucleotides and was activated only by oxidized but not reduced CoQ. Proton transport of native UCPl correlated with the endogenous CoQ content.
The disclosed NON6 nucleic acid of the invention encoding a Leucine-Rich Glioma- Inactivated Protein-like protein includes the nucleic acid whose sequence is provided in Table 6A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 6A while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.
The disclosed ΝOV6 protein of the invention includes the Leucine-Rich Glioma- Inactivated Protein-like protein whose sequence is provided in Table 6B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 6B while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 29 percent of the residues may be so changed.
The above defined information for this invention suggests that these Leucine-Rich Glioma-Inactivated Protein-like proteins (NOV6) may function as a member of a "Leucine- Rich Glioma-Inactivated Protein family". Therefore, the NOV6 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The nucleic acids and proteins of NOV6 are useful in any inflammatory diseases such as obesity, hyperphagia, and or other pathologies and disorders.
NOV6 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. For example the disclosed NOV6 protein have multiple hydrop ilic regions, each of which can be used as an immunogen. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV7
NOV7 includes three novel Leucine-Rich Glioma-Inactivated Protein -like proteins disclosed below. The disclosed sequences have been named NOV7a, and NOV7b. NOV7a
A disclosed NOV7a nucleic acid of 1859 nucleotides (also referred to CG56077-01) encodmg a novel Leucine-Rich Glioma-Inactivated Protein-like protein is shown in Table 7A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 101-103 and ending with a TGA codon at nucleotides 1760-1762. In Table 7A, the 5' and 3' untranslated regions are underlined and the start and stop codons are in bold letters.
Table 7A. NOV7a Nucleotide Sequence (SEQ ID NO:27)
GTAACTCCTCTTCATCCACTGGGGAGGAAGGTGAGGCAGGCGGGCCCAATTCATTCGCCTCCGGTACTTGC AAGCCTCGCTCAGTCTTAAGCAAGAGGGGATGGATTCGCCCGCAGCACTGAGAATCCAGGGGCAGGCGGGA TGGCGTTCAGGCGCTGTTGCTAGAAATCTCTGTCTTTACTCTGTTTTGGTCATTACGGAGGGAAGACAGCC CCCAAAGGGAAAGTGTCCCCTGCGCTGCTCCTGCTCTAAAGACAGCGCCCTGTGTGAGGGCTCCCCGGACC TGCCCGTCAGCTTCTCTCCGACCCTGCTGTCACTCTCACTCGTCAGGACGGGAGTCACCCAGCTGAAGGCC GGCAGCTTCCTGAGAATTCCGTCTCTGCACCTGCTCCTCTTCACCTCCAACTCCTTCTCCGTGATTGAGGA CGATGCATTTGCGGGCCTGTCCCACCTGCAGTACCTCTTCATCGAGGACAATGAGATTGGCTCCATCTCTA AGAATGCCCTCAGAGGACTTCGCTCGCTTACACACCTAAGCCTGGCCAATAACCATCTGGAGACCCTCCCC AGATTCCTGTTCCGAGGCCTGGACACCCTTACTCATGTGGACCTCCGCGGGAACCCGTTCCAGTGTGACTG CCGCGTCCTCTGGCTCCTGCAGTGGATGCCCACCGTGAATGCCAGCGTGGGGACCGGCGCCTGTGCGGGCC CCGCCTCCCTGAGCCACATGCAGCTCCACCACCTCGACCCCAAGACTTTCAAGTGCAGAGCCATAGAGCTG TCCTGGTTCCAGACGGTGGGGGAGTCGGCACTGAGCGTAGAGCCCTTCTCCTACCAAGGGGAGCCTCACAT TGTGCTGGCACAGCCCTTCGCCGGCCGCTGCCTGATTCTCTCCTGGGACTACAGCCTGCAGCGCTTCCGGC CCGAGGAAGAGCTGCCCGCGGCCTCCGTGGTGTCCTGCAAGCCACTGGTGCTGGGCCCGAGCCTCTTCGTG CTGGCTGCCCGCCTGTGGGGGGGCTCACAGCTGTGGGCCCGGCCCAGTCCCGGCCTGCGCCTGGCCCCAAC GCAGACCCTGGCCCCGCGGCGGCTGCTGCGGCCCAATGACGCCGAGCTCCTGTGGCTGGAAGGGCAACCCT GCTTCGTGGTGGCCGATGCCTCCAAGGCGGGCAGCACCACGCTGCTGTGCCGCGACGGGCCCGGCTTTTAC CCGCACCAGAGCCTGCACGCCTGGCACCGGGACACGGACGCTGAGGCCCTGGAGCTGGACGGCCGGCCCCA CCTGCTGCTGGCCTCGGCTTCCCAGCGGCCCGTGCTCTTCCACTGGACCGGTGGCCGCTTCGAGAGACGCA CAGACATCCCGAGGGCCGAGGATGTCTATGCCACACGCCACTTCCAGGCTGGTGGGGACGTGTTCCTGTGC CTCACACGCTACATTGGGGACTCCATGGTCATGCGCTGGGACGGCTCCATGTTTCGTCTGCTGCAGCAACT TCCCTCGCGCGGTGCCCACGTCTTCCAGCCACTGCTCATCGCCAGGGACCAGCTGGCCATCCTAGGCAGCG ACTTCGCCTTCAGCCAGGTCCTCCGCCTTGAGCCTGACAAGGGGCTCCTGGAGCCACTGCAGGAGCTGGGG CCTCCGGCCCTGGTGGCCCCCCGTGCCTTTGCCCACATCACTATGGCCGGCAGACGCTTCCTCTTTGCTGC TTGCTTTAAGGGCCCCACACAGATCTACCAGCATCACGAGATCGACCTCAGTGCCTGAGACCACCAACGGG ACTCTGGGCATGGCTGGGGCCCCTGGACGGCCCCTTGGCTGGCTCCTGGCCCTACTTGGGGTGATGGCCCG CCTGTGAGCTGCT
The disclosed NO V7a nucleic acid sequence, localized to the ql2 region of chromosome 19, has 940 of 1619 bases (58%) identical to a gb:GENBANK- ID:HSU53204|acc:U53204.1 mRNA from Homo sapiens (Human plectin (PLEC1) mRNA, complete eds) (E = 7.0e"301).
A disclosed NOV7a polypeptide (SEQ ID NO:28) encoded by SEQ ID NO:27 is 553 amino acid residues and is presented using the one-letter amino acid code in Table 7B. Signal P, Psort and/or Hydropathy results predict that NOV7a has a signal peptide and is likely to be localized in the microbody (peroxisome) with a certainty of 0.6562. In other embodiments, NOV7A is also likely to be localized to the lysosome (lumen) with a certainty of 0.2474, or to the mitochondrial matrix space with a certainty of 0.1000.
Table 7B. Encoded NOV7a protein sequence (SEQ ID NO:28).
MDSPAALRIQGQAGWRSGAVARNLCLYSVLVITEGRQPPKGKCPLRCSCSKDSALCEGSPDLPVSFSPTLL SLSLVRTGVTQLKAGSFLRIPSLHLLLFTSNSFSVIEDDAFAGLSHLQYLFIΞDNEIGSISKNALRGLRSL THLSLANNHLETLPRFLFRGLDTLTHVDLRGNPFQCDCRVLWLLQWMPTVNASVGTGACAGPASLSHMQLH HLDPKTFKCRAIELSWFQTVGESALSVEPFSYQGEPHIVLAQPFAGRCLILSWDYSLQRFRPEEELPAASV VSCKPLVLGPSLFVLAARLWGGSQLWARPSPGLRLAPTQTLAPRRLLRPNDAELLWLEGQPCFWADASKA GSTTLLCRDGPGFYPHQSLHAWHRDTDAEALELDGRPHLLLASASQRPVLFHWTGGRFERRTDIPRAEDVY ATRHFQAGGDVFLCLTRYIGDSMVMRWDGSMFRLLQQLPSRGAHVFQPLLIARDQLAILGSDFAFSQVLRL ΞPDKGLLEPLQELGPPALVAPRAFAHITMAGRRFLFAACFKGPTQIYQHHEIDLSA
The disclosed NOV7a amino acid sequence has 274 of 557 amino acid residues (49%) identical to, and 380 of 557 amino acid residues (68%o) similar to, the 557 amino acid residue ptnr:SPTREMBL-ACC:Q9JIAl protein from Mus musculus (Mouse) (Leucine-Rich Glioma- Inactivated 1 Protein Precursor) (E = 2.5e"143). NOV7a is expressed in at least the following tissues: Adipose, Brain, Cervix, Heart,
Hippocampus, Hypothalamus, Kidney Cortex, Liver, Lung, Myometrium, Nasoepithelium, Pancreas, Prostate, Retina, Small Intestine, Spinal Chord, Stomach, Substantia Nigra, Testis, Thalamus, Thymus, Vein. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.
In addition, the sequence is predicted to be expressed in skin and muscle because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSU53204|acc:U53204.1) a closely related Human plectin (PLEC1) mRNA, complete eds homolog. NOV7b In the present invention, the target sequence identified previously, NOV7a, was subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95%> over 50 bp. In addition, sequence traces
were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported below, which is designated Accession Number NOV7b. This differs from the previously identified sequence (Accession Number NOV7a) in being a splice variant.
A disclosed NOV7b nucleic acid of 1482 nucleotides (also referred to CG56077-02) encoding a novel Leucine-Rich Glioma-Inactivated Protein-like protein is shown in Table 7C. An open reading frame was identified beginning with an TTC initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1480-1482. In Table 7C, the 5' and 3' untranslated regions are underlined and the start and stop codons are in bold letters. Because the start codon for NOV7b is not a traditional initiation codon, NOV7b may be a partial reading frame that extends further in the 5' direction.
Table 7C. NOV7b Nucleotide Sequence (SEQ ID NO:29)
TCCCGAGACTTTGGAAGTTCTCAGCTATTACTTTATTACATAGGATTTCTGTGTCTTTTCTCATCTCTTTT CCTTTTGGAAATTGGAAGACCCCCAAAGGGAAAGTGTCCCCTGCGCTGCTCCTGCTCTAAAGACAGCGCCC TGTGTGAGGGCTCCCCGGACCTGCCCGTCAGCTTCTCTCCGACCCTGCTGTCACTGACTGCCCACATCCCC AGCTCACTCGTCAGGACGGGAGTCACCCAGCTGAAGGCCGGCAGCTTCCTGAGAATTCCGTCTCTGCACCT GCTGCTCTTCACCTCCAACTCCTTCTCCGTGATTGAGGACGATGCATTTGCGGGCCTGTCCCACCTGCAGT ACCTGTTCATCGAGGACAATGAGATTGGCTCCATCTCTAAGAATGCCCTCAGAGGACTTCGCTCGCTTACA CACCTGAGCCTGGCCAATAACCATCTGGAGACCCTCCCCAGATTCCTGTTCCGAGGCCTGGACACCCTTAC TCATGTGGACCTCCGCGGGAACCCGTTCCAGTGTGACTGCCGCGTCCTCTGGCTCCTGCAGTGGATGCCCA CCGTGAATGCCAGCGTGGGGACCGGCGCCTGTGCGGGCCCCGCCTCCCTGAGCCACATGCAGCTCCACCAC CTCGACCCCAAGACTTTCAAGTGCACAGCGGCCTCCGTGGTGTCCTGCAAGCCACTGGTGCTGGGCCCGAG CCTCTTCGTGCTGGCTGCCCGCCTGTGGGGGGGCTCACAGCTGTGGGCCCGGCCCAGTCCCGGCCTGCGCC TGGCCCCAACGCAGACCCTGGCCCCGCGGCGGCTGCTGCGGCCCAATGACGCCGAGCTCCTGTGGCTGGAA GGGCAACCCTGCTTCGTGGTGGCCGATGCCTCCAAGGCGGGCAGCACCACGTGCAGCGCTTCCGGCCCGAG GAAGAGCTGCCCGAGCCTGCACGCCTGGCACCGGGACACGGACGCTGAGGCCCTGGAGCTGGACGGCCGGC CCCACCTGCTGCTGGCCTCGGCTTCCCAGCGGCCCGTGCTCTTCCACTGGACCGGTGGCCGCTTCGAGAGA CGCACGGACATCCCCGAGGCCGAGGATGTCTATGCCACACGCCACTTCCAGGCTGGTGGGGACGTGTTCCT GTGCCTCACACGCTACATTGGGGACTCCATGGTCATGCGCTGGGACGGCTCCATGTTTCGTCTGCTGCAGC AACTTCCCTCGCGCGGTGCCCACGTCTTCCAGCCACTGCTCATCGCCAGGGACCAATTGGCCATCCTAGGC AGCGACTTCGCCTTCAGCCAGGTCCTCCGCCTTGAGCCTGACAAGGGGCTCCTGGAGCCACTGCAGGAGCT GGGGCCTCTGGCCCTGGTGGCCCCCCGTGCCTTTGCCCACATCACTATGGCCGGCAGACGCTTCCTCTTTG CTGCTTGCTTTAAGGGCCCCACACAGATCTACCAGCATCACGAGATCGACCTCAGTGCCTGA
The disclosed NOV7b nucleic acid sequence, localized to the q24 region of chromosome 10, has 559 of 919 bases (60%) identical to a gb:GENBANK- ID:SC6D10|acc:AL138538.1 mRNA from Streptomyces coelicolor A3(2) (Streptomyces coelicolor cosmid 6D10) (E = 9.8e"10).
A disclosed NOV7b polypeptide (SEQ ID NO:30) encoded by SEQ ID NO:29 is 493 amino acid residues and is presented using the one-letter amino acid code in Table 7D. Signal P, Psort and or Hydropathy results predict that NOV7b has a signal peptide and is likely to be localized in the endoplasmic reticulum (membrane) with a certainty of 0.8200. i other embodiments, NOV7b is also likely to be localized to the microbody (peroxisome) with a certainty of 0.3264, to th plasma membrane with a certainty of 0.1900, or to the endoplasmic
reticulum (lumen) with a certainty of 0.1000. The most likely cleavage site for NOV7b is between positions 25 and 26: LFL-LE.
Table 7D. Encoded NOV7b protein sequence (SEQ ID NO:30).
SRDFGSSQLLLYYIGFLCLFSSLFLLEIGRPPKGKCPLRCSCSKDSALCEGSPDLPVSFSPTLLSLTAHIP SSLVRTGVTQLKAGSFLRIPSLHLLLFTSNSFSVIEDDAFAGLSHLQYLFIEDNEIGSISKNALRGLRSLT HLSLANNHLETLPRFLFRGLDTLTHVDLRGNPFQCDCRVLWLLQWMPTVNASVGTGACAGPASLSHMQLHH LDPKTFKCTAASWSCKPLVLGPSLFVLAARLWGGSQLWARPSPGLRLAPTQTLAPRRLLRPNDAELLWLE GQPCFWADASKAGSTTCSASGPRKSCPSLHAWHRDTDAEALELDGRPHLLLASASQRPVLFHWTGGRFER RTDIPEAEDVYATRHFQAGGDVFLCLTRYIGDSMVMRWDGSMFRLLQQLPSRGAHVFQPLLIARDQLAILG SDFAFSQVLRLEPDKGLLEPLQELGPLALVAPRAFAHITMAGRRFLFAACFKGPTQIYQHHEIDLSA
The disclosed NOV7b amino acid sequence has 137 of 295 amino acid residues (46%) identical to, and 191 of 295 amino acid residues (64%) similar to, the 557 amino acid residue ptnr:SPTREMBL-ACC:Q9JIAl protein from Mus musculus (Mouse) (Leucine-Rich Glioma- Inactivated 1 Protein Precursor) (E = 5.7e"122).
NOV7b is expressed in at least brain. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of CuraGen Ace. No. CG56077-02.
NOV7 also has homology to the amino acid sequence shown in the BLASTP data listed in Table 7E.
Table 7E. BLAST results for NOV7
Gene Index/ Protein/ Organism Length Identity Positives Expect Identifier (aa) (%) (%) gi I 9938002 I ref |NP_06 leucine-rich, 557 271/561 375/561 e-157 4674.1 j (NM 020278) glioma (48%) (66%) inactivated 1 [Mus musculus] gi I 4826816 | ref |NP_00 leucine-rich, 557 265/542 354/542 e-151 5088. ll (NM 005097) glioma (48%) (66%) inactivated 1 precursor [Homo sapiens] gi 115722102 I emb | CAC7 bA512J3.1 461 225/464 308/464 e-129 8757.1| (AL358154) (leucine-rich, (48%) (55%) glioma inactivated 1)
[Homo sapiens] gi 1156208911 dbj |BAB6 KIAA1916 protein 542 211/513 312/513 e-113 7809. ll (AB067503) [Homo sapiens] (41%) (50%) gi I 4590406 |gb|AAD265 slit protein 1504 58/187 89/187 2e-l8
67.1|AF126540_1 [Drosophila (31%) (47%)
(AF126540) melanogaster]
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 7F.
Table 7F. Information for the ClustalW proteins
1) NOV7 ( SEQ ID NO : 30 )
2) gi I 9938002 | ref | NP_064674.11 (NM_020278) leucine-rich, glioma inactivated 1 [Mus musculus] (SEQ ID NO: 94)
3) gi I 4826816 I ref |NP_005088.11 (NM_005097) leucme-rich, glioma inactivated 1 precursor [Homo sapiens] (SEQ ID NO: 95)
4) gi|l5722102|emb|CAC78757.l| (AL358154) bA512J3.1 (leucine-rich, glioma inactivated 1) [Homo sapiens] (SEQ ID NO.96)
5) gi|l562089l|dbj |BAB67809.l| (AB067503) KIAA1916 protein [Homo sapiens] (SEQ ID NO:97)
6) gi|4590406|gb|AAD26567.l|AFl26540_l (AF126540) slit protein [Drosophila melanogaster] (SEQ ID NO: 98)
370 380 390 400 410 420
970 980 990 1000 1010 1020
NOV7a 553 NOV7b 493
91 9938002 I ref I 557 gi 4826816 I re 557 gi 15722102 emb 461 gi 15620891 dbj 542 gi 4590406 I gb I A QREYQCLCQPGYHGKHCEFMIDACYGNPCRNNATCTVLEEGRFSCQCAPGYTGARCETNI 1010
1030 1040 1050 1060 1070 1080
NOV7a 553
0
1090 1100 1110 1120 1130 1140
N0V7 553
0
1150 1160 1170 1180 1190 1200
N0V7 553 N0V7b 493
0
1210 1220 1230 1240 1250 1260
NOV7a 553
0
1270 1280 1290 1300 1310 1320
N0V7a 553
0
1330 1340 1350 1360 1370 1380
NOV7a 553
0
1390 1400 1410 1420 1430 1440
NOV7a 553
0
1450 1460 1470 1480 1490 1500
N0V7a 553
0
1510
N0V7 553 N0V7b 493 gi 9938002|ref I 557 gi 4826816 ref 557 gi 15722102 emb 46 gi 15620891 dbj 542 gi 4590406|gb|A LDIVRKCGCTKKCY 1504
Tables 7E-G list the domain description from DOMAIN analysis results against NOV7. This indicates that the NOV7 sequence has properties similar to those of other proteins known to contain this domain.
Table 7E. Domain Analysis of NOV7 gnl I Smart I smart00082, LRRCT, Leucine rich repeat C-terminal domain (SEQ ID NO: 99)
CD-Length = 51 residues, 100.0% aligned Score = 46.6 bits (109), Expect = 3e-06
Query: 173 NPFQCDCRVLWLLQWMPTVNASVGTGA--CAGPASLSHMQLHHLDPKTFKCT 222
III III + lll + k ll l ll I I I +111
Sbjct: 1 NPFICDCELRWLLRWLQANRHLQDPVDLRCASPESL-RGPLLLLLPSSFKCP 51
Table 7F. Domain Analysis of NOV7 gnl I Pfam|pfam01463 , LRRCT, Leucine rich repeat C-terminal domain. Leucine Rich Repeats pfam00560 are short sequence motifs present in a number of proteins with diverse functions and cellular locations. Leucine Rich Repeats are often flanked by cysteine rich domains. This domain is often found at the C-terminus of tandem leucine rich repeats. (SEQ ID NO:100) CD-Length = 51 residues, 98.0% aligned Score = 45.4 bits (106), Expect = 7e-06
Query: 173 NPFQCDCRVLWLLQWMPTVNASVGTGA--CAGPASLSHMQLHHLDPKTFKC 221
III III + lll + k ll l ll l l l l l
Sbjct: 1 NPFICDCELRWLLRWLREPRRLEDPEDLRCASPESL-RGPLLELLPSDFSC 50
Table 7G. Domain Analysis of NOV7 gnl I Smart I smart00369, LRR_TYP, Leucine-rich repeats, typical (most populated) subfamily (SEQ ID NO: 101) CD-Length = 24 residues, 100.0% aligned Score = 35.8 bits (81), Expect = 0.006
Query: 138 LRSLTHLSLANNHLETLPRFLFRG 161
I +1 I l+ll I +11 l+l
Sbjct: 1 LPNLRELDLSNNQLSSLPPGAFQG 24
Loss of heterozygosity for 10q23-26 is seen in over 80% of glioblastoma multiforme tumors. A novel gene, LGIl (Leucine-rich gene-Glioma Inactivated), is rearranged as a result of the t(10;19)(q24;ql3) balanced translocation in the T98G glioblastoma cell line lacking any normal chromosome 10. Rearrangement of the LGIl gene was also detected in the A172 glioblastoma cell line and several glioblastoma tumors. These rearrangements lead to a complete absence of LGIl expression in glioblastoma cells. The LGIl gene encodes a protein
with a calculated molecular mass of 60 kD and contains 3.5 leucine-rich repeats (LRR) with conserved flanking sequences, hi the LRR domain, LGIl has the highest homology with a number of transmembrane and extracellular proteins which function as receptors and adhesion proteins. LGIl is predominantly expressed in neural tissues, especially in brain; its expression is reduced in low grade brain tumors and it is significantly reduced or absent in malignant gliomas. Its localization to the 10q24 region, and rearrangements or inactivation in malignant brain tumors, suggest that LGIl is a candidate tumor suppressor gene involved in progression of glial tumors.
The disclosed NOV7 nucleic acid of the invention encodmg a Leucine-Rich Glioma- Inactivated Protein-like protein includes the nucleic acid whose sequence is provided in Table 7A, 7C or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 7A or 7C while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 40 percent of the bases may be so changed. The disclosed NOV7 protein of the invention includes the Leucine-Rich Glioma-
Inactivated Protein-like protein whose sequence is provided in Table 7B or 7D. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 7B or 7D while still encoding a protein that maintains its Leucine-Rich Glioma-Inactivated Protein-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 69 percent of the residues may be so changed.
The protein similarity information, expression pattern, and map location for the Leucine-Rich Glioma-Inactivated Protein-like protein and nucleic acid (NOV7) disclosed herein suggest that NOV7 may have important structural and or physiological functions
characteristic of the Leucine-Rich Glioma-Inactivated Protein-like family. Therefore, the NOV7 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo. The NOV7 nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, anemia , bleeding disorders, scleroderma,diabetes, Von Hippel-Lindau (VHL) syndrome, pancreatitis, obesity, fertility, cirrhosis, inflammatory bowel disease, diverticular disease,hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, cerebral palsy, epilepsy, Lesch- Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, multiple sclerosis, leukodystrophies, neuroprotection, systemic lupus erythematosus, autoimmune disease, asthma, emphysema, scleroderma, allergy, ARDS, autoimmune disease, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, systemic lupus erythematosus, renal tubular acidosis, IgA nephropathy Cholesteryl ester storage disease; Corneal dystrophy, Thiel-Behnke type; Dubin- Johnson syndrome; Leukemia, T-cell acute lymphocytic; Retinol binding protein, deficiency of; SEMD, Pakistani type; Spmocerebellar ataxia, infantile-onset, with sensory neuropathy; Split hand/foot malformation, type 3; Tolbutamide poor metabolizer; Urofacial syndrome; Warfarin sensitivity; Wolman disease, and/or other pathologies/disorders. The NOV7 nucleic acid, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed.
NOV7 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. For example the disclosed NOV7 protein have multiple hydrophihc regions, each of which can be used as an immunogen. This novel protein also has value in development of powerful assay system for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV8
A disclosed NOV8 nucleic acid of 430 nucleotides (also referred to as AL163195_dal) encoding a novel RNase-like protein is shown in Table 8A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 16-18 and ending with a TAA codon at nucleotides 408-410. A putative untranslated region upstream from the initiation codon is underlined in Table 8 A. The start and stop codons are in bold letters.
Table 8A. NOV8 nucleotide sequence (SEQ ID NO:31).
GGGGAATTCGCCCTTATGATATGTCTTCCACATTACTGACATTCAGAAGTTTACATTATAATGACCCCAAGG GAAACAGTTCGGGTAATGACAAAGAGTGTTGCAATGACATGACAGTCTGGAGAAAAGTTTCAGAAGCAAACG GATCGTGCAAGTGGAGCAATAACTTCATCCGCAGCTCCACAGAAGTGATGCGCAGGGTCCACAGGGCCCCCA GCTGCAAGTTTGTACAGAATCCTGGCATAAGCTGCTGTGAGAGCCTAGAACTGGAAAATACAGTGTGCCAGT TCACTACAGGCAAACAATTCCCCAGGTGCCAATACCATAGTGTTACCTCATTAGAGAAGATATTGACAGTGC TGACAGGTCATTCTCTGATGAGCTGGTTAGTTTGTGGCTCTAAGTTGTAAATCCCACAGAGCTTTAGGAC
The NOV8 nucleic acid sequence is located on chromsome 14. The disclosed NOV8 polypeptide (SEQ ID NO:32) encoded by SEQ LD NO:31 has
129 amino acid residues and is presented in Table 8B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV8 has a signal peptide and is likely to be localized to the microbody (peroxisome) with a certainty of 0.8000. In other embodiments, NOV8 may also be localized to the mitochondrial matrix space with a certainty of 0.1000, orthe lysosome (lumen) with a certainty of 0.1000.
Table 8B. Encoded NOV8 protein sequence (SEQ ID NO:32).
MSSTLLTFRSLHYNDPKGNSSGNDKECCNDMTVWRKVSEANGSCKWSNNFIRSSTEVMRRVHRAPSCKFVQN PGISCCESLELENTVCQFTTGKQFPRCQYHSVTSLEKILTVLTGHSLMSWLVCGSKL
A search of sequence databases reveals that the NOV8 amino acid sequence has 35 of 115 amino acid residues (30%) identical to, and 56 of 115 amino acid residues (48%) similar to, the 124 amino acid residue Ribonuclease Pancreatic (EC 3.1.27.5) (RNASE 1) (RNASE A) protein from Balaenopter a acutorostrata (Minke whale) (Lesser rorqual) (SWISSPROT- ACC:P00673) (E = 1.2e"7).
NOV8 also has homology to the amino acid sequence shown in the BLASTP data listed in Table 8C.
The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 8D.
Table 8D. Information for the ClustalW proteins
1) NOV8 (SEQ ID NO: 32) 2) gι|l7476497|ref |XP_058653.1 | (XM_058653) similar to RIBONUCLEASE PANCREATIC (RNASE 1) (RNASE A) (SEQ ID NO: 102)
3) gi|l33196|sp|P00673|RNP_BALAC RIBONUCLEASE PANCREATIC (RNASE 1) (RNASE A) (SEQ ID NO: 103)
10 20 30 40 50 60
0
NOV8 50 gi 117476497 I ref 120 gijl33196|sp|P0
46
190 200
NOV8 ^ IL^TV^L^TG^H^SL^M^SW^L^VC^G^SK^L 129 gi 17476497 I ref BILKTSVBLKTBGSSHSSLBMESWffiLVgCSlGtHSKBLI 199 g 133196 | sp | P0 J3.IVACEgNPYyPVHFDNgV- 124
Pancreatic ribonuclease (EC 3.1.27.5 ) is one of the digestive enzymes secreted in abundance by the pancreas. Elliott et al. (Cytogenet. Cell Genet. 42: 110-112, 1986) mapped the mouse gene to chromosome 14 by Southern blot analysis of genomic DNA from recombinant inbred strains of mice, using a probe isolated from a pancreatic cDNA library with the rat cDNA. A polymorphic BamHI site was used to demonstrate complete concordance of the Rib-1 locus with Tcra and Np-2, encoding the alpha subunit of the T-cell receptor (186880) and nucleoside phosphorylase (164050), respectively. The assignment to mouse 14 and the close linkage to the other 2 loci was confirmed by study of one of Snell's congenic strains: the 3 loci went together. Elliott et al. (Cytogenet. Cell Genet. 42: 110-112, 1986) predicted that the homologous human gene RLBl is on chromosome 14.
Human pancreatic RNase is monomeric and is devoid of any biologic activity other than its RNA degrading ability. Piccoli et al. (Proc. Nat. Acad. Sci. 96: 7768-7773, 1999) engineered the monomeric form into a dimeric protein with cytotoxic action on mouse and human tumor cells, but lacking any appreciable toxicity on human and mouse normal cells. The dimeric variant of human pancreatic RNase selectively sensitized cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein was thought to represent an attractive tool for anticancer therapy.
The disclosed NOV8 nucleic acid of the invention encoding a RNase-like protein includes the nucleic acid whose sequence is provided in Table 8A, or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 8A while still encoding a protein that maintains its RNase-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 10% percent of the bases may be so changed.
The disclosed NOV8 protein of the invention includes the RNase-like protein whose sequence is provided in Table 8B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2 while still encoding a protein that maintains its RNase-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 72 percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fa or (Fab)2,that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this RNase-like protein (NOV8) may function as a member of a "RNase family". Therefore, the NOV8 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOV8 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in DiabetesNon Hippel-Lindau (VHL) syndrome , PancreatitiSjObesity, Hyperthyroidism and Hypothyroidism and Cancers including, but no limited to Thyroid and Pancreas, and/or other diseases or pathologies.
NOV8 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV8 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies" section below. The disclosed NOV8 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV9
A disclosed NOV9 nucleic acid of 1860 nucleotides (also referred to as CG56069-01) encoding a novel Insulin like growth factor binding protein-like protein is shown in Table 9A.
An open reading frame was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 1858-1860. The start and stop codons are in bold letters in Table 9A.
Table 9A. NOV9 nucleotide sequence (SEQ ID NO:33).
ATGGACAGGCACTTGCTGTTGCCTGGTCTGCTCCTGTCCCTTCCTCTGACCGCAGGCTGGACCATCTCCAAT AGTTTAGTGACTGAAGGCTCCCGGCTGTCTATGGTCTCCCGCTTCTTCCTGATTTGCCTCTTGGACTCCAGC CTGCCTTTCCTCACCACATGCCTCTCAGTGATCAACTTGGTGCGGGCCTTGGAAACTGTGCTGCAGAACGTG GAGGGTCTCTGTCAATCTGGTTCCACTTCTGCTCTGCCTCAGGATGCCTTCTCCCGCTTTCCTGGGCTCAAG GCTGAAGCTGGCCAGTCCTGGAGCCTTCCAGGTCCTCAAGCTGGGGACTCTGAATCTGGACCACACAAAGAT GAAGGCAGATGCACTGGTGGGACGGGGGCTGCAGAGATTGGATGCCCTGTGACACTCACTGACATGGCTGAG CTGCCTGCCAGGATGGTTGCCCATTTTGAGCTTCAGGAGCTGAATTTGGGGATTAATCGGACAAGGCACATA GCCCTGGAAGGCCTGGCTTCCTGTCACAGCCTGAAGAGCTCGGGTCTTCGGAGCAATGGCCTGATTGAGTTA CCACGAGGTTTCCTGGCTGCCATGCCCAGGCTTCAGAGACTGAACCTGGCCAACAACCAACTGAGGAGCGCC ATGTTGTGTATGAATGAGACAGGGTTTGTGTCAGGATTGTGGGCCCTGGATCTGTCCAAGAATAGGCTGTGT ACCCTGTCCCCAGTCATCTTCTCCTGTTTGCCCCACCTGCGGGAGCTGCTACTTCAAGGGAACCAACTGGTT TGCTTGAAAGACCAGGTATTCCAGGGCCTACAGAGGCTACAGACCTTGAACTTGGGCAATAATCCACTGGTA ACCCTGGGTGAGGGCTGGCTGGCTCCTCTGCCTACACTGACCACCCAAAACCTGGTAGGTACTCACATGGTG CTGAGCCCAACCTGGGGCTTCCGGGGCCCAGAAAGTCTGCACAGCTTGAGAATACAGTTTCCCTTTGGCCCT GCGGGAGTAGCATTTTCCCTGCTCACAAGACTGACTAGCTTGGAGCTCCACGCAGTTTCAGGCATGAAGCAT TGGAGGTTGTCTCCTAATGTCTTTCCAGTCTTGCAGATCCTGACTTTAAAGGGCTGGGGACTGCAGCTAGAG ACCCAGAATATCTCCAAGATCTTCCCTGCCCTTCATCAACTCTCCCTGCTTGGCACTCCCGAAGCTCAAGTC CTTGAAGGATGGGGAAACAGGCATAGCCCTAGGCCCTACTGCATCACGGGACTGCCCAGTCTACAGGAGCTG AAGCTGCAGGCACTGCAGTCTCAAGCATGCCCCTGCCCAGTGCGGCTTGAGGAGCTGGTGGGGTTGGAGACA CTGTCTGCTGCTGCTTTTGGGGGCCTCGGCAGTCTCCAGGTCTTAGTACTAGACAGGGAGAAAGACTTCATG CTGGATGACAGCCTCCAGGAGCACAGTCCTCGGATGCCCCAGTACATCTATATTCTGACCTCATCCTTGGCC TGCCAGTGTGCCAATGCCTGCCTCTGCCCTGCTGCTTCTGCTGGTCTCCTTGCCCTTCCTAAAGGAAGCCAG GAATTCCTGGATCCTCTAACTCAAGGCCTTGCTCAGGGTTTGGTTCCAGAGTCTGAGGAGTCAGAAGGGCAA GACCAGGGCTGGATGGTGCAGGAGCTGCTGCCTGCTCTAGAGGACTGCCCTCCAGCTGGCCGGGGGCTGCCA CTCTGCCTCCATGAGTGGGATTTTGAGCCAGGCAAGGATGTGGCTGACAATGCAGCAGACAGCATGATTGGC CTGGTTGCTCCGCTGAAGAGACTATTGCATGTGGCCCAAGGAAGAGGAAAGAAAGAATGA
The disclosed NOV9 nucleic acid sequence, localized to the ql2 region of chromosome 1, has 410 of 699 bases (58%) identical to a gb:GENBANK- ID:MMU91967|acc:U91967.1 mRNA fromMus musculus (Mus musculus platelet glycoprotem lb-alpha gene, complete eds) (E = 0.031). The disclosed NOV9 polypeptide (SEQ ID NO:34) encoded by SEQ ID NO:33 has
619 amino acid residues is presented in Table 9B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV9 has a signal peptide and is likely to be localized in the lysosome (lumen) with a certainty of 0.6400. In other embodiments, NOV9 is predicted to be localized extracellularly with a certainty of 0.5087, to the endoplasmic reticulum (membrane) with a certainty of 0.1000, or to the endoplasmic reticulum (lumen) with a certainty of 0.1000. The most likely ceavage site for NOV9 is between positions 19 and 20, TAG-WT.
Table 9B. Encoded NOV9 protein sequence (SEQ ID NO:34).
MDRHLLLPGLLLSLPLTAGWTISNSLVTEGSRLSMVSRFFLICLLDSSLPFLTTCLSVINLVRALETVLQNV
EGLCQSGSTSALPQDAFSRFPGLKAEAGQSWSLPGPQAGDSESGPHKDEGRCTGGTGAAEIGCPVTLTDMAE LPARMVAHFELQELNLGINRTRHIALEGLASCHSLKSSGLRSNGLIELPRGFLAAMPRLQRLNLANNQLRSA MLCMNETGFVSGLWALDLSKNRLCTLSPVIFSCLPHLRELLLQGNQLVCLKDQVFQGLQRLQTLNLGNNPLV TLGEGWLAPLPTLTTQNLVGTHMVLSPTWGFRGPESLHSLRIQFPFGPAGVAFSLLTRLTSLELHAVSGMKH WRLSPNVFPVLQILTLKGWGLQLETQNISKIFPALHQLSLLGTPEAQVLEGWGNRHSPRPYCITGLPSLQEL KLQALQSQACPCPVRLEELVGLETLSAAAFGGLGSLQVLVLDREKDFMLDDSLQEHSPRMPQYIYILTSSLA CQCANACLCPAASAGLLALPKGSQEFLDPLTQGLAQGLVPESEESEGQDQGWMVQELLPALEDCPPAGRGLP LCLHEWDFEPGKDVADNAADSMIGLVAPLKRLLHVAQGRGKKE
A BLASTX of NOV9 shows that it has 77 of 253 amino acid residues (30%) identical to, and 114 of 253 amino acid residues (45%) similar to, the 605 amino acid residue ptnr:SWISSNEW-ACC:O02833 protein from Papio hamadryas (Hamadryas baboon) (Insulin- Like Growth Factor Binding Protein Complex Acid Labile Chain Precursor (ALS)) (E = ie"
9).
NOV9 is expressed in at least brain and liver. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources. hi addition, the sequence is predicted to be expressed in B-cells and blood cells because of the expression pattern of (GENBANK-LO: gb:GENBANK- ID:MMU91967|acc:U91967.1) a closely related Mus musculus platelet glycoprotein lb-alpha gene, complete eds homolog.
The disclosed NOV9 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 9C.
The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 9D. hi the ClustalW alignment of the NOV9 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (i.e., regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 9D. ClustalW Analysis of NOV9 1) Novel N0V9 (SEQ ID NO -34)
2) gι|566980θ|gb|AAD4S477.l]AF113614_l (AF113614) Toll-like receptor 2 [Cricetulus griseus] (SEQ ID NO: 104)
3) g I 6449037|gb|AAF08787.l| (AF163101) platelet glycoprotein V [Mus musculus] (SEQ ID NO:105) 4) gi|6680055|ref |NP_032174.l| (NM_008148) glycoprotein V (platelet); GP V [Mus musculus] (SEQ ID NO: 106)
5) gι| 6678754 I re |NP_032559.11 (NM_008533) lymphocyte antigen 78 [Mus musculus] (SEQ ID NO: 107)
6) gi 1112908 | sp| P02750 |A2GL_HUMAN LEUCINE-RICH ALPHA-2-GLYCOPROTEIN (LRG) (SEQ ID NO: 108)
10 20 30 40 50 60
NOV9 - -MDRHLLLPGfflLLSLPLTAGWTISNSLVTEGgRLSMVSRFFLICLLDSSLPF[jTTCLSV 58
91 5669800|gb|A -MLHVLWTFWlfflvAitTDLSRKGCSAQASLSCpAAGVCDGRSRSFTSIP SG 49 9i 6449037 jgbJA -MLRSALLSAv^L^RAQPFPCPKTCKCWRTiAAQCSGGSVAHΪAEJLG fflPTNLTH 54 gi 6680055Jref I -MLRSALLSAVHPLL,RAQPFPCPKTCKC R AAQCSGGSVAH3iAEp G HpTNIfCjH 54 gi 6678754Jref j MAPDI SCFFLVALFItASCRATTSSDQKCsrEKEVNKTYNCENLGJjNESljPG- - - TlJPNSTEC 57 gi 112908|sp|P0 . ' . ' i
250 260 270 280 290 300
Table 9E lists the domain description from DOMAIN analysis results against NOV9. This indicates that the NOV9 sequence has properties similar to those of other proteins known to contain this domain.
Table 9E. Domain Analysis of NO 9 gnl I Pfam|pfam01582, TIR, TIR domain. The TIR domain is an intracellular signaling domain found in MyD88, interleukin 1 receptor and the Toll receptor. Called TIR (by SMART?) for Toll - Interleukin - Resistance. (SEQ ID NO: 109) CD-Length = 141 residues, 29.1% aligned Score = 38.9 bits (89), Expect = 9e-04
Query: 549 SEGQDQGWMVQELLPALEDCPPAGRGLPLCLHEWDFEPGKDVADN 593
I 1 + I I I 1 1 + I + I + + I I I + + + I
Sbj ct : 6 SGKDDRDTFVSHLLKELEE KPGIKLFIDDRDELPGESILEN 46
The predicted sequence described here belongs to the leucine-rich repeat protein family. It is homologous to insulin like growth factor binding protein (IGFBP) and RP105, a novel B cell surface molecule. It contains five leucine-rich repeat domains. Leucine-rich repeats (LRRs) are relatively short motifs (22-28 residues in length) found in a variety of cytoplasmic, membrane and extracellular proteins (1) . Although these proteins are associated with widely different functions, a common property involves protein-protein interaction. Other functions of LRR-containing proteins include, for example, binding to enzymes and vascular repair (1) . LRRs form elongated non-globular structures and are often flanked by cysteine rich domains. The circulating insulin-like growth factors (IGF-I and -II) occur largely as components of a 140kDa protein complex with IGF binding protein-3 and the acid-labile subunit (ALS). This ternary complex regulates the metabolic effects of the serum IGFs by limiting their access to tissue fluids. A cDNA for baboon ALS was isolated by Delhanty and Baxter (2) and used to screen Northern blots of total RNA from the lung, liver, kidney, adrenal, muscle, intestine, and spleen of adult baboons. The expression of the single approximately 2.2 kb baboon ALS mRNA transcript was restricted to the liver, suggesting that serum ALS levels are controlled by regulation of hepatic expression of this peptide in primates (2).
The RP105 Ag is a murine B cell surface molecule that transmits an activation signal into B cells or dexamethasone-induced apoptosis, and to B cell proliferation. A cDNA encoding the RP 105 Ag was isolated by Miyake, et al (3). An encoded protein is a type I transmembrane protein consisting of 641 amino acids in a mature form. Northern
hybridization with a probe specific for the cDNA clone detected a transcript with a size of approximately 3 kb. The transcript was observed in spleen, but not in thymus, kidney, muscle, heart, brain, or liver. Stable transfection of the cDNA clone conferred the expression of the RP105 Ag on a pro-B cell line, which was confirmed by immunofluorescence staining and immunoprecipitation with anti-RP 105 mAb. The RP 105 molecule possesses 22 tandem repeats of a leucine-rich motif. These repeated motifs are observed in members of the leucine-rich repeat protein family, and have been implicated in protein-protein interactions, such as cell adhesion or receptor-ligand binding. Amino- and carboxyl-flanking regions that are characteristically conserved among members of the family are located on both sides of tandemly repeated leucine-rich motifs in RP 105 molecule. These results demonstrate that
RP105 is a novel member of the leucine-rich repeat protein family, and the first member that is specifically expressed on B cells (3).
Because of the presence of the Leucine rich repeat domains and the homology to the IGFBP and RP105, we anticipate that the novel sequence described here will have useful properties and functions similar to these genes.
References: 1. Artavanis-Tsakonas S., Goodman C.S., Rothberg J.M., Jacobs J.R. (1990) Slit: an extracellular protein necessary for development of midline glia and commissural axon pathways contains both EGF and LRR domains. Genes Dev. 4: 2169-2187. 2. Delhanty P, Baxter RC. (1992) The cloning and expression of the baboon acid-labile subunit of the insulin-like growth factor binding protein complex. Biochem Biophys Res
Commun. 227(3): 897-902. 3. Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M. (1995) RP105, a novel B cell surface molecule implicated inB cell activation, is a member of the leucine-rich repeat protein family. J Immunol . 154(7):3333-40
The disclosed NOV9 nucleic acid of the invention encoding a Insulin like growth factor binding protein-like protein includes the nucleic acid whose sequence is provided in
Table 9A, or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 9A while still encoding a protein that maintains its Insulin like growth factor binding protein-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar
phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. The disclosed NOV9 protein of the invention includes the Insulin like growth factor binding protein-like protein whose sequence is provided in Table 9B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 2 while still encoding a protein that maintains its Insulin like growth factor binding protein-like activities and physiological functions, or a functional fragment thereof, h the mutant or variant protein, up to about 74 percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fa or (Fab)2, that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Insulin like growth factor binding protein-like protein (NOV9) may function as a member of a "Insulin like growth factor binding protein family". Therefore, the NOV9 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOV9 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in diabetes, obesity, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, tuberous sclerosis, hypercalceimia, Parkinson's disease,
Huntington's disease, cerebral palsy, epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, neuroprotection, cirrhosis, transplantation, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmume disease, allergies, immunodeficiencies, graft versus host disease (GVHD), lymphaedema, and other diseases, disorders and conditions of the like. NOV9 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV9 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti-NOVX Antibodies"
section below. The disclosed NOV9 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV10
A disclosed NOV10 nucleic acid of 4660 nucleotides (also referred to as SC133419534_A) encoding a novel pregnancy zone protein precursor -like protein is shown in Table 10A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 141-143 and ending with a TAA codon at nucleotides 4578-4580. A putative untranslated region upstream from the initiation codon and downstream from the termination codon is underlined in Table 10A. The start and stop codons are in bold letters.
Table 10A. NOV10 nucleotide sequence (SEQ ID NO:35).
AATTCTGAACTCTATTCAGAGGCCTTGGGGTGGGGCTTGTTTGTACATAGTGGCCACATAAAGCCTGGTAAA CTCAGCTGGTCTCCAGGGCGAGGCTGAGGGCAGAGAGTTGGACACAACCCTGAGATTTATCCCTCACAATGC GGAAAGACAGACTTCTTCATTTATGTCTTGTGCTACTTCTTATCCTGCTTTCTGCCAGTGACTCAAACTCTA CAGAACCGCAGTATATGGTGCTGGTCCCCTCCCTGCTCCACACTGAGGCCCCTAAGAAGGGCTGTGTCCTTC TGAGCCACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGGCAGGGAAAACAGGAGCCTCTTCA CTGACCTGGTGGCGGAGAAGGACTTATTCCACTGTGTCTCCTTCACTGTGCCAAGGATCTCAGCCTCTTCAG AGGTGGCATTCCTTAGCATCCAGATAAAGGGGCCTACGCAAGATTTCAGGAAGAGGAACACAGTTCTGGTAC TGAACACCCAAAGTCTGGTCTTTGTCCAGACAGACAAACCCATGTATAAACCAGGACAGACAGGTAAGGTAA GATTCCGTGTTGTCTCCGTGGATGAAAATTTTCGCCCTCGAAATGAACTGGTAAGCCTTGTTTCCCTTCAGA ACCCAAGAAGAAATCGAATTGCACAATGGCAGAGTCTCAAGCTAGAAGCTGGCATCAATCAGTTGTCCTTTC CCCTCTCATCAGAGCCCATTCAGGGCTCCTACAGGGTGGTGGTACAGACAGAATCAGGTGGAAGGATACAGC ACCCCTTCACCGTGGAGGAATTTGTGCTTCCCAAGTTTGAGGTCAAAGTTCAGGTGCCAAAGATAATCAGTA TCATGGATGAAAAAGTGAACATAACAGTCTGTGGATGTTATAGGTACACATATGGAGAGCCTGTCCCTGGTC TGGTGACACTTAGTGTATGCAGAAGATATTCACTATGCCGTTCCGACTGCCACAACACACATTCACAGCTTA ACAGCAATGGCTGCATCACCCAACAAGTACACACCAAAATGCTCCAGATTACAAATACGGGCTTTGAAATGA AGCTTAGAGTGGAAGCCAGGATCAGAGAAGAGGGGACAGGTGTGGAAGTCACTGCAAACAGGATCAGTGAAA TCACAAACATTGTATCCAAACTCAAATTCGTGAAAGTGGATTCACACTTTAGACAAGGAATCCCCTTTTTTG CACAGGTAAGACTGGTGGATGGAAAAGGTGTGCCCATCCCCAATAAACTCTTCTTCATCTCTGTGAATGACG CCAATTATTACTCCAATGCAACCACCAATGAGCAGGGTCTTGCACAGTTTTCAATCAATACTACCAGTATCT CGGTTAATAAACTTTTTGTCCGGGTAAGTTACAAAGAGAGTAACAATTGTTCTGATAACTGGTGGCTTGATG AATTTCATACGCAAACATCTCATACTGCAAAGCATTTTTTTTCCCCAAGCAAGAGTTATATTCACCTCAAAC CTATTATTGGTACTTTGACCTGTGGACAAACCCAGGAGATTCAAGCACACTACATTCTGAATAAACAGATTC TCAGGGATGAAAAAGAATTAACCTTCTACTATTTGGTAAAAGCAAGAGGAAAAATCTCCCAATCAGGAATCC ATGTGTTATCCATTGAACAAGGAAACAGTAAAGGCAGTTTTGCCTTATCCTTCCCTGTGGAGTCAGACGTTG CCCCCATTGCACGAATGTTCATCTTTGCCATTTTACCAGATGGAGAAGTTGTTGGAGACTCTGAAAAATTTG AGATTGAAAACTGTCTAGCCAACAAGGTGGATTTGAGCTTCAGCCCAGCACAAAGTCCCCCAGCCTCACATG CCCACCTGCAAGTAGCAGCTGCTCCGCAGTCCCTCTGTGCCCTTCGTGCTGTGGACCAAAGTGTGCTGCTCA TGAAGCCTGAGGCTGAGCTCTCTGTGTCCTCAGTGTATAATCTGCTAACTGTGAAGGATCTCACCAATTTTC CTGACAATGTGGACCAGCAGGAGGAAGAACAAGGACACTGTCCCCGTCCTTTCTTCATTCATAATGGAGCCA TCTATGTTCCCTTATCAAGTAATGAAGCAGATATTTATAGCTTCCTCAAGGGGATGGGATTGAAGGTGTTCA CTAACTCAAAAATCCGAAAACCAAAGTCGTGTTCAGTCATCCCTTCCGTGTCTGCAGGAGCAGTAGGTCAAG GATACTATGGAGCAGGTCTAGGAGTAGTAGAGAGACCATATGTTCCTCAATTAGGCACATATAATGTGATAC CCTTAAATAATGAACAAAGTTCAGGGCCAGTCCCTGAAACGGTGCGAAGCTATTTTCCTGAGACTTGGATCT GGGAGTTGGTGGCAGTGAGCTCATCAGGTGTGGCTGAGGTAGGAGTAACAGTCCCTGACACCATCACCGAGT GGAAGGCAGGGGCCTTCTGCCTGTCCGAAGATGCTGGACTTGGTATCTCTTCCACTGCCTCTCTCCGAGCCT TCCAGCCCTTCTTTGTGGAGCTCACAATGCCTTACTCTGTGATTCGTGGAGAGGTCTTCACACTCAAGGCCA CGGTCCTAAACTACCTTCCCAAATGCATCCGGGTAGTTGTGCAGCTGGAGGTCTCTTCCGCTTTCCTGGCTG TTCCAACAGAGAAGAATGAAGAATCTCACTGTGTCTGTAGAAATGGGCGGAAAACCGTGTCCTGGGTTGTGA CTCCGAAGTCACTGGGTAATGTGAACTTCTCAGTGAGTGCAGAGGCAATGCAGTCCTTAGAACTCTGTGGAA ATGAGGTTGTTGAGGTCCCTGAGATTAAAAGAAAAGACACAGTCATCAAAACCCTGTTGGTGGAGCCTGAAG
GAATAGCAAAGGAGGAAACTTTCAACACGCTGCCCTGTGCATCAGGTGCTAATGTGTCTGAGCAGTTGTCCT TGAAGCTCCCATCAAATGTGGTCAAAGAATCTGCCAGAGCTTCTTTCTCAGTTCTGGGTGGTGACATATTAG GTTCTGCTATGCAAAATATACAAAATCTCCTCCAGATGCCATATGGCTGTGGAGAACAGAACATGGTCCTAT TTGCTCCTAACATCTATGTCTTGAACTATCTGAATGAAACCCAGCAGCTGACGCAGGAGATCAAGGCCAAGG CCGTTGGCTATCTCATCACTGGTTACCAGAGACAGCTGAACTACAAACACCAAGATGGCTCCTACAGCACCT TTGGGGAACGATATGGCAGGAACCAGGGCAACACTTGGCTCACAGCTTTTGTACTGAAGACTTTCGCCCAGG CTCGATCCTACATCTTCATTGATGAAGCACACATTACCCAATCTCTCACGTGGCTCTCCCAGATGCAGAAGG ACAATGGCTGTTTCAGGAGCTCTGGGTCACTGCTCAACAATGCCATAAAGGGAGGTGTAGAAGATGAAGCGA CCCTCTCCGCCTATGTTACTATTGCCCTTCTGGAAATTCCTCTCCCAGTCACTAACCCTATTGTTCGCAATG CCCTGTTCTGCCTGGAGTCAGCCTGGAATGTAGCAAAGGAGGGGACCCATGGGAGCCATGTCTACACCAAGG CATTGCTGGCCTATGCTTTTTCCCTACTGGGAAAGCAAAATCAGAATAGAGAAATACTGAACTCACTTGATA AGGAAGCTGTGAAAGACAACCTCGTCCATTGGGAGCGCCCTCAGAGACCCAAGGCACCAGTGGGGCATCTTT ACCAAACCCAGGCTCCCTCTGCTGAGGTGGAGATGACATCCTATGTGCTCCTCGCTTATCTCACGGCCCAGC CAGCCCCCACCTCAGGGGACCTGACCTCTGCAACTAACATTGTGAAGTGGATCATGAAGCAGCAGAACGCCC AAGGTGGTTTCTCCTCCACCCAGGACACAGTGGTGGCTCTCCATGCCCTGTCCAGGTATGGAGCAGCCACTT TCACCAGAACTGAGAAAACTGCACAGGTCACCGTTCAGGATTCACAGACCTTTTCTACAAATTTCCAAGTAG ACAACAACAACCTCCTATTACTGCAGCAGATCTCATTGCCAGAGCTCCCTGGAGAATATGTCATAACAGTAA CTGGGGAAAGATGTGTGTATCTTCAGACATCCATGAAATACAATATTCTTCCAGAGAAAGAGGACTCCCCAT TTGCTTTAAAAGTGCAGACTGTGCCCCAAACTTGCGATGGACACAAAGCCCACACCAGCTTTCAGATCTCAC TGACCATCAGTTACACAGGAAACCGTCCTGCTTCCAATATGGTGATTGTTGATGTAAAGATGGTATCTGGTT TTATTCCCCTGAAACCAACAGTAAAAATGCTTGAAAGATCTAGCTCTGTGAGCCGGACAGAAGTGAGCAACA ACCATGTCCTCATTTATGTGGAACAGGTGCTAACCCATCAAACCCTGCATTTTTCCTTCTTTGTGGAACAAG ACATCCAAATAAAGAATTTAAAACCAGCTACAGTAAAAGCCTATGATTATTATGAGACATCAGATGAATTCA CCTTTGAAGAATACAATGCCCCTTGCAGTGCTGGTAAAGTATAAATGATTCAATCTAATGCCACTTGAAAGA AAATAAATAAGCATCTCAGTTAAACAGTAAAGTCTAATCCCAACTTCAAAAT
hi a search of public sequence databases, the NOVIO nucleic acid sequence, localized to chromosome 12, has 4170 of 4478 bases (93%) identical to a gb:GENBANK- ID:HSPZHEP|acc:X54380 mRNA from Homo sapiens (Human mRNA for pregnancy zone protein (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOV10 polypeptide (SEQ ID NO:36) encoded by SEQ ID NO:35 has 1479 amino acid residues and is presented in Table 10B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOV10 has no signal peptide and is likely to be localized extracellularly with a certainty of 0.8200. In other embodiments, NOV10 may also be localized to the lysosome (lumen) with a certainty of 0.1900, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or in the endoplasmic reticulum (lumen) with a certainty of 0.1000. The most likely cleavage site for NOV10 is between positions 23 and 24: SDS-NS.
Table 10B. Encoded NOV10 protein sequence (SEQ ID NO:36).
MRKDRLLHLCLVLLLILLSASDSNSTEPQYMVLVPSLLHTEAPKKGCVLLSHLNETVTVSASLESGRENRSL FTDLVAEKDLFHCVSFTVPRISASSEVAFLSIQIKGPTQDFRKRNTVLVLNTQSLVFVQTDKPMYKPGQTGK VRFRWSVDENFRPRNELVSLVSLQNPRRNRIAQWQSLKLEAGINQLSFPLSSEPIQGSYR VQTESGGRI QHPFTVEEFVLPKFEVKVQVPKIISIMDEKVNITVCGCYRYTYGEPVPGLVTLSVCRRYSLCRSDCHNTHSQ LNSNGCITQQVHTKMLQITNTGFEMKLRVEARIREEGTGVEVTANRISEITNIVSKLKFVKVDSHFRQGIPF FAQVRLVDGKGVPIPNKLFFISVNDANYYSNATTNEQGLAQFSINTTSISVNKLFVRVSYKESNNCSDNWWL DEFHTQTSHTAKHFFSPSKSYIHLKPIIGTLTCGQTQEIQAHYILNKQILRDEKELTFYYLVKARGKISQSG IHVLSIEQGNSKGSFALSFPVESDVAPIARMFIFAILPDGEWGDSEKFEIENCLANKVDLSFSPAQSPPAS HAHLQVAAAPQSLCALRAVDQSVLLMKPEAΞLSVSSVYNLLTVKDLTNFPDNVDQQEEEQGHCPRPFFIHNG AIYVPLSSNEADIYSFLKGMGLKVFTNSKIRKPKSCSVIPSVSAGAVGQGYYGAGLGWERPYVPQLGTYNV
IPLNNEQSSGPVPETVRSYFPETWIWELVAVSSSGVAEVGVTVPDTITEWKAGAFCLSEDAGLGISSTASLR AFQPFFVELTMPYSVIRGEVFTLKATVLNYLPKCIRWVQLEVSSAFLAVPTEKNEESHCVCR GRKTVSWV VTPKSLGNVNFSVSAEAMQSLELCGNEWEVPEIKRKDTVIKTLLVEPEGIAKEETFNTLPCASGANVSEQL SLKLPSNWKESARASFSVLGGDILGSAMQNIQNLLQMPYGCGEQNMVLFAPNIYVLNYLNETQQLTQEIKA KAVGYLITGYQRQLNYKHQDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARSYIFIDEAHITQSLTWLSQMQ KDNGCFRSSGSLLNNAIKGGVEDEATLSAYVTIALLEIPLPVTNPIVRNALFCLESAWNVAKEGTHGSHVYT KALLAYAFSLLGKQNQNREILNSLDKEAVKDNLVHWERPQRPKAPVGHLYQTQAPSAΞVEMTSYVLLAYLTA QPAPTSGDLTSATNIVKWIMKQQNAQGGFSSTQDTWALHALSRYGAATFTRTEKTAQVTVQDSQTFSTNFQ VDNNNLLLLQQISLPELPGEYVITVTGERCVYLQTSMKYNILPEKEDSPFALKVQTVPQTCDGHKAHTSFQI SLTISYTGNRPASNMVIVDVKMVΞGFIPLKPTVKMLERSSSVSRTEVSNNHVLIYVEQVLTHQTLHFSFFVE QDIQIKNLKPATVKAYDYYETSDEFTFEEYNAPCSAGKV
A search of sequence databases reveals that the NOVIO amino acid sequence has 1348 of 1475 amino acid residues (91%) identical to, and 1387 of 1475 amino acid residues (94%) similar to, the 1482 amino acid residue ptnr:SWISSPROT-ACC:P20742 protein from Homo sapiens (Human) (Pregnancy Zone Protein Precursor (E = 0.0). Public amino acid databases include the GenBank databases, SwissProt, PDB and PLR.
NOV10 is predicted to be expressed in late-pregnancy sera because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:HSPZHEP|acc:X54380) a closely related mRNA for pregnancy zone protein homolog in species Homo sapiens.
The disclosed NOV10 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table IOC.
The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 10D. In the ClustalW ahgnment of the NOV10 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (i. e. , regions that may be required to preserve structural or
functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 10D. ClustalW Analysis of NOVIO i ) Novel NOVIO (SEQ ID NO: 36)
2) gi] 13551966] re |XP_006924.3 | (XM_006924) pregnancy-zone protein [Homo sapiens] (SEQ ID NO: 110)
3) gi I 6680608 | ref |NP_03140 .l| (NM_007376) alpha-2-macroglobulin [Mus musculus] (SEQ ID NO: 111)
4) gi j 1171932 I sp I P20740 I OVOS_CHICK OVOSTATIN PRECURSOR (OVOMACROGLOBULIN) (SEQ ID NO: 112) i
5) gi 224053 |prf I |1009174A macroglobulin alpha2 [Homo sapiens] (SEQ ID NO: 113)
6) gi 667896 | ref |NP_032671.1 | (NM_008645) murinoglobulin 1 [Mus musculus] (SEQ ID NO: 114)
10 20 30 40 50 60
70 80 90 100 110 120 107 106
119
310 320 330 340 350 360
970 980 990 1000 1010 1020
1030 1040 1050 1060 1070 1080
1090 1100 1110 1120 1130 1140
1210 1220 1230 1240 1250 1260
gi 1224053 |prf I | 1196 gi 6678964 I ref
1222
1270 1280 1290 1300 1310 1320
1390 1400 1410 1420 1430 1440
1450 1460 1470 1480 1490 1500
Tables 10E-10F lists the domain description from DOMAIN analysis results against
NOVIO. This indicates that the NOVIO sequence has properties similar to those of other proteins known to contain this domain.
Table 10E Domain Analysis ofNOVIO gnl |Pfam|pfam00207, A2M, Alpha-2- macroglobulin family. This family includes the C-terminal region o: the alpha-2- •nacroglobulin family. (SEQ ID NO: 115) CD-Length = 751 residues , 99.9% aligned Score = 785 bits (2028) , Expect = 0.0
Query: 730 GPVPETVRSYFPETWIWEL VAVSSSGVAEVGVrVPDTITEWKAGAFCLSEDAGLGISSTA 89 l l l l +I+II+II 1+ I II II ++
Sbjct: 2 DEDDITIRSYFPESWLWEVEEVDRSPVLTVNITLPDSITTWEILAVSLSNTKGLCVADPV 61
Query: 790 SLRAFQPFFVELTMPYSVIRGEVFTLKATVLNYLP-KCIRVWQLEVSSAFLAVPTEKNE 848
I II ll+ll +IIII+III l+l + llll +
Sbjct: 62 ELTVFQDFFLELRLPYSWRGEQVELRAVLYNYLPSQDIKWVQLEVEP LCQ 113
Query: 849 ESHCVCRNGRKTVSWWTPKSLGNVNFSVSAEAMQSLELCGNEWEVPEIKRKDTVIKTL 908
I I I I llll +1+1 l + l I III II l+lll
Sbjct: 114 AGFCSLATQRTRSSQSVRPKSLSSVSFPWWPLASGLSLVEWASVPEFFVKDAWKTL 173
Query: 909 LVEPEGIAKEETFNTLPC ASGANVSEQLSLKLPSNWKESARASFSVLGGDILGS 963 lllll llll ++I I III +1111 +1 I I II II +
Sbjct: 174 KVEPEGARKEETVSSLLLPPEHLGGGLEVSEVPALKLPDDVPDTEAEAVISVQ-GDPVAQ 232
Query: 964 AMQN IQNLLQMPYGCGEQNMVLFAPNIYVLNYLNETQQLTQ EIKAKAVGYL 1014 l+ll + III++I II +III+II+II I + + I 11+ +
Sbjct: 233 AIQNTLSGEGLNNLLRLPSGCGEQNMIYMAPTVYVLHYLDETWQWEKPGTKKKQKAIDLI 292
Query: 1015 ITGYQRQLNYKHQDGSYSTFGERYGRNQGNTWLTAFVLKTFAQARSYIFIDEAHITQSLT 1074 1111+ I I l+lll+l+llll II ++
Sbjct: 293 NKGYQRQLNYRKADGSYAAFLHR ASSTWLTAFVLKVFSQARNYVFIDEEHICGAVK 348
Query: 1075 WLS-QMQKDNGCFRSSGSLLNNAIKGGVED EATLSAYVTIALLEIPLPVTNPIVRN 1129
II lll+l II II +++I +1111 I I I +1+1 I
Sbjct: 349 WLILNQQKDDGVFRESGPVIHNEMKGGVGDDAEVEVTLTAFITIALLEAKLVCISPWAN 408
Query: 1130 ALFCLESAWNVAKEGTHGSHVYTKALLAYAFSLLGKQNQNREILNSLDKEAVK-DNLVHW 1188
II I+++ + + +1 lll ll III +1 I ++ +111 II +1 I II
Sbjct: 409 ALSILKASDYLLENYANGQRVYTLALTAYALALAGVLHKLKEILKSLKEELYKALVKGHW 468
Query: 1189 ERPQRPKAPVGHLYQTQAPSAEVEMTSYVLLAYLTAQPAPTSGDLTSATNIVKWIMKQQN 1248 iiii+n u i i +i linn m n i i i +111+ +11
Sbjct: 469 ERPQKPKDAPGHPYSPQPQAAAVEMTΞYALLALLTLLPFPKVE---MAPKWKWLTEQQY 525
Query: 1249 AQGGFSSTQDTVVALHALSRYGAATFTRTEKTAQVTVQ-DSQTFSTNFQVDNWNLLLLQQ 1307
III lll+ll II I II ll+l I +1 ++II+ III 11+
Sbjct: 526 YGGGFGSTQDTVMALQALSKYGIATPTHKEKNLSVTIQSPSGSFKSHFQILNNNAFLLRP 585
Query: 1308 ISLPE-LPGEYVITVTGERCVYLQTSMKYNILPEKEDSPFALKVQTVPQTCDGHK-AHTS 1365
+ II 111+ + 1 1+ +1 +1 +1 I II++III II I I I
Sbjct: 586 VELPLNEGFTVTAKVTGQGTLTLVTTYRYKVLDKKNTFCFDLKIETVPDTCVEPKGAKNS 645
Query: 1366 FQISLTISYTGNRPASNMVIVDVKMVSGFIPLKPTVKML- - ERSSSVSRTEVSNN V lY 1423
+1+ l l+l I I I 1+ +1 I 11+ 1+ llll+l
Sbjct: 646 DYLSICTRYAGSRSDSGMAIADISMLTGFIPLKPDLKKLENGVDRYVSKYEIDGNHVLLY 705
Query: 1424 VEQVLTHQTLHFSFFVEQDIQIKNLKPATVKAYDYYETSDEFTFEEY 1470
+++I +1 l + ll ++ l+ll+ll lllll II I
Sbjct: 706 LDKVSHSETECVGFKIHQDFEVGLLQPASVKVYDYYEP-DEQCTAFY 751
Table 10F Domain Analysis of NOVIO gnl I Pfam|pfam01835, A2M_N, Alpha-2-macroglobulin family N-terminal region. This family includes the N-terminal region of the alpha-2- macroglobulin family. (SEQ ID NO: 116) CD-Length = 620 residues, 98.4% aligned Score = 617 bits (1592) , Expect = le-177
Query: 19 SASDSNSTEPQYMVLVPSLLHTEAPKKGCVLLSHLNETVTVSASLESGRENR SLFTD 75
11+ +I+III+III+I II l+l II I II I I llll
Sb]Ct: 11 LFFDSSLQKPRYMVIVPSILRTETPEKVCVQLHDLNETVTVTVSLHΞFPGKRNLSΞLFTV 70
Query: 76 LVAEKDLFHCVSFTVPRI SASSEVAFLSIQIKGPTQDFRKRNTVLVLNTQSLVFVQ 131
I++ 1+ I +1+ +I+IIII I+++ llll + + lll+l
Sbjct: 71 LLSSKDLFHCVSFTVPQPGLFKSSKGEESFVWQVKGPTHTFKEKVTVLVSSRRGLVFIQ 130
Query: 132- TDKPMYKPGQTGKVRFRWSVDENFRPRNELVSLVSLQNPRRNRIAQWQSLKLEAGINQL 191 llll+l llll 11+11 lllll II 111+ II +++I 11+ 11+ III II II
Sbjct: 131 TDKPIYTPGQT--VRYRVFSVDENLRPLNELI-LVYIEDPEGNRVDQWEVNKLEGGIFQL 187
Query: 192 SFPLSSEPIQGSYRVWQTESGGR- - IQHPFTVEEFVLPKFEVKVQVPKIISIMDEKVNI 249
111+ + 111 I I l+l+lll III + II I
SbjC : 188 SFPIPSEPIQGTWKIVARYESGPESNYTHYFEVKEYVLPSFEVSITPPKPFIYYDNFKEF 247
Query: 250 TVCGCYRYTYGΞPVPGLVTLSVCRRYSLCRSD CHNTHSQLNSNG- -CITQQVHTKM 303
I I IIIII+IIII+ + + + + l+ ll I++I+I I
Sbj ct : 248 EVTICARYTYGKPVPGVAYVRFGVKDEDGKKELLAGLEERAKLLDGNGEICLSQEVLLKE 307
Query: 304 LQITNTGFEMK--LRVEARIREEGTGVEVTANRISEITNIVSKLKFVKVDSHFRQGIPFF 361 ii+ i I I i i ii +i +ι mill ιιι+ mil
Sbjct: 308 LQLKNEDLEGKSLYVAVAVIESEGGDMEEAELGGIKIVRSPYKLKFVKTPSHFKPGIPFF 367
Query: 362 AQVRLVDGKGVPIPNKLFFISVNDANYYSNATTNEQGLAQFSINTTSISVNKLFVRVSYK 421
+1 +11 l l ll +1 ll+llll ll+l II + II ++I
Sbjct: 368 LKVLWDPDGSPAPNVPVKVSAQDASYYSNGTTDEDGLAQFSINTSGISSLSITVRTNHK 427
Quer : 422 ESNNCSDNWWLDEFHTQTSHTAKHFFSPSKSYIHLKPIIGTLTCGQTQEIQAHYILNKQI 481 i + i + ii i mini i n u 11++11 +
Sbjct: 428 ELP EEVQAHAEAQATAYSTVSLSKSYIHLS-IERTLPCGPGVGEQANFILRGKS 480
Query: 482 LRDEKELTFYYLVKARGKISQSGIHVLSIEQGNSKGSFALSFPVESDVAPIARMFIFAIL 541 l + l l 1111+ ++II! ++I II l+ll II l+ll 1+ + II
Sb Ct: 481 LGELKILHFYYLIMSKGKIVKTGREPREPGQGL FSLSIPVTPDLAPSFRLVAYYIL 536
Query: 542 PDGEWGDSEKFEIENCLANKVDLSFSPAQS - - PPASHAHLQVAAAPQSLCALRAVDQSV 599
I IIII II ++1+1 III+IIIIH++ II i+i i IIII iinni+i
Sb Ct: 537 PQGEWADSVWIDVEDCCANKLDLSFSPSKDYRLPAQQVKLRVEADPQSLVALRAVDQAV 596
Query: 600 LLMKPEAELSVSSVYNLLTVKDLT 623 l+ll+l+ll+l 11+11 11
SbJCt: 597 YLLKPKAKLSMSKVYDLLEKSDLG 620
Pregnancy zone protein (PZP), one of the major pregnancy-associated plasma proteins (see 260100 for another example), was described by Smithies (1959) who used zone- electrophoresis in starch gels. PZP is a prominent constituent of late-pregnancy sera. In healthy, nonpregnant females and in males, PZP is present in trace amounts only: females, 10- 30 mg/1; males, less than 10 mg/1. During pregnancy, PZP levels may reach 1000-1400 mg/1 just before term. Sottrup- Jensen et al. (1984) showed that PZP closely resembles alpha-2- macroglobulin (103950) in structure. Both have a quaternary structure of 2 covalently bound
180-kD subunits which are further noncovalently assembled into a tetramer of 720 kD. Amino acid sequence of the 2 proteins are extensively homologous. Marynen et al. (1989) used in situ hybridization and somatic cell hybrid DNA analysis to demonstrate that PZP, alpha-2- macroglobulin, and an alpha-2-macroglobulin pseudogene mapped to human chromosome 12pl3-pl2.2. Although the function of PZP in pregnancy is largely unknown, its close structural relationship to alpha 2M suggests analogous proteinase binding properties and a potential for being taken up in cells by receptor-mediated endocytosis. I
The disclosed NOVIO nucleic acid of the invention encoding a Pregnancy Zone Protein Precursor -like protein includes the nucleic acid whose sequence is provided in Table 10A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 10A while still encodmg a protein that maintains its Pregnancy Zone Protein Precursor -like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 7 percent of the bases may be so changed.
The disclosed NOV10 protein of the invention includes the Pregnancy Zone Protein Precursor -like protein whose sequence is provided in Table 10B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 10B while still encoding a protein that maintains its Pregnancy Zone Protein Precursor -like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 46 percent of the residues may be so changed. The invention further encompasses antibodies and antibody fragments, such as FaD or
(Fat>)2, that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Pregnancy Zone Protein Precursor -like protein (NOV10) may function as a member of a "Pregnancy Zone Protein Precursor family". Therefore, the NOV10 nucleic acids and proteins identified here
may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOVIO nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in pregnancy, hypertensive toxemia, pre- eclampsia/eclampsia (gestational proteinuric hypertension), glomerular endotheliosis, cholestasis, and pruritic urticarial papules and plaques of pregnancy, and/or other pathologies and disorders.
NOVIO nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVIO substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti- NOVX Antibodies" section below. The disclosed NOVIO protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV11
A disclosed NOVl 1 nucleic acid of 2895 nucleotides (also referred to as SC139725617_A) encoding a novel Transmembrane Receptor UNC5H2-like protein is shown in Table 11 A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 31-33 and ending with a TGA codon at nucleotides 2866-2868. A putative untranslated region upstream from the initiation codon is underlined in Table 11 A. The start and stop codons are in bold letters.
Table 11A. NOV11 nucleotide sequence (SEQ ID NO:37).
CTCCAGGTCCGCCTGTCCCTGGAATGTTCTATGCAGGCCAGGGGTTATGGTAGAAATAGCGTCTTGTTGGCC GGGCTCCTCTGCTGGACCCCTTACCCAGCCTTAGCAGGCACTGATTCTGGCAGCGAGGTGCTCCCTGACTCC TTCCCGTCAGCGCCAGCAGAGCCGCTGCCCTACTTCCTGCAGGAGCCACAGGACGCCTACATTGTGAAGAAC AAGCCTGTGGAGCTCCGCTGCCGCGCCTTCCCCGCCACACAGATCTACTTCAAGTGCAACGGCGAGTGGGTC AGCCAGAACGACCACGTCACACAGGAAGGCCTGGATGAGGCCACCGGTCTGCGGGTGCGCGAGGTGCAGATC GAGGTGTCGCGGCAGCAGGTGGAGGAGCTCTTTGGGCTGGAGGATTACTGGTGCCAGTGCGTGGCCTGGAGC TCCGCGGGCACCACCAAGAGTCGCCGAGCCTACGTCCGCATCGCCTGTCTGCGCAAGAACTTCGATCAGGAG CCTCTGGGCAAGGAGGTGCCCCTGGACCATGAGGTTCTCCTGCAGTGCCGCCCGCCGGAGGGGGTGCCTGTG GCCGAGGTGGAATGGCTCAAGAATGAGGATGTCATCGACCCCACCCAGGACACCAACTTCCTGCTCACCATC GACCACAACCTCATCATCCGCCAGGCCCGCCTGTCGGACACTGCCAACTATACCTGCGTGGCCAAGAACATC GTGGCCAAACGCCGGAGCACCACTGCCACCGTCATCGTCTACGTGAATGGCGGCTGGTCCAGCTGGGCAGAG TGGTCACCCTGCTCCAACCGCTGTGGCCGAGGCTGGCAGAAGCGCACCCGGACCTGCACCAACCCCGCTCCA CTCAACGGAGGGGCCTTCTGCGAGGGCCAGGCATTCCAGAAGACCGCCTGCACCACCATCTGCCCAGTCGAT GGGGCGTGGACGGAGTGGAGCAAGTGGTCAGCCTGCAGCACTGAGTGTGCCCACTGGCGTAGCCGCGAGTGC ATGGCGCCCCCACCCCAGAACGGAGGCCGTGACTGCAGCGGGACGCTGCTCGACTCTAAGAACTGCACAGAT GGGCTGTGCATGCAAAGTGAGTCACAGTGTGGTCCTCCTGTCCCCGCAGTGCTGGAGGCCTCAGGGGATGCG GCGCTGTATGCGGGGCTCGTGGTGGCCATCTTCGTGGTCGTGGCAATCCTCATGGCGGTGGGGGTGGTGGTG TACCGCCGCAACTGCCGTGACTTCGACACAGACATCACTGACTCATCTGCTGCCCTGACTGGTGGTTTCCAC CCCGTCAACTTTAAGACGGCAAGGCCCAGTAACCCGCAGCTCCTACACCCCTCTGTGCCTCCTGACCTGACA GCCAGCGCCGGCATCTACCGCGGACCCGTGTATGCCCTGCAGGACTCCACCGACAAAATCCCCATGACCAAC TCTCCTCTGCTGGACCCCTTACCCAGCCTTAAGGTCAAGGTCTACAGCTCCAGCACCACGGGCTCTGGGCCA GGCCTGGCAGATGGGGCTGACCTGCTGGGGGTCTTGCCGCCTGGCACATACCCTAGCGATTTCGCCCGGGAC ACCCACTTCCTGCACCTGCGCAGCGCCAGCCTCGGTTCCCAGCAGCTCTTGGGCCTGCCCCGAGACCCAGGG AGCAGCGTCAGCGGCACCTTTGGCTGCCTGGGTGGGAGGCTCAGCATCCCCGGCACAGGTGTCAGCTTGCTG GTGCCCAATGGAGCCATTCCCCAGGGCAAGTTCTACGAGATGTATCTACTCATCAACAAGGCAGAAAGTACC CTGCCGCTTTCAGAAGGGACCCAGACAGTATTGAGCCCCTCGGTGACCTGTGGACCCACAGGCCTCCTGCTG TGCCGCCCCGTCATCCTCACCATGCCCCACTGTGCCGAAGTCAGTGCCCGTGACTGGATCTTTCAGCTCAAG ACCCAGGCCCACCAGGGCCACTGGGAGGAGGTGGTGACCCTGGATGAGGAGACCCTGAACACACCCTGCTAC TGCCAGCTGGAGCCCAGGGCCTGTCACATCCTGCTGGACCAGCTGGGCACCTACGTGTTCACGGGCGAGTCC TATTCCCGCTCAGCAGTCAAGCGGCTCCAGCTGGCCGTCTTCGCCCCCGCCCTCTGCACCTCCCTGGAGTAC AGCCTCCGGGTCTACTGCCTGGAGGACACGCCTGTAGCACTGAAGGAGGTGCTGGAGCTGGAGCGGACTCTG GGCGGATACTTGGTGGAGGAGCCGAAACCGCTAATGTTCAAGGACAGTTACCACAACCTGCGCCTCTCCCTC CATGACCTCCCCCATGCCCATTGGAGGAGCAAGCTGCTGGCCAAATACCAGGAGATCCCCTTCTATCACATT TGGAGTGGCAGCCAGAAGGCCCTCCACTGCACTTTCACCCTGGAGAGGCACAGCTTGGCCTCCACAGAGCTC ACCTGCAAGATCTGCGTGCGGCAAGTGGAAGGGGAGGGCCAGATATTCCAGCTGCATACCACTCTGGCAGAG ACACCTGCTGGCTCCCTGGACACTCTCTGCTCTGCCCCTGGCAGCACTGTCACCACCCAGCTGGGACCTTAT GCCTTCAAGATCCCACTGTCCATCCGCCAGAAGATATGCAACAGCCTAGATGCCCCCAACTCACGGGGCAAT GACTGGCGGATGTTAGCACAGAAGCTCTCTATGGACCGGTACCTGAATTACTTTGCCACCAAAGCGAGCCCC ACGGGTGTGATCCTGGACCTCTGGGAAGCTCTGCAGCAGGACGATGGGGACCTCAACAGCCTGGCGAGTGCC TTGGAGGAGATGGGCAAGAGTGAGATGCTGGTGGCTGTGGCCACCGACGGGGACTGCTGAGCCTCCTGGGAC AGCGGGCTGGCAGGG
hi a search of public sequence databases, the NOVl 1 nucleic acid sequence, located on chromosome 10 has 2425 of 2811 bases (86%) identical to a gb:GENBANK- ID:RNU87306|acc:U87306 mRNA from Rattus norvegicus (Rattus noi-vegicus transmembrane receptor Unc5H2 mRNA, complete eds (E = 0.0). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOVl 1 polypeptide (SEQ ID NO:38) encoded by SEQ D NO:37 has 945 amino acid residues and is presented in Table 1 IB using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVl 1 has a signal peptide and is likely to be localized in the plasma membrane with a certainty of 0.4600. In other embodiments, NOVl 1 may also be localized to the endoplasmic reticulum (membrane) with a certainty of 0.1000, the endoplasmic reticulum (lumen) with a certainty of 0.1000, or
extracellularly with a certainty of 0.1000. The most likely cleavage site for NOVIO is between positions 26 and 27: ALA-GT
Table 11B. Encoded NOV11 protein sequence (SEQ ID NO:38).
MQARGYGRNSVLLAGLLCWTPYPALAGTDSGSEVLPDSFPSAPAEPLPYFLQEPQDAYIVKNKPVELRCRAF PATQIYFKCNGEWVSQNDHVTQEGLDEATGLRVREVQIEVSRQQVEELFGLEDYWCQCVAWSSAGTTKSRRA YVRIACLRKNFDQEPLGKEVPLDHEVLLQCRPPEGVPVAEVEWLKNEDVIDPTQDTNFLLTIDHNLIIRQAR LSDTANYTCVAKNIVAKRRSTTATVIVYVNGGWSSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQ AFQKTACTTICPVDGAWTEWSKWSACSTECAHWRSRECMAPPPQNGGRDCSGTLLDSKNCTDGLCMQSESQC GPPVPAVLEASGDAALYAGLWAIFVWAILMAVGVWYRRNCRDFDTDITDSSAALTGGFHPVNFKTARPS NPQLLHPSVPPDLTASAGIYRGPVYALQDSTDKIPMTNSPLLDPLPSLKVKVYSSSTTGSGPGLADGADLLG VLPPGTYPSDFARDTHFLHLRSASLGSQQLLGLPRDPGSSVSGTFGCLGGRLSIPGTGVSLLVPNGAIPQGK FYEMYLLINKAESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKTQAHQGHWEE WTLDEETLNTPCYCQLEPRACHILLDQLGTYVFTGESYSRSAVKRLQLAVFAPALCTSLEYSLRVYCLEDT PVALKEVLELERTLGGYLVEEPKPLMFKDSYHNLRLSLHDLPHAHWRSKLLAKYQEIPFYHIWSGSQKALHC TFTLERHSLASTELTCKICVRQVEGEGQIFQLHTTLAETPAGSLDTLCSAPGSTVTTQLGPYAFKIPLSIRQ KICNSLDAPNSRGNDWRMLAQKLSMDRYLNYFATKASPTGVILDLWEALQQDDGDLNSLASALEΞMGKSEML VAVATDGDC
A search of sequence databases reveals that the NOVl 1 amino acid sequence has 855 of 945 amino acid residues (90%) identical to, and 892 of 945 amino acid residues (94%) similai- to, the 945 amino acid residue ptnr:SPTREMBL-ACC:O08722 protein from Rattus norvegicus (Rat) (transmembrane receptor UNC5H2 (E = 9.7e"307). Public amino acid databases include the GenBank databases, SwissProt, PDB and PLR. NOVl 1 is expressed in at least Epidermis. This information was derived by determining the tissue sources of the sequences that were included in the invention. In addition, the sequence is predicted to be expressed in brain because of the expression pattern of (GENBANK-ID: RNU87306) a closely related {Rattus norvegicus transmembrane receptor Unc5H2 mRNA, complete eds homolog. The disclosed NOVl 1 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 1 IC.
The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 11D. h the ClustalW alignment of the NOVl 1 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (t.e., regions that maybe required to preserve structural or functional properties), whereas non-liighlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 11D. ClustalW Analysis of NO 11
1) Novel N0V11 (SEQ ID N0 : 38 )
2) g I 6678505|ref |NP_0334S8.l] (NM_009472) UNC-5 homolog (C. elegans) 3 [Mus musculus] (SEQ ID NO: 117)
3) gi|3789765|gbJAAC67491.l| (AF055634) transmembrane receptor UNC5C [Homo sapiens] (SEQ ID NO:118)
4) gij 16933525 I ef |NP_003719.2 | (NM_003728) unc5 (C. elegans homolog) C; homolog of C. elegans transmembrane receptor Unc5 [Homo sapiens] (SEQ ID NO:119)
5) gi 1161596811 re |χp_042940.3 | (XM J42940) unc5 (C. elegans homolog) c [Homo sapiens] (SEQ ID NO -.120)
6) gι| 11559982 | re |NP_071543.l| (NM_022207) transmembrane receptor Unc5H2 [Rattus norvegicus] (SEQ ID NO: 121)
70 30 90 100 110 120
NOVll gγi31θl5BθDb.V iliiιMjaiMF- FiJΛrfΛ4 ^a5^d5Msι g^τoi5GL5!i TΞiR 106 gi|6678505|ref I LPHFLIEPEEAYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDHBVDERVDETSGLIVI 120 gi|3789765Jgb|A LPHFLIEPEEAYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDHi DERVDETSGLIVI 120 gijl6933525|ref LPHFLIEPEEAYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDHI DERVDETSGLIVI 120 gijl615968ljref LPHFLIEPEEAYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDH1VDERVDETSGLIVI 120 gijll559982 jref Fijjattuaaatii^GlaMs'qaGlaVTQBSLitaAT 106
NOVll
g 6678505 I ref ] ttMTt.itϋiiiiiHϊtritt.VΛtirattMfirittiu iMMotϊMtMia: 180 gi 3789765 jgbJA VSIEISRQQVEELFGPEDYWCQCVAWSSAGTTKSRKAYVRIAYLRKTFEQEPLGKEVSI 180 gi 16933525 ref VSIEISRQQVEELFGPΞDYWCQCVAWSSAGTTKSRKAYVRIAYLRKTFEQEPLGKEVSI 180 gi 16159681 ref VSIEISRQQVEELFGPEDYWCQCVAWSSAGTTKSRKAYVRIAYLRKTFEQEPLGKEVSI 180 gi 11559982 ref »W iMfeftlSMlllll)«adfiJ I [iaDWM3BAI»WiPli 166
190 200 210 220 230 240
NOVll ^^i^fcMr d^rfcivt^ ^ ^a^ ^i^imTOig iTiaLfcra^itittft^fe 226
91 6678505 ref I ilTrtli*i*ir»T«i-l.l.Wrt* iki>-|«lAafk**V*Y 4il»>l»Λ^^ ll!alt; 240 g 3789765 gb|A QEVLLQCRPPEGIPVAEVEWLKNEDIIDPΛEDRNFYITIDHNLIIKQARLSDTANYTC^ 240 gi 16933525 I ef QEVLLQCRPPEGIPVAEVEWLKNEDIIDP|EDRNFYITIDHNLIIKQARLSDTANYTC 240 gi 16159681 jref QEVLLQCRPPEGIPVAEVEWLKNEDIIDPSEDRNFYITIDHNLIIKQARLSDTANYTC* 240 gi 11559982 ref DHiw«Mi«aaaaciVigfeWi ft wwιT^ 226
430 440 450 460 470 480
NOVll bfjraτ^SA^T^j5HiMFl5τEl!gpS POL HPBrfiaaM 466 gi I 6678505 I ref I iaMBiiiτ>ra-ι»a*MtfaaBaaB8iτiB^jaBB- gi|3789765Jgb|A .LAVPPDLTSAAAMYRGPVYALHDVSDK gij 16933525 I ef JLAVPPDLTSAAAMYRGPVYALHDVSDK: g j 16159681 jref MΛUM-mmκdMMmuMi- LLAVPPDLTSAAAMYRGPVYALHDVSDK: gij 11559982 jref DTlWτffiHSA^Tggy3ffl3BSiFl5τ^a SNPOLLH Sii IT.TSB
610 620 630 640 650 660
910 920 930 940 950
Nθλ Til iMMmiάMbϊ SLQQDB§DIΪNS!E5S SUMLB VSTDSDC 945 gi 6678505 ref | jNLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLAAVLEEMGRHETVVΞLAAEGQ'ϊ 931 gi 3789765 gb|A LNLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLAAVLEEMGRHETWSLAAEGQΪ 931 gi 16933525 | ref LNLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLAAVLEEMGRHETWSLAAEGQΥ 931 gi 1615968] L|ref NLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLAAVLEEMGRHET SLAAEGQΥ 931 gi 1 11559982 I ef )RYLNYFATKiSPTGVILDLW] a QQDS DiHsESAJBHSKSlόl Lil •JTTDB C 945
Tables 1E-M list the domain descriptions from DOMAIN analysis results against NOVl 1. This indicates that the NOVl 1 sequence has properties similar to those of other proteins known to contain this domain.
Table HE Domain Analysis of NOVll gnl |Smart I smart00218, ZU5, Domain present in ZO-1 and Unc5-like netrin receptors; Domain of unknown function. (SEQ ID MO: 122) CD-Length = 104 residues, 100.0% aligned Score = 149 bits (376) , Expect = 7e-37
Query: 541 PGSSVSGTFGCLGGRLSIPGTGVSLLVPNGAIPQGKFYEMYLLINKAESTLPLSEGTQTV 600
I lllll llll I III IH I II+++ II I I + 1 +
Sbjct: 1 PSFLVSGTFDARGGRLRGPRTGVRLIIPPGAIPQGTRYTCYLWHDKLSTPPPLEEGETL 60 Query: 601 LSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKTQAHQG 644 in I III I I IIIII mil + in i + i
Sbjct: 61 LSPWECGPHGALFLRPVILEVPHCASLRPRDWEIVLLRSENGG 104
Table 11F Domain Analysis of NOVll gnl I Pfam|pf m00791, ZU5, ZU5 domain. Domain present in ZO-1 and Unc5- like netrin receptors Domain of unknown function. (SEQ ID NO: 123) CD-Length = 104 residues, 100.0% aligned Score = 147 bits (371), Expect = 3e-36
Query: 541 PGSSVSGTFGCLGGRLSIPGTGVSLLVPNGAIPQGKFYEMYLLINKAESTLPLSEGTQTV 600
1 lllll llll I III I++I I II+++ II I I
Sbjct: 1 SGFLVSGTFDARGGRLRGPRTGVRLIIPPGAIPQGTRYTCYLWHDKLSTPPPLEEGETL 60 Query: 601 LSPSVTCGPTGLLLCRPVILTMPHCAEVSARDWIFQLKTQAHQG 644 ui I III I I IIIII mn + MI i + i
Sbjct: 61 LSPWECGPHGALFLRPVILEVPHCASLRPRDWELVLLRSENGG 104
Table 11G Domain Analysis of NOVll gnl I Smart I smart00005, DEATH, DEATH domain, found in proteins involved in cell death (apoptosis) . ; Alpha-helical domain present in a variety of proteins with apoptotic functions. Some (but not all) of these domains form homotypic and heterotypic dimers. (SEQ ID 110:124) CD-Length = 95 residues, 99.0% aligned Score = 64.7 bits (156), Expect = 2e-ll
Query: 852 GPYAFKIPLSIRQKICNSLDAPNSRGNDWRMLAQKLSM-DRYLNYFATKAS PTGV 905
I I + |+|+ II + l+lll ll+ll + + ++ I++ +
Sbjct: 1 PPGAASLTELTREKLAKLLD--HDLGDDWRELARKLGLSEADIDQIETESPRDLAEQSYQ 58
Query: 906 ILDLWEALQQDDGDLNSLASALEEMGKSEMLVAVATD 942
+1 III + + l +l II +II+++ +++ Sbjct: 59 LLRLWEQREGKNATLGTLLEALRKMGRDDAVELLRSE 95
Table 11H Domain Analysis of NOVll gnl I Smart I smart00209, TSPl, Thrombospondin type 1 repeats; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta. (SEQ ID
NO: 125)
CD-Length = 51 residues, 100.0% aligned
Score = 62.4 bits (150), Expect = le-10
Query: 249 WSSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACTT-ICP 300
I II I I III I I lll l l + II II
Sbjct: 1 WGEWSEWSPCSVTCGGGVQTRTRCCNPPP--NGGGPCTGPDTETRACNEQPCP 51
Table HI Domain Analysis ofNOVll gnl | Smart | smart00209, TSPl, Thrombospondin type 1 repeats ; Type 1 repeats in thrombospondin-1 bind and activate TGF-beta. (SEQ ID NO:125) CD-Length = 51 residues, 98.0% aligned Score = 49.3 bits (116), Expect = le-06
Query: 305 WTEWSKWSACSTECAH-WRSRECMAPPPQNGGRDCSGTLLDSKNCTDGLC 353
I 11 l + l I II I ++I II III l + l +++ I + I
Sbjct: 1 WGEWSEWSPCSVTCGGGVQTRTRCCNPPPNGGGPCTGPDTETRACNEQPC 50
Table 11 J Domain Analysis of NOVll gnl|Pfam|pfam00531, death, Death domain. (SEQ ID NO -.126) CD-Length = 83 residues, 98.8% aligned Score = 59.7 bits (143), Expect = 7e-10
Query: 864 QKICNSLDAPNSRGNDWRMLAQKLSM-DRYLNYFATKA SPTGVILDLWEALQQDDG 918
Sbjct: 1 R ++E+LCιKLL u HI DDPi --LG iRDWRRL iAi+RKnLG +LSE +EE +ID+QIEH +ENPRLAS mPTYQ mLLDLmWEQRGGKNA 58
Query: 919 DLNSLASALEEMGKSEMLVAVATD 942
+ +I 11 +11+ + + + +
Sbjct: 59 TVGTLLEALRKMGRDDAVELLESA 82
Table UK Domain Analysis of NOVll gnl I Pfam|pfam00090, tsp_l, Thrombospondin type 1 domain. (SEQ ID
NO:127)
CD-Length = 48 residues, 91.7% aligned
Score = 49.3 bits (116), Expect = le-06
Query: 250 SSWAEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACT 296
I 11+1 + 1 111 +11 11 1 1 1 + 11
Sbjct: 1 SPWSEWSPCSVTCGKGIRTRQRTCNSPA GGKPCTGDAQETEACM 44
Table 11L Domain Analysis of NOVll gnl|Pfam|pfam00090, tsp_l, Thrombospondin type 1 domain. (SEQ ID
NO: 127)
CD-Length = 48 residues, 100.0% aligned
Score = 36.2 bits (82), Expect = 0.009
Query: 306 TEWSKWSACSTEC AHWRSRECMAPPPQNGGRDCSGTLLDSKNCTDGLC 353
+ i i+n H I i i i +ι ι ι+ |+| +++ | |
Sbjct: 1 SPWSEWSPCSVTCGKGIRTRQRTCNSPA GGKPCTGDAQETEACMMDPC 48
Table 11M Domain Analysis of NOVll gnl jSmart |smart00408, IGc2 , Immunoglobulin C-2 Type (SEQ ID N0:128) CD-Length = 63 residues, 87.3% aligned Score = 42.7 bits ( 99 ) , Expect = 9e-05
Query: 170 VLLQCRPPEGVPVAEVEWLKNEDVIDPTQDTNFLLTIDHNLIIRQARLSDTANYTCVAKN 229
I I I I I I I + 1 1 1 + + ++ ++ l l + l 1 + l l l l l + l Sbjct: 6 VTLTC-PASGDPVPNITWLKDGKPLPESR WASGSTLTIKNVSLEDSGLYTCVARN 60
PMID: 10908620, UI: 20370928 Netrin-1 promotes thalamic axon growth and is required for proper development of the thalamocortical projection. Braisted JE, Catalano SM, Stimac R, Kennedy TE, Tessier-Lavigne M, Shatz CJ, O'Leary DD Molecular Neurobiology Laboratory, The Salk Institute, La Jolla, CA 92037, USA.
The thalamocortical axon (TCA) projection originates in dorsal thalamus, conveys sensory input to the neocortex, and has a critical role in cortical development. We show that the secreted axon guidance molecule netrin-1 acts in vitro as an attractant and growth promoter for dorsal thalamic axons and is required for the proper development of the TCA projection in vivo. As TCAs approach the hypothalamus, they turn laterally into the ventral telencephalon and extend toward the cortex through a population of netrin-1 -expressing cells. DCC and neogenin, receptors implicated in mediating the attractant effects of netrin-1, are expressed in dorsal thalamus, whereas unc5h2 and unc5h3, netrin-1 receptors implicated in repulsion, are not. hi vitro, dorsal thalamic axons show biased growth toward a source of netrin-1, which can be abolished by netrin-1 -blocking antibodies. Netrin-1 also enhances overall axon outgrowth from explants of dorsal thalamus. The biased growth of dorsal thalamic axons toward the internal capsule zone of ventral telencephalic explants is attenuated, but not significantly, by netrin-1 -blocking antibodies, suggesting that it releases another attractant activity for TCAs in addition to netrin-1. Analyses of netrin-1 -/- mice reveal that the TCA proj ection through the ventral telencephalon is disorganized, their pathway is abnormally restricted, and fewer dorsal thalamic axons reach cortex. These findings demonstrate that
netrin-1 promotes the growth of TCAs through the ventral telencephalon and cooperates with other guidance cues to control their pathfinding from dorsal thalamus to cortex.
PMLD: 10366627, UI: 99296863 Netrin-3, a mouse homolog of human NTN2L, is highly expressed in sensory ganglia and shows differential binding to netrin receptors. Wang H, Copeland NG, Gilbert DJ, Jenkins NA, Tessier-Lavigne M Departments of Anatomy, and Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco, California 94143-0452, USA.
The netriris comprise a small phylo genetically conserved family of guidance cues important for guiding particular axonal growth cones to their targets. Two netrin genes, netrin- 1 and netrin-2, have been described in chicken, but in mouse so far a single netrin gene, an ortholog of chick netrin-1, has been reported. We report the identification of a second mouse netrin gene, which we name netrin-3. Netrin-3 does not appear to be the ortholog of chick netrin-2 but is the ortholog of a recently identified human netrin gene termed NTN2L ("netrin- 2-like"), as evidenced by a high degree of sequence conservation and by chromosomal localization. Netrin-3 is expressed in sensory ganglia, mesenchymal cells, and muscles during the time of peripheral nerve development but is largely excluded from the CNS at early stages of its development. The murine netrin-3 protein binds to netrin receptors of the DCC (deleted in colorectal cancer) family [DCC and neogenin] and the UNC5 family (UNC5H1, UNC5H2 and UNC5H3). Unlike chick netrin-1, however, murine netrin-3 binds to DCC with lower affinity than to the other four receptors. Consistent with this finding, although murine netrin-3 can mimic the outgrowth-promoting activity of netrin-1 on commissural axons, it has lower specific activity than netrin-1. Thus, like netrin-1, netrin-3 may also function in axon guidance during development but may function predominantly in the development of the peripheral nervous system and may act primarily through netrin receptors other than DCC. PMID: 10399920, UI: 99325507 A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Hong K, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, Stein E Department of Biology, University of California, San Diego, 92093, USA.
Netrins are bifunctional: they attract some axons and repel others. Netrin receptors of the Deleted in Colorectal Cancer (DCC) family are implicated in attraction and those of the
UNC5 family in repulsion, but genetic evidence also suggests involvement of the DCC protein UNC-40 in some cases of repulsion. To test whether these proteins form a receptor complex for repulsion, we studied the attractive responses of Xenopus spinal axons to netrin-1, which are mediated by DCC. We show that attraction is converted to repulsion by expression of
UNC5 proteins in these cells, that this repulsion requires DCC function, that the UNC5 cytoplasmic domain is sufficient to effect the conversion, and that repulsion can be initiated by netrin-1 binding to either UNC5 or DCC. The isolated cytoplasmic domains of DCC and UNC5 proteins interact directly, but this interaction is repressed in the context of the full- length proteins. We provide evidence that netrin-1 triggers the formation of a receptor complex of DCC and UNC5 proteins and simultaneously derepresses the interaction between their cytoplasmic domains, thereby converting DCC-mediated attraction to UNC5 DCC- mediated repulsion.
PMID: 10341242, UI: 99274743 Floor plate and netrin-1 are involved in the migration and survival of inferior olivary neurons. Bloch-Gallego E, Ezan F, Tessier-Lavigne M, Sotelo C histitut National de la Sante et de la Recherche Medicale U106, Hopital de la Salpetriere, 75013 Paris, France.
During their circumferential migration, the nuclei of inferior olivary neurons translocate within their axons until they reach the floor plate where they stop, although their axons have already crossed the midline to project to the contralateral cerebellum. Signals released by the floor plate, including netrin-1, have been implicated in promoting axonal growth and chemoattraction during axonal pathfinding in different midline crossing systems. In the present study, we report experiments that strongly suggest that the floor plate could also be involved in the migration of inferior olivary neurons. First, we show that the pattern of expression of netrin receptors DCC (for deleted in colorectal cancer), neogenin (a DCC-related protein), and members of the Unc5 family in wild-type mice is consistent with a possible role of netrins in directing the migration of precerebellar neurons from the rhombic lips. Second, we have studied mice deficient in netrin-1 production. In these mice, the number of inferior olivary neurons is remarkably decreased. Some of them are located ectopically along the migration stream, whereas the others are located mediovenfrally and form an afrophic inferior olivary complex: most subnuclei are missing. However, axons of the remaining olivary cell bodies located in the vicinity of the floor plate still succeed in entering their target, the cerebellum, but they establish an ipsilateral projection instead of the normal contralateral projection. In vitro experiments involving ablations of the midline show a fusion of the two olivary masses normally located on either side of the ventral midline, suggesting that the floor plate may function as a specific stop signal for inferior olivary neurons. These results establish a requirement for netrin-1 in the migration of inferior olivary neurons and suggest that it may function as a specific guidance cue for the initial steps of the migration from the rhombic lips and then later in the development of the normal crossed projection of the inferior olivary
neurons. They also establish a requirement for netrin- 1, either directly or indirectly, for the survival of inferior olivary neurons.
PMID: 9126742 Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors. Leonardo ED, Hinck L, Masu M, Keino-Masu K, Ackerman SL, Tessier-Lavigne M Howard Hughes Medical Institute, Department of Anatomy, Programs in Cell and
Developmental Biology and Neuroscience, University of California, San Francisco 94143- 0452, USA.
In the developing nervous system, migrating cells and axons are guided to their targets by cues in the extracellular environment. The netrins are a family of phylogenetically conserved guidance cues that can function as diffusible atfractants and repellents for different classes of cells and axons. hi vertebrates, insects and nematodes, members of the DCC subfamily of the immunoglobulin superfamily have been implicated as receptors that are involved in migration towards netrin sources. The mechanisms that direct migration away from netrin sources (presumed repulsions) are less well understood. In Caenorhabditis elegans, the transmembrane protein UNC-5 (ref. 14) has been implicated in these responses, as loss of unc-5 function causes migration defects and ectopic expression of unc-5 in some neurons can . redirect their axons away from a netrin source. Whether UNC-5 is a netrin receptor or simply an accessory to such a receptor has not, however, been defined. We now report the identification of two vertebrate homologues of UNC-5 which, with UNC-5 and the product of the mouse rostral cerebellar malformation gene (rcrn), define a new subfamily of the immunoglobulin superfamily, and whose messenger RNAs show prominent expression in various classes of differentiating neurons. We provide evidence that these two UNC-5 homologues, as well as the rcm gene product, are netrin-binding proteins, supporting the hypothesis that UNC-5 and its relatives are netrin receptors. The disclosed NOVl 1 nucleic acid of the invention encoding a Transmembrane
Receptor UNC5H2 -like protein includes the nucleic acid whose sequence is provided in Table 11A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 11 A while still encoding a protein that maintains its Transmembrane Receptor UNC5H2-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way
of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 14 percent of the bases may be so changed.
The disclosed NOVl 1 protein of the invention includes the Transmembrane Receptor UNC5H2-like protein whose sequence is provided in Table 1 IB. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 1 IB while still encoding a protein that maintains its Transmembrane Receptor UNC5H2-like activities and physiological functions, or a functional fragment thereof, hi the mutant or variant protein, up to about 39 percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fa or (Fab)2; that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Transmembrane Receptor UNC5H2-like protein (NOVl 1) may function as a member of a "Transmembrane Receptor UNC5H2 family". Therefore, the NOVl 1 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOVl 1 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and pathologies.
NOVl 1 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVl 1 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti- NOVX Antibodies" section below. The disclosed NOVl 1 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in
understanding of pathology of the disease and development of new drug targets for various disorders.
NOV12 A disclosed NOVl 2 nucleic acid of 192 nucleotides (also referred to as Curagen
Accession No. SC134999661_A) encoding a novel Thymosin -like protein is shown in Table 12A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 31-33 and ending with a TAA codon at nucleotides 175-177. Putative untranslated regions upstream from the initiation codon and downstream of the termination codon are underlined in Table 12 A. The start and stop codons are in bold letters.
Table 12A. NOV12 nucleotide sequence (SEQ ID NO:39).
TTTTTCTTTTCAGGCTTTCTTCTAGTCAAGATGAGTGATAAACCAGACTTGTCGGAAGTGGAGAAGTTTGAC AGGTCAAAACTGAAGAAAACTAATACTGAAGAAAAAAATACTCTTCCCTCAAAGGAAAGTAAGTCATGTGGG GTTCTACTGGAAACAAACAATAGAGGAAGTTAATAGGTTCAGTAAATA
In a search of public sequence databases, the NOV12 nucleic acid sequence, localized to the X chromosome, has 192 of 192 bases (100%) identical to a gb:GENBANK- ID:HSV362H12|acc:Z70227 mRNA from Homo sapiens (E = 2.8e"36). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOV12 polypeptide (SEQ LO NO:40) encoded by SEQ ID NO:39 has
48 amino acid residues and is presented in Table 12B using the one-letter amino acid code.
Signal P, Psort and/or Hydropathy results predict that NOV12 has no signal peptide and is likely to be localized to the nucleus with a certainty of 0.5392. In other embodiments, NOV12 may also be localized to the microbody (peroxisome) with acertamty of 0.3000, the mitochondrial membrane space with a certainty of 0.1000, or to the lysosome (lumen) with a certainty of 0.1000.
Table 12B. Encoded NOV12 protein sequence (SEQ ID NO:40).
MSDKPDLSEVEKFDRSKLKKTNTEEKNTLPSKESKSCGVLLETNNRGS
A search of sequence databases reveals that the NOVl 2 amino acid sequence has 33 of 34 amino acid residues (97%) identical to, and 34 of 34 amino acid residues (100%) similar to, the 45 amino acid residue ptnr:pir-id: JC5274 protein from human thymosin beta (E = 1.6e"12). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
NOV12 is expressed in at least the following tissues: Brain, Foreskin, Heart, Kidney, Lung, Mammary gland/Breast, Muscle, Parathyroid Gland, Peripheral Blood, Prostate, Testis, Uterus. This information was derived by determining the tissue sources of the sequences that were included in the invention, hi addition, the sequence is predicted to be expressed in Brain, Breast, and Prostate because of the expression pattern of (GENBANK-ID: HSV362H12) a closely related {Human DNA sequence from cosmid V362H12, between markers DXS366 and DXS87 on chromosome X homolog.
The disclosed NOVl 2a polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 12C.
The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 12D. In the ClustalW alignment of the NOV12 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (t.e., regions that may be required to preserve stmctural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 12D. ClustalW Analysis of NOV12 1) Novel NOV12 (SEQ ID NO: 40)
9) gi I 2143995 | ir | 1152084 thymosin beta-4 precursor - rat (fragment) (SEQ ID NO -.129)
LFAQLAQ LPAl j JMHBBST IEQHKQAGΞ|
Thymosin beta-4 is a small polypeptide whose exact physiological role is not yet known [1] . It was first isolated as a thymic hormone that induces terminal deoxynucleotidylfransferase. It is found in high quantity in thymus and spleen but is widely distributed in many tissues. It has also been shown to bind to actin monomers and thus to inhibit actin polymerization [2] . • function: exact physiological role is not yet known, thymic hormone that induces terminal deoxynucleotidylfransferase. can bind to actin monomers and
thus to inhibit actin polymerization. • function: hematopoietic system regulatory peptide has inhibitory activity on the proliferation of hematopoeitic pluripotent stem cells. • subcellular location: cytoplasmic. • tissue specificity: originally found in thymus but it is widely distributed in many tissues. ■ induction: by alpha-interferon, nerve and fibroblast growth factors. • similarity: belongs to the thymosin beta family. Blocks protein family: BL00500 Thymosm beta-4 family proteins.
PMLD: 2325669, UI: 90220652 Thymosin beta 4 is expressed in ROS 17/2.8 osteosarcoma cells in a regulated manner. Atkinson MJ, Freeman MW, Kronenberg HM Endocrine Unit, Massachusetts General Hospital, Boston. The differential expression of RNAs between the closely related rat osteosarcoma cell lines ROS 17/2.8 and ROS 25/1 was used to identify genes whose expression is associated with the osteoblast phenotype. Thymosin beta 4 cDNA was cloned from an ROS 17/2.8 complimentary DAN library on the basis of its differential hybridization with radiolabeled cDNA prepared from ROS 17/2.8 and ROS 25/1 cells. Northern blot analysis confirmed that thymosin beta 4, hitherto a putative immunodulatory hormone, was indeed differentially expressed. Steady state mRNA levels were severalfold higher in ROS 17/2.8 cells exhibiting an osteoblast-like phenotype, compared with the less osteoblast-like ROS 25/1. Thymosin beta 4 transcripts were also detected in rat UMR 106 osteosarcoma cells and in intact neonatal and fetal rat calvaria. Sequence analysis of the cDNA indicated that thymosm beta 4 transcripts may arise by processing at a more distal polyadenylation signal. Treatment of ROS 17/2.8 cells with dexamethasone increased, while addition of 1,25-dihydroxyvitamin D3 decreased thymosin beta 4 mRNA. The phenotype-dependent expression in the ROS cells and the response to steroid hormone suggest that thymosin beta 4 expression contributes to the osteoblast phenotype. PMLD: 10777749, UI: 20241883 De La Cruz EM, Ostap EM, Brundage RA, Reddy
KS, Sweeney HL, Safer D Pennsylvania Muscle Institute and Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 USA. enriquem@mail.med.upemi.edu
Thymosin-beta(4) (Tbeta(4)) binds actin monomers stoichiometrically and maintains the bulk of the actin monomer pool in metazoan cells. Tbeta(4) binding quenches the fluorescence of N-iodoacetyl-N'-(5-sulfo-l-naphthyl)ethylenediamine (AEDANS) conjugated to Cys(374) of actin monomers. The K(d) of the actin-Tbeta(4) complex depends on the cation and nucleotide bound to actin but is not affected by the AEDANS probe. The different stabilities are determined primarily by the rates of dissociation. At 25 degrees C, the free
energy of Tbeta(4) binding MgATP-actin is primarily enthalpic in origin but entropic for CaATP-actin. Binding is coupled to the dissociation of bound water molecules, which is greater for CaATP-actin than MgATP-actin monomers. Proteolysis of MgATP-actin, but not CaATP-actin, at Gly(46) on subdomain 2 is >12 times faster when Tbeta(4) is bound. The C terminus of Tbeta(4) contacts actin near this cleavage site, at His(40). By tritium exchange, Tbeta(4) slows the exchange rate of approximately eight rapidly exchanging amide protons on actin. We conclude that Tbeta(4) changes the conformation and structural dynamics ("breathing") of actin monomers. The conformational change may reflect the unique ability of Tbeta(4) to sequester actin monomers and inhibit nucleotide exchange. PMLD: 10581087, UI: 20048164 Young JD, Lawrence AJ, MacLean AG, Leung BP,
Mchrnes IB, Canas B, Pappin DJ, Stevenson RD Division of hifection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK.
The possibility that glucocorticoids upregulate the expression of anti-inflairimatory mediators is an exciting prospect for therapy in inflammatory diseases, because these molecules could give the therapeutic benefits of steroids without toxic side effects.
Supematants from monocytes and macrophages cultured in the presence of glucocorticoids increase the dispersion of neutrophils from a cell pellet in the capillary tube migration assay. This supernatant factor, unlike other neutrophil agonists, promotes dispersive locomotion of neutrophils at uniform concentration, lowers their adhesion to endothelial cells, inhibits their chemotactic response to fMLP and induces distinctive morphological changes. Here we show that thymosin beta4 sulfoxide is generated by monocytes in the presence of glucocorticoids and acts as a signal to inhibit an inflammatory response. In vitro, thymosm beta4 sulfoxide inhibited neutrophil chemotaxis, and in vivo, the oxidized peptide, but not the native form, was a potent inhibitor of carrageenin-induced edema in the mouse paw. Thymosin beta4 is unique, because oxidation attenuates its intracellular G-actin sequestering activity, but greatly enhances its extracellular signaling properties. This description of methionine oxidation conferring extracellular function on a cytosolic protein may have far-reaching implications for future strategies of anti-inflammatory therapy.
PMID: 10469335, UI: 99398473 MalindaKM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK Craniofacial Developmental Biology and
Regeneration Branch, National Institute of Dental and Craniofacial Research, N H, Bethesda, MD 20892-4370, USA.
Angiogenesis is an essential step in the repair process that occurs after injury. In this study, we investigated whether the angiogenic thymic peptide thymosm beta4 (Tbeta4)
enhanced wound healing in a rat full thickness wound model. Addition of Tbeta4 topically or., intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61 > at 7 d post- wounding. Treated wounds also contracted at least 11% more than controls by day 7. Increased collagen deposition and angiogenesis were observed in the treated wounds. We also found that Tbeta4 stimulated keratinocyte migration in the Boyden chamber assay. After 4-5 h, migration was stimulated 2-3-fold over migration with medium alone when as little as 10 pg of Tbeta4 was added to the assay. These results suggest that Tbeta4 is a potent wound healing factor with multiple activities that may be useful in the clinic.
The disclosed NOV12 nucleic acid of the invention encoding a Thymosin -like protein includes the nucleic acid whose sequence is provided in Table 12A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 12A while still encoding a protein that maintains its Thymosin-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject, hi the mutant or variant nucleic acids, and their complements, up to about 10 percent of the bases may be so changed.
The disclosed NOV12 protein of the invention includes the Thymosin-like protein whose sequence is provided in Table 12B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 12B while still encodmg a protein that maintains its Thymosin -like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 53 percent of the residues maybe so changed. The invention further encompasses antibodies and antibody fragments, such as Fa or
(Fab)2,that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Thymosin-like protein (NOV12) may function as a member of a "Thymosm family". Therefore, the NOV12 nucleic acids and proteins identified here may be useful in potential therapeutic applications
implicated in (but not limited to) various pathologies and disorders. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOV12 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various pathologies and disorders.
NOV12 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV12 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti- NOVX Antibodies" section below. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOV13
A disclosed NOV13 nucleic acid of 594 nucleotides (also referred to as Curagen Accession No. AC025256_da7) encoding a novel neuromodulin-like protein is shown in Table 13A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 193-195 and ending with a TAA codon at nucleotides 535-537. The untranslated regions are underlined and the start and stop codons are in bold letters in Table 13 A.
Table 13A. NOV13 nucleotide sequence (SEQ ID NO:41).
CTGGGTTTTGGCGGCCGATCAGGCGCAGCCGGTGTACCTGCGTGACCAGGTCGCCACGCCGAAAGCACCGCC GGCATGACAACTGGTCGGATGCTTGGCGTCAGGATTCCTTCGGCATTTGCCAAGGACGCAGCCCGCCGCTAC ATTGCCAGCACTGTCCCTTGTTCAGCCGAGCCCACCGAGCAGTCCTAGATGCGGATCGACGGTTACCTACCT TCCTACTCGCCAGATCGTGGCCCCCGTTCGGGGACTGCGGTCACGCCCTATCGAGAGGCGCAGCGGGAGGTC GAGGCTCAGCGTGAACAGCCGGCTGCCCCAGCCAGCAGCCAGGGGCTGGAGCAGGCGCCGCAGATTCGCCGC GTGCAGGCCAGCAGCAGTAACACCGATAGCCTGCCGACCCGCTCGCAGGACCTCGGTTATCAACAACCTACG TTGAGCAACCGTGCCGCTCAGGCGTTGGCCAGCTACAGCACCACCGCCGCTTACGCCAGCGAGTACGATGCG CAGGAAGTGCTCGGCCTCGATCTCTACGCGTAACCCCGTTTCACGGCGTGGGTCAGCCCCTCAGCTGGACCG TCGCATAGATCGATGAGC
In a search of public sequence databases, the NOV13 nucleic acid sequence, located on the ql3 region of chromosome 12, has 126 of 204 bases (61%) identical to a gb:GENBANK- ID:AF072132|acc:AF072132.1 mRNA from Pseudomonas aeruginosa Hypothetical 12.1 Kda
Protein (E = 0.0073). Public nucleotide databases include all GenBank databases and the GeneSeq patent database.
The disclosed NOVl 3 polypeptide (SEQ ID NO 42) encoded by SEQ ID NO:41 has 114 amino acid residues and is presented in Table 13B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVl 3 has no signal peptide and is likely to be localized in the cytoplasm with a certainty of 0.6500.
Table 13B. Encoded NOV13 protein sequence (SEQ ID NO:42).
MRIDGYLPSYSPDRGPRSGTAVTPYREAQREVEAQREQPAAPASSQGLEQAPQIRRVQASSSNTDSLPTRSQ DLGYQQPTLSNRAAQALASYSTTAAYASEYDAQEVLGLDLYA
A search of sequence databases reveals that the NOVl 3 amino acid sequence has 68 of 115 amino acid residues (59%) identical to, and 87 of 115 amino acid residues (75%) similar to, the 115 amino acid residue ptnr:TREMBLNEW-ACC: AAG07072 protein from Pseudomonas aeruginosa Hypothetical 12.1 KDA Protein (E = ie"27). Public amino acid databases include the GenBank databases, SwissProt, PDB and PIR.
Neuromodulin (GAP -43), neurogranin (RC3), and PEP-19 are small acid-stable proteins that bind calcium-poor calmodulin through a loosely conserved IQ-motif. Even though these proteins have been known for many years, much about their function in cells is not understood. It has recently become appreciated that calmodulin activity in cells is tightly controlled and that pools of otherwise free calmodulin are sequestered so as to restrict its availability for activating calcium/calmodulin-dependent enzymes. Neuromodulin, neurogranin, and PEP-19 appear to be major participants in this type of regulation. One way in which they do this is by providing localized increases in the concentration of calmodulin in cells so that the maximal level of target activation is increased. Additionally, they can function as calmodulin antagonists by directly inhibiting the association of calcium calmodulin with enzymes and other proteins. Although neuromodulin, neurogranin, and PEP-19 were early representatives of the small IQ-motif-containing protein family, newer examples have come to light that expand the number of cellular systems through which the IQ-peptide/calmodulin interaction could regulate biological processes including gene transcription. It is the purpose of this review to examine the behavior of neuromodulin, neurogranin, and PEP-19 in paradigms that include both in vitro and in situ systems in order to summarize possible biological consequences that are linked to the expression of this type of protein. The use of proteimprotein interaction chromatography is also examined in the recovery of anew calmodulin-binding peptide, CAP-19 (ratMBFl). Consistent with earlier predictions, at least
one function of small IQ-motif proteins appears to be that they lessen the extent to which calcium-cahnodulin-dependent enzymes become or stay activated. It also appears that these polypeptides can function to selectively inhibit activation of intracellular targets by some agonists while simultaneously permitting activation of these same targets by other agonists. Much of the mechanism for how this occurs is unknown, and possible explanations are examined. One of the biological consequences for a cell that expresses a calmodulin- regulatory protein could be an increased resistance to calcium-mediated toxicity. This possibility is examined for cells expressing PEP-19 and both anatomical and cell-biological data is described. The study of IQ-motif-containing small proteins has stimulated considerable thought as to how calcium signaling is refined in neurons. Current evidence suggests that signaling through calmodulin is not a fulminating and homogenous process but a spatially limited and highly regulated one. Data from studies on neuromodulin, neurogranin, and PEP- 19 suggest that they play an important role in establishing some of the processes by which this regulation is accomplished. The disclosed NOVl 3 nucleic acid of the invention encoding a Neuromodulin -like protein includes the nucleic acid whose sequence is provided in Table 13 A or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases may be changed from the corresponding base shown in Table 13A while still encoding a protein that maintains its Neuromodulin-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 39 percent of the bases may be so changed. The disclosed NOV13 protein of the invention includes the Neuromodulin-like protein whose sequence is provided in Table 13B. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 13B while still encoding a protein that maintains its Neuromodulin -like activities and
physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 30 percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fa or (Fab)2, that bind immunospecifically to any of the proteins of the invention. The above defined information for this invention suggests that this Neuromodulin-like protein (NOV13) may function as a member of a "Neuromodulin family". Therefore, the NOVl 3 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOV13 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various pathologies and disorders.
NOVl 3 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVl 3 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti- NOVX Antibodies" section below. The disclosed NOVl 3 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders. NOV14
NOVl 4 includes three novel Prostatin Precursor -like proteins disclosed below. The disclosed sequences have been named NOV14a and NOV14b.
NOV14a
A disclosed NOV14a nucleic acid of 1102 nucleotides (also referred to as CG56075- 01) encoding a novel Prostatin Precursor-like protein is shown in Table 14A. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 19-21 and ending with aTGG codon at nucleotides 1051-1053. A putative untranslated region upstream from the initiation codon is underlined in Table 14A. The start and stop codons are in bold letters.
Because the stop codon is not a traditional termination codon, NOV14a could be a partial reading frame. Therefore, it could extend further in the 3' direction.
Table 14A. NOV14a nucleotide sequence (SEQ ID NO:43).
GGGCCCTTGTCCTGGGCCATGGCCCAGAAGGGGGTCCTGGGGCCTGGGCAGCTGGGGGCTGTGGCCAATTCT GACTCATACTCACTTTACGGGTTGGTGCCGTCCGGACCCGCTAGGGGCCCCCCGTACTGCGGGCGCCCTGAG CCCTCGGCCCGCATCGTGGGGGGCTCAAACGCGCAGCCGGGCACCTGGCCTTGGC'AAGTGAGCCTGCACCAT GGAGGTGGCCACATCTGCGGGGGCTCCCTCATCGCCCCCTCCTGGGTCCTCTCCGCTGCTCACTGTTTCATG ACGAATGGGACGTTGGAGCCCGCGGCCGAGTGGTCGGTACTGCTGGGCGTGCACTCCCAGGACGGGCCCCTG GACGGCGCGCACACCCGCGCAGTGGCCGCCATCGTGGTGCCGGCCAACTACAGCCAAGTGGAGCTGGGCGCC GACCTGGCCCTGCTGCGCCTGGCCTCACCCGCCAGCCTGGGCCCCGCCGTGTGGCCTGTCTGCCTGCCCCGC GCCTCACACCGCTTCGTGCACGGCACCGCCTGCTGGGCCACCGGCTGGGGAGACGTCCAGGAGGCAGATCCT CTGCCTCTCCCCTGGGTGCTACAGGAAGTGGAGCTAAGGCTGCTGGGCGAGGCCACCTGTCAATGTCTCTAC AGCCAGCCCGGTCCCTTCAACCTCACTCTCCAGATATTGCCAGGGATGCTGTGTGCTGGCTACCCAGAGGGC CGCAGGGACACCTGCCAGGGTGACTCTGGGGGGCCCCTGGTCTGTGAGGAAGGCGGCCGCTGGTTCCAGGCA GGAATCACCAGCTTTGGGTTTGGCTGTGGACGGAGAAACCGCCCTGGAGTTTTCACTGCTGTGGCTACCTAT GAGGCATGGATACGGGAGCAGGTGATGGGTTCAGAGCCTGGGCCTGCCTTTCCCACCCAGCCCCAGAAGACC CAGTCAGATTGTTTACATCAAACGGCATTCCTGGATTCTGCCAGAATCCTTTTGAGGCCCTTGTCCCATATA TCAGTAGGAGTCTCAACTGGGACCAAAAGCCTTGTCCTCCCCTGGCTCTCTCCACACTCTCTCCTGGGCCTC TGGGGGTTCTGATGGGGCCTCC
In a search of public sequence databases, the NOVl 4a nucleic acid sequence, located on chromosome 16 has 469 of 795 bases (58%) identical to a gb:GENBANK- LO:BTTRYPTMR|acc:X94982.1 mRNA from Bos taurus (B.taurus mRNA for tryptase) (E = 2.7e"21). Public nucleotide databases include all GenBank databases and the GeneSeq patent database. The disclosed NOV14a polypeptide (SEQ ID NO:44) encoded by SEQ ID NO:43 has
344 amino acid residues and is presented in Table 14B using the one-letter amino acid code. Signal P, Psort and/or Hydropathy results predict that NOVl 4a has no signal peptide and is likely to be localized extracellularly with a certainty of 0.4500. hi other embodiments, NOV14a may also be localized to the microbody (peroxisome) with a certainty of 0.4370, the lysosome (lumen) with a certainty of 0.3047, or to the mitochondrial matrix space with a certainty of 0.1000.
Table 14B. Encoded NOV14a protein sequence (SEQ ID NO:44).
MAQKGVLGPGQLGAVANSDSYSLYGLVPSGPARGPPYCGRPEPSARIVGGSNAQPGTWPWQVSLHHGGGHIC GGSLIAPSWVLSAAHCFMTNGTLEPAAEWSVLLGVHSQDGPLDGAHTRAVAAIWPANYSQVELGADLALLR LASPASLGPAVWPVCLPRASHRFVHGTACWATGWGDVQEADPLPLPWVLQEVELRLLGEATCQCLYSQPGPF NLTLQILPGMLCAGYPEGRRDTCQGDSGGPLVCEEGGRWFQAGITSFGFGCGRRNRPGVFTAVATYEAWIRE QVMGSEPGPAFPTQPQKTQSDCLHQTAFLDSARILLRPLSHISVGVSTGTKSLVLP
A search of sequence databases reveals that the NOV14a amino acid sequence has 149 of 340 amino acid residues (43%) identical to, and 197 of 340 amino acid residues (57%) similar to, the 343 amino acid residue ptnr:SWISSPROT-ACC:Q16651 protein from Homo
sapiens (Human) (Prostasin Precursor (EC 3.4.21.-)) (E = 3.9e"65). Public amino acid databases include the GenBank databases, SwissProt, PDB and PLR.
NOV14a is expressed in at least Heart. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources. hi addition, the sequence is predicted to be expressed in Heart because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:BTTRYPTMR|acc:X94982.1) a closely related B. taurus mRNA for tryptase homolog.
NOV14b
A disclosed NOV14b nucleic acid of 1102 nucleotides (also referred to as CG56075- 01) encoding a novel Prostatin Precursor -like protein is shown in Table 14C. An open reading frame was identified beginning with an ATG initiation codon at nucleotides 19-21 and ending with a TGA codon at nucleotides 1090-1092. A putative untranslated region upstream from the initiation codon is underlined in Table 14C. The start and stop codons are in bold letters.
Table 14C. NOV14b nucleotide sequence (SEQ ID NO:45).
GGGCCCTTGTCCTGGGCCATGGCCCAGAAGGGGGTCCTGGGGCCTGGGCAGCTGGGGGCTGTGGCCAATTCT GACTCATACTCACTTTACGGGTTGGTGCCGTCCGGACCCGCTAGGGGCCCCCCGTACTGCGGGCGCCCTGAG CCCTCGGCCCGCATCGTGGGGGGCTCAAACGCGCAGCCGGGCACCTGGCCTTGGCAAGTGAGCCTGCACCAT GGAGGTGGCCACATCTGCGGGGGCTCCCTCATCGCCCCCTCCTGGGTCCTCTCCGCTGCTCACTGTTTCATG ACGAATGGGACGTTGGAGCCCGCGGCCGAGTGGTCGGTACTGCTGGGCGTGCACTCCCAGGACGGGCCCCTG GACGGCGCGCACACCCGCGCAGTGGCCGCCATCGTGGTGCCGGCCAACTACAGCCAAGTGGAGCTGGGCGCC GACCTGGCCCTGCTGCGCCTGGCCTCACCCGCCAGCCTGGGCCCCGCCGTGTGGCCTGTCTGCCTGCCCCGC GCCTCACACCGCTTCGTGCACGGCACCGCCTGCTGGGCCACCGGCTGGGGAGACGTCCAGGAGGCAGATCCT CTGCCTCTCCCCTGGGTGCTACAGGAAGTGGAGCTAAGGCTGCTGGGCGAGGCCACCTGTCAATGTCTCTAC AGCCAGCCCGGTCCCTTCAACCTCACTCTCCAGATATTGCCAGGGATGCTGTGTGCTGGCTACCCAGAGGGC CGCAGGGACACCTGCCAGGGTGACTCTGGGGGGCCCCTGGTCTGTGAGGAAGGCGGCCGCTGGTTCCAGGCA GGAATCACCAGCTTTGGGTTTGGCTGTGGACGGAGAAACCGCCCTGGAGTTTTCACTGCTGTGGCTACCTAT GAGGCATGGATACGGGAGCAGGTGATGGGTTCAGAGCCTGGGCCTGCCTTTCCCACCCAGCCCCAGAAGACC CAGTCAGATTGTTTACATCAAACGGCATTCCTGGATTCTGCCAGAATCCTTTTGAGGCCCTTGTCCCATATA TCAGTAGGAGTCTCAACTGGGACCAAAAGCCTTGTCCTCCCCTGGCTCTCTCCACACTCTCTCCTGGGCCTC TGGGGGTTCTGATGGGGCCTCC
The disclosed NOV14b polypeptide (SEQ ID NO:46) encoded by SEQ LO NO:45 has 357 amino acid residues and is presented in Table 14D using the one-letter amino acid code.
Table 14D. Encoded NOV14b protein sequence (SEQ ID NO:46).
MAQKGVLGPGQLGAVANSDSYSLYGLVPSGPARGPPYCGRPEPSARIVGGSNAQPGTWPWQVSLHHGGGHIC GGSLIAPSWVLSAAHCFMTNGTLEPAAEWSVLLGVHSQDGPLDGAHTRAVAAIWPANYSQVELGADLALLR LASPASLGPAVWPVCLPRASHRFVHGTACWATGWGDVQEADPLPLPWVLQEVELRLLGEATCQCLYSQPGPF NLTLQILPGMLCAGYPEGRRDTCQGDSGGPLVCEEGGRWFQAGITSFGFGCGRRNRPGVFTAVATYEAWIRE QVMGSEPGPAFPTQPQKTQSDCLHQTAFLDSARILLRPLSHISVGVSTGTKSLVLPWLSPHSLLGLWGF
The disclosed NOV14 polypeptide has homology to the amino acid sequences shown in the BLASTP data listed in Table 14E.
Table 14E. BLAST results for NO 14
Gene Index/ Protein/ Organism Length Identity Positives Expect Identifier (aa) (%) (%) gi I 4506153 | ref |NP_0 protease, serine, 343 140/333 180/333 le-51 02754. l| 8 (prostasin) (42%) (54%) (NM 002773) [Homo sapiens] gi I 5009515 I bj |BAA8 epidermis 389 104/265 144/265 2e-49 4941. ll (AB018694) specific serine (39%) (54%) protease [Xenopus laevis] gi I 12249015 I dbj | BAB prostamin [Homo 855 103/249 140/249 4e-47 20376. l| (AB030036) sapiens] (41%) (55%) gi 111181573 | gb |AAG3 prostasin [Rattus 342 130/347 175/347 4e-47 2641.1 |AF202076_1 norvegicus] (37%) (49%) (AF202076) gi I 13632973 I sp|Q9ES Prostasin 342 130/347 175/347 6e-47 87 PSS8 RAT precursor (37%) (49%)
The homology between these and other sequences is shown graphically in the ClustalW analysis shown in Table 14F. In the ClustalW alignment of the NOV14 protein, as well as all other ClustalW analyses herein, the black outlined amino acid residues indicate regions of conserved sequence (i.e., regions that may be required to preserve structural or functional properties), whereas non-highlighted amino acid residues are less conserved and can potentially be altered to a much broader extent without altering protein structure or function.
Table 14F. ClustalW Analysis of NOVl 4
1) Novel NOV14a (SEQ ID NO: 44) 2) Novel NOV14b (SEQ ID NO -.45)
3) gi I 4506153 ] ref |NP_002764. l| (NM_002773) protease, serine, 8 (prostasin) [Homo sapiens] (SEQ ID NO:130)
4) gi I 6009515 j dbj |BAA84941.l| (AB018694) epidermis specific serine protease [Xenopus laevis] (SEQ ID NO: 131) 5) gi 12249015 dbj |BAB20376.1 | (AB030036) prostamin [Homo sapiens] (SEQ ID NO:132)
6) gi 11181573 gb| AAG32641.1 | AF202076_1 (AF202076) prostasin [Rattus norvegicus] (SEQ ID NO:133)
7) gi| 13632973 I sp|Q9ES87|PSS8_RAT Prostasin precursor (SEQ ID NO:134)
10 20 30 40 50 60
....|....|....|....|....|....|....|....|....|....|....|....|
NOV14a 1
NOV14b ! gi 4506153 |ref) τ gi 6009515|dbj χ gi 12249015 |db;j MGSDRARKGGGGPKDFGAGLKYNSRHEKVNGLEEGVEFLPVNNVKKVEKHGPGRWVVLAA 60 gi 11181573 |gb 1 gi 13632973|sp x
70 80 90 100 110 120
N0V14 1
20
130 140 150 160 170 180
N0V14 1 N0V14b 1
91 4506153 I ref 1 gi 6009515|dbj 1 gi 12249015 db] KDALKLLYSGVPFLGPYHKESAVTAFSEGSVIAYYWSEFSIPQHLVEEAERVMAEERWM 180 gi 11181573 gb 1 gi 13632973 sp
190 200 210 220 230 240
N0V14a 1
40
250 260 270 280 290 300
N0V14a X
00
310 320 330 340 350 360
N0V14a X
60
370 380 390 400 no 420
N0V14 X
20
430 440 450 460 470 480
N0V14a X
80
970 980
Tables 14G-H lists the domain descriptions from DOMAIN analysis results against NOV14. This indicates that the N0V14 sequence has properties similar to those of other proteins known to contain this domain.
Table 14G Domain Analysis of NOVl 4 gnl I Smart I smar 00020, Tryp_SPc, Trypsin-like serine protease,- Many of these are synthesised as inactive precursor zymogens that are cleaved during limited proteolysis to generate their active forms. A few, however, are active as single chain molecules, and others are inactive due to substitutions of the catalytic triad residues . (SEQ ID NO: 135)
CD-Length = 230 residues, 100.0% aligned Score = 209 bits (531) , Expect = 3e-55
Query: 46 RIVGGSNAQPGTWPWQVSLH-HGGGHICGGSLIAPSWVLSAAHCFMTNGTLEPAAEWSVL 104 I 11 I lll+llll + + I
Sbjct: 1 RIVGGSEANIGSFPWQVSLQYRGGRHFCGGSLISPRWVLTAAHCVYGS APSSIRVR 56
Query: 105 LGVHSQDGPLDGAHTRAVAAIWPANYSQVELGADLALLRLASPASLGPAVWPVCLPRAS 154
II I + 1 1+ ++I 11+ I+III+I+ I +1 I l+lll +
Sbjct: 57 LGSHDLSSG-EETQTVKVSKVIVHPNYNPSTYDNDIALLKLSEPVTLSDTVRPICLPSSG 115 Query. 165 HRFVHGTACWATGWGDVQEADPLPLPWVLQEVELRLLGEATCQCLYSQPGPFNLTLQILP 224
II I +111 1+ II llll + ++ 111+ II 1
Sbjct: 116 YNVPAGTTCTVSGWGRTSESSG-SLPDTLQEVNVPIVSNATCRRAYSGGPA ITD 168
Query: 225 GMLCAGYPEGRRDTCQGDSGGPLVCEEGGRWFQAGITSFG-FGCGRRNRPGVFTAVATYE 283 lllll II +1 11111111111 II II l + l +|.| I l + lll + l I++I
Sbjct: 169 NMLCAGGLEGGKDACQGDSGGPLVC-NDPRWVLVGIVSWGSYGCARPNKPGVYTRVSSYL 227 Query: 284 AWI 286
11
Sbjct: 228 DWI 230
Table 14H Domain Analysis of NOV14 gnl I Pfam|pfam00089, trypsin, Trypsin. Proteins recognized include all proteins in families Si, S2A, S2B, S2C, and S5 in the classification of peptidases. Also included are proteins that are clearly members, but that lack peptidase activity, such as haptoglobin and protein Z (PRTZ*) . (SEQ ID N0:136) CD-Length = 217 residues, 100.0% aligned Score = 155 bits (417) , Expect = 5e-42
Query: 47 IVGGSNAQPGTWPWQVSLHHGGGHICGGSLIAPSWVLSAAHCFMTNGTLEPAAEWSVLLG 106 llll II I++IIIIM II +III+IIII 1+ l+ll
Sbj ct : 1 IVGGREAQAGSFPWQVSLQVSSGHFCGGSLISENWVLTAAHCVSG ASSVRWLG 54
Query : 107 VHSQDGPLDGAHTRAVAAIWPANYSQVELGADLALLfiLASPASLGPAVWPVCLPRASHR 165
1+ I l+l 11+ l+lll+l II +11 I l+lll II
Sbjct: 55 EHNLGTTEGTEQKFDVKKIIVHPNYNP--DTNDIALLKLKSPVTLGDTVRPICLPSASSD 112 Query: 167 FVHGTACWATGWGDVQEADPLPLPWVLQEVELRLLGEATCQCLYSQPGPFNLTLQILPGM 226
II I +111 + llll + ++ ll+ l + 1
Sbjct : 113 LPVGTTCSVSGWGRTKNLGT SDTLQEVWPIVSRETCRSAYGGT VTDTM 161
Query : 227 LCAGYPEGRRDTCQGDSGGPLVCEEGGRWFQAGITSFGFGCGRRNRPGVFTAVATYEAWI 286
+111 I +1 +1 II l+l+ll I lll+l 1+ I II
Sbjct: 162 ICAGALGG-KDACQGDSGGPLVCSDG ELVGIVSWGYGCAVGNYPGVYTRVSRYLDWI 217
Human seminal fluid contains a variety of proteolytic enzymes, including prostate- specific antigen and acrosin. These enzymes are involved in the postejaculatory hydrolysis of proteins and in semen coagulation and liquefaction. Yu et al. (1995) obtained partial amino acid sequence of a 40-kD protein isolated from seminal fluid originally by Yu et al. (1994). Yu et al. (1995) designed degenerate primers based on the amino acid sequence and used to screen a human prostate cDNA library by PCR. The 3-prime end of the cDNA was obtained by the RACE (rapid amplification of cDNA ends) method. A 1.8-kb cDNA sequence was assembled encoding a predicted protein of 343 amino acids which contains a 32-amino acid signal peptide. The protein, designated serine protease-8 (gene symbol = PRSS8), was called prostasin by the authors. The precursor, proprostasin, is cleaved between residues 12 and 13 to produce a 12-amino acid light chain and a 299-amino acid heavy chain which are associated through a disulfide bond. The predicted amino acid sequence is between 34 and 42% identical to human acrosin, plasma kallikrein, and hepsin . The deduced protein has a hydrophobic domain at the C terminus, indicating to the authors that it may be membrane anchored. The authors showed that the hydrophobic region is cleaved between residues 290 and 291 during secretion. Expression levels of the prostasin mRNA were assayed by Southern blots of RT- PCR products. Expression was noted in a wide variety of tissues. In the prostate gland, expression was localized to the epithelial cells. Yu et al. (1996) isolated and characterized the full length PRSS8 gene. They found that it consists of 6 exons and 5 infrons. The authors characterized the 5-prime flanking region of the gene and found a number of potential
regulatory elements, including an AP2 site, 2 erythroid-specific promoter elements, and a sterol regulatory element, although no TATA box was found. In addition, there were a variant GC box and a variant API site in the promoter region. Prostasin, denoted as PRSS8, is a newly identified human serine proteinase that shares high sequence identity with acrosin, plasma kallikrein, and hepsin (Yu et al., 1994, 1995). In the present study, a full-length PRSS8 gene has been isolated and characterized. A 7-kb PRSS8 gene fragment has been sequenced, including a 1.4-kb 5'-flanking region, the 4.4-kb PRSS8 gene, and a 1.2-kb 3'-flanking region. The gene consists of six exons and five introns based on comparison with its cDNA sequence. The sizes of these exons are 417, 18, 163, 272, 167, and 899 bp, while those of the introns are 243, 1763, 271, 85, and 92 bp. A number of potential regulatory elements have been revealed in the 5'-flanking region, including an AP2 site, two erythroid-specific promoter elements, and a sterol regulatory element, hi addition, there are a variant GC box and a variant API site in the promoter region. The transcription initiation site of the PRSS8 gene has been defined at the G residue and its adjacent A residue in a sequence CTCATGACT, which is similar to an initiator element CTCANTCT. Between the transcription initiation site and these putative regulatory elements, there is an AC-rich repetitive sequence that spans over 300 bp. Human PRSS8 is a single-copy gene and has been localized on chromosome 16pl 1.2 by in situ hybridization.
The disclosed NOV14 nucleic acid of the invention encoding a Prostatin Precursor - like protein includes the nucleic acid whose sequence is provided in Table 14A, 14C or a fragment thereof. The invention also includes a mutant or variant nucleic acid any of whose bases maybe changed from the corresponding base shown in Table 14A, or 14C while still encoding a protein that maintains its Prostatin Precursor-like activities and physiological functions, or a fragment of such a nucleic acid. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. In the mutant or variant nucleic acids, and their complements, up to about 43 percent of the bases may be so changed.
The disclosed NOV14 protein of the invention includes the Prostatin Precursor-like protein whose sequence is provided in Table 14B, or 14D. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in Table 14B, or 14D while still encoding a protein that maintains its Prostatin Precursor-like activities and physiological functions, or a functional fragment thereof. In the mutant or variant protein, up to about 43% percent of the residues may be so changed.
The invention further encompasses antibodies and antibody fragments, such as Fab or (Fab)2,that bind immunospecifically to any of the proteins of the invention.
The above defined information for this invention suggests that this Prostatin Precursor- like protein (NOV14) may function as a member of a "Prostatin Precursor family". Therefore, the NOV14 nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.
The NOV14 nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis ,Atrial septal defect (ASD),Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases,Tuberous sclerosis, Scleroderma, Obesity,Transplantation, and/or other diseases and pathologies.
NOV14 nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOV14 substances for use in therapeutic or diagnostic methods. These antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the "Anti- NOVX Antibodies" section below. The disclosed NOV14 protein has multiple hydrophihc regions, each of which can be used as an immunogen. These novel proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.
NOVX Nucleic Acids and Polypeptides
One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and or mutation of NOVX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double- stranded DNA.
An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a "mature" form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal metliionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-teπninal methionine, would have residues 2 through N remaining after removal of the N-terminal metliionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+l to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.
The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as
approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.
The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (t.e., sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.
A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence infoπnation provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, et al., (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.) A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore,
oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g. , using an automated DNA synthesizer.
As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.
In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID
NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encodmg a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, or 197 is one that is sufficiently complementary to the nucleotide sequence shown SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, or 197 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, thereby forming a stable duplex.
As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.
Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species. Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence
does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.
An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be franslated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bonafide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.
The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and or cloning NOVX homologues in other cell types, e.g. from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, or 197; or an anti-sense strand nucleotide sequence of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, or 197; or of a naturally occurring mutant of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g. the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis- express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.
"A polypeptide having a biologically-active portion of an NOVX polypeptide" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity ofa polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encodmg a "biologically- active portion of NOVX" can be prepared by isolating a portion SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, or 197, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.
NOVX Nucleic Acid and Polypeptide Variants
The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197. hi another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198. In addition to the human NOVX nucleotide sequences shown in SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.
Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ LD NOS:l, 3, 5, 7, 9,
11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length, hi yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.
Homologs (t.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.
As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50%) of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 ntto 50 nt) and at least about 60°C for longer probes, primers and
oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.
Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%>, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in IX SSC, 0.1% SDS at 37°C. Oilier conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY. hi a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species
hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. Proc Natl Acad Sci USA 78: 6789-6792.
Conservative Mutations
In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.
Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198. Preferably, the protein encoded by the nucleic acid molecule is at least about 60%> homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198; more preferably at least about 70% homologous SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198; still more preferably at least about 80% homologous to SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198; even more preferably at least about 90% homologous to SEQ LD NOS:2, 4, 6, 8, 10, 12,
14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198.
An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into SEQ LD NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23,
25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined. The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be
substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLLM, HFY, wherein the letters within each group represent the single letter amino acid code. hi one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form proteimprotein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex fonnation between a mutant NOVX protein and an NOVX ligand; or (Hi) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).
In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).
Antisense Nucleic Acids
Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding strand ofa double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, are additionally provided.
In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues, hi another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).
Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides hi length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used). Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl- 2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5 -methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,
3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (e.g. , by inhibiting transcription and or translation). The hybridization can be by conventional
nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are prefened.
In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987. Nucl. Acids Res. 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (See, e.g., Lnoue, et al. 1987. Nucl. Acids Res. 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987. FEBS Lett. 215: 327-330.
Ribozymes and PNA Moieties
Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject. h one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in
Haselhoff and Gerlach 1988. Nature 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (i.e., SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17,
19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197). For example, a derivative ofa Tetrahymena L-19 LVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. See, e.g., U.S. Patent 4,987,071 to Cech, et al. and U.S. Patent 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.
Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991. Anticancer Drug Des. 6: 569-84; Helene, et al. 1992. Ann. NY. Acad. Sci. 660: 27-36; Maher, 1992. Bioassays 14: 807-15. hi various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996. BioorgMed
Chem 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Peπy-O'Keefe, et al, 1996. Proc. Natl. Acad. Sci. USA 93: 14670-14675.
PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., Si nucleases (See, Hyrup, et al, I996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al, 1996, supra; Perry-O'Keefe, et al, 1996. supra). h another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that
may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al, 1996. supra and Finn, et al, 1996. Nucl Acids Res 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. See, e.g., Mag, et al, 1989. Nucl Acid Res 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. See, e.g., Finn, et al, 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, e.g., Petersen, et al, 1975. Bioorg. Med. Chem. Lett. 5: 1119-11124.
In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al, 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 6553-6556; Lemaifre, et al, 1987. Proc. Natl. Acad. Sci. 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). hi addition, oligonucleotides can be modified with hybridization triggered cleavage agents (see, e.g., Krol, et al, 1988. BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988. Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.
NOVX Polypeptides
A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.
In general, an NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention, hi favorable circumstances, the substitution is a conservative substitution as defined above.
One aspect of the invention pertains to isolated NOVX proteins, and biologically- active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, t.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.
The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations
of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20%> chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.
Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence shown in SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.
Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.
In an embodiment, the NOVX protein has an amino acid sequence shown SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198. h other embodiments, the NOVX protein is substantially homologous to SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198, and retains the functional activity of the NOVX proteins of SEQ ED NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198.
Determining Homology Between Two or More Sequences
To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at
corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").
The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. JMol Biol 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197. The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.
Chimeric and Fusion Proteins The invention also provides NOVX chimeric or fusion proteins. As used herein, an
NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively- linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence conesponding to an NOVX protein SEQ ED NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, or 198, whereas a "non-NOVX
polypeptide" refers to a polypeptide having an amino acid sequence conesponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can coπespond to all or a portion of an NOVX protein, hi one embodiment, an NOVX fusion protein comprises at least one biologically- active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide. hi one embodiment, the fusion protein is a GST-NO VX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.
In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.
In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the NOVX-iinmunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.
An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. hi another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.
NOVX Agonists and Antagonists
The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g. , discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins. Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene
library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983. Tetrahedron 39: 3; Itakura, et al, 1984. Annu. Rev. Biochem. 53: 323; Itakura, et al, 1984. Science 198: 1056; Ike, et al, 1983. Nucl. Acids Res. 11: 477.
Polypeptide Libraries
In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein, hi one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with Si nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.
Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates
isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992. Proc. Natl. Acad. Sci. USA 89: 7811-7815; Delgrave, et al, 1993. Protein Engineering 6:327-331.
NOVX Antibodies
The term "antibody" as used herein refers to immunoglobulin molecules and immuno logically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fa , Fa ' and F(ab')2 fragments, and an Fab expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgGi, LgG2, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.
An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophihc regions. i certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophihc region. A hydrophobicity analysis of the human NOVX protein sequence will
indicate which regions of a NOVX polypeptide are particularly hydrophihc and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doohttle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein. A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.
Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below. Polyclonal Antibodies
For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogemc protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar irnmunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
The polyclonal antibody molecules directed against the immunogemc protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, maybe immobilized on a column to purify the immune specific antibody by immunoaffmity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, hie, Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).
Monoclonal Antibodies
The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product, hi particular, the complementaiity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized.by a unique binding affinity for it.
Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature. 256:495 (1975). hi a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.
The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice. Academic Press, (1986) pp. 59- 103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused,
immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More prefened immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell hnes also have been described for the production of human monoclonal antibodies [Kozbor, J. hnmunol.. 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].
The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem.. 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.
After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding,1986). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI- 1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of
the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a prefened source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368. 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immuno globulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
Humanized Antibodies
The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen- binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature. 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the conesponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by conesponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions conespond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally
also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; andPresta, Cun. Op. Struct. Biol.. 2:593-596 (1992)).
Human Antibodies
Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 hi: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Ban Virus in vitro (see Cole, et al., 1985 hi: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).
In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Monison ( Nature 368. 812-13 (1994)); Fishwild et al,( Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar flntern. Rev. Immunol. 13 65-93 (1995)).
Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are
incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The prefened embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This ariimal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.
An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent reanangement of the locus and to prevent formation of a transcript of a reaπanged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.
A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain. hi a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a conelative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.
Fab Fragments and Single Chain Antibodies
According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not h ited to: (i) an F(ay)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fa fragment generated by reducing the disulfide bridges of an F(a ')2 fragment; (iii) an Fa fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.
Bispecific Antibodies
Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.
Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature. 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture often different antibody molecules, of which only one has the conect bispecific structure. The purification of the conect molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is prefened to have the first heavy-chain constant region (CHI) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-
transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzvmolo y. 121:210 (1986).
According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The prefened interface comprises at least a part of the CH3 region of an antibody constant domain, hi this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')2 bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes. Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')2 molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5): 1547-1553
(1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by HoUinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the VH and VL domains of one fragment are forced to pair with the complementary V and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991). Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD 16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).
Heteroconjugate Antibodies
Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HLV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by
forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.
Effector Function Engineering
It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191- 1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research. 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).
Immunoconjugates
The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., aradioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricofhecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include 212Bi, 1311, 131Ln, 90Y, and ls6Re.
Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro- 2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science. 238: 1098 (1987). Carbon-14-labeled l-isothiocyanatobenzyl-3- methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026.
In another embodiment, the antibody can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.
Immunoliposomes
The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA. 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA. 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG- derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al .,_L Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer hist., 81(19): 1484 (1989).
Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention
Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies
against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds (see below).
An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part ofa clinical testing procedure, e.g., to, for example, determine the efficacy ofa given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example ofa luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S or 3H.
Antibody Therapeutics
Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question, hi the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the
naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.
Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule, hi this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a sunogate effector ligand, initiating a receptor-based signal transduction event by the receptor.
A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be admimstered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.
Pharmaceutical Compositions of Antibodies
Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gemiaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances hi Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York. If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are prefened. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is prefened. For example, based upon the variable-region sequences of an antibody, peptide
molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
Sustained-release preparations can be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT ™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
ELISA Assay
An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab)2) can be used. The term "labeled", with regard to the probe or antibody, is intended to
encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The tenn "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include
Southern hybridizations. Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Thory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
NOVX Recombinant Expression Vectors and Host Cells
Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a
"plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a
bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-hiiked. Such vectors are refened to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The tenn "regulatory sequence" is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).
The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression
vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non- usion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (Hi) to aid in the purification of the recombinant protein by acting as a ligand in affimty purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 61: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc
(Amrann et al, (1988) Gene 69:301-315) and pET lid (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS ΓN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (see, e.g., Wada, et al, 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharomyces cerivisae include pYepSecl (Baldari, et al, 1987. EMBOJ. 6: 229-234), pMFa (Kurjan and Herskowitz, 1982. Cell 30:
933-943), pJRY88 (Schultz et al, 1987. Gene 54: 113-123), pYES2 (hivifrogen Corporation, San Diego, Calif), and picZ (hiVitrogen Corp, San Diego, Calif).
Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al, 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).
In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al, 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1 89. In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al, 1987. Genes Dev. 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. Adv. Immunol. 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Banerji, et al, 1983. Cell 33: 729-740; Queen and Baltimore, 1983. Cell 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Natl. Acad. Sci. USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al, 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Grass, 1990. Science 249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989. Genes Dev. 3: 537-546).
The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to
NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al, "Antisense RNA as a molecular tool for genetic analysis," Reviews-Trends in Genetics, Vol. 1(1) 1986.
Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g. , DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dexfran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.
For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the
host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. , cells that have incorporated the selectable marker gene will survive, while the other cells die).
A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.
Transgenic NOVX Animals The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinj ection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Lntronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinj ection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. hi: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals canying the transgene. Moreover, transgenic animals canying a transgene-encoding NOVX protein can further be bred to other transgenic animals canying other transgenes.
To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also refened to as a "knock out" vector).
Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein), hi the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3 '-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-tennini) are included in the vector. See, e.g., Thomas, et al, 1987. Cell 51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al, 1992. Cell 69: 915. The selected cells are then injected into a blastocyst of an animal (e.g. , a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. hi: TERATOCARCΓNOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. LRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. Curr. Opin. Biotechnol. 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169. In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage PI . For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al, 1992. Proc. Natl. Acad. Sci. USA 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae. See, O'Gorman, et al, 1991. Science 251 :1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by
mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al, 1997. Nature 385: 810-813. hi brief, a cell (e.g. , a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter Go phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transfened to pseudopregnant female foster animal. The offspring bome of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.
Pharmaceutical Compositions
The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also refened to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incoφorated herein by reference. Prefened examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5%» human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdeπnal (i.e., topical), fransmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile
diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N. J.) or phosphate buffered saline (PBS), hi all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The canier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of
the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds ofa similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For admimstration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal admimstration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished througli the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals. The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al, 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.
The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
Screening and Detection Methods
The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below, hi addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or abenant activity
compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease(possesses anti-microbial activity) and the various dyslipidemias. hi addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity, hi yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.
The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.
Screening Assays
The invention provides a method (also refened to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drags) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein. hi one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997 '. Anticancer Drug Design 12: 145.
A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.
Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al, 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al, 1994. Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, etal, 1994. J Med. Chem. 37: 2678; Cho, et al, 1993. Science 261: 1303; Caπell, et al, 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al, 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al, 1994. J Med. Chem. 37: 1233.
Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, et al, 1992. Proc. Natl. Acad. Sci. USA 89:
1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al, 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J Mol. Biol. 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).
In one embodiment, an assay is a cell-based assay in which a cell which expresses a' membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with I, S, C, or H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product, hi one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein detennining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.
In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically- active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface ofa cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.
Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for deteimining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction ofa cellular second messenger of the target (i.e. intracellular Ca2+, diacylglycerol, LP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation. In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically- active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises
contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and deteπnining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically- active portion thereof as compared to the known compound. hi still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and detennining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding, hi an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the abihty of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra. hi yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically- active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule. The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-mefhylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, N-dodecyl~N,N-dimethyl-3-ammonio-l-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1 -propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-l-propane sulfonate (CHAPSO).
In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity detennined using standard techniques.
Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, 111.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.
In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX
mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.
In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, et al, 1993. Cell 72: 223-232; Madura, et al, 1993. J Biol. Chem. 268: 12046-12054; Bartel, et al, 1993. Biotechniques 14: 920-924; Iwabuchi, et al, 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upsfream or downstream elements of the NOVX pathway. The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g. , GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, in vivo, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g. , LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.
The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.
Detection Assays
Portions or fragments of the cDNA sequences identified herein (and the conesponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (Hi) aid in forensic identification ofa biological sample. Some of these applications are described in the subsections, below.
Chromosome Mapping
Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in conelating these sequences with genes associated with disease. Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers
(preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene conesponding to the NOVX sequences will yield an amplified fragment.
Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small
number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D'Eustachio, et al, 1983. Science 220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with franslocations and deletions.
PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub- localization can be achieved with panels of fragments from specific chromosomes. Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).
Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents conesponding to noncoding regions of the genes actually are prefened for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be conelated with genetic map data. Such data are found, e.g., in McKusick, MENDELIAN INHERITANCE ΓN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al, 1987. Nature, 325: 783-787.
Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be detennined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or franslocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence ofa mutation and to distinguish mutations from polymorphisms.
Tissue Typing
The NOVX sequences of the invention can also be used to identify individuals from minute biological samples, hi this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).
Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3 '-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
Panels of conesponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).
Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are
necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
Predictive Medicine
The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with abenant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.
Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (refened to herein as "phannacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)
Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.
These and other agents are described in further detail in the following sections.
Diagnostic Assays
An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.
An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently- labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include
Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. hi one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A prefened biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample. The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.
Prognostic Assays
The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with abenant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with abenant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with abenant NOVX expression or activity. As used herein, a "test sample" refers to a biological sample obtained
from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.
Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with abenant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with abenant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g. , wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with abenant NOVX expression or activity).
The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by abenant cell proliferation and/or differentiation, hi various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (Hi) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) abenant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non- wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A prefened biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells. hi certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such
as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al, 1988. Science 2A1: 1077-1080; and Nakazawa, et al, 1994. Proc. Natl. Acad. Sci. USA 91 : 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al, 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amphfication product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al, 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwoh, et al, 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density anays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al, 1996. Human Mutation 1: 244-255; Kozal, et al, 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional anays containing light-generated DNA probes as described in Cronin, et al, supra. Briefly, a first hybridization anay of probes can be used to scan through long stretches of DNA in a sample and control to identify base
changes between the sequences by making linear anays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization anay that allows the characterization of specific mutations by using smaller, specialized probe anays complementary to all variants or mutations detected. Each mutation anay is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the conesponding wild-type (control) sequence. Examples of sequencing reactions include those based on teclmiques developed by Maxim and Gilbert, 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 14: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al, 1996. Adv. Chromatography 36: 127-162; and Griffm, et al, 1993. Appl. Biochem. Biotechnol 38: 147-159).
Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al, 1985. Science 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with Si nuclease to enzymatically digesting the mismatched regions, hi other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al, 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al, 1992. Methods Enzymol. Ill: 286-295. hi an embodiment, the control DNA or RNA can be labeled for detection.
In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA
mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al, 1994. Carcinogenesis 15: 1657-1662. According to an exemplary embodiment, a probe based on an NOVX sequence, e.g. , a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.
In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al, 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al, 1991. Trends Genet. 1: 5. hi yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGΕ). See, e.g., Myers, et al, 1985. Nature 313: 495. When DGGΕ is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. hi a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. Biophys. Chem. 265: 12753.
Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit
hybridization only if a perfect match is found. See, e.g., Saiki, et al, 1986. Nature 324: 163; Saiki, et al, 1989. Proc. Natl. Acad. Sci. USA 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may cany the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al, 1989. Nucl. Acids Res. 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. Tibtech. 11: 238). hi addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al, 1992. Mol. Cell Probes 6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. i such cases, ligation will occur only if there is a perfect match at the 3 '-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.
Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.
Pharmacogenomics Agents, or modulators that have a stimulatory or inliibitory effect on NOVX activity
(e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer- associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's
Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) hi conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drag. Thus, the pharmacogenomics of the individual pennits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. Pharmacogenomics deals with clinically significant hereditary variations in the response to drags due to altered drag disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol, 23: 983-985; Linder, 1997. Clin. Chem., 43: 254-266. i general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drags act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drag metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.
As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drag action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome PREGNANCY ZONE PROTEIN PRECURSOR enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is
highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drag response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be detennined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drag-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.
Monitoring of Effects During Clinical Trials Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate abenant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.
By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drag or small molecule) that modulates
NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.
In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drag candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (Hi) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent maybe desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.
Methods of Treatment
The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with abenant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity,
transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, ALDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, and other diseases, disorders and conditions of the like. These methods of treatment will be discussed more fully, below.
Disease and Disorders
Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with
Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (Hi) nucleic acids encoding an aforementioned peptide; (tv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators ( i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.
Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.
Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.)
and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).
Prophylactic Methods In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an abenant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by abenant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX abenancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX abenancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.
Therapeutic Methods
Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by abenant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or
combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity, h another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or abenant NOVX expression or activity. Stimulation of NOVX activity is desirable in stations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by abenant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).
Determination of the Biological Effect of the Therapeutic
In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect ofa specific Therapeutic and whether its administration is indicated for treatment of the affected tissue. hi various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.
Prophylactic and Therapeutic Uses of the Compositions of the Invention
The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer- associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.
As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof.
By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's
Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.
Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (t.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods. The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.
Examples
Example 1. Identification of NOVX clones The novel NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. Table 15A shows the sequences of the PCR primers used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from hivitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1
vector. Table 15B shows a list of these bacterial clones. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for conections if appropriate. These procedures provide the sequence reported herein.
Table 15A. PCR Primers for Exon Linking
Physical clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually conected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.
Table 15B. Physical Clones for PCR products
Example 2. Quantitative expression analysis of clones in various cells and tissues
The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied
Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and refened to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from noπnal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer' s diseased brains) .
RNA integrity from all samples is controlled for quality by visual assessment of agarose gel elecfropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s: 18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.
First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.
In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42°C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using IX TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. Probes and primers were designed for each assay according to Applied Biosystems
Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (Tm) range = 58°-60°C, primer optimal
Tm = 59°C, maximum primer difference = 2°C, probe does not have 5'G, probe Tm must be 10°C greater than primer Tm, amplicon size 75bp to lOObp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900nM each, and probe, 200nM.
PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48°C for 30 minutes followed by amplifϊcation/PCR cycles as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. When working with sscDNA samples, nonnalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using IX TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were analyzed and processed as described previously. Panels 1, 1.1, 1.2, and 1.3D
The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using
the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone manow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.
Ln the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used: ca. = carcinoma, * = established from metastasis, met = metastasis, s cell var = small cell variant, non-s = non-sm = non-small, squam = squamous, pi. eff = pi effusion = pleural effusion, glio = glioma, astro = astrocytoma, and neuro = neuroblastoma.
General_screening_panel_vl.4 The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone manow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine,
colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D. Panels 2D and 2.2
The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue sunounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen. Panel 3D
The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature. Panels 4D, 4R, and 4.1D
Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cinhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).
Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately l-5ng/ml, TNF alpha at approximately 5-lOng/ml, LFN gamma at approximately 20-50ng/ml, IL-4 at approximately 5-10ng/ml, IL-9 at approximately 5-10ng/ml, IL-13 at approximately 5- lOng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum. Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco/Life Technologies, Rockville, MD), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xl0"5M (Gibco), and lOmM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20ng/ml PMA and l-2μg/ml ionomycin, IL-12 at 5-10ng/ml, LFN gamma at 20-50ng/ml and LL-18 at 5- lOng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xl0"5M (Gibco), and lOmM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2xl06cells/ml in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol (5.5xl0"5M) (Gibco), and lOmM Hepes (Gibco).
The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.
Monocytes were isolated from mononuclear cells using CD 14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), and lOmM Hepes (Gibco), 50ng/ml GMCSF and 5ng/ml LL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5%o FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), lOmM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50ng ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at lOOng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at lOμg/ml for 6 and 12-14 hours. CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5 10"5M (Gibco), and lOmM Hepes (Gibco) and plated at 106cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5μg/ml anti-CD28 (Pharmingen) and 3ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xl0"5M (Gibco), and lOmM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco),
mercaptoethanol 5.5xlO"5M (Gibco), and lOmM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.
To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 106cells/ml in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), and lOmM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately lOμg/ml and IL-4 at 5-lOng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours. To prepare the primary and secondary Thl/Th2 and Trl cells, six-well Falcon plates were coated overnight with lOμg/ml anti-CD28 (Pharmingen) and 2μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 105-106cells/ml in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5x10" 5M (Gibco), lOmM Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (5ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Thl, while IL-4 (5ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5ng/ml was used to direct to Trl. After 4-5 days, the activated Thl, Th2 and Trl lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), lOmM Hepes (Gibco) and IL-2 (lng/ml). Following this, the activated Thl, Th2 and Trl lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Thl, Th2 and Trl lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Thl and Tlι2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Thl, Th2 and Trl after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.
The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in O.l M dbcAMP at 5xl05cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5xl05cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), lOmM Hepes
(Gibco). RNA was either prepared from resting cells or cells activated with PMA at lOng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), lOOμM non essential amino acids (Gibco), lmM sodium pyruvate (Gibco), mercaptoethanol 5.5xlO"5M (Gibco), and lOmM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and lng/ml EL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5ng/ml IL-4, 5ng/ml LL-9, 5ng/ml IL-13 and 25ng/ml LFN gamma.
For these cell lines and blood cells, RNA was prepared by lysing approximately 107cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane
(Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15ml Falcon Tube. An equal volume of isopropanol was added and left at -20°C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300μl of RNAse-free water and 35μl buffer (Promega) 5μl DTT, 7μl RNAsin and 8μl DNAse were added. The tube was incubated at 37°C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at -80°C. Al comprehensive panel_vl.O
The plates for AI_comprehensive panel_vl.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.
Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.
Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of
25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.
Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.
Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha- lanti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators. hi the labels employed to identify tissues in the AI_comprehensive panel_vl.O panel, the following abbreviations are used:
Al = Autoimmunity Syn = Synovial Nonnal = No apparent disease
Rep22 /Rep20 = individual patients RA = Rheumatoid arthritis Backus = From Backus Hospital OA = Osteoarthritis (SS) (BA) (MF) = Individual patients Adj = Adjacent tissue Match control = adjacent tissues -M = Male -F = Female COPD = Chronic obstructive pulmonary disease Panels 5D and 51
The plates for Panel 5D and 51 include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were
obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.
In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was πnsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descnptions are as follows:
Patient 2 Diabetic Hispanic, overweight, not on insulin
Patient 7-9 Nondiabetic Caucasian and obese (BMI>30) Patient 10 Diabetic Hispanic, overweight, on insulin
Patient 11 Nondiabetic African American and overweight
Patient 12 Diabetic Hispanic on insulin
Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found m Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:
Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated Donor 2 and 3 AD: Adipose, Adipose Differentiated
Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.
Panel 51 contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 51. hi the labels employed to identify tissues in the 5D and 51 panels, the following abbreviations are used:
GO Adipose = Greater Omentum Adipose SK = Skeletal Muscle UT = Uterus PL = Placenta
AD = Adipose Differentiated AM = Adipose Midway Differentiated U = Undifferentiated Stem Cells Panel CNSD.01 The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.
Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supernuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration. hi the labels employed to identify tissues in the CNS panel, the following abbreviations are used:
PSP = Progressive supranuclear palsy Sub Nigra = Substantia nigra Glob Palladus= Globus palladus Temp Pole = Temporal pole Cing Gyr = Cingulate gyms BA 4 = Brodman Area 4
Panel CNS_Neurodegeneration_V1.0
The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology. Disease diagnoses are taken from patient records. The panel contains six brains from
Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.
In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:
AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy
Control = Control brains; patient not demented, showing no neuropathology Control (Path) = Control brains; pateint not demented but showing sever AD-like pathology
SupTemporal Ctx = Superior Temporal Cortex Inf Temporal Ctx = Inferior Temporal Cortex
NOV4
Expression of gene NOV4 was assessed using the primer-probe set Ag3802, described in Table 16.
Table 16. Probe Name Ag3802
General_screening_panel_vl.4 Summary: Ag3082 Expression of the NOV4 gene is low/undetectable in all samples on this panel (CTs>35). (Data not shown.) The data suggest that these expression levels may be due to a probe failure.
NOV3a and NOV3b
Expression of gene NOV3a and variant NOV3b was assessed using the primer-probe set Ag4849, described in Table 17. Results of the RTQ-PCR runs are shown in Tables 18 and 19.
Table 17. Probe Name Ag4849
Table 18. General_screening_panel_vl.5
General_screening_panel_vl.5 Summary: Ag4849 The NOV3a gene is a splice variant of SET-binding factor and is moderately expressed in all tissues and cell lines in this panel. The ubiquitous expression of this gene suggests a role in cell survival and proliferation. As demonstrated in the abstract below, this gene may regulate the activity of other genes by direct interaction. In addition, highest expression of this gene in this panel is seen in the brain, with high levels of expression detected in all regions of the brain examined. Since SBF proteins are believed to play a role in the cell cycle, this protein may be of use in neural stem cell therapy, specifically in controlling the transition of stem cells to post mitotic neurons. References:
Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9. Mol Cell Biol 2000 Jul;20(13):4900-9
Mammalian SET domain-containing proteins define a distinctive class of chromatin- associated factors that are targets for growth control signals and oncogenic activation.
SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9, contains both SET and chromo domains, signature motifs for proteins that contribute to epigenetic control of gene expression through effects on the regional organization of chromatin structure. In this report we demonstrate that SUV39H1 represses transcription in a transient transcriptional assay when tethered to DNA through the GAL4 DNA binding domain. Under these conditions, SUV39H1 displays features of a long-range repressor capable of acting over several kilobases to silence basal promoters. A possible role in chromatin-mediated gene silencing is supported by the localization of exogenously expressed SUV39H1 to nuclear bodies with morphologic features suggestive of heterochromatin in interphase cells. In addition, we show that SUV39H1 is phosphorylated specifically at the G(l)/S cell cycle transition and when forcibly expressed suppresses cell growth. Growth suppression as well as the ability of SUV39H1 to form nuclear bodies and silence transcription are antagonized by the oncogenic antiphosphatase Sbfl that when hyperexpressed interacts with the SET domain and stabilizes the phosphorylated form of SUV39H1. These studies suggest a phosphorylation-dependent mechanism for regulating the chromatin organizing activity of a mammalian su(var) protein and implicate the SET domain as a gatekeeper motif that integrates upstream signaling pathways to epigenetic regulation and growth control.
Cui X, De Vivo I, Slany R, Miyamoto A, Firestein R, Cleary ML.Nat Genet 1998 Apr;18(4):331-7; Association of SET domain and myotubularin-related proteins modulates growth control.
Several proteins that contribute to epigenetic mechanisms of gene regulation contain a characteristic motif of unknown function called the SET (Suvar3-9,Enhancer-of-zeste, Trithorax) domain. We have demonstrated that SET domains mediate highly conserved interactions with a specific family of proteins that display similarity with dual-specificity phosphatases (dsPTPases). These include myotubularin, the gene of which is mutated in a subset of patients with X-linked myotubular myopathy, and Sbfl, a newly isolated homologue of myotubularin. In contrast with myotubularin, Sbfl lacks a functional catalytic domain which dephosphorylates phospho-tyrosine and serine-containing peptides in vitro. Competitive interference of endogenous SET domain-dsPTPase interactions by forced expression of Sbfl induced oncogenic transformation of NLH 3T3 fibroblasts and impaired the in vitro differentiation of C2 myoblast cells. We conclude that myotubularin-type phosphatases link SET-domain containing components of the epigenetic regulatory machinery with signalling pathways involved in growth and differentiation.
Firestein R, Cleary ML. Pseudo-phosphatase Sbfl contains an N-terminal GEF homology domain that modulates its growth regulatory properties. J Cell Sci 2001 Aug; 114(Pt 16):2921-7 Sbfl (SET binding factor 1) is a pseudo-phosphatase related to the myotubularin family of dual specificity phosphatases, some of which have been implicated in cellular growth and differentiation by virtue of their mutation in human genetic disorders. Sbfl contains germline-encoded alterations of its myotubularin homology domain that render it non-functional as a phosphatase. We report here the complete structure of Sbfl and further characterization of its growth regulatory properties. In addition to its similarity to myotubularin, the predicted full-length Sbfl protein contains pleckstrin (PH) and GEF homology domains that are conserved in several proteins implicated in signaling and growth control. Forced expression of wild-type Sbfl in NTH 3T3 cells inhibited their proliferation and altered their morphology. These effects required intact PH, GEF and myotubularin homology domains, implying that growth inhibition may be an intrinsic property of wild-type Sbfl. Conversely, deletion of its conserved N-terminal 44 amino acids alone was sufficient to convert Sbfl from an inhibitor of cellular growth to a transforming protein in NTH 3T3 cells. Oncogenic forms of Sbfl partially localized to the nucleus, in contrast to the exclusively cytoplasmic subcellular localization of endogenous Sbfl in all cell lines and mammalian
tissues tested. These data show that the N-terminal GEF homology domain serves to inhibit the transforming effects of Sbfl, possibly sequestering the protein to the cytoplasm, and suggest that this region may be a modulatory domain that relays growth control signals.
Panel 4.1D Summary: Ag4849 The NOV3a gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_ panel_vl.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.
NOVla and NOVlc
Expression of gene NOVla and variant NOVlc was assessed using the primer-probe sets Ag400, Ag2866 and Ag3077, described in Tables 20, 21 and 22. Results of the RTQ-PCR runs are shown in Tables 23, 24, 25, and 26.
Table 20. Probe Name Ag400
Table 21. Probe Name Ag2866
Table 23. Panel 1
Table 24. Panel 1.3D
Table 25. Panel 2D
Table 26. Panel 4D
Panel 1 Summary: Ag400 Two experiments with the same probe and primer produce results that are in very good agreement, with highest expression of the NOVla gene in a lung cancer cell line and the brain. There are also significant levels of expression in clusters of cell lines derived from prostate, renal, ovarian, brain, and colon cancers. This suggests that expression of this gene may be associated with these cancers. Therefore, therapeutic modulation of this gene might be of use in the treatment of these cancers.
In addition, this gene, a laminin alpha 5 homolog, is expressed in several metabolic tissues including liver, pancreas and skeletal muscle. The gene also shows moderate to high levels of expression in several endocrine tissues including, pituitary, thyroid and testes, indicating an importance in general endocrine physiology. Thus, these levels of expression indicate that laminin alpha 5 may be involved in both endocrine and metabolic processes. Therapeutic modulation of this gene and/or gene product may therefore aid in the treatment of a number of endocrine disorders including metabolic disease.
This panel confirms the expression of this gene at moderate levels in all regions of the CNS examined. For a discussion of utility of this gene in the central nervous system, please see panel 1.3D.
Panel 1.3D Summary: Ag2866/3077 The expression of the NOVla gene was assessed in two independent runs on this panel using two independent probes. There is reasonably good concordance between the runs with the highest expression in liver adenocarcinoma (CTs=24- 28). There is also significant expression of this gene in prostate, renal, ovarian, lung, brain and colon cancer cell lines. This pattern is in agreement with the expression seen in Panel 1, with these data indicating that the expression of this gene might be associated with cancer of these tissues. Therefore, therapeutic modulation of this gene might be of use in the treatment of these cancers. The gene, a laminin alpha 5 homolog, is also expressed in several metabolic tissues including adipose, liver, pancreas and skeletal muscle. The gene also has moderate to high levels of expression in several endocrine tissues as well, including pituitary, thyroid, and ovaries and testes. This expression profile suggests that this gene product may play a role in general endocrine physiology and be involved in both endocrine and metabolic processes. Therefore, therapeutic modulation of this gene and/or gene product may aid in the treatment of a number of endocrine disorders including metabolic disease.
In addition, this gene is expressed at moderate levels in all regions of the CNS examined. Laminin has been implicated in muscular dystrophy. Laminin alpha2 chain deficiency causes merosin-deficient congenital muscular dystrophy. Furthermore, laminin
alpha 5 may be a functional component of the neuromuscular synapse. Therefore, therapeutic modulation of this gene maybe of use in the treatment of muscular dystrophy. References:
Nakagawa M, Miyagoe-Suzuki Y, Lkezoe K, Miyata Y, Nonaka I, Harii K, Takeda S. Schwann cell myelination occurred without basal lamina formation in laminin alpha2 chain- null mutant (dy3K/dy3K) mice. Glia 2001 Aug;35(2): 101-10
The laminin alpha2 chain is a major component of basal lamina in both skeletal muscle and the peripheral nervous system. Laminin alpha2 chain deficiency causes merosin-deficient congenital muscular dystrophy, which affects not only skeletal muscles, but also the peripheral and central nervous systems. It has been reported that the formation of basal lamina is required for myelination in the peripheral nervous system. In fact, the spinal root of dystrophic mice (dy/dy mice), whose laminin alpha2 chain expression is greatly reduced, shows lack of basal lamina and clusters of naked axons. To investigate the role of laminin alpha2 chain and basal lamina in vivo, we examined the peripheral nervous system of dy3K/dy3K mice, which are null mutants of laminin alpha2 chain. The results indicate the presence of myelination although Schwann cells lacked basal lamina in the spinal roots of dy3K/dy3K mice, suggesting that basal lamina is not an absolute requirement for myelination in vivo, fmmunohistochemically, the expression of laminin alpha4 chain was increased and laminin alpha5 chain was preserved in the endoneurium of the spinal root. Laminin alpha4 and alpha5 chains may play the critical role in myelination instead of laminin alpha2 chain in dy3K dy3K mice. In addition, the motor conduction velocity of the sciatic nerve was significantly reduced compared with that of wild-type littennate. This reduction in conduction velocity may be due to small axon diameter, thin myelin sheath and the patchy disruption of the basal lamina of the nodes of Ranvier in dy3K/dy3K mice. Son YJ, Scranton TW, Sunderland WJ, Baek SJ, Miner JH, Sanes JR, Carlson SS. The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve teπninal surface. J Biol Chem 2000 Jan 7;275(l):451-60
Interactions between growing axons and synaptic basal lamina components direct the formation of neuromuscular junctions during nerve regeneration. Isoforms of laminin containing alpha5 or beta2 chains are potential basal lamina ligands for these interactions. The nerve terminal receptors are unknown. Here we show that SV2, a synaptic vesicle transmembrane proteoglycan, is complexed with a 900-kDa laminin on synaptosomes from the electric organ synapse that is similar to the neuromuscular junctions. Although two laminins are present on synaptosomes, only the 900-kDa laminin is associated with SV2. Other nerve
terminal components are absent from this complex. The 900-kDa laminin contains an alpha5, a betal, and a novel gamma chain. To test whether SV2 directly binds the 900-kDa laminin, we looked for interaction between purified SV2 and laminin-1, a laminin isoform with a similar structure. We find SV2 binds with high affimty to purified laminin-1. Our results suggest that a synaptic vesicle component may act as a laminin receptor on the presynaptic plasma membrane; they also suggest a mechanism for activity-dependent adhesion at the synapse.
Panel 2.2 Summary: Ag3077 Data from one run with the NOVla gene is not included because the amp plot indicates that there were experimental difficulties with this run.
Panel 2D Summary: Ag2866 The NOVla gene is moderately expressed in all the tissues used in this panel. There is increased expression in stomach, breast and ovarian cancer samples compared to normal adjacent tissues from the same sample. Therefore, expression of this gene could potentially be used as a diagnostic marker for the presence of these cancers. Furthermore, therapeutic modulation of the activity of the gene product through the use of antibodies, small molecule inhibitors and chimeric molecules may be effective in the treatment of these cancers.
Panel 4D Summary: Ag2866/Ag3077 Two experiments with two different probe and primer sets produce results that are in very good agreement, with highest expression of the NOV1A gene in activated-NCI-H292 mucoepidermoid cells (CTs=24-28). Significant levels of expression are seen in IL-4, IL-9, IL-13 and LFN gamma activated-NCI-H292 mucoepidermoid cells as well as untreated NCI-H292 cells. Moderate/low expression is also detected in IL-4, IL-9, IL-13 and LFN gamma activated lung fibroblasts, human pulmonary aortic endothelial cells (treated and untreated), small airway epithelium (treated and untreated), treated bronchial epithelium and lung microvascular endothelial cells (treated and untreated). The expression of this gene in cells derived from or within the lung suggests that this gene may be involved in normal conditions as well as pathological and inflammatory lung disorders that include chronic obstructive pulmonary disease, asthma, allergy and emphysema. Moderate/low expression of NOVl A is also detected in treated and untreated HUVECs (endothelial cells), coronary artery smooth muscle cells (treated and untreated), treated and untreated astrocytes, treated KU-812 basophils, treated and untreated CCD1106 keratinocytes, IL-4 treated dennal fibroblasts, and normal tissues that include lung, colon, thymus and kidney. Low level expression is also detected in treated and untreated Ramos (B cell) cells as well as liver cirehosis and lupus kidney samples. Expression in the various immune cell types (as well as in diseased tissue samples) suggests that therapeutic modulation of NOVla may ameliorate symptoms associated with infectious conditions as well as inflammatory and
autoimmune disorders that include psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis. Also, owing to the importance of immune cells/lymphoid cells (eg. T and B cells) in lupus and cinhosis, therapeutic modulation of NOVl A may ameliorate symptoms associated with lupus and other autoimmune diseases as well as liver cinhosis. NOVla may also serve as a marker for these diseases.
NOV14b
Expression of gene NOVl 4b was assessed using the primer-probe set Ag2908, described in Table 27. Results of the RTQ-PCR runs are shown in Table 28.
Table 27. Probe Name Ag2908
Table 28. Panel 4D
CNS_neurodegeneration_vl.O Summary: Ag2908 Expression of theNOV14b gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)
Panel 1.3D Summary: Ag2908 Expression of the NOV14b gene is restricted to bone manow (01=34.78). Thus, expression of this gene could be used as a marker for this tissue.
Panel 4D Summary: Ag2908 The NOV14b gene is expressed at low levels in resting lymphokine activated killer cells (LAK), resting macrophages and monocytes., and CCD1070 dermal fibroblasts treated with TNF alpha. Low level expression is also detected in both stimulated and resting dendritic cells. The expression of this gene in resting cells of these lineages suggests that the protein encoded by this transcript may be involved in normal immunological processes associated with immune homeostasis. Expression in TNFalpha treated dermal fibroblasts also suggests that this gene product maybe involved in skin disorders, including psoriasis. hi addition, low level expression of this transcript is detected in stimulated lymphokine-activated killer cells (LAK). Since these cells are involved in tumor immunology and tumor cell clearance, as well as virally and bacterial infected cells, therapeutic modulation of this gene product may alter the functions of these cells and lead to improvement in cancer cell killing as well as host immunity to microbial and viral infections. This expression in immune cells suggests that therapeutic modulation of this gene product may ameliorate symptoms associated with inflammatory and autoimmune disorders that include psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.
NOVll
Expression of gene NOVl 1 was assessed using the primer-probe sets Agl522, Agl848, Ag2263 and Ag2422, described in Tables 29, 30, 31and 32. Results of the RTQ-PCR runs are shown in Tables 33, 34, 35, 36, 37, 38, 39 and 40.
Table 30. Probe Name Agl848
Table 33. Al comprehensive panel vl.O
Table 34. CNS neurodegeneration vl.O
Table 35. Panel 1.2
Table 36. Panel 1.3D
Adipose 3.6 2.3 5.1 2.9
Table 37. Panel 2D
Table 38. Panel 3D
Table 39. Panel 4D
Table 40. Panel CNS 1
AT_comprehensive panel_vl.O Summary: Agl 522/1848: The results of two runs with the same probe and primer set are in good agreement. Low to moderate levels of expression of the NOVl 1 gene are detected in samples derived from osteoarthritic (OA) bone and adjacent bone as well as OA cartilage, OA synovium and OA synovial fluid samples. Low level expression is also detected in cartilage, bone, synovium and synovial fluid samples from rheumatoid arthritis patients. With the exception of the cartilage Rep20 sample, no significant expression is detected in nonnal samples of cartilage, synovium, bone or synovial fluid cells. Low level expression is also detected in samples derived from normal lung samples, COPD lung, emphysema, atopic asthma, asthma, allergy, Crohn's disease (normal matched control and diseased), ulcerative colitis(normal matched control and diseased), and psoriasis (nonnal matched control and diseased). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, allergy, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.
CNS neurodegeneration vl.O Summary: Agl848/Ag2263/Ag2422 Multiple experiments using different probe/primer sets produce results that are in good agreement. Highest expression of the NOVl 1 gene is detected in the occipital cortex of a control patient. Significant levels of expression are also detected in the hippocampus, inferior temporal cortex, and the superior temporal cortex of brain tissue from an Alzheimer's patient.
Based on its homology, the NOVl 1 gene product is most similar to an UNC5H receptor, which as a class are known to act both in axon guidance and neuronal migration during development, as well as inducers of apoptosis (except when stimulated by the ligand netrin-1). Panel CNS_Neurodegeneration_V1.0 shows a moderate increase (1.5 to 2-fold) in the temporal cortex of the Alzheimer's disease brain when compared to non-demented elderly either with or without a high amyloid plaque load [this difference is apparent after scaling the RTQ-PCR data based upon overall RNA amount/quality, and is most apparent on Aq2263]. Thus, the NOVl 1 gene represents a protein that differentiates demented and non-demented elderly who have a severe amyloid plaque load, making it an excellent drug target in Alzheimer's disease. The modulation and/or selective stimulation of this receptor may be of
use in enhancing or directing compensatory synaptogenesis and axon/dendritic outgrowth in response to neuronal death (stroke, head trauma) neurodegeneration (Alzheimer's, Parkinson's, Huntington's, spmocerebellar ataxia, progressive supranuclear palsy) or spinal cord injury. Furthermore, antagonism of this receptor may decrease apoptosis in Alzheimer's disease. References:
Ellezam B, Selles-Navaπo I, Manitt C, Kennedy TE, McKeπacher L. Expression of netrin-1 and its receptors DCC and UNC-5H2 after axotomy and during regeneration of adult rat retinal ganglion cells. Exp Neurol 2001 Mar;168(l):105-15
Netrins are a family of chemofropic factors that guide axon outgrowth during development; however, their function in the adult CNS remains to be established. We examined the expression of the netrin receptors DCC and UNC5H2 in adult rat retinal ganglion cells (RGCs) after grafting a peripheral nerve (PN) to the transected optic nerve and following optic nerve transection alone. In situ hybridization revealed that both Dec and Unc5h2 mRNAs are expressed by normal adult RGCs. In addition, netrin-1 was found to be constitutively expressed by RGCs. Quantitative analysis using in situ hybridization demonstrated that both Dec and Unc5h2 were down-regulated by RGCs following axotomy. In the presence of an attached PN graft, Dec and Unc5h2 were similarly down-regulated in surviving RGCs regardless of their success in regenerating an axon. Northern blot analysis demonstrated expression of netrin-1 in both optic and sciatic nerve, and Western blot analysis revealed the presence of netrin protein in both nerves. Lmmunohistochemical analysis indicated that netrin protein was closely associated with glial cells in the optic nerve. These results suggest that netrin-1, DCC, and UNC5H2 may contribute to regulating the regenerative capacity of adult RGCs.
Braisted JE, Catalano SM, Stimac R, Kennedy TE, Tessier-Lavigne M, Shatz CJ, O'Leary DD Netrin-1 promotes thalamic axon growth and is required for proper development of the thalamocortical projection. J Neurosci 2000 Aug 1;20(15):5792-801
The thalamocortical axon (TCA) projection originates in dorsal thalamus, conveys sensory input to the neocortex, and has a critical role in cortical development. We show that the secreted axon guidance molecule netrin-1 acts in vitro as an attractant and growth promoter for dorsal thalamic axons and is required for the proper development of the TCA projection in vivo. As TCAs approach the hypothalamus, they turn laterally into the ventral telencephalon and extend toward the cortex through a population of netrin-1 -expressing cells. DCC and neogenin, receptors implicated in mediating the attractant effects of netrin-1, are expressed in dorsal thalamus, whereas unc5h2 and unc5h3, netrin-1 receptors implicated in
repulsion, are not. In vitro, dorsal thalamic axons show biased growth toward a source of netrin-1, which can be abolished by netrin-1 -blocking antibodies. Netrin-1 also enhances overall axon outgrowth from explants of dorsal thalamus. The biased growth of dorsal thalamic axons toward the internal capsule zone of ventral telencephalic explants is attenuated, but not significantly, by netrin-1 -blocking antibodies, suggesting that it releases another attractant activity for TCAs in addition to netrin-1. Analyses of netrin-1 -/- mice reveal that the TCA projection through the ventral telencephalon is disorganized, their pathway is abnoπnally ' restricted, and fewer dorsal thalamic axons reach cortex. These findings demonstrate that netrin-1 promotes the growth of TCAs through the ventral telencephalon and cooperates with other guidance cues to confrol their pathfinding from dorsal thalamus to cortex.
Panel 1.2 Summary: Agl522 Expression of the NOVl 1 gene is highest in CNS cancer cell lines (CT=26.1). Of nine tissue samples derived from CNS cancer cell lines, expression of the NOVll gene occurs in all samples, with expression high (CT=26.1, 26.6, 27.6) in three samples, moderate in five samples and low in one sample. High expression is also detectable in melanoma cell lines (CT=27.9). Significant expression of the NOVl 1 gene is seen in gastric cancer (28.1) and all ten samples of lung cancer cell lines in this sample. Thus, expression of the NOVl 1 gene could be used to distinguish those cancer cell lines from normal tissues, hi addition, therapeutic modulation of the expression, or activity of the NOVl 1 gene product, might be of use in the treatment of melanoma, gastric cancer, lung cancer and brain cancer.
Panel 1.3D Summary: Agl522/Agl848/Ag2263/Ag2422 Four experiments using different probe/primer sets on the same tissue panel produce results that are in excellent agreement. In all four experiments, highest expression of the NOVl 1 gene is detected in CNS cancer cell lines. Expression is also significant in lung cancer and melanoma cell lines and in healthy brain tissue from the hippocampus and thalamus regions. Thus, the expression of the NOVl 1 gene could be used to distinguish these tissue samples from other samples. Moreover, therapeutic modulation of the expression, or function, of the NOVl 1 gene, through the use of small molecule drugs or antibodies, might be beneficial in the treatment of melanoma, lung cancer and brain cancer. Among metabolic tissues, there is high expression of the NOVl 1 gene in adult heart tissue (CT=27.8) and moderate expression in fetal heart, adult and fetal liver, pancreas, adrenal gland, thyroid and pituitary. The NOVl 1 gene appears to be differentially expressed in fetal (CT value = 31) and adult skeletal muscle (CT value = 37) using the probe and primer set
Agl848 and maybe useful for the differentiation of the adult from the fetal phenotype in this tissue.
Panel 2D Summary: Agl522/Agl848/Ag2263/Ag2422 Results from multiple experiments with four different probe and primer sets are in very good agreement. In all experiments, highest expression of the NOVl 1 gene is detected in thyroid and ovarian cancers (CTs = 27-30), with lower expression also seen in most of the other tissues on this panel. Thus, the expression of the NOVl 1 gene could be used to distinguish ovarian and thyroid cancer cell lines from other tissues. Moreover, therapeutic modulation of the expression this gene, or its function, through the use of small molecule drags or antibodies, might be of benefit in the treatment of ovarian and thyroid cancer. In addition, experiments with Ag2263 show differential expression between samples derived from lung cancer and their adjacent normal tissues. Thus, expression of the NOVl 1 gene could be used to distinguish cancerous lung tissue from normal lung tissue. Moreover, therapeutic modulation of the expression or function of this gene or its protein product, through the use of antibodies or small molecule drugs, might be of benefit in the treatment of lung cancer.
Panel 3D Summary: Ag2263 Expression of the NOVl 1 gene occurs at moderate levels across all the tissues in this panel. Highest expression is detected in a small cell lung cancer (CT = 30.6) and neuroblastoma (CT = 30.7). In addition, significant expression is detected in a cluster of small cell lung cancer lines. Thus, this gene could be used to distinguish lung cancer cell lines from other samples. Moreover, therapeutic modulation of the NOVl 1 gene or its protein product, through the use of small molecule drags or antibodies might be of benefit in the treatment of small cell lung cancer.
Panel 4D Summary: Agl522/Agl848/Ag2263/Ag2422 Experiments using each of the four probe and primer sets that conespond to the NOVl 1 gene produce results that are in excellent agreement. In all the experiments, expression of the NOVl 1 gene occurs at moderate to low levels in many of the tissues h the sample. Highest expression in each experiment occurs in lung fibroblasts (CT = 29). Moderate expression in lung fibroblasts treated with LL-4 is also consistent among all four experiments (CT = 30). Lower expression is also detected in a variety of fibroblasts, endothelial and smooth muscle cells. The expression of the NOVl 1 gene produces a complex profile; it is upregulated by TNF-alpha in small airway epithelium, but clearly downregulated by the same stimulus in lung fibroblasts. The gene most probably encodes a netrin receptor that may be important in understanding cell migration. Regulation of the protein encoded for by the NOVl 1 gene could potentially control the progression of keloid
formation, emphysema and other conditions in which TNF-alpha and IL-1 beta are present and tissue remodeling may occur.
Panel CNS_1 Summary: Ag2263 Expression of the NOVl 1 gene is moderate to low across many of the tissues in this panel. Highest expression is detected in the substantia nigra (CT = 31.4). Although no disease-specific expression is seen in this panel, the expression profile confirms the expression of this gene in the central nervous system. Please see panel_CNS_neurodegeneration for potential utility of the NOVl 1 gene regarding the CNS.
NOVIO
Expression of gene NOVIO was assessed using the primer-probe set Ag2421, described in Table 41. Results of the RTQ-PCR runs are shown in Tables 42 and 43.
Table 42. Panel 1.3D
Panel 1.3D Summary: Ag2421 Expression of the NOVIO gene is restricted to samples from liver, lung and trachea in this panel (CTs=32-33), while none of the cancer cell lines appear to make this protein. Thus, lack of expression of this gene might be significant for cell proliferation and growth.
Furthermore, the difference in expression between adult liver and fetal liver (CT=40) could be used to distinguish between the two sources of liver tissue.
Panel 2D Summary: Ag2421 The NOV10 gene encodes a protein homologous to pregnancy zone protein (PZP), a liver protein, and. is expressed primarily in liver tissue. This gene shows a higher level of expression in nonnal liver than the matched tumor tissue, metastatic melanoma and metastatic colon cancer. There is also higher expression in normal lung compared to lung cancer samples. This expression profile is in agreement with the results from Panel 1.3D. Thus, this expression could potentially be used as a diagnostic marker for liver and lung cancer. Furthermore, the protein product could potentially be used as a therapy for lung and liver cancer.
References:
Mavroidis M, Sunyer JO, Lambris ID. Isolation, primary stracture, and evolution of the third component of chicken complement and evidence for a new member of the alpha 2- macroglobulin family. J Immunol 1995 Mar l;154(5):2164-74
Although the third component of complement, C3, has been isolated and its primary structure determined from most living classes of vertebrate, limited information is available on its stracture and function for aves, which represent a significant stage in complement
evolution, hi this study, we present the complete cDNA sequence of chicken C3, the cDNA sequences of the hioester region for two chicken alpha 2-macro globulin (alpha 2M)-related proteins, a simplified method for purifying chicken C3, and an analysis of the C3 convertase and factor I-mediated cleavages in chicken C3. Using the reverse-transcriptase PCR, with degenerate oligonucleotide primers derived from two conserved C3 sequences
(GCGEQN/TM, TWLTAY/FV) and liver mRNA as template, we isolated three distinct 220- bp PCR products, one with a high degree of sequence similarity to C3 and two to alpha 2M and pregnancy zone protein from other species. The complete cDNA sequence of chicken C3 was obtained by screening a chicken liver lambda gtlO library with the C3 PCR product and probes from the 5' end of the partial-length C3 clones. The obtained sequence is in complete agreement with the protein sequence of several tryptic peptides of purified chicken C3. Chicken pro-C3 consists of an 18-residue putative signal peptide, a 640-residue beta-chain (70 kDa), a 989-residue alpha-chain (111 kDa), and an RKRR linker region. It contains an internal thioester and three potential N-glycosylation sites, all in the alpha-chain. The convertase cleavage site, predicted to be Arg-Ser, was confirmed by sequencing the zymosan-bound C3 fragments generated upon complement activation. NH2-terminal sequencing of the purified C3 chains showed that 1) pro-C3 is indeed cleaved at the RKRR linker sequence to generate the mature two-chain molecule, and 2) the beta-chain of chicken C3 is blocked. The deduced amino acid sequence shows 54, 54, 54, 53, 52, 57, and 55% amino acid identities to human, mouse, rat, guinea pig, rabbit, cobra, and Xenopus C3, respectively, and an identity of 44, 31, and 33% to trout, hagfish, and lamprey C3, respectively. The identities to human C4, C5, and alpha 2M are 31, 29 and 23%, respectively. A phylogenetic tree for C3, C4, C5, and alpha 2M- related proteins was constructed based on the sequence data and is discussed.
PMLD: 7532662
Panel 4D Summary: Ag2421 Results from one experiment with the NOV10 gene are not included. The amp plot indicates that there is a high probability of a probe failure. (Data not shown.)
NOV9
Expression of gene NOV9 was assessed using the primer-probe set Ag2873, described in Table 44.
Table 44. Probe Name Ag2873
CNS_neurodegeneration_vl.O Summary: Ag2873 Expression of theNOV9 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)
Panel 1.3D Summary: Ag2873 Expression of the NOV9 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)
Panel 2D Summary: Ag2873 Expression of the NOV9 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)
Panel 4D Summary: Ag2873 Results from experiment with the NOV9 gene are not included. The amp plot indicates that there were experimental difficulties with this ran.
NOV7a
Expression of gene NOV7a was assessed using the primer-probe set Ag2878, described in Table 45. Results of the RTQ-PCR rans are shown in Tables 46, 47, and 48.
Table 45. Probe Name Ag2878
Table 46. CNS_neurodegeneration_vl.0
Table 47. Panel 1.3D
Table 48. Panel CNS 1
CNS_neurodegeneration_vl.O Summary: Ag2878 No differential expression of the NOV7a gene is found between Alzheimer's disease and control postmortem brains. This panel confirms the expression of this gene at moderate level in the CNS m an independent group of patients. Please see panel 1.3D for a discussion of utility of this gene in the central nervous system.
Panel 1.3D Summary: Ag2878 The expression of the NOV7a gene shows a CNS- preferential expression profile. Because it is not detected in any cancers, this gene is an excellent diagnostic device to differentiate normal CNS tissue from glioma. Furthermore, it may be useful as a tumor suppressor gene in the treatment of brain cancer.
Panel 4D Summary: Ag2878 Expression of the NOV7a gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.)
Panel CNS_1 Summary: Ag2878 This panel confirms the expression of the NOV7a gene at moderate level in the CNS in an independent group of patients. Please see panel 1.3D for a discussion of utility of this gene in the central nervous system.
NOV6
Expression of gene NOV6 was assessed using the primer-probe set Agl799, described in Table 49. Results of the RTQ-PCR rans are shown in Tables 50, 51 and 52.
Table 49. Probe Name Agl799
Table 50. Panel 1.3D
Table 51. Panel 2D
Table 52. Panel 4D
CNS_neurodegeneration_vl.0 Summary: Agl799 Expression of the NOV6 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.
Panel 1.3D Summary: Agl799 Expression of the NOV6 gene is restricted to a few samples, with highest expression in the trachea and adrenal gland (CTs=31). Thus, expression of this gene could be used as a marker of these tissue types.
Panel 2D Summary: Agl799 Expression of the NOV6 gene is restricted to a samples derived from thyroid (CT=33.5). Thus, expression of this gene could be used as a marker of thyroid tissue.
Panel 4D Summary: Agl799 Expression of the NOV6 gene is restricted to a samples derived from thymus and kidney (CTs=33-34). Thus, expression of this gene could be used as a marker of these tissues.
Panel 5D Summary: Agl799 Expression of the NOV6 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The amp plot indicates that there is a high probability of a probe failure.
NOV5
Expression of gene NOV5 was assessed using the primer-probe set Ag2911, described in Table 53. Results of the RTQ-PCR runs are shown in Table 54.
Table 53. Probe Name Ag2911
Table 54. Panel 1.3D
CNS_neurodegeneration_vl.O Summary: Ag2911 Amp plot shows that there were experimental difficulties with this run and gene NOV5. (Data not shown.)
Panel 1.3D Summary: Ag2911 The NOV5 gene, a fatty acid binding homolog, appears to be differentially expressed in adult (CT value = 34) vs fetal skeletal muscle (CT value = 38). This gene product may be useful for the differentiation of the adult from the fetal source of this tissue. Fatty acid binding proteins sequester fatty acid moieties thereby protecting against intracellular lipotoxicity. Thus, an activator of this gene product maybe a treatment for the prevention of lipotoxicity in skeletal muscle. Furthennore, increased intracellular triglyceri.de accumulation is considered to be pathogenically important in skeletal muscle insulin resistance and Type 2 diabetes. Thus, therapeutic modulation of the expression or function of this gene may be effective in the treatment of Type 2 diabetes.
References:
Unger R, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001 Feb;15(2):312-21. Review. Obesity-related diseases now threaten to reach epidemic proportions in the United
States. Here we review in a rodent model of genetic obesity, the fa/fa Zucker diabetic fatty (ZDF) rat, the mechanisms involved in the most common complications of diet-induced human obesity, i.e., noninsulin-dependent diabetes mellitus, and myocardial dysfunction. In ZDF rats, hyperphagia leads to hyperinsulinemia, which up-regulates transcription factors that stimulate lipogenesis. This causes ectopic deposition of triacylglycerol in nonadipocytes, providing fatty acid (FA) substrate for damaging pathways of nonoxidative metabolism, such as ceramide synthesis. In beta cells and myocardium, the resulting functional impairment and apoptosis cause diabetes and cardiomyopathy. Interventions that lower ectopic lipid accumulation or block nonoxidative metabolism of FA and ceramide formation completely prevent these complications. Given the evidence for a similar etiology for the complications of human obesity, it would be appropriate to develop strategies to avert the predicted epidemic of lipotoxic disorders.
PMLD: 11156947
Unger R, Orci L. Lipotoxic diseases of nonadipose tissues in obesity, hit J Obes Relat Metab Disord. 2000 Nov;24 Suppl 4:S28-32. Review.
It is proposed that an important function of leptin is to confine the storage of triglycerides (TG) to the adipocytes, while limiting TG storage in nonadipocytes. Excess TG deposition in nonadipocytes leads to impairment of functions, increased ceramide formation, which triggers nitric oxide-mediated lipotoxicity and lipoapoptosis. The fact that TG content
in nonadipocytes noπnally remains within a very nanow range inespective of excess caloric intake, while TG content of adipocytes rises, is consistent with a system of fatty acid (FA) homeostasis in nonadipose tissues. When leptin is deficient or leptin receptors are dysfunctional, TG content in nonadipose tissues such as pancreatic islets, heart and skeletal muscle, can increase 10-50-fold, suggesting that leptin controls the putative homeostatic system for intracellular TG. The fact that function and viability of nonadipocytes is compromised when their TG content rises above normal implies that nonnal homeostasis of their intracellular FA is critical for prevention of complications of obesity. FA overload of skeletal muscle, myocardium and pancreatic islets cause, respectively, insulin resistance, lipotoxic heart disease and adipogenic type 2 diabetes. All can be completely prevented by treatment with antisteatotic agents such as troglitazone. hi diet-induced obesity, leptin signaling is normal initially and lipotoxic changes are at first prevented; later, however, post- receptor leptin resistance appears, leading to dysfunction and lipoapoptosis in nonadipose tissues, the familiar complications of obesity.
PMLD: 11126236
Panel 2D Summary: Ag2911 Expression of geneNOV5 is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)
Panel 4D Summary: Ag2911 Expression of gene NOV5 is low/undetectable in all samples on this panel (CTs>35). (Data not shown.)
NOV13
Expression of gene NOV13 was assessed using the primer-probe set Agl559, described in Table 55. Results of the RTQ-PCR runs are shown in Table 56.
Table 56. Panel 5D
Cells
Panel 1.3D Summary: Agl559 Expression of the NOV13 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The data suggest that there was a possible probe failure. Panel 2.2 Summary: Agl559 Expression of the NOV13 gene is low/undetectable in all samples on this panel. (CTs>35). (Data not shown.) The data suggest that there was a possible probe failure.
Panel 5D Summary: Agl559 Expression of the NOV13 gene is limited to placental tissue (CT=34.7). Thus, expression of this gene could be used as a marker for this tissue. Furthermore, this novel cytoplasmic protein may be important for the patho genesis, diagnosis, and/or treatment of reproductive diseases.
Example 3. SNP analysis of NOVX clones
SeqCallingTM Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, cell lines, primary cells or tissue cultured primary cells and cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression for example, growth factors, chemokines, steroids. The cDNA thus derived was then sequenced using CuraGen's proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for conections if appropriate. cDNA sequences from all samples were assembled with themselves and with public ESTs using bioinformatics programs to generate CuraGen's human SeqCalling database of SeqCalling assemblies. Each assembly contains one or more overlapping cDNA sequences derived from one or more human samples. Fragments and ESTs were included as components for an assembly when the extent of identity with another component of the assembly was at least 95% over 50 bp. Each assembly can represent a gene and/or its variants such as splice forms and/or single nucleotide polymorphisms (SNPs) and their combinations.
Variant sequences are included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be refened to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or
a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion ofa nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, however, in the case that a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region ofa gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern for example, alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, stability of transcribed message.
Method of novel SNP Identification: SNPs are identified by analyzing sequence assemblies using CuraGen's proprietary SNPTool algorithm. SNPTool identifies variation in assemblies with the following criteria: SNPs are not analyzed within 10 base pairs on both ends of an alignment; Window size (number of bases in a view) is 10; The allowed number of mismatches in a window is 2; Minimum SNP base quality (PHRED score) is 23; Minimum number of changes to score an SNP is 2/assembly position. SNPTool analyzes the assembly and displays SNP positions, associated individual variant sequences in the assembly, the depth of the assembly at that given position, the putative assembly allele frequency, and the SNP sequence variation. Sequence traces are then selected and brought into view for manual validation. The consensus assembly sequence is imported into CuraTools along with variant sequence changes to identify potential amino acid changes resulting from the SNP sequence variation. Comprehensive SNP data analysis is then exported into the SNPCalling database.
Method of novel SNP Confirmation: SNPs are confirmed employing a validated method know as Pyrosequencing (Pyrosequencing, Westborough, MA). Detailed protocols for Pyrosequencing can be found in: Alderboni et al. Determination of Single Nucleotide
Polymorphisms by Real-time Pyrophosphate DNA Sequencing. (2000). Genome Research. 10, Issue 8, August. 1249-1265. hi brief, Pyrosequencing is a real time primer extension process of genotyping. This protocol takes double-stranded, biotinylated PCR products from genomic DNA samples and binds them to streptavidin beads. These beads are then denatured producing single stranded bound DNA. SNPs are characterized utilizing a technique based on an indirect bioluminometric assay of pyrophosphate (PPi) that is released from each dNTP upon DNA chain elongation. Following Klenow polymerase-mediated base incorporation, PPi is released and used as a substrate, together with adenosine 5'-phosphosulfate (APS), for ATP sulfurylase, which results in the formation of ATP. Subsequently, the ATP accomplishes the conversion of
luciferin to its oxi-derivative by the action of luciferase. The ensuing light output becomes proportional to the number of added bases, up to about four bases. To allow processivity of the method dNTP excess is degraded by apyrase, which is also present in the starting reaction mixture, so that only dNTPs are added to the template during the sequencing. The process has been fully automated and adapted to a 96-well format, which allows rapid screening of large SNP panels. The DNA and protein sequences for the novel single nucleotide polymorphic variants are reported. Variants are reported individually but any combination of all or a select subset of variants are also included. In addition, the positions of the variant bases and the variant amino acid residues are underlined.
Results j
Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.
NOV2a SNP data: NOV2a has two SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ LD NOs:9 and 10, respectively. The nucleotide sequence of the NOV2a variant differs as shown in Table 57.
NOV2b SNP data:
NOV2b has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ LD NOs:l 1 and 12, respectively. The nucleotide sequence of the NOV2b variant differs as shown in Table 58.
NOV2c SNP data:
NOV2c has four SNP variants, whose variant positions for its nucleotide and amino acid sequences is numbered according to SEQ ED NOs:13 and 14, respectively. The nucleotide sequence of the NOV2c variant differs as shown in Table 59.
NOV6 SNP data:
NOV6 has one SNP variant, whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:25 and 26, respectively. The nucleotide sequence of the NOV6 variant differs as shown in Table 60.
NOV7a SNP data: NOV7a has one SNP variant, whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:27 and 28, respectively. The nucleotide sequence of the NOV7a variant differs as shown in Table 61.
NOV8 SNP data:
NOV8 has one SNP variant, whose variant position for its nucleotide and amino acid sequences is numbered according to SEQ ID NOs:31 and 32, respectively. The nucleotide sequence of the NOV8 variant differs as shown in Table 62.
Example 4. In-frame Cloning NOV2e
For NOV2e the cDNA coding for the DOMAIN of NOVla from residues 51 to 400 was targeted for "in-frame" cloning by PCR. The PCR template was based on the previously identified plasmid, when available, or on human cDNA(s).
Table 99. Oligonucleotide primers used to clone the target cDNA sequence:
For downstream cloning purposes, the forward primer includes an in-frame Hind III restriction site and the reverse primer contains an in-frame Xho I restriction site. Two parallel PCR reactions were set up using a total of 0.5-1.0 ng human pooled cDNAs as template for each reaction. The pool is composed of 5 micro grams of each of the following human tissue cDNAs: adrenal gland, whole brain, amygdala, cerebellum, thalamus, bone manow, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, liver, lymphoma, Burkitt's Raji cell line, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small Intestine, spleen, stomach, thyroid, trachea, uterus.
When the tissue of expression is known and available, the second PCR was performed using the above primers and 0.5ng-1.0 ng of one of the following human tissue cDNAs: skeleton muscle, testis, mammary gland, adrenal gland, ovary, colon, normal cerebellum, normal adipose, normal skin, bone manow, brain amygdala, brain hippocampus, brain substantia nigra, brain thalamus, thyroid, fetal lung, fetal liver, fetal brain, kidney, heart, spleen, uterus, pituitary gland, lymph node, salivary gland, small intestine, prostate, placenta, spinal cord, peripheral blood, trachea, stomach, pancreas, hypothalamus.
The reaction mixtures contained 2 microliters of each of the primers (original concentration: 5 pmol/ul), 1 microliter of lOmM dNTP (Clontech Laboratories, Palo Alto CA) and 1 microliter of 50xAdvantage-HF 2 polymerase (Clontech Laboratories) in 50 microliter- reaction volume. The following reaction conditions were used:
PCR condition 1: a) 96°C 3 minutes b) 96°C 30 seconds denaturation c) 60°C 30 seconds, primer annealing d) 72°C 6 minutes extension
Repeat steps b-d 15 times e) 96°C 15 seconds denaturation f) 60°C 30 seconds, primer annealing g) 72°C 6 minutes extension
Repeat steps e-g 29 times e) 72°C 10 minutes final extension
PCR condition 2: a) 96°C 3 minutes b) 96°C 15 seconds denaturation c) 76°C 30 seconds, primer annealing, reducing the temperature by 1 °C per cycle d) 72°C 4 minutes extension
Repeat steps b-d 34 times e) 72°C 10 minutes final extension
An amplified product was detected by agarose gel electrophoresis. The fragment was gel-purified and ligated into the pCR2.1 vector (Invitrogen, Carlsbad, CA) following the manufacturer's recommendation. Twelve clones per PCR reaction were picked and sequenced. The inserts were sequenced using vector-specific Ml 3 Forward and Ml 3 Reverse primers and the gene-specific primers in Tables 88 and 89.
Table 88. Gene-specific Primers
Table 89. Gene-specific Primers
OTHER EMBODIMENTS
Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.
Claims
WHAT IS CLAIMED IS:
An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting SEQ ID NOS :2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198; and
(d) a variant of an amino acid sequence selected from the group consisting of SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
The polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of a naturally-occurring allelic variant of an amino acid sequence selected from the group consisting SEQ ED NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198.
The polypeptide of claim 2, wherein said allelic variant comprises an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
The polypeptide of claim 1, wherein the amino acid sequence of said variant comprises a conservative amino acid substitution.
An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
(a) a mature fonn of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198;
(b) a variant of a mature fonn of an amino acid sequence selected from the group consisting of SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting of SEQ ED NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198;
(d) a variant of an amino acid sequence selected from the group consisting SEQ LD NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ED NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and
(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).
6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally-occurring allelic nucleic acid variant.
7. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of a naturally-occurring polypeptide variant.
8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197.
9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence selected from the group consisting of SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197;
(b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, provided that no more than 20% of the nucleotides differ from said nucleotide sequence;
(c) a nucleic acid fragment of (a); and
(d) a nucleic acid fragment of (b).
10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting SEQ LD NOS:l, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 197, or a complement of said nucleotide sequence.
11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
(a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid
sequence, provided that no more than 20% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence;
(b) an isolated second polynucleotide that is a complement of the first polynucleotide; and
(c) a nucleic acid fragment of (a) or (b).
12. A vector comprising the nucleic acid molecule of claim 11.
13. The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.
14. A cell comprising the vector of claim 12.
15. An antibody that binds immunospecifically to the polypeptide of claim 1.
16. The antibody of claim 15 , wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for deteimining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
(a) providing the sample;
(b) contacting the sample with an antibody that binds immunospecifically to the polypeptide; and
(c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
(a) providing the sample;
(b) contacting the sample with a probe that binds to said nucleic acid molecule; and
(c) determining the presence or amount of the probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. The method of claim 20 wherein the cell or tissue type is cancerous.
22. A method of identifying an agent that binds to a polypeptide of claim 1, the method comprising:
(a) contacting said polypeptide with said agent; and
(b) determining whether said agent binds to said polypeptide.
23. The method of claim 22 wherein the agent is a cellular receptor or a downstream effector.
24. A method for identifying an agent that modulates the expression or activity of the polypeptide of claim 1, the method comprising:
(a) providing a cell expressing said polypeptide;
(b) contacting the cell with said agent, and
(c) determining whether the agent modulates expression or activity of said polypeptide, whereby an alteration in expression or activity of said peptide indicates said agent modulates expression or activity of said polypeptide.
25. A method for modulating the activity of the polyp eptide of claim 1 , the method comprising contacting a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
26. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the polypeptide of claim 1 in an amount sufficient to treat or prevent said NOVX- associated disorder in said subject.
27. The method of claim 26 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.
28. The method of claim 26 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
29. The method of claim 26, wherein said subject is a human.
30. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the nucleic acid of claim 5 in an amount sufficient to treat or prevent said NOVX- associated disorder in said subject.
31. The method of claim 30 wherein the disorder is selected from the group consisting of cardiomyopathy and atherosclerosis.
32. The method of claim 30 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
33. The method of claim 30, wherein said subject is a human.
34. A method of treating or preventing a NOVX-associated disorder, said method comprising administering to a subject in which such treatment or prevention is desired the antibody of claim 15 in an amount sufficient to treat or prevent said NOVX- associated disorder in said subject.
35. The method of claim 34 wherein the disorder is diabetes.
36. The method of claim 34 wherein the disorder is related to cell signal processing and metabolic pathway modulation.
37. The method of claim 34, wherein the subject is a human.
38. A pharmaceutical composition comprising the polypeptide of claim 1 and a phaπnaceutically-acceptable carrier.
39. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically-acceptable carrier.
41. A kit comprising in one or more containers, the pharmaceutical composition of claim 38.
42. A kit comprising in one or more containers, the pharmaceutical composition of claim 39.
43. A kit comprising in one or more containers, the pharmaceutical composition of claim 40.
44. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
(a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
(b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease; wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
45. The method of claim 44 wherein the predisposition is to a cancer.
46. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
(a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
(b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
47. The method of claim 46 wherein the predisposition is to a cancer.
48. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 26, 28, 40, 42, 44, 46, and 198, or a biologically active fragment thereof.
49. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26001801P | 2001-01-05 | 2001-01-05 | |
US260018P | 2001-01-05 | ||
US26036001P | 2001-01-08 | 2001-01-08 | |
US260360P | 2001-01-08 | ||
US27241101P | 2001-02-28 | 2001-02-28 | |
US272411P | 2001-02-28 | ||
US27281701P | 2001-03-02 | 2001-03-02 | |
US272817P | 2001-03-02 | ||
US30323101P | 2001-07-05 | 2001-07-05 | |
US303231P | 2001-07-05 | ||
US30506001P | 2001-07-12 | 2001-07-12 | |
US305060P | 2001-07-12 | ||
US31840501P | 2001-09-10 | 2001-09-10 | |
US318405P | 2001-09-10 | ||
US31870001P | 2001-09-12 | 2001-09-12 | |
US318700P | 2001-09-12 | ||
US37417 | 2002-01-04 | ||
US10/037,417 US6903201B2 (en) | 2001-01-05 | 2002-01-04 | Proteins and nucleic acids encoding same |
PCT/US2002/000375 WO2002053742A2 (en) | 2001-01-05 | 2002-01-07 | Proteins and nucleic acids encoding same |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1383893A2 true EP1383893A2 (en) | 2004-01-28 |
Family
ID=27578133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02707409A Withdrawn EP1383893A2 (en) | 2001-01-05 | 2002-01-07 | Proteins and nucleic acids encoding same |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1383893A2 (en) |
JP (1) | JP2005509400A (en) |
CA (1) | CA2433782A1 (en) |
WO (1) | WO2002053742A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012054870A2 (en) * | 2010-10-21 | 2012-04-26 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030017457A1 (en) * | 2000-04-06 | 2003-01-23 | Fernandes, Elma R. | Novel polynucleotides and polypeptides encoded thereby |
US6635616B2 (en) * | 2000-05-01 | 2003-10-21 | The General Hospital Corporation | Laminin 15 |
NZ523122A (en) * | 2000-06-22 | 2004-06-25 | Smithkline Beecham Corp | Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases |
-
2002
- 2002-01-07 WO PCT/US2002/000375 patent/WO2002053742A2/en not_active Application Discontinuation
- 2002-01-07 EP EP02707409A patent/EP1383893A2/en not_active Withdrawn
- 2002-01-07 CA CA002433782A patent/CA2433782A1/en not_active Abandoned
- 2002-01-07 JP JP2002555249A patent/JP2005509400A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO02053742A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002053742A2 (en) | 2002-07-11 |
CA2433782A1 (en) | 2002-07-11 |
JP2005509400A (en) | 2005-04-14 |
WO2002053742A3 (en) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060063200A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
US20050287564A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
US6903201B2 (en) | Proteins and nucleic acids encoding same | |
EP1401858A2 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2002085922A2 (en) | Proteins and nucleic acids encoding same | |
EP1356047A2 (en) | Human proteins, polynucleotides encoding them and methods of using the same | |
US20040006205A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
CA2448540A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2002090500A2 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
EP1463747A2 (en) | Novel antibodies that bind to antigenic polypeptides,nucleic acids encodings the antigens, and methodes of use | |
US20060211031A1 (en) | Novel proteins and nucleic acids encoding same | |
US20030203843A1 (en) | Proteins and nucleic acids encoding same | |
WO2002046408A2 (en) | Human proteins, polynucleotides encoding them and methods of using the same | |
US20030212257A1 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
EP1383893A2 (en) | Proteins and nucleic acids encoding same | |
AU2002241820A1 (en) | Proteins and nucleic acids encoding same | |
WO2002072770A2 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
US20060210559A1 (en) | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use | |
US20030195149A1 (en) | Endozepine-like proteins, polynucleotides encoding them and methods of using the same | |
EP1401486A2 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
AU2002312258A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2002257115A1 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
AU2002243346A1 (en) | Proteins, polynucleotides encoding them and methods of using the same | |
AU2002303959A1 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
AU2002254605A1 (en) | Proteins and nucleic acids encoding same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20030725 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20051102 |